

CDIL HEALTH SCIENCES PROFESSIONAL TEXTBOOK SERIES

VOLUME 10F-B

Immunohematology & Blood Bank Serology

Clinical Laboratory Science

Dr. Charles D. Bunbury II
Author

PLATINUM REVISION MASTER
PUBLICATION AUDIT IN PROGRESS

C. Douglas Institute of Learning
Making Education Easier

CDIL HEALTH SCIENCES
PROFESSIONAL TEXTBOOK SERIES

VOLUME 10F-B

Immunohaematology & Blood Bank Serology

Compatibility science, investigation and accountable decisions

Dr. Charles D. Bunbury II

C. Douglas Institute of Learning
Making Education Easier

CORRECTED ILLUSTRATED STUDENT EDITION

September 2026 • Controlled six-book production release

An educational text, not an authorisation to practise or a substitute for current local law, validated clinical procedures and supervised competence. Fictional teaching cases are not patient records.

Approved individual cover artwork is retained. Source notes distinguish original teaching models from credited photographs. Publisher identifiers and printer-specific approval are managed in the separate release record.

Scope, evidence and responsible use

This textbook teaches the mechanisms, interpretation and professional reasoning of immunohaematology & blood bank serology. It is an educational resource, not an instrument instruction sheet, a substitute for supervised competency, or an independent authorisation to practise.

The worked patients, panels, numerical datasets and case organisations in the newly authored chapters are fictional teaching constructions. They are deliberately bounded models. Actual patient testing requires the laboratory’s validated procedures, manufacturer instructions, clinical context, local law and appropriate professional authority.

Bracketed source identifiers resolve to the reference section. Established biological mechanisms are distinguished from jurisdiction-specific rules and time-sensitive guidance. Sources were checked for this production work on 10 September 2026. Later changes require controlled revision.

Original CDIL diagrams are labelled schematics or synthetic data. Third-party photographs retain their individual creator, source and licence notes. A photograph demonstrates the stated observation; it does not establish a diagnosis without the accompanying investigation.

The approved individual cover artwork is retained from the controlled series archive. This file does not assert an ISBN assignment, external accreditation, provider endorsement, independent clinical peer-review approval or printer-specific conformance certification.

How to learn from this book

Read the mechanism before the case. Identify what each measurement actually observes, then ask which biological or analytical explanations could produce the pattern. The worked answers show how to move from observations to a defensible interpretation without hiding uncertainty.

Use each figure actively: trace the arrows, explain why a compartment or control matters, and identify what the model deliberately leaves out. In a reaction panel, choose cells that separate competing targets rather than merely counting positive wells. In a calculation, write the denominator and units before evaluating the number.

For retrieval, close the text and answer the case or mastery question in your own words. Compare the mechanism, limitations and proposed action with the reasoned answer. A correct label without a defensible explanation is not the same as professional competence.

Page numbers in the contents and subject index refer to PDF positions, with the front cover counted as page 1. Internal links support navigation. The teaching in this book does not depend on another PDF being stored in the same folder.


Immunohematology and Blood Bank Serology

ANTIGENS. ANTIBODIES. COMPATIBILITY. SAFER TRANSFUSIONS.


1 ABO and Rh Basics

Blood type	RBC antigens (on red cell)	Naturally occurring antibodies (in plasma)	Can receive RBCs from
A	A antigen	Anti-B	A, O
B	B antigen	Anti-A	B, O
AB	A and B antigens	None	A, B, AB, O (universal recipient)
O	No A or B antigens	Anti-A and Anti-B	O only (universal donor)

2 Antigen–Antibody Reactions on Red Cells




3 Agglutination Grading



4 Direct vs Indirect Antiglobulin Test (DAT and IAT)


Direct antiglobulin test (DAT)

Detects antibodies or complement already bound to the patient's red cells (*in vivo*).




Indirect antiglobulin test (IAT)

Detects antibodies in the patient's plasma that can bind to reagent red cells (*in vitro*).



5 Crossmatch Workflow



6 Transfusion Safety Checks

1. **Confirm patient identity** (use two identifiers)
2. **Verify ABO/Rh type and compatibility** with the unit label and crossmatch results
3. **Inspect the unit** (correct component, expiration date, no hemolysis or clots)
4. **Perform bedside check** (at patient, immediately before transfusion)
5. **Use approved administration set** with standard filter
6. **Monitor the patient** (vital signs; watch for adverse reactions)
7. **Document transfusion** and patient response




Figure 12.1 Key Concepts in Immunohematology and Blood Bank Serology. (1) ABO and Rh antigens, naturally occurring antibodies, and basic RBC compatibility. (2) Antigen–antibody reactions leading to agglutination. (3) Grading of agglutination reactions. (4) Direct antiglobulin test (DAT) versus indirect antiglobulin test (IAT). (5) Crossmatch workflow. (6) Essential transfusion safety checks. These principles guide the safe and effective use of blood components in clinical practice.

Contents

1 | The Purpose and Responsibility of the Immunohaematology Laboratory 8

2 | Red-Cell Membranes, Antigens and Inheritance 15

3 | Antibodies, Sensitisation and Clinical Significance 21

4 | Agglutination, Antiglobulin Testing and Reaction Phases 27

5 | Patient History, Specimen Identity and Sample Validity 33

6 | ABO and H: Biosynthesis, Inheritance and Compatibility 39

7 | ABO Discrepancies: A Structured Investigation 45

8 | The Rh System: D, C, c, E, e and Variant Expression 51

9 | The Kell System and Erythroid Consequences 57

10 | The Kidd System: Dosage, Evanescence and Delayed Reactions 63

11 | The Duffy System and Tissue-Specific Expression 69

12 | MNS: Glycophorins, Dosage and Variable Clinical Significance 74

13 | Lewis, P1PK, Globoside and I: Beyond the Common Shortcut 79

14 | Less Common Systems and Rare Antigen Problems 84

15 | Antigen Frequency, Dosage and the Mathematics of Finding Units 90

16 | Reagents, Controls and the Meaning of a Valid Reaction 96

17 | DAT, IAT and Elution: Three Related but Different Questions 102

18 | From Antibody Screening to Identification 108

19 | Panel Interpretation: Evidence, Dosage and Exclusion 114

20 | Multiple Alloantibodies: Separating Overlapping Patterns 120

21 | Enzyme Methods and Chemical Treatment of Red Cells 126

22 | Adsorption and Elution: Separating Antibody Populations 132

23 | Warm Autoantibodies and Autoimmune Haemolytic Anaemia 138

24 | Cold Antibodies, Complement and Biphasic Haemolysis 143

25 | Drugs, Therapeutic Antibodies and Serological Interference 149

26 | Serological and Electronic Crossmatching 155

27 | Selecting Red Cells, Plasma and Platelets 160

28 | Pregnancy, Maternal Antibodies and HDFN 166

29 | Neonatal and Paediatric Compatibility 172

30 | Suspected Transfusion Reactions and the Laboratory Investigation 177

31 | Repeated Transfusion, Haemoglobinopathies and Alloimmunisation 183

32 | Genotyping, Mixed Populations and Haematopoietic Transplantation 189

33 | Antibodies to High-Frequency Antigens and Rare-Donor Support 194

34 | Platelet Antibodies, HLA, HPA and Refractoriness 199

35 | The Reference-Laboratory Consultation 204

36 | Automation, Information Systems and Controlled Downtime 209

37 | Validation, Quality Control and Measurement Reasoning 214

38 | Haemovigilance, Incidents and Effective Corrective Action 220

39 | Emergency Contingencies, Scarcity and Accountable Allocation 225

40 | Integrated Immunohaematology Case Conference 230

Applied laboratory workshops | From reaction to accountable decision 235

Cumulative mastery assessment | 120 questions with reasoned answers 256

Applied glossary | Meaning, use and limits 287

References and evidence notes 310

Additional learning resources

B1 | ABO discrepancy: two questions, not a majority vote **314**

B2 | Panel interpretation: separate two overlapping targets **317**

B3 | Historical anti-Jka: a negative screen does not erase a risk **320**

B4 | Daratumumab and DTT: removing interference creates a blind spot **323**

B5 | A positive DAT: distinguish coating, destruction and causation **326**

B6 | Adsorption: the cells used determine what can disappear **329**

B7 | Platelet increments: preserve the denominator and the timing **332**

B8 | Finding antigen-negative units: an expectation is not a guarantee **335**

B9 | Delayed haemolysis: reconstruct the sequence before assigning a label **338**

B10 | Emergency release: uncertainty must travel with the component **341**

B11 | Verification study: agreement is not the same as truth **344**

B12 | Transfusion handover: resolve a discrepancy without destroying evidence **347**

What an antiglobulin result actually observes **350**

Reaction strength is not a concentration **351**

Evidence and navigation for the advanced cases **352**

Subject index **353**

1 | The Purpose and Responsibility of the Immunohaematology Laboratory

Immunohaematology connects the biology of red-cell antigens and antibodies with decisions about transfusion, pregnancy and selected immune disorders. A result is useful only when it belongs to the correct patient, was produced by a suitable method and reaches the team in time to influence care. The laboratory therefore works on two linked problems: whether the measurement is scientifically valid and whether the information is being used safely. A technically perfect reaction performed on the wrong specimen fails both purposes. [FB01, FB02]

1.1 Compatibility is more than an ABO label

ABO and RhD are familiar blood-group designations, but red cells carry many other antigens. A patient may have an antibody to an antigen outside ABO and RhD, including one that is no longer detectable in the current specimen. Selecting an ABO-compatible unit does not automatically address that history. Compatibility assessment combines current testing, historical findings, component characteristics and the clinical situation.

The word compatible also requires a specified component. Red-cell compatibility concerns the interaction of recipient antibodies with donor red cells, whereas plasma compatibility concerns antibodies in the donor plasma and antigens on recipient cells. Platelets introduce additional considerations, including their plasma content and, in selected settings, HLA or platelet-specific antibodies. A single "universal donor" slogan cannot safely describe all these products.

A negative crossmatch means that the method did not demonstrate incompatibility under the conditions tested. It does not guarantee that no adverse event can occur. Nonimmune reactions, emerging

antibodies, clerical errors after testing and clinical complications remain possible. The laboratory should provide a reliable compatibility conclusion without representing it as an absolute promise of risk-free transfusion.

1.2 The specimen is part of the scientific experiment

The patient's name, unique identifier, collection time and collector information are not separate from the test. They define whose biological material was examined and when it represented the patient's condition. Antibody status can change after pregnancy or transfusion, so chronology affects the validity of using an older sample. A result released today may come from a specimen collected several days earlier.

Specimen acceptance rules exist because some uncertainties cannot be repaired analytically. If the identity of the blood in a tube is uncertain, repeating ABO grouping on that tube does not establish whose blood it contains. A new, correctly identified specimen may be required. Relabelling a tube from memory can preserve the appearance of a complete record while leaving the original uncertainty unresolved.

Historical records provide an independent line of evidence when they arise from a genuinely separate collection and identification event. Two tests from aliquots of the same misidentified tube are not equivalent to two independently collected specimens. This distinction is important in policies designed to reduce wrong-blood-in-tube risk. The exact confirmation requirements belong to the applicable standards and local validated procedure.

1.3 Clinical urgency changes the pathway, not the need for accountability

Routine compatibility testing aims to resolve relevant serological questions before issue. In life-threatening bleeding, the harm of waiting may exceed the risk of releasing components before all testing is complete. Emergency release is therefore a controlled clinical pathway, not an admission that laboratory science no longer matters. The authorised decision, information available, components issued and testing still underway must be recorded. [FB01]

Communication should state the actual position. "ABO group established; antibody investigation incomplete" is more useful than "blood not ready." The treating team needs to know what uncertainty remains, the likely time to resolve it and which emergency options are available under policy. The laboratory should not independently delay urgent treatment while pursuing a perfect panel explanation without discussing the clinical consequences.

Equally, urgency does not justify erasing a known antibody history or guessing a blood group. Emergency procedures should anticipate these situations, define escalation and preserve traceability. The goal is the safest achievable decision under the circumstances, with the remaining uncertainty made explicit.

1.4 From a reaction to a report

A visible reaction is an observation. Assigning an antibody specificity is an interpretation. Selecting a component is a decision made through an authorised process. Keeping these stages distinct prevents a weak or ambiguous reaction from becoming a confident diagnosis without the necessary investigation.

For example, a reactive antibody screen indicates that additional investigation may be required; it does not identify the antibody by itself. A panel pattern may suggest anti-E, but confirmation and exclusion of additional clinically significant antibodies remain necessary. The patient's phenotype or genotype, transfusion history and method effects can strengthen or weaken the interpretation. The final report should reflect the evidence actually established.

The same discipline applies to negative findings. A negative screen does not exclude antibodies to antigens absent from the screening cells, very weak antibodies below detection or historical antibodies that have evanesced. These limitations are addressed by appropriate reagent selection, history review and compatibility policies, not by pretending that the screen has unlimited scope.

1.5 Competence and quality are observable practices

Competence includes correct technique, recognition of invalid results, interpretation within scope and timely escalation. A learner who obtains the expected answer but ignores a failed control has not demonstrated safe practice. A learner who identifies an uncertainty and obtains appropriate help may be acting more competently than one who offers a confident but unsupported conclusion.

Quality systems make these expectations reproducible. Controlled procedures, reagent acceptance, equipment maintenance, training, assessment, incident review and document control support the individual scientist. They do not replace professional judgement, but they reduce avoidable variation and make decisions traceable. The laboratory should be able to explain why a result was accepted and how a later concern would be investigated.

This book teaches scientific reasoning and professional application. It does not replace current manufacturer instructions, licensed standards or the authorised procedures of a transfusion service. Numerical exercises, reaction panels and patients are fictional teaching constructions unless explicitly identified otherwise. Their purpose is to develop transferable judgement, not to provide an unvalidated recipe for issuing blood.

Why compatibility has several independent dimensions

ABO compatibility, antigen matching, infectious-risk controls, component quality and correct bedside identification protect against different mechanisms. An ABO-compatible red-cell unit can still carry an antigen targeted by a patient's anti-K. An antigen-negative unit can still be given to the wrong person. A serologically compatible product can still contribute to circulatory overload. These are not contradictions: the word compatible describes a specified immunological relationship, not every possible consequence of transfusion.

The laboratory therefore constructs a layered argument. Identity establishes whose specimen was tested. Grouping establishes selected antigens and expected plasma reactions. Screening and history identify antibody-related risk. Crossmatching or a validated electronic process connects those findings with a particular unit. Clinical assessment determines whether the expected benefit of transfusion justifies the remaining risks. No single layer can legitimately claim the work of all the others. [FB01, FB02]

This distinction improves reporting. "No unexpected antibodies detected by this method" is narrower and more accurate than "no antibodies present." "Compatible by the specified testing procedure" is different from "no transfusion risk." Precision in language is part of clinical safety because the receiving team uses the report to make decisions under time pressure.




Figure FB01. Correct identity, valid testing, suitable unit selection and bedside confirmation protect against different failures. Passing one check does not replace the others. Original CDIL educational schematic; not patient data.

Worked cases 1–3

Case 1 — Correct group, wrong patient

A specimen repeatedly types as group A. The identifiers on the tube conflict with the request, and the collector cannot establish the original collection event. A trainee proposes accepting the group because three repeats agree.

Reasoned answer. Repetition confirms the reaction pattern in that tube, not the patient's identity. The uncertainty is preanalytical and cannot be solved by more tests on the same material. The laboratory must follow its specimen-rejection and recollection pathway, with urgent clinical escalation if transfusion is time sensitive. A consistent result from an unidentified specimen is not a valid patient result.

Case 2 — An old antibody that is not visible today

A patient has a documented history of anti-Jka, but the current antibody screen is negative. A student recommends electronic issue without considering the historical specificity.

Reasoned answer. Clinically significant antibodies can fall below detection and still be associated with an anamnestic response after re-exposure. The historical finding remains relevant to component selection and compatibility testing. The current negative screen does not erase it. The authorised pathway should account for Jka-negative red cells and appropriate compatibility testing, subject to the complete clinical and laboratory context.

Case 3 — A vague delay during haemorrhage

The laboratory is investigating broad reactivity while the patient is bleeding heavily. The only message sent is "crossmatch delayed."

Reasoned answer. The message does not give the clinical team enough information to balance urgency and risk. The laboratory should communicate the established group, relevant antibody history, unresolved question, expected investigation time and emergency-release options through the authorised escalation pathway. Testing and communication should proceed together. The laboratory must not imply that unresolved serology automatically prohibits every clinically necessary transfusion.

2 | Red-Cell Membranes, Antigens and Inheritance

A red cell is a flexible, specialised cell whose membrane supports gas transport and survival in the circulation. Blood-group antigens are carried by proteins, glycoproteins and glycolipids associated with that membrane. Some antigens are determined directly by the structure of a membrane protein; others depend on enzymes that add particular sugars. Understanding this distinction helps explain inheritance, variant expression and the effects of laboratory treatments. [FB03, FB04]

2.1 Antigen, gene, allele and phenotype

A gene is a DNA sequence associated with a functional product. Alleles are alternative forms at a locus. A genotype describes the inherited sequence information identified by a method, while a phenotype describes an expressed characteristic, such as reactivity with an antigen-typing reagent. The relationship is often strong but not always one-to-one. Regulation, hybrid genes, null alleles and method coverage can complicate prediction.

A serological phenotype answers whether a particular reagent demonstrated the corresponding antigen under the test conditions. A negative reaction can reflect true absence, weak expression, a variant not recognised by that reagent or a technical problem. The conclusion must therefore be supported by controls and knowledge of the reagent. Genotyping can clarify selected discrepancies but has its own limits, including the variants included in the assay and the interpretation of novel sequences.

The International Society of Blood Transfusion maintains a controlled blood-group terminology and database. The system is updated as genetic and serological evidence develops. This edition uses the database as the current nomenclature authority rather than freezing an old textbook count of systems as permanent fact. The September 2026 release lists 49 systems and 400 antigens; those numbers describe that release, not a biological maximum. [FB03]

2.2 Proteins and carbohydrates produce different kinds of variation

ABO specificity is produced by glycosyltransferase activity that modifies precursor structures. Rh antigens are associated with membrane proteins encoded by closely related genes. Kidd antigens occur on a urea transporter, and Duffy antigens on an atypical chemokine receptor. These examples show that blood-group molecules are not merely decorative labels placed on the cell for transfusion testing.

Changes in a protein sequence can remove an epitope, weaken expression or create an altered recognition pattern. Changes in an enzyme can alter the sugar structure produced. Regulatory changes can affect expression in one tissue differently from another. A molecular result should therefore be interpreted in relation to the mechanism by which the antigen is generated and displayed.

Mature red cells lack nuclei, but their membrane phenotype reflects products made during development and retained on the circulating cell. A DNA-based red-cell genotype is usually obtained from nucleated cells in the specimen, not from the mature red cells themselves. This distinction becomes important after haematopoietic transplantation or when donor-derived nucleated cells may be present.

2.3 Codominance and dosage

Many blood-group alleles are expressed codominantly. A person inheriting two different alleles may express both corresponding antigens. In selected systems, antibody reactions can be stronger with cells that have homozygous expression for the relevant antigen than with heterozygous cells. This is called dosage. It is particularly important when excluding antibodies using nonreactive panel cells.

Dosage is not a universal numerical rule that every homozygous cell has exactly twice the detectable antigen or gives exactly twice the reaction strength. Antigen density, antibody properties and method conditions influence the observation. A weak antibody may react with a homozygous cell and not with a heterozygous cell, making the latter

inadequate for a confident exclusion in a system where dosage is relevant.

A phenotype table should therefore preserve the paired antigen information. For Kidd, Jk(a+b-) and Jk(a+b+) cells are both Jka-positive, but they may not be equally informative in an exclusion strategy. The antigen profile is more useful than a single isolated plus sign.

2.4 Population frequencies are not individual identities

Antigen frequencies differ among populations, and this information can support donor-search planning. It must not be used to assign an individual's blood group from appearance, nationality or a broad ancestry label. Direct testing and reliable records establish the patient's result. Population categories are imperfect descriptions of genetic diversity and can conceal substantial variation within a group.

Frequency calculations can estimate the number of units that may need to be screened, but they rely on assumptions. If 20% of a hypothetical donor population lacks antigen X, screening ten independent units gives an expected number of two X-negative units. It does not guarantee exactly two. Linked antigen expression and nonrandom donor selection can make simple multiplication of separate frequencies inaccurate.

The practical response to a rare phenotype is collaboration with appropriate donor and reference networks, not stereotyping. A well-characterised donor population and accurate genotyping can improve supply while respecting the individual nature of every result.

2.5 Treatment of cells changes the information available

Enzymes and reducing agents can alter membrane proteins or carbohydrate-associated structures. Their effects are antigen-specific and reagent-dependent. A treated-cell panel may enhance some reactions while destroying others. A negative treated-cell result cannot exclude an antibody to an antigen that the treatment removed.

This principle underlies many advanced investigations. Treatment is an analytical intervention, not a neutral preparation step. The laboratory must know which information has been gained and which has been lost. Controls should demonstrate the intended treatment effect and the preservation of relevant targets where required.

Membrane anchoring determines antigen behaviour

Red-cell antigens can be carried on proteins, glycoproteins or glycolipids. Rh proteins traverse the membrane; glycophorins project carbohydrate-rich domains from the surface; ABO determinants are terminal carbohydrate structures on suitable precursors. These different physical arrangements help explain why enzymes or reducing agents affect systems differently. An enzyme that cleaves an exposed protein segment may remove one antigen while leaving an unrelated glycolipid determinant intact.

The membrane is supported by a cytoskeletal network that preserves shape and mechanical flexibility. Antigen expression and membrane function can therefore intersect. A blood-group protein may also act as a transporter, receptor or structural partner. Its absence can have consequences beyond a missing label, although many common polymorphisms do not cause a clinically apparent membrane disorder. [FB03, FB04]

Serology observes the accessible epitope under the test conditions. Genetics describes the underlying sequence or predicted expression. An altered epitope, reduced quantity, acquired adsorption or a mixed cell population can make these observations appear discordant. The correct response is to investigate the biological level at which the

difference arises, not to assume that all blood-group antigens behave like identical coloured dots.




Figure FB02. Original membrane model: carbohydrate determinants, membrane-spanning Rh proteins and glycoprotein carriers have different structures. Treatment effects therefore vary by antigen system. Original CDIL educational schematic; not patient data.

Worked cases 4–6

Case 4 — Genotype is not the same as a complete sequence

A targeted genotyping panel reports common antigen predictions. A trainee describes the patient as having a fully sequenced blood-group genome.

Reasoned answer. The panel identifies the variants included in its design and supports predictions within that scope. It may not detect every rare, regulatory or structural variant. The report should state the method and its limitations. A targeted molecular result can be highly useful without being a complete sequence-level characterisation of every blood-group locus.

Case 5 — Excluding with the wrong cell

A weak plasma antibody does not react with a Jk(a+b+) panel cell. The investigator uses that single cell to exclude anti-Jka despite other findings that raise concern for dosage.

Reasoned answer. Heterozygous expression may be insufficiently sensitive for exclusion of a dosage-dependent antibody. Appropriate homozygous antigen-positive cells and the validated exclusion policy are needed. The negative reaction is an observation, but the proposed exclusion is stronger than the evidence supports. The full pattern, method and history should guide the next step.

Case 6 — An expected number mistaken for a promise

Antigen-negative frequency is estimated at 20%. The laboratory screens ten units and finds none negative. A learner concludes that the frequency estimate must be fraudulent.

Reasoned answer. An expectation of two is not a guarantee. Under an illustrative independent model, the probability of no negative units is 0.8 to the tenth power, approximately 10.7%. The estimate may also differ from the actual local donor population. The correct response is to examine the assumptions and continue the donor-search strategy, not to treat ordinary sampling variation as proof of error.

3 | Antibodies, Sensitisation and Clinical Significance

A red-cell antibody is clinically important when its properties and the clinical setting create a meaningful risk, such as haemolysis or fetal injury. Detection alone does not determine that risk. Class, thermal range, complement activity, antigen expression, previous exposure and the patient's condition all contribute. The laboratory must therefore move from "antibody present" to a mechanism-aware interpretation. [FB02, FB04]

3.1 Alloantibodies and autoantibodies

An alloantibody recognises an antigen absent from the individual's own cells but present in another person of the same species. Exposure through transfusion or pregnancy can stimulate such a response. Some antibodies arise without a recognised transfusion or pregnancy exposure, often in association with environmental antigens that resemble blood-group structures. The term naturally occurring does not mean that the antibody has no immunological stimulus or can never be clinically significant.

An autoantibody reacts with the individual's own cells or associated structures. Autoantibodies can interfere with testing with or without causing clinically important haemolysis. A positive autocontrol or direct antiglobulin test does not, by itself, diagnose autoimmune haemolytic anaemia. Evidence of haemolysis and the broader clinical context are required.

Alloantibodies and autoantibodies can coexist. Broad autoantibody reactivity can obscure an alloantibody that matters for component selection. The investigation must therefore address both the dominant pattern and the possibility of an underlying specificity. Declaring a specimen "autoimmune" is not a substitute for completing the compatibility problem.

3.2 Primary and secondary responses

After a first relevant exposure, antibody production may develop over time. A subsequent exposure can produce a more rapid or stronger response from memory populations. A previously identified antibody may become undetectable between exposures, a phenomenon often described as evanescence. The historical record remains important because re-exposure can trigger an anamnestic response.

This mechanism helps explain delayed haemolytic transfusion reactions. The pretransfusion specimen may show no detectable antibody, yet transfused antigen-positive cells can stimulate a response that becomes evident later. The apparent change does not necessarily mean that the original laboratory made a technical error. It demonstrates why current testing and historical information are complementary safeguards.

Not every exposed patient becomes alloimmunised. Antigen immunogenicity, dose, inflammation, immune status and individual biological factors influence the response. A textbook should avoid the absolute statement that every nonself antigen inevitably produces an antibody. Risk is real without being deterministic.

3.3 IgM, IgG and visible reactions

IgM is large and multivalent and can produce visible agglutination efficiently under suitable conditions. It is often associated with reactions at lower temperatures, but class and thermal behaviour are not interchangeable definitions. Some clinically important antibodies have IgM components, and some IgG antibodies show substantial cold reactivity.

IgG can sensitise red cells without producing visible direct agglutination in saline. Antiglobulin methods detect such sensitisation by adding a reagent that recognises human immunoglobulin or complement components attached to cells. The method's sensitivity and specificity depend on the reagent, washing, incubation and detection system.

IgG can cross the placenta through receptor-mediated transport, making selected IgG red-cell antibodies relevant to haemolytic

disease of the fetus and newborn. IgM generally does not cross in the same manner. However, predicting fetal risk requires more than antibody class: the fetal antigen, antibody specificity, history and current specialist assessment matter.

3.4 Thermal amplitude and complement

Thermal amplitude describes the range of temperatures over which an antibody reacts under specified conditions. It can be more clinically informative than a high titre measured only at a very low temperature. An antibody that reacts at temperatures encountered in the circulation may have different implications from one that is reactive only under markedly colder laboratory conditions.

Complement activation can contribute to intravascular haemolysis or to deposition of complement fragments that promote clearance. The final effect depends on the pathway, regulation and target. A complement-positive DAT is evidence of coating under the assay's definition, not a complete demonstration of current intravascular haemolysis.

Extravascular haemolysis involves removal of sensitised cells by phagocytic systems, often in the spleen or liver. It can occur without dramatic free haemoglobin in plasma. The laboratory investigation of haemolysis therefore combines several observations rather than relying on one visible feature.

3.5 Reporting significance responsibly

An antibody's established association with transfusion reactions or fetal injury informs policy, but the report should remain specific to the result. The laboratory may identify a clinically significant alloantibody and recommend the corresponding antigen-negative, appropriately crossmatched red cells through the authorised pathway. It should not predict the exact severity of a future reaction from reaction strength alone.

Weak reactivity can still matter. A low-level antibody to a clinically significant antigen may become more evident after exposure. Conversely, strong in-vitro reactivity does not always imply severe in-vivo destruction. Clinical significance is a biological and clinical

property interpreted with laboratory evidence, not a direct conversion of a 1+ or 4+ grade into a severity score.

Affinity, avidity and thermal amplitude answer different questions

Affinity describes the strength of one antigen-binding interaction. Avidity describes the combined stability of multiple interactions. Pentameric IgM can form a stable multivalent attachment even when individual sites are not exceptionally strong. IgG has fewer binding sites but can interact effectively with effector systems through its Fc region. Neither class alone establishes whether a patient's antibody will cause clinically important red-cell destruction.

Thermal amplitude describes the range of temperatures over which an antibody reacts under specified conditions. An antibody that reacts at temperatures encountered in the body can be more consequential than one detected only under substantially colder laboratory conditions. However, the method, complement activity and clinical context still matter. A cold-reactive label should not be used as a blanket statement of harmlessness. [FB04, FB14, FB16]

Antibody concentration is another variable. A previously significant antibody may fall below an assay's detection limit while memory B cells persist. Later antigen exposure can stimulate an anamnestic response. This is why historical specificity can remain important when the current tube appears nonreactive: the tube measures the present assay response, not the entire immune memory of the patient.




Figure FB03. Simplified multivalent IgM bridging and IgG sensitisation. Class alone does not determine clinical significance; temperature, target, concentration and effector function matter. Original CDIL educational schematic; not patient data.

Worked cases 7–9

Case 7 — A weak but important antibody

A patient's anti-K reacts weakly in the current investigation. A trainee proposes ignoring it because stronger reactions have been seen with other antibodies.

Reasoned answer. Reaction strength is not a reliable ranking of clinical significance. Anti-K is relevant to transfusion and pregnancy in appropriate settings, and its history and identification must be respected. Component selection should follow the authorised antigen-negative and compatibility pathway. Weak current reactivity does not erase biological risk or immunological memory.

Case 8 — A positive DAT without haemolysis

A patient has a positive DAT but no current laboratory or clinical evidence of haemolysis. The draft report diagnoses autoimmune haemolytic anaemia.

Reasoned answer. The DAT demonstrates coating detectable by the method, not the clinical syndrome by itself. Possible explanations include treatment, passive antibodies, recent transfusion and other settings. The report should describe the DAT findings and support further interpretation as appropriate. Diagnosis of haemolytic anaemia requires evidence that red-cell destruction is occurring and assessment of its cause.

Case 9 — A cold titre treated as a universal risk score

A high antibody titre is measured at 4°C, but reactivity at warmer temperatures has not been evaluated. A learner predicts severe haemolysis solely from the titre.

Reasoned answer. The titre describes an endpoint under one set of conditions. Thermal amplitude, specificity, complement behaviour and clinical evidence are needed to assess significance. A high cold titre alone is not a universal severity predictor. The investigation should answer the relevant clinical question rather than overinterpret the most dramatic number.

4 | Agglutination, Antiglobulin Testing and Reaction Phases

Blood-bank methods turn molecular binding into an observable result. The transformation can involve direct agglutination, antiglobulin-mediated detection, retention in a column or adherence to a solid phase. Each format has its own signal logic. Understanding that logic allows the scientist to recognise invalid results and to avoid transferring a visual grading rule from one platform to another. [FB01, FB02, FB05]

4.1 Sensitisation precedes visible agglutination

Antibody can bind to a red-cell antigen without creating a visible aggregate. Sensitisation is the binding stage; agglutination is the formation of a network large enough to observe by the method. Antibody size, valency, antigen spacing and the physical environment influence whether the second stage occurs.

Red-cell surfaces carry a net negative charge and interact with surrounding ions. The resulting forces affect the distance between cells and the ability of antibodies to bridge them. Enhancement media modify selected aspects of the reaction environment. Their use must follow the validated method because changing ionic strength, protein concentration or incubation can alter sensitivity and specificity.

A centrifuged cell button is not automatically an agglutinate. Appropriate resuspension distinguishes a cohesive reaction from cells that disperse. Excessively vigorous handling can disrupt weak agglutinates; inadequate resuspension can create a false impression of positivity. Training with actual validated materials remains essential.

4.2 The indirect antiglobulin test

The indirect antiglobulin test examines whether antibodies in plasma or serum sensitise reagent or donor red cells during an in-vitro incubation. After the relevant binding stage, unbound immunoglobulin is removed or separated according to the method, and antiglobulin reagent provides detection. In a conventional tube method, inadequate washing can leave free immunoglobulin that neutralises the antiglobulin reagent and produce a false-negative result.

Appropriate check cells are used in specified tube antiglobulin procedures to validate negative reactions. If the expected positive reaction does not occur after their addition, the negative test is invalid and must be investigated under the procedure. The control is not an optional decoration added after the "real" result has already been accepted.

The exact incubation, washing, reagent and validation requirements depend on the platform. A gel or solid-phase system should not be operated using a tube procedure reconstructed from memory. Manufacturer instructions and the validated laboratory method define the operational sequence.

4.3 The direct antiglobulin test

The DAT examines red cells for immunoglobulin or complement coating that is already present on the cells at the time of testing. It does not require the same in-vitro sensitisation step as the IAT. Polyspecific and monospecific reagents provide different information, and the pattern can help guide investigation.

A positive DAT must be interpreted with specimen handling, recent transfusion, medication, passive antibody and clinical evidence. Complement can attach or change ex vivo under some conditions, so specimen choice and processing matter. A negative DAT does not exclude every immune haemolytic process; the density or class of coating and the method's detection limit may be relevant.

An eluate examines antibody recovered from sensitised cells through a defined procedure. It answers a different question from the plasma

antibody screen. Antibody may be concentrated on cells, present in plasma, or both. The relationship between plasma and eluate findings can be informative when interpreted with the transfusion and clinical history.

4.4 Columns and solid phases

In a column-agglutination method, the distribution of cells after processing reflects their interaction with the column and reaction system. A strong positive, weak positive, mixed-field pattern and negative pellet have characteristic appearances within the validated platform. These appearances are not interchangeable with tube grades. The manufacturer's grading guide and local competency process control interpretation.

Solid-phase methods use adherence or another surface-associated signal to indicate binding under the system's design. The visual meaning of a dispersed layer versus a compact button depends on the platform. A learner must understand which pattern represents positivity rather than assume that "more clumping" is always the positive endpoint in every method.

Automation improves standardisation and traceability but does not eliminate errors. Pipetting problems, sample quality, reagent deterioration, instrument flags and incorrect patient association remain possible. Automated images should be reviewed according to policy, particularly when the system identifies an indeterminate or atypical pattern.

4.5 Grade, record and interpret

Reaction grades should be recorded using the laboratory's defined scale. Haemolysis, mixed-field reactions and unusual appearances should not be forced into a simple positive/negative category when the method requires more detail. The raw observation provides the foundation for later interpretation and comparison.

A repeat is useful when it addresses a specific concern. Repeating until a preferred result appears is not quality assurance. The laboratory should document why a test was repeated, what changed and how the final result was selected. This protects against

unconscious cherry-picking and makes the investigation reproducible.

Why sensitisation may be invisible

The red-cell surface carries a net negative charge, and cells in suspension tend to remain separated. An IgG molecule can bind an antigen on one red cell without spanning the distance needed to produce visible cell-to-cell agglutination. The cells are sensitised even though the suspension appears unagglutinated. Antihuman globulin can bridge appropriately coated cells and make the interaction detectable.

In a conventional tube antiglobulin procedure, washing removes unbound immunoglobulin that could neutralise the antiglobulin reagent. Inadequate washing can therefore produce a false-negative result. Appropriate control cells added to a negative antiglobulin test help demonstrate that active reagent remains and that the negative result is technically interpretable. The exact control procedure follows the validated method. [FB02, FB05]

Column and solid-phase methods use different physical arrangements to reveal sensitisation. They should not be taught as if their reagent sequence, reading rules and controls were identical to a tube method. The common principle is detection of a defined antigen–antibody interaction; the route from that interaction to a visible signal is method-specific.




Figure FB04. Sensitised cells may not visibly agglutinate until antihuman globulin links bound IgG. Unbound immunoglobulin must be removed in a conventional washed-tube procedure; method controls remain essential. Original CDIL educational schematic; not patient data.

Worked cases 10–12

Case 10 — Failed check cells

A tube IAT is negative. After check cells are added, no expected positive reaction occurs. A trainee reports the original negative result because the patient has no antibody history.

Reasoned answer. The negative reaction has not been validated. Possible causes include inadequate washing, omitted or inactive antiglobulin reagent and other procedural problems. The test must be repeated or investigated according to the procedure. Clinical history cannot convert a failed analytical control into a valid result.

Case 11 — A button mistaken for agglutination

A centrifuged red-cell button remains partly intact because it was not resuspended as required. The operator records a positive tube reaction.

Reasoned answer. The appearance may reflect handling rather than an antigen–antibody lattice. The operator should use the validated resuspension and reading technique, with appropriate controls. The lesson is not to shake every tube vigorously; excessive handling can also damage weak reactions. Technique must be standardised and assessed with the actual method.

Case 12 — A platform switch without retraining

A scientist experienced in tube testing begins reading solid-phase results using the assumption that a compact button always represents positivity.

Reasoned answer. Signal meaning is platform-specific. In some solid-phase systems, adherence across the well represents a positive result and a compact button a negative one. The scientist needs method-specific training, manufacturer guidance and demonstrated competency. Familiarity with one assay principle does not authorise transferring its visual rules to another.

5 | Patient History, Specimen Identity and Sample Validity

Pretransfusion testing begins before blood reaches the analyser. Identification, collection, labelling and history determine whether the specimen can support a valid decision. Many serious transfusion hazards arise not from an inability to recognise an antigen–antibody reaction but from applying a correct result to the wrong person or the wrong time point. [FB01, FB02]

5.1 Identify the patient actively

Where the patient can participate, asking the person to state identifying information provides a different safeguard from asking a leading yes-or-no question. The information must be reconciled with the authorised identification system and request. A bed number, room location or verbal description is not a stable unique identifier.

Patients who cannot identify themselves require the institution's alternative process. Emergency identifiers must remain consistent across specimens, components and records. When a temporary identity is replaced with a confirmed identity, the reconciliation must preserve the original links and prevent two records from being merged incorrectly. The laboratory should not improvise an identity correction without the authorised clinical and information-system process.

Labels belong to the collection event. Applying a label before approaching the patient or labelling several patients' tubes later increases the opportunity for substitution. The collection date and time, collector and required patient identifiers must be recorded according to policy. The purpose is to establish a defensible chain from patient to tube, not merely to fill every box on a form.

5.2 History changes the interpretation

Previous transfusions, pregnancies, antibody findings, stem-cell transplantation, immunoglobulin administration and selected therapeutic antibodies can alter testing. A recent transfusion may create a mixed red-cell population that complicates phenotyping. A historical alloantibody may require antigen-negative components even when the current screen is negative. Anti-CD38 treatment can produce broad IAT reactivity that needs a specific laboratory strategy.

History should be sought from reliable records and the treating team, not only from patient recall. Patients may not know the name of an antibody or may have received treatment elsewhere. Interoperable records and patient-held antibody information can help, but every imported finding must be associated with the correct person and interpreted within its documented context.

A negative history is not always a reliable absence of exposure. "Unknown" should remain distinct from "none." Sample-validity policies commonly treat uncertain exposure history conservatively because a new immune response may be developing. The laboratory should not change an unknown history to a negative one merely to avoid recollection.

5.3 Sample validity is jurisdiction- and policy-specific

There is no single globally valid number of hours that can be copied into every transfusion service. Applicable standards, patient exposure history and local validated policies determine how long a specimen can support testing. The Canadian Blood Services clinical guide describes a 96-hour interval for patients recently transfused, pregnant within the preceding three months or with uncertain history. Other jurisdictions and institutions use different rules. This example is explicitly Canadian and must not be converted into a universal requirement. [FB01]

The biological reason for shorter validity after relevant exposure is the possibility of developing or changing antibodies. An older specimen may no longer represent the patient's current immune

state. The precise clock must be defined in policy: collection time, expiry calculation and the relationship to transfusion or testing should be unambiguous in the information system.

Extended validity for selected preadmission patients may be permitted under defined conditions. It is not simply an administrative convenience that any staff member can apply. The absence of recent pregnancy or transfusion, the reliability of the history and the applicable standard must be established. A change in clinical circumstances can invalidate the earlier assumption.

5.4 Specimen quality and investigation limits

Haemolysis, clotting problems, insufficient volume, contamination and storage conditions can affect testing. A haemolysed specimen also complicates interpretation when haemolysis itself is part of the clinical question. The laboratory should distinguish in-vivo findings from collection-related damage where possible and state when the specimen cannot support a reliable conclusion.

Recollection may be the correct scientific action. It should be explained as resolving a specific uncertainty rather than as a bureaucratic refusal. In urgent situations, specimen limitations and emergency options must be discussed promptly with the authorised team. A rejected specimen should not disappear from the record; the reason and communication are part of quality improvement.

Sample retention and traceability support later investigation. The ability to compare pre- and post-transfusion material can be valuable when a reaction is suspected. Storage conditions, retention periods and access controls belong to the laboratory's current policy and applicable requirements.

5.5 A reliable handover preserves unresolved questions

At shift change, the next scientist needs to know the patient, urgency, established findings, pending tests, relevant history, specimen expiry and component plan. A handover that says only "positive screen" omits the information needed to continue safely. The record should also identify who has been contacted and which decisions have already been authorised.

The laboratory information system can support this process but cannot infer missing context. Free-text warnings, structured antibody history, issue restrictions and audit trails should be designed to remain visible at the point of decision. A warning that is buried in a scanned document may exist technically while failing operationally.

A validity interval protects against biological change

A pretransfusion specimen is not timeless. Recent transfusion or pregnancy can stimulate antibodies that were absent or undetectable when an earlier sample was collected. A defined validity interval limits the chance that component selection relies on an obsolete view of the patient's circulating antibodies. It is a risk-control rule, not a claim that antibodies appear at one exact hour.

The interval also depends on the governing programme and the patient's exposure history. The Canadian guidance cited in this book uses a 96-hour requirement in specified circumstances. Other jurisdictions and institutions use different rules. Staff should calculate validity using the precise local definition of collection time, expiry and applicable exceptions rather than substituting a remembered number from another system. [FB01]

A new sample does not replace historical information. Current testing and verified history protect against different problems: the new specimen can reveal a developing antibody, while the historical record can retain an evanescent specificity. Both should be linked to the correct patient before routine component release.




Figure FB05. The specimen-to-record relationship begins at collection. A perfectly scanned label can still identify the wrong patient if the original collection process failed. Original CDIL educational schematic; not patient data.

Worked cases 13–15

Case 13 — Release time versus collection time

A specimen was collected Monday at 09:00 and reported Tuesday at 15:00. A trainee starts the validity clock from report release rather than collection.

Reasoned answer. The specimen represents the patient's biology at collection. The applicable policy defines the exact expiry calculation, but a report-release timestamp does not renew the specimen. The laboratory should use the correct collection event and validated clock. Delayed reporting must not silently extend sample validity.

Case 14 — An unknown history changed to "none"

The patient cannot recall whether blood was given during an earlier admission. To avoid another collection, the request is marked "no transfusion."

Reasoned answer. Uncertain history and confirmed absence are different evidence states. The record should remain accurate, and the

laboratory should apply the policy for uncertainty while seeking reliable records. Altering the history to obtain a convenient validity interval undermines the biological safeguard the rule is intended to provide.

Case 15 — A recent transfusion and an apparent phenotype

A specimen collected soon after red-cell transfusion appears positive for an antigen the patient historically lacked. A student concludes that the patient has changed inherited blood group.

Reasoned answer. Donor cells can contribute to the circulating population and produce a mixed or altered serological appearance. The patient's inherited genotype has not simply changed because of a red-cell transfusion. Historical records, transfusion timing and an appropriate molecular or reference investigation may be needed. The report should distinguish the phenotype of the current mixed specimen from the patient's underlying antigen profile.

6 | ABO and H: Biosynthesis, Inheritance and Compatibility

ABO antigens are carbohydrate structures built through enzyme-mediated modification of precursor chains. The inherited ABO information determines the activity of glycosyltransferases rather than directly encoding a membrane protein called "A" or "B." This distinction explains why precursor availability, enzyme variants and tissue expression can produce different serological patterns. ABO compatibility is fundamental because clinically important antibodies can be present before any recognised transfusion exposure. [FB03, FB06]

6.1 Building H, A and B structures

On red cells, FUT1-associated fucosyltransferase activity contributes to formation of H antigen on appropriate precursor chains. A and B transferases then modify H structures by adding different terminal sugars. The A transferase adds N-acetylgalactosamine, whereas the B transferase adds galactose. Common group O alleles do not produce the same functional A or B modification, leaving more unmodified H on the red-cell surface.

The statement "group O has no antigens" is therefore incorrect. Group O red cells lack A and B antigens under the usual classification but carry H and many non-ABO antigens. A group O unit can be incompatible with a recipient who has a clinically significant antibody to another antigen. ABO terminology describes one system, not the entire red-cell surface.

FUT2 influences related structures in secretions. Secretor status and red-cell H expression are connected biochemically but are not identical tests of the same gene. The distinction becomes important in unusual H-deficient phenotypes and in the relationship between ABO, H and Lewis expression.

6.2 Forward and reverse grouping examine different evidence

Forward grouping tests the patient's red cells with reagents directed at A and B antigens. Reverse grouping tests the patient's plasma or serum with reagent cells carrying known A and B antigens. In the usual adult pattern, the two sides provide complementary evidence. Agreement is expected before routine assignment of a valid ABO group under the laboratory's procedure. [FB01]

The reverse group depends on the patient's antibodies. Infants, immunodeficient patients and some other clinical settings may not show the expected pattern. A weak or missing reverse reaction should therefore be investigated with age and history in mind. It must not be "corrected" by entering the result expected from the forward group.

ABO antibodies are often described as naturally occurring because they may develop without a recognised red-cell exposure through transfusion or pregnancy. Their development is associated with environmental stimulation and maturation of the immune response. They are not present in every newborn at adult strength, and the term naturally occurring does not imply harmlessness.

6.3 Common inheritance and its limits

A simplified inheritance model treats common A and B alleles as codominant and common O alleles as lacking functional A/B transferase activity. An individual with an A and a B allele can express both antigens. An individual with an A and an O allele commonly expresses group A. This model is useful for introductory genetics but does not cover every subgroup, rare allele or regulatory effect.

Serology remains central to assigning the ABO group used for transfusion. Genotyping can help investigate selected anomalies but should not be used as an unqualified replacement for the validated serological assignment. Variant alleles and incomplete assay coverage can create discrepancies. The report should describe the

evidence and resolve conflicts rather than selecting whichever result seems easier to explain. [FB02]

Family relationships should not be adjudicated from a simplified classroom inheritance chart. Rare variants, technical errors and incomplete information can invalidate a superficial conclusion. Blood-group testing for clinical care is not a substitute for an authorised genetic relationship investigation.

6.4 H deficiency and the danger of an apparently ordinary O group

In an H-deficient phenotype such as the classic Bombay phenotype, red cells may lack the H precursor needed for ordinary A or B expression. The forward group can therefore resemble group O, while the plasma may react with ordinary group O cells because those cells carry H. This creates a serious compatibility problem that cannot be solved by the slogan "give O blood."

An unexpected reaction with group O reagent or donor cells, together with the complete serological pattern, may prompt investigation of H deficiency and related possibilities. Specialist reagents, phenotype and molecular work may be required. Component selection should involve the reference laboratory and rare-donor pathway. The exact phenotype and antibody characteristics determine the plan.

Para-Bombay and other variant expression patterns demonstrate why the H system should not be reduced to a single exceptional diagram. Secretor-related expression and weak antigen adsorption can complicate the observed phenotype. The laboratory must describe what is established rather than forcing every unusual pattern into the most familiar rare label.

6.5 Component-specific compatibility

For red-cell transfusion, donor A and B antigens must be compatible with the recipient's antibodies, alongside all other relevant requirements. For plasma, the direction is reversed: donor plasma antibodies must be considered against the recipient's red-cell antigens. AB plasma lacks the usual anti-A and anti-B and can be useful in selected settings, but product selection remains governed by current policy, supply and the clinical situation.

Whole blood contains both red cells and plasma. Its use cannot be inferred directly from a red-cell-only compatibility chart. Low-titre group O whole-blood programmes use specific selection, testing and clinical protocols. The phrase low titre belongs to the programme's validated definition; it is not a universal number that can be assumed from the label "O."

A compatibility table is therefore a teaching aid, not an issue authorisation. The actual decision includes patient identity, antibody history, component modifications, expiry, clinical urgency and local policy. ABO is the beginning of compatibility reasoning, not its endpoint.

ABO determinants are terminal sugars, not separate membrane proteins

The H structure provides a substrate on which functional A or B glycosyltransferases can act. The A transferase adds a terminal N-acetylgalactosamine residue, whereas the B transferase adds a terminal galactose residue to suitable H-bearing chains. In common group O phenotypes, functional A or B transferase activity is absent, leaving H unmodified by either enzyme. The amount and distribution of these determinants depend on precursor chains and expression.

This mechanism explains why group O red cells are not antigen-free. They retain H and many non-ABO blood-group antigens. It also explains why an H-deficient phenotype cannot be managed by the simplistic instruction to give ordinary group O cells: ordinary O cells carry H, which can be the target of clinically important anti-H in the relevant rare setting. [FB03, FB06]

Secretor status concerns expression of soluble ABH substances through a related but distinct pathway. It should not be confused with the basic ABO group on red cells. Subgroups, weak expression and acquired changes require careful investigation because a weak forward reaction can reflect several mechanisms rather than a single universal diagnosis.




Figure FB06. A transferase adds N-acetylgalactosamine; B transferase adds galactose. Common O phenotypes retain H without either terminal addition. This is a symbolic glycan model, not a complete structural formula. Original CDIL educational schematic; not patient data.

Worked cases 16–18

Case 16 — Group O is not antigen-free

A group O patient with anti-K is offered a group O, K-positive red-cell unit because a learner believes group O blood lacks all relevant antigens.

Reasoned answer. Group O describes absence of A and B in the ordinary ABO classification, not absence of Kell or other antigens. The anti-K history remains relevant, and appropriate K-negative, compatible units should be selected through the authorised process.

The error comes from applying an ABO shortcut to the entire red-cell antigen repertoire.

Case 17 — An O-like forward group with unexpected O-cell reactivity

A specimen has no forward reaction with anti-A or anti-B, but its plasma reacts with ordinary group O cells as well as other routine cells. Routine assignment as group O would leave unexplained reactions.

Reasoned answer. The pattern requires investigation rather than automatic O assignment. H deficiency with anti-H is one important possibility, alongside other causes of broad reactivity. The laboratory should review controls, history and specialised testing and involve the reference service. Ordinary group O units may be unsafe in an H-deficient patient with clinically significant anti-H.

Case 18 — A plasma chart read in the red-cell direction

A learner selects group O plasma for an AB recipient using the reasoning that group O red cells are broadly ABO-compatible.

Reasoned answer. Plasma contains donor antibodies, so compatibility is assessed in the opposite direction from red-cell antigen compatibility. Group O plasma can contain anti-A and anti-B that are relevant to an AB recipient. Selection must follow the component-specific policy. The same blood-group label cannot be interpreted without knowing which part of the donation is being transfused.

7 | ABO Discrepancies: A Structured Investigation

An ABO discrepancy exists when the observed reactions do not support a consistent, expected assignment under the method and patient context. The discrepancy is a safety signal, not an inconvenience to be hidden. A structured investigation begins with identity and technique, then considers weak or missing antigens, weak or missing antibodies, unexpected reactions and mixed cell populations. [FB01, FB02]

7.1 Start with the raw observations

Record each forward and reverse reaction, relevant controls, haemolysis and mixed-field appearance. Do not replace a weak result with a stronger expected grade or enter an inferred group before the conflict is resolved. The raw pattern determines which explanations are plausible.

The first review includes patient and specimen identity, reagent identity, expiry, quality control, cell suspension and instrument flags. A simple transposition can imitate an unusual biological pattern. Repeating the test is useful when it checks a defined technical possibility, but repeated testing on a misidentified specimen cannot establish the patient's group.

Historical grouping provides an important comparison. A conflict with a reliable earlier result may indicate a specimen error, transfusion effect, transplantation or a genuine change in expression. The history should guide the investigation without being used to overwrite current unexplained observations.

7.2 Weak or missing reverse reactions

Expected ABO antibodies may be weak or absent in infants, some older or immunocompromised patients and selected disease or treatment settings. The absence of a reverse reaction does not necessarily mean that the forward group is wrong. It means that one part of the usual adult confirmation is unavailable or atypical.

The laboratory may use method adjustments permitted by its validated procedure to improve detection, but it should not invent incubation conditions from a textbook description. Increasing sensitivity can also reveal unrelated cold-reactive antibodies and create new interpretive problems. The aim is to understand the pattern, not simply to force a positive reaction.

In young infants, reverse grouping is not interpreted as it is in adults. The age threshold and testing approach belong to the applicable policy. The Canadian guide specifically describes reverse grouping as not required under four months because detected antibodies may be maternal. This is a labelled Canadian example, not a universal replacement for local neonatal procedures. [FB01]

7.3 Weak or altered forward reactions

A or B expression can vary with inherited subgroups and selected clinical conditions. Reagent differences may reveal a variant differently. A weak reaction should be assessed with controls, history and appropriate specialised testing rather than treated as a numerical vote for one group.

A1 and A2 are common subgroup concepts, but not every weak A pattern is A2. Anti-A1 can occur in some individuals with non-A1 phenotypes and may create an unexpected reverse reaction with A1 reagent cells. Its clinical significance depends on thermal behaviour and the complete investigation. A reaction at room temperature alone should not be converted automatically into a broad transfusion restriction.

Acquired changes in antigen expression or bacterial modification can also produce unusual patterns. These are specialised investigations that require careful correlation with the patient's condition and

method. The laboratory should not assign a rare subgroup from one anomalous reaction without confirmatory evidence.

7.4 Unexpected extra reactions

Cold-reactive alloantibodies or autoantibodies can react with reverse-grouping cells independently of ABO. A plasma protein effect such as rouleaux can also mimic agglutination in some methods. The investigator should ask whether the unexpected reaction follows the ABO antigen or another property of the reagent cell and specimen.

Rouleaux is a nonimmune stacking phenomenon associated with the surrounding protein environment. A validated saline-replacement or other appropriate method can help distinguish it from true agglutination in selected tube investigations. The method must be applied correctly; simply adding saline to any reactive test without controls can dilute or alter a true antibody reaction.

Positive reagent controls or panreactivity in forward testing require attention to cell coating, reagent formulation and technical conditions. A DAT may contribute useful information, but it does not by itself resolve the ABO assignment. The complete pattern must be evaluated through the authorised discrepancy procedure.

7.5 Mixed-field reactions and two populations

A mixed-field appearance suggests that some cells behave differently from others in the test. Recent transfusion, haematopoietic transplantation, selected subgroups and other circumstances can produce such a pattern. The investigator should distinguish a genuine mixed population from artefact or incomplete resuspension.

After transfusion, the observed red-cell population may include donor and recipient cells. After haematopoietic transplantation, the relationship among recipient history, donor type, current red cells and plasma antibodies can change over time. Component selection requires a defined transplant-support plan, not simply the latest apparent forward group.

Until an ABO group can be assigned confidently, the laboratory follows its unresolved-group and emergency-selection policy. The

safest temporary component strategy depends on the component and patient context. It should be documented and communicated, with the unresolved question carried forward until closure.

Reverse grouping measures the current plasma response

Forward grouping asks which selected antigens are detected on the patient's red cells. Reverse grouping asks how the patient's plasma reacts with known reagent cells. Agreement between these complementary observations supports the group assignment in the population where both tests are applicable. Disagreement is a signal to investigate, not an invitation to choose whichever half is more convenient.

Weak reverse reactions can occur when expected antibodies are poorly developed or reduced, including early infancy and some immunodeficient or immunosuppressed states. Additional reverse reactions can arise from non-ABO antibodies, cold reactivity or other interference. Protein-related rouleaux can mimic agglutination in some settings, so the method and appropriate corrective investigation matter. [FB01, FB02]

A mixed-field forward reaction has a different meaning from a uniformly weak reaction. Mixed-field indicates visibly different reacting populations under the method, whereas uniform weakness describes the intensity of a population response. Transfusion, transplantation and some subgroup situations can produce mixed patterns. The laboratory should preserve this distinction in both the worksheet and the information system.




Figure FB07. Synthetic group O pattern: anti-A 0, anti-B 0, anti-D positive in this D-positive example; plasma reacts with A1 and B cells. Controls and local testing requirements remain necessary. Original CDIL educational schematic; not patient data.

Worked cases 19–21

Case 19 — Weak reverse group in an immunocompromised patient

Forward testing supports group A, but the expected reaction with B reagent cells is weak. The patient has a documented immune disorder. The trainee changes the weak grade to 4+ to make the record look consistent.

Reasoned answer. The raw result must remain accurate. The clinical context may explain reduced antibody strength, but the discrepancy should be investigated and resolved according to policy. Altering the grade destroys the evidence and can conceal another problem. A valid interpretation can acknowledge an atypical reverse reaction without falsifying the observation.

Case 20 — Anti-A1 as a hypothesis, not an automatic answer

A group A specimen reacts unexpectedly with A1 reverse-grouping cells. A learner immediately labels the patient A2 with anti-A1.

Reasoned answer. The pattern suggests a line of investigation, but other antibodies or technical effects can produce extra reactions. Appropriate subgroup and antibody investigations, controls and thermal assessment are needed. The final report should distinguish the observed reaction from a confirmed specificity and phenotype. A familiar explanation should not replace evidence.

Case 21 — Mixed field after transfusion

A patient historically group A receives group O red cells during an emergency. A later forward anti-A test shows a mixed-field pattern.

Reasoned answer. The circulating sample can contain A-positive recipient cells and A-negative donor cells. The pattern is consistent with the recent transfusion history, provided identity and technical checks are satisfactory. It does not mean that the patient's inherited ABO genotype changed. Future component selection should follow the complete current and historical assessment, not an isolated mixed-field label.

8 | The Rh System: D, C, c, E, e and Variant Expression

Rh is a complex protein blood-group system with major importance in transfusion and pregnancy. The familiar positive or negative label usually refers only to D. It does not describe the full Rh phenotype. C, c, E and e, together with numerous other Rh antigens and variants, can be clinically relevant. Understanding the relationship between RHD, RHCE and expressed epitopes prevents oversimplification of weak or discrepant results. [FB03, FB07]

8.1 Two related genes and a complex membrane phenotype

RHD and RHCE are closely related genes whose products contribute to Rh antigen expression. RHCE variants commonly encode combinations associated with C or c and E or e. The proteins interact with the red-cell membrane environment and associated molecules. Hybrid genes and sequence changes can produce complex patterns that are not captured by a simple classroom positive/negative model.

Traditional haplotype shorthand can help organise inheritance, but it should be translated into the actual antigens or molecular result when used in a clinical report. A symbol such as R1 is not self-explanatory to every reader and may imply a probable haplotype rather than a fully established genotype. Clear antigen notation reduces misunderstanding.

Rh antigens are generally well developed on fetal red cells, contributing to the importance of maternal IgG antibodies in HDFN. Anti-D, anti-c and other Rh antibodies can have significant consequences. The degree of risk requires the current pregnancy-specific assessment rather than a prediction from a single reaction grade.

8.2 Weak D and partial D are not interchangeable

Weak D describes reduced serological expression under defined testing conditions, while partial D refers to qualitative alteration or absence of some D epitopes. The categories can overlap in observed behaviour. A person with a partial D variant may type D-positive with some reagents yet be capable of forming an alloantibody to epitopes not expressed on their own cells.

Serological reagent patterns can suggest variation, but molecular typing often provides more precise information for management. Decisions about classifying a patient as D-positive or D-negative and about Rh immune globulin depend on the identified variant and applicable guidance. Common weak D types 1, 2 and 3 are managed as D-positive in many established genotype-based frameworks, but that approach must not be generalised to every weak or partial D result. [FB08]

Donor and recipient testing policies have different safety objectives. A donor unit with weak D expression may need to be labelled in a way that prevents exposure of a D-negative recipient, whereas a patient with an unresolved variant may be managed conservatively until clarified. A single laboratory rule cannot be copied between donor qualification and patient management without considering the purpose.

8.3 Rh antibodies and dosage

Rh antibodies are commonly IgG and can react at the antiglobulin phase. They are relevant to transfusion and pregnancy. Some Rh specificities show dosage, making the antigen expression of nonreactive panel cells important when excluding additional antibodies. The exact exclusion criteria belong to the validated identification procedure.

A patient with anti-E may also be at risk of having or developing anti-c depending on the patient's phenotype and exposure. Component-selection policies may address this combination in particular circumstances. The laboratory should establish the patient's antigen profile and follow its authorised strategy rather

than automatically assuming that every anti-E specimen contains anti-c.

Enzyme treatment often enhances Rh antibody reactions in commonly used methods, but enhancement does not identify a specificity by itself. A pattern still requires antigen correlation and exclusion of alternatives. The treatment can simultaneously remove information about other systems, which must remain part of the interpretation.

8.4 Rh immune globulin and passive anti-D

Rh immune globulin can produce detectable passive anti-D. A reactive result after administration must be interpreted with timing, dose history, previous antibody results and the clinical context. No single routine reaction strength universally distinguishes passive from immune anti-D. The history and serial pattern may be important, and uncertainty should be communicated rather than hidden.

Rh immune globulin is preventive; it is not a treatment that removes an established immune anti-D response. Eligibility and dosing are clinical decisions under current local guidance, including the assessment of relevant sensitising events and fetomaternal haemorrhage where indicated. This textbook does not provide a universal dosing schedule because products and national programmes differ.

A patient should not lose appropriate prophylaxis solely because a laboratory result has been casually labelled passive or immune without sufficient evidence. The laboratory and obstetric team should resolve the interpretation through the authorised pathway.

8.5 Genotype-informed matching

Patients with complex Rh variants, particularly those requiring repeated transfusions, may benefit from molecular characterisation and a specialised matching strategy. A serological phenotype that appears matched at the common antigen level can still conceal relevant epitope differences. The appropriate level of matching depends on the patient's history, clinical condition, available donors and specialist guidance.

Molecular prediction is not infallible. Assay coverage, novel alleles, phase and chimerism can complicate interpretation. The best approach integrates serology, molecular evidence and history, with reference-laboratory support when the findings do not agree.

A partial antigen can be present and still immunologically incomplete

The RhD protein contains multiple epitopes. A qualitative variant can preserve some epitopes while altering or lacking others. Such a person may react with certain anti-D reagents yet remain capable of forming alloanti-D against epitopes not represented on their own cells. This is the central reason that a simple positive/negative serological label can be insufficient for selected variant cases.

Quantitatively weak expression is a different concept, although serological patterns can overlap. Genotyping can distinguish defined variants whose clinical management is supported by evidence. The familiar weak D types 1, 2 and 3 have specific recommendations in recognised genotype-based frameworks; the conclusion must not be extended automatically to every weak or discrepant D result. [FB07, FB08]

Donor and recipient policies serve different safety goals. A donor unit with weak D expression may need to be labelled to protect D-negative recipients from exposure, while the management of a patient with a defined genotype considers that individual's alloimmunisation risk. An apparent difference between donor and patient rules can therefore be deliberate rather than inconsistent.




Figure FB08. Different symbols represent different D epitopes. A partial-D model lacks one epitope while retaining others; a weak-expression model has fewer otherwise represented targets. Genotyping resolves selected clinically important variants. Original CDIL educational schematic; not patient data.

Worked cases 22–24

Case 22 — Every weak D result treated alike

A patient has weak serological D reactivity, but the molecular type is not known. A learner applies the management used for weak D type 1 to this unresolved result.

Reasoned answer. The genotype-specific recommendation cannot be extended to an unidentified variant. Some variants have different alloimmunisation risks. The laboratory should follow the local unresolved-D policy and obtain appropriate molecular or reference investigation. The term weak describes the observed serology, not a complete biological classification.

Case 23 — Passive or immune anti-D?

Anti-D is detected after documented Rh immune globulin, but a prior specimen is unavailable. The trainee claims that the low reaction grade proves the antibody is passive.

Reasoned answer. Reaction strength alone is not a universal discriminator. Administration history, timing, earlier results and follow-up may be needed. The report should state the likely context and uncertainty according to policy, with communication to the obstetric team. An unsupported categorical label can affect prophylaxis and fetal-risk assessment.

Case 24 — D-positive does not mean fully Rh-matched

A repeatedly transfused D-positive patient forms anti-E. A student is surprised because every unit was labelled Rh-positive.

Reasoned answer. The Rh-positive label usually refers to D only. Units can differ in C, c, E, e and other Rh epitopes. A D-positive patient can form antibodies to Rh antigens they lack. The case demonstrates why extended matching and antibody history are distinct from routine D classification.

9 | The Kell System and Erythroid Consequences

Kell-system antigens are carried on a membrane glycoprotein associated with Kx through a disulfide linkage. The system includes K and k and several other clinically relevant antigens. Antibodies to Kell antigens can cause transfusion reactions, and anti-K has particular importance in pregnancy because it can affect erythroid precursors as well as contribute to red-cell destruction. [FB03, FB09, FB10]

9.1 K and k are antithetical antigens, not "positive and negative Kell"

K and k describe alternative antigenic forms associated with the Kell protein. A K-negative person is not necessarily Kell-null; most K-negative individuals express k and other Kell-system antigens. The phrase "Kell-negative" can therefore be ambiguous. A clinical request should specify K-negative when that is the intended requirement.

K0 describes a Kell-null phenotype in which Kell antigens are absent. Individuals with such a phenotype can form antibodies to high-frequency Kell determinants after exposure. This is a different compatibility problem from ordinary anti-K. The laboratory should not use the same shorthand for absence of one antigen and absence of the whole system's expression.

Kx is associated with the XK protein, not simply another name for Kell. The McLeod phenotype involves deficient Kx expression with altered Kell expression and can have clinical associations beyond transfusion. The biochemical relationship between the proteins helps explain the serology but does not make the systems interchangeable.

9.2 Anti-K and transfusion

Anti-K is commonly an IgG alloantibody and is clinically significant. A current or historical anti-K should be incorporated into component selection through the authorised antigen-negative and compatibility pathway. A weak current reaction does not make the antibody irrelevant.

K antigen frequency differs among donor populations, affecting the ease of finding K-negative units. Frequency estimates support planning, but the actual selected unit must have reliable antigen information where required. A population estimate cannot replace testing or a validated donor record.

Other Kell antibodies can create more difficult searches when the target antigen is common. Anti-k, for example, concerns an antigen expressed by most donors in many populations. The laboratory may need reference support and rare-donor resources. The urgency and clinical plan should be communicated early rather than waiting until routine stock has been repeatedly screened without success.

9.3 Pregnancy and suppression of erythropoiesis

Maternal anti-K can affect fetal red-cell production by targeting erythroid precursors, in addition to mechanisms of haemolysis. This helps explain why the relationship between titre and fetal severity is not identical to that of every other antibody. A low titre should not be treated as automatic reassurance without the appropriate specialist assessment. [FB10]

Fetal risk depends on whether the fetus carries the relevant antigen and on the complete obstetric and laboratory history. Paternal or fetal antigen investigation may be considered within current clinical guidance and consent requirements. The laboratory should provide accurate antibody identification and monitoring data while avoiding unsupported predictions about fetal genotype or outcome.

Titres are method-dependent. Serial monitoring should use a consistent, validated approach, and changes should be interpreted in the disease-specific framework. The laboratory must not transfer a

numerical threshold from another method or antibody simply because both tests are called titres.

9.4 Reducing agents create a Kell blind spot

Dithiothreitol and other reducing treatments can disrupt Kell antigens by altering disulfide-dependent structures. This property is useful in selected investigations, including strategies for anti-CD38 interference, but it removes the ability to detect antibodies to affected antigens using those treated cells.

A negative DTT-treated panel therefore does not exclude anti-K. The laboratory must account for the blind spot through pretreatment records, phenotype or genotype and appropriate component-selection policy. The treatment does not make the sample universally safe or the antibody investigation complete. [FB11]

Controls should demonstrate that treatment achieved the intended effect and that the method remains valid for the questions being asked. An untreated and a treated panel answer different analytical questions. Their results should be recorded separately rather than merged into one unexplained conclusion.

9.5 A mechanism-based report

A useful report identifies the antibody, states the relevant component requirement and records limitations of any modified method. In pregnancy, it should support the authorised referral and monitoring pathway. The report should avoid vague phrases such as "Kell problem" that fail to distinguish anti-K, anti-k, a null phenotype or treatment-related loss of antigen detection.

Kell antibodies can affect production as well as survival

Kell is carried on a membrane glycoprotein associated with Kx. The system includes multiple antigens, not only the common K/k pair. Chemical treatments that disrupt relevant disulphide-dependent structures can abolish detection of important Kell antigens. A test performed after such treatment has a changed antigen landscape and cannot exclude antibodies against determinants that are no longer available.

In pregnancy, anti-K can cause severe fetal anaemia through effects on erythroid precursors as well as destruction of circulating cells. This helps explain why the relationship between maternal titre and fetal risk is not identical to a simple model of red-cell haemolysis alone. Specialist fetal assessment and current pregnancy guidance are required. [FB09, FB10]

The mechanism also changes how a laboratory communicates uncertainty. A low or stable titre cannot be promoted to a universal assurance of fetal safety. Similarly, a DTT-treated negative antibody screen does not remove the need to consider Kell protection when the patient's antigen status and treatment-related interference require it.




Figure FB09. Kell-associated fetal anaemia can involve erythroid precursors as well as circulating red cells. A maternal titre is not a complete measure of fetal risk. Original CDIL educational schematic; not patient data.

Worked cases 25–27

Case 25 — K-negative versus Kell-null

A student describes a common K-negative, k-positive donor as lacking all Kell-system antigens.

Reasoned answer. K-negative means that K was not demonstrated; it does not imply a K0 phenotype. The donor can express k and other Kell antigens. Accurate antigen notation is necessary for selecting blood for antibodies to different targets. The incorrect shorthand could be dangerous if used for a patient with an antibody to a high-frequency Kell antigen.

Case 26 — A low anti-K titre in pregnancy

A maternal anti-K titre is low by the local method. The learner tells the team that fetal anaemia is impossible.

Reasoned answer. Anti-K can affect erythroid precursors, and titre alone does not exclude important fetal risk. The result must be integrated with fetal antigen status, history and current specialist

guidance. The laboratory should communicate the finding and support the appropriate pathway, not provide categorical reassurance from one number.

Case 27 — DTT removes the evidence being sought

A DTT-treated panel is nonreactive in a patient receiving anti-CD38 therapy. The investigator reports that anti-K has been excluded.

Reasoned answer. DTT destroys or alters Kell antigens, so the treated cells cannot provide a valid exclusion for antibodies to affected targets. The component plan must account for that limitation, using reliable pretreatment or molecular information and the authorised policy. A successful interference-removal step can create an important diagnostic blind spot.

10 | The Kidd System: Dosage, Evanescence and Delayed Reactions

Kidd antigens are carried by a urea transporter encoded by SLC14A1. The system is especially important in transfusion because Kidd antibodies may be difficult to detect, can show dosage and may become undetectable between exposures. A negative current screen therefore cannot safely erase a documented Kidd antibody history. [FB03, FB12]

10.1 The transporter and its antigenic forms

Jka and Jkb are antithetical antigens associated with alternative forms of the Kidd protein. Common phenotypes include Jk(a+b-), Jk(a-b+) and Jk(a+b+). The Jk(a-b-) null phenotype lacks both common antigens and the high-frequency Jk3 determinant. It is uncommon in many populations but has particular relevance in selected donor and patient groups.

The protein's urea-transport function provides a mechanistic connection between blood-group expression and membrane physiology. Kidd-null red cells show altered behaviour in specialised urea-lysis investigations. Such methods belong to reference-laboratory procedures and must not be improvised from a classroom description.

The absence of both Jka and Jkb in a serological result requires appropriate confirmation. Weak expression, recent transfusion, reagent limitations and technical problems must be considered before assigning a rare null phenotype. Molecular and reference investigations can help establish the result.

10.2 Why dosage matters

A Kidd antibody may react more strongly with cells homozygous for the corresponding antigen. A weak anti-Jka can therefore fail to react with some Jk(a+b+) cells while reacting with Jk(a+b-) cells. Exclusion based only on heterozygous nonreactive cells can miss the antibody.

A panel should be read as a pattern of antigen expression and reaction strength, not as a search for one convenient positive cell. The investigator should identify suitable homozygous cells, assess the complete reaction phases and consider other antibodies that could explain the same pattern. Dosage supports a hypothesis but does not prove specificity by itself.

Enzyme treatment often enhances Kidd reactions in commonly used methods. This can assist investigation, but treated cells may lose antigens from other systems. A positive enzyme pattern cannot be interpreted without considering what the treatment changed. The untreated investigation remains important for excluding clinically significant antibodies to destroyed antigens.

10.3 Evanescence and anamnestic responses

Kidd antibodies are well known for becoming weak or undetectable over time. A later antigen exposure can stimulate a renewed response and contribute to a delayed haemolytic transfusion reaction. The historical record is therefore a biological safeguard, not an optional archive.

A patient may have a satisfactory initial haemoglobin increment followed by a fall, with new serological findings and other evidence of haemolysis. The investigation must consider timing, transfused units, pretransfusion specimens and competing causes. A newly detectable antibody does not alone prove that every clinical change is due to haemolysis, but it is an important finding that requires integration.

Records should retain the specificity and the evidence supporting it. A vague historical note saying "positive antibody" is less useful than a verified anti-Jka identification with date and relevant testing. When

historical information is incomplete, the laboratory should seek the original service's record and document the uncertainty.

10.4 Complement and clinical consequences

Kidd antibodies can bind complement and are associated with haemolytic transfusion reactions. Both acute and delayed presentations are possible, depending on the antibody and circumstances. The absence of a dramatic immediate reaction does not establish that the transfused cells will have normal survival.

Kidd antibodies can also be relevant in pregnancy, although the clinical pattern varies. The laboratory should not use a general statement about common severity to dismiss an individual pregnancy. Identification, fetal antigen considerations and specialist assessment guide the response.

Anti-Jk3 can react with most ordinary donor cells because Jk3 is present when the Kidd protein is expressed. A confirmed Kidd-null patient with anti-Jk3 may require rare compatible units. Early reference-laboratory and donor-network involvement is important, especially before planned procedures.

10.5 A specific component plan

For a patient with a clinically significant Kidd antibody, the authorised plan generally includes red cells lacking the corresponding antigen and appropriate serological compatibility testing. The exact requirements depend on the complete antibody history and current standards. A current negative screen does not convert the patient into the same category as someone with no significant antibody history.

The laboratory should also consider whether a recent transfusion makes patient phenotyping unreliable. Genotyping can provide useful information about the patient's underlying antigen profile when the circulating red cells are mixed. The interpretation must account for the molecular method and any history of haematopoietic transplantation.

Dosage and evanescence create two different Kidd blind spots

A dosage-sensitive antibody may react more strongly with cells expressing a homozygous antigen pattern than with heterozygous cells. If the screening or panel cells provide weak expression for the relevant target, an antibody can be missed or underestimated. This is an analytical sampling problem involving the antigen-bearing cells used in the test.

Evanescence is a temporal problem: a previously formed antibody becomes undetectable in the patient's plasma. The relevant target can be well expressed on the reagent cells, yet the amount or activity of antibody is below detection. An anamnestic response after re-exposure can then contribute to a delayed haemolytic reaction. [FB12]

The two mechanisms require complementary protections. Appropriate cell selection and method sensitivity address dosage-related detection. Accurate historical records address evanescence. Repeating the same negative screen without consulting the history does not solve the second problem, and recording history does not remove the need for a technically adequate current test.




Figure FB10. Synthetic antibody-response timeline. The dashed line is a hypothetical assay detection limit. An undetectable interval does not erase immune memory or a verified antibody history. Original CDIL educational schematic; not patient data.

Worked cases 28–30

Case 28 — A dosage clue

A specimen reacts with three Jk(a+b-) cells but not with two Jk(a+b+) cells. Other antigen differences have not yet been excluded.

Reasoned answer. The pattern is compatible with dosage and supports investigation of anti-Jka, but it is not a complete identification. The laboratory must examine all relevant antigens, controls, patient phenotype or genotype and additional cells. The nonreactive heterozygous cells should not be used as decisive evidence against anti-Jka.

Case 29 — A delayed fall after a negative screen

A patient with no available local antibody history has a negative pretransfusion screen. Several days after transfusion, haemoglobin falls and anti-Jka is detected. An outside hospital later confirms a previous anti-Jka.

Reasoned answer. The sequence is consistent with an evanescent antibody and an anamnestic response, requiring a full delayed-reaction investigation. The original negative screen does not exclude this mechanism. The recovered history should be permanently linked to the correct patient and incorporated into future selection. Clinical causation still requires the complete haemolysis and transfusion assessment.

Case 30 — A rare null phenotype

A patient appears Jk(a-b-) and has broad reactivity compatible with anti-Jk3. Routine antigen-negative searches for only Jka or only Jkb fail to provide suitable cells.

Reasoned answer. If anti-Jk3 and the null phenotype are confirmed, cells lacking only one common Kidd antigen still express Jk3 and may remain incompatible. The investigation requires reference support and a rare-donor strategy. The case demonstrates why an antibody to a shared high-frequency determinant cannot be managed as two unrelated searches for ordinary single-antigen-negative units.

11 | The Duffy System and Tissue-Specific Expression

Duffy antigens are associated with the atypical chemokine receptor ACKR1, historically also called DARC. The system demonstrates an important principle: a regulatory variant can alter antigen expression on red cells without producing the same effect in every tissue. Serology, genotype and the biological meaning of a null phenotype therefore require careful distinction. [FB03, FB13]

11.1 Fya, Fyb and the underlying protein

Fya and Fyb are antithetical antigens associated with different forms of the Duffy protein. Common serological phenotypes include Fy(a+b-), Fy(a-b+) and Fy(a+b+). A Fy(a-b-) phenotype can arise through different molecular mechanisms, so the same surface result does not necessarily imply the same underlying genetic or tissue-expression pattern.

The protein has chemokine-binding properties and is involved in interactions relevant to selected malaria parasites. These functions help explain population variation and biological interest, but they should not be simplified into a claim that one phenotype provides complete protection from all malaria. Parasite species, invasion mechanisms and contemporary evidence matter. Blood-group testing is not a malaria-risk certificate.

The common erythroid-silent regulatory mechanism associated with absent red-cell Duffy expression in many people of African ancestry affects expression in erythroid cells while preserving expression in other tissues. This differs from variants that remove the protein more broadly. The distinction can influence which Duffy antibodies are plausible and how molecular predictions are interpreted.

11.2 Serological behaviour and enzyme sensitivity

Anti-Fya and anti-Fyb are commonly IgG and can be clinically significant. They may show dosage, making homozygous antigen-positive cells important in a validated exclusion strategy. A weak or negative reaction with a heterozygous cell should not be overinterpreted when the pattern raises concern for a dosage-dependent antibody.

Common proteolytic enzyme treatments can destroy Duffy antigens. An antibody that reacts with untreated cells but loses reactivity after enzyme treatment may therefore fit a Duffy specificity, among other possibilities. The treatment pattern is a clue, not a complete identification. The investigator must consider every antigen altered by the reagent and the full panel pattern.

A negative enzyme-treated panel cannot exclude anti-Fya or anti-Fyb when the relevant antigens have been removed. This limitation is particularly important when enzyme testing is used to clarify another antibody. Enhancing one system can erase evidence from another, so the untreated investigation must remain part of the record.

11.3 Clinical significance and history

Duffy antibodies can cause haemolytic transfusion reactions and can be relevant in pregnancy. Their significance should be incorporated into component selection and the appropriate obstetric pathway. Reaction strength alone does not determine severity, and a historical antibody remains relevant even if current reactivity is weak.

Anti-Fy3 recognises a high-frequency determinant associated with the Duffy protein and can create a more difficult compatibility problem than an antibody to only Fya or Fyb. A rare-donor or specialised matching strategy may be necessary. The laboratory should not assume that ordinary Fya-negative units are also Fy3-negative.

Repeatedly transfused patients may have complex combinations of antibodies, making an extended phenotype or genotype valuable. Interpretation must account for recent transfusion and the exact

molecular mechanism of Duffy expression. A broad ancestry label should never replace the patient's actual result.

11.4 Genotype-informed interpretation

A molecular report should distinguish an erythroid-silent promoter variant from a coding-null variant where the method can establish that distinction. The predicted phenotype belongs to the tested loci and interpretation. If a panel detects only common variants, a discordant serological result may require a broader investigation.

The clinical use of a prediction also matters. A patient with an erythroid-silent Duffy pattern may not require the same restrictions as a patient lacking Duffy expression through another mechanism, depending on the antibody history and current specialist guidance. Such decisions should be made through the transfusion service's authorised matching policy, not inferred from a simplified classroom rule.

11.5 Integrating the pattern

A sound Duffy investigation connects untreated reactions, enzyme effects, dosage, patient phenotype or genotype and historical findings. It does not depend on one characteristic in isolation. The scientist should be able to explain why the proposed specificity fits and which alternative antibodies have been adequately excluded.

A regulatory variant can have tissue-specific consequences

Duffy antigens are associated with ACKR1. Some variants affect coding sequence, while a well-known regulatory change can suppress expression in erythroid cells without eliminating expression in all other tissues. A red-cell-negative phenotype therefore need not mean that the protein is absent everywhere in the body.

This distinction matters when molecular findings are translated into antigen-matching decisions. In sickle cell transfusion guidance, the erythroid regulatory variant has a specific interpretation for anti-Fyb risk. The conclusion should follow the verified genotype and the

applicable guidance, not an assumption based on ancestry or skin colour. [FB13, FB21]

Population frequencies can help a blood service plan donor recruitment, but they cannot determine an individual patient's phenotype. Serology or validated molecular testing provides the patient-specific evidence. Respectful, accurate practice separates useful population biology from unsupported personal inference.




Figure FB11. A regulatory variant can suppress erythroid ACKR1 expression without eliminating expression in all tissues. Individual genotype evidence, not ancestry alone, supports interpretation. Original CDIL educational schematic; not patient data.

Worked cases 31–33

Case 31 — Enzyme negativity used as an exclusion

A specimen is nonreactive with enzyme-treated cells, and the investigator reports that anti-Fya is excluded without examining suitable untreated cells.

Reasoned answer. The enzyme treatment may have destroyed Fya. A negative result on cells lacking the target cannot exclude the corresponding antibody. The investigation needs appropriate untreated antigen-positive cells and the validated exclusion process.

The result demonstrates the importance of knowing what a treatment removes, not merely what it enhances.

Case 32 — Two null-looking phenotypes, different mechanisms

Two patients type Fy(a-b-), but one has an erythroid-silent regulatory variant and the other a coding mechanism affecting expression more broadly. A student calls the molecular distinction irrelevant.

Reasoned answer. The same red-cell phenotype can arise through different biological mechanisms with different tissue expression and antibody implications. The molecular distinction may affect interpretation and matching strategy. It should be evaluated with the complete antibody history and specialist guidance rather than discarded because the initial plus/minus pattern is the same.

Case 33 — Fya-negative is not automatically Fy3-negative

A patient has confirmed anti-Fy3. A routine Fya-negative, Fyb-positive unit is proposed as suitable solely because Fya is absent.

Reasoned answer. The unit still expresses Duffy protein and can carry Fy3. Anti-Fy3 is not equivalent to anti-Fya. The component search must target the relevant high-frequency determinant and involve the appropriate reference and rare-donor resources. Precise antibody naming directly affects safe selection.

12 | MNS: Glycophorins, Dosage and Variable Clinical Significance

The MNS system is associated principally with glycophorin A and glycophorin B, encoded by GYPA and GYPB, together with complex variant and hybrid structures. M and N are carried on glycophorin A, while S and s are associated with glycophorin B. The system includes antibodies that are often insignificant under routine conditions and others that can cause serious transfusion or fetal complications. [FB03, FB14]

12.1 Structural organisation

Glycophorins are heavily glycosylated membrane proteins that contribute to the red-cell surface environment. Sequence differences and hybrid genes can change antigen expression. A simple M/N or S/s table introduces the common antithetical pairs but does not describe the full system.

U is a high-frequency antigen associated with glycophorin B expression. An S-s- phenotype may raise questions about U expression, but variant U phenotypes exist and require specialised characterisation. The laboratory should not assign a complete U result from a limited common-antigen panel without the necessary evidence.

MNS variants can be particularly relevant in patients requiring repeated transfusion. Molecular and reference investigations help resolve patterns that routine reagents cannot fully explain. Population information may guide donor searches but never substitutes for individual testing.

12.2 Anti-M and anti-N

Anti-M is commonly predominantly IgM and often reacts best at lower temperatures. In many patients it is not clinically significant for routine transfusion, but its behaviour must be assessed rather than assumed. An IgG component or reactivity at 37°C can make the interpretation more important, particularly in pregnancy or selected clinical settings. [FB14]

Anti-N is also often cold-reactive and commonly has limited significance, but unusual clinically important examples exist. The laboratory should follow the current specificity- and method-based policy. A textbook should not describe every antibody in either group as invariably harmless.

Prewarming or an alternative validated method can help manage selected cold-reactive interference, but these approaches can reduce detection of other antibodies. Their purpose and limitations must be documented. The goal is not to make the specimen negative at any cost; it is to detect clinically relevant reactivity reliably.

12.3 Anti-S, anti-s and anti-U

Anti-S and anti-s are commonly IgG and can cause haemolytic transfusion reactions and HDFN. Anti-U can also be clinically significant and may create a difficult donor search because U is common in many populations. The corresponding antigen-negative requirements and compatibility testing should be incorporated into the authorised plan.

Dosage can affect MNS reactions. Appropriate homozygous antigen-positive cells may be necessary for exclusion, depending on the specificity and method. A nonreactive heterozygous cell should not automatically close the investigation when the pattern remains suspicious.

Enzyme effects vary with the antigen and treatment. Common proteolytic enzymes destroy M and N and can affect S and s depending on the reagent and conditions. The laboratory must know the validated effect of the actual treatment used. A memorised

statement that "all MNS antigens are destroyed by every enzyme" is too broad for reliable interpretation.

12.4 Pregnancy and erythroid effects

An IgG anti-M that is reactive under clinically relevant conditions can be associated with fetal or neonatal anaemia, including effects on erythroid precursors in some cases. The absence of a dramatic DAT or a low apparent titre should not be treated as universal reassurance. The obstetric and neonatal teams need the specific antibody information and current specialist guidance.

The laboratory should distinguish antibody class, thermal behaviour and fetal antigen possibility. A naturally occurring IgM anti-M detected in pregnancy is not automatically evidence that the fetus is M-positive or affected. Paternal or fetal testing and monitoring decisions belong to the authorised clinical pathway.

12.5 Context-specific component selection

Recommendations can differ by patient group. For example, Canadian Blood Services guidance describes IAT-compatible units at 37°C for many patients with anti-M, while recommending antigen-negative units in selected populations such as people with sickle cell disease. This illustrates why a general statement must be linked to its jurisdiction and patient context rather than presented as a universal rule. [FB14]

The scientist should communicate the actual reactivity, relevant history and proposed matching plan. An antibody name without thermal and clinical context may not be sufficient for a safe decision, especially when multiple antibodies coexist.

Glycophorin structure explains MNS complexity

M and N are associated primarily with glycophorin A, while S and s are associated with glycophorin B. These proteins project carbohydrate-rich regions from the red-cell surface. Recombination and hybrid structures can create variant expression and additional antigens, so the system is more complex than two independent pairs of letters.

Proteolytic enzyme treatment can alter relevant exposed structures. A loss of reactivity after treatment can therefore be informative, but it is not a standalone identification. The laboratory must consider every antigen affected by the treatment and any antibodies that may have been enhanced at the same time. [FB03, FB04, FB14]

Clinical significance depends on the antibody's characteristics. Anti-M is often detected under conditions that do not imply a major transfusion risk, but reactivity at 37°C, an IgG component and pregnancy-related circumstances can change the interpretation. The correct lesson is conditional reasoning, not the categorical statement that an entire named specificity is always insignificant.




Figure FB12. Simplified glycophorin carriers illustrate why M/N and S/s are related but distinct. Hybrid structures and treatment effects require more than a two-letter mnemonic. Original CDIL educational schematic; not patient data.

Worked cases 34–36

Case 34 — Anti-M automatically called harmless

A maternal anti-M has an IgG component and reacts at 37°C. A learner dismisses it because anti-M is "usually cold."

Reasoned answer. A common pattern does not exclude a clinically important exception. The actual class, thermal behaviour, history and

fetal-risk assessment matter. The laboratory should support the current obstetric pathway and communicate the specific findings. "Usually" must not be converted into "always."

Case 35 — An S-s- result used to assign U without evidence

Routine typing shows S-s-. No specialised U testing has been performed. The report draft states that U is definitely absent.

Reasoned answer. The limited phenotype does not fully characterise all glycophorin B variants or U expression. Specialised serology or molecular investigation may be needed. The report should state the established S and s findings and reserve the U conclusion until supported. A rare-donor search depends on accurate, not assumed, antigen requirements.

Case 36 — Prewarming makes everything negative

A cold-reactive antibody disappears after a prewarm method, and the investigator assumes that no clinically significant antibody can be present.

Reasoned answer. The method may reduce selected interference but can also affect detection of other reactivity. Its validated sensitivity and limitations must be considered, with appropriate controls and history review. The desired outcome is not a negative tube; it is a reliable assessment of clinically relevant antibodies.

13 | Lewis, P1PK, Globoside and I: Beyond the Common Shortcut

Several blood-group systems are associated with antibodies that often react at lower temperatures or have context-dependent significance. Lewis, P1PK, Globoside and I provide useful examples. They also demonstrate why old terminology and broad claims such as "all cold antibodies are harmless" can mislead. Current ISBT nomenclature should be used alongside clear clinical interpretation. [FB03, FB14]

13.1 Lewis antigens are acquired from the plasma environment

Lewis antigens on red cells are acquired by adsorption from circulating material rather than being produced as a fixed red-cell membrane protein in the same way as Rh antigens. FUT3 and FUT2-related pathways influence the common Lewis phenotypes. This relationship helps explain changes in apparent red-cell Lewis expression under physiological conditions, including pregnancy.

The phenotype Le(a-b-) can arise in different biological contexts. It should not be treated as a simple permanent genetic label without considering secretor status, age and clinical setting. Newborn red cells do not show the mature adult Lewis pattern, which contributes to the usual limited role of Lewis antibodies in HDFN.

Lewis antibodies are commonly IgM and often reactive at lower temperatures, but clinically significant examples can occur, particularly when reactivity extends to 37°C. The laboratory should follow the validated specificity- and patient-based selection policy. A frequent pattern of low significance does not justify ignoring an actual warm-reactive or clinically concerning antibody. [FB14]

13.2 P1PK and Globoside terminology

The historical "P system" terminology has been reorganised as molecular knowledge developed. P1 and Pk belong to the P1PK system, while P is associated with the Globoside system. Using current names prevents confusion when discussing rare phenotypes and antibodies that recognise related glycolipid structures. [FB03]

Anti-P1 is often a cold-reactive antibody with limited significance under routine transfusion conditions, but exceptions require assessment. Antibodies associated with rare phenotypes can have broader and more serious implications. A specimen reacting with many routine cells should not be dismissed as ordinary anti-P1 without the appropriate antigen correlation and reference investigation.

Paroxysmal cold haemoglobinuria is associated classically with a biphasic haemolysin, often anti-P. The Donath–Landsteiner investigation addresses a specific mechanism involving binding under one temperature condition and haemolysis after warming. It is a specialised test requiring appropriate collection, handling and controls. The name "cold" does not mean that the clinical consequences are necessarily minor.

13.3 I and i reflect carbohydrate branching

I and i describe related carbohydrate structures whose expression changes during development. Adult red cells generally express more I, while neonatal cells have relatively greater i expression. This developmental difference can help in investigating selected cold-reactive antibodies, but it should not be used as a complete identification from one comparison alone.

Anti-I is commonly associated with cold autoantibody patterns. Thermal amplitude, complement activity and clinical evidence determine whether the finding is significant. A high titre at a low temperature is not a universal measure of haemolytic risk. The laboratory should distinguish an incidental cold-reactive antibody from a clinically important cold-antibody-mediated process.

Rare adult i phenotypes and associated antibodies require specialised investigation. The routine pattern is a useful starting model, not a substitute for individual characterisation.

13.4 Neutralisation and inhibition are controlled experiments

Some antibodies can be inhibited using appropriate soluble substances. The experiment can help identify a specificity or remove interference so that other antibodies become detectable. A dilution control is necessary where the treatment also dilutes the specimen, because reduced reactivity may otherwise be attributed incorrectly to specific inhibition.

An inhibited specimen must still be examined for underlying clinically significant antibodies. Removing the dominant reaction does not prove that the remaining plasma is free of relevant antibodies. The report should record the treatment and the information it supports, including any limitations introduced.

13.5 The clinical question governs the response

A cold-reactive antibody found during routine screening, a haemolytic syndrome after cold exposure and a pregnancy investigation are different problems. The same broad system name can have different significance in each. The laboratory should avoid categorical conclusions based only on the antibody's usual class or a historical mnemonic.

Adsorbed Lewis substances behave differently from intrinsic antigens

Lewis substances are synthesised outside the red cell and can adsorb from plasma onto the red-cell membrane. Their expression is influenced by interactions between Lewis and secretor pathways. Changes in plasma composition and physiological state can therefore alter the apparent red-cell Lewis phenotype without changing the person's underlying genotype.

This helps explain why Lewis serology should not be interpreted as if it were a stable count of a red-cell membrane protein. It also helps explain the relationship between soluble substances and antibody neutralisation in specialised investigations. Any neutralisation method must be validated and interpreted with controls because a reduced reaction can have more than one cause. [FB03, FB04, FB14]

P1PK, globoside and I-related structures illustrate another form of complexity: related carbohydrate pathways can generate antigens assigned to distinct systems or collections. Historical names may not map neatly onto current ISBT classification. Reports should use current nomenclature and preserve the specific antibody identified rather than compress several different targets into an imprecise "P antibody" label.




Figure FB13. Lewis determinants can be acquired from plasma onto the red-cell surface. This differs from an antigen produced as an intrinsic membrane protein. Original CDIL educational schematic; not patient data.

Worked cases 37–39

Case 37 — Lewis expression changes in pregnancy

A patient previously typed Lewis-positive appears Le(a-b-) during pregnancy. A learner assumes a specimen substitution without considering physiology.

Reasoned answer. Identity must always be checked, but Lewis expression on red cells can change because the antigens are adsorbed from the plasma environment. The history and current physiological setting provide a plausible biological explanation. The laboratory should investigate according to policy rather than automatically declaring either error or permanent genetic change.

Case 38 — A neutralisation experiment without a dilution control

Reactivity decreases after soluble substance is added. The investigator declares specific neutralisation, although no parallel dilution control was tested.

Reasoned answer. The decrease may be due partly or wholly to dilution. A properly designed control is needed to distinguish the specific treatment effect from the change in concentration. The experiment should be repeated or interpreted within its limitation. An apparently helpful result is not conclusive when the comparison needed to explain it is missing.

Case 39 — "Cold" interpreted as harmless

A patient has haemolysis and a suspected biphasic haemolysin. A student dismisses the investigation because the antibody binds under cold conditions.

Reasoned answer. Cold binding can be part of a clinically important mechanism, including complement-mediated injury after warming. The clinical syndrome and specialised testing must be considered. Temperature terminology describes reaction behaviour; it does not assign a universal severity category.

14 | Less Common Systems and Rare Antigen Problems

A transfusion laboratory must know more than the systems most often encountered in routine panels. Antibodies to less common or high-frequency antigens can create major compatibility challenges. The aim of foundational learning is not to memorise every allele in an expanding database, but to recognise the mechanism, interpret the available evidence and involve the appropriate reference service before unsafe assumptions are made. [FB02, FB03]

14.1 Lutheran and related interpretation issues

Lutheran antigens are carried on the basal cell adhesion molecule encoded by BCAM. Lua is relatively uncommon in many donor populations, whereas Lub is common. An antibody to a low-frequency antigen may be missed by routine screening cells and appear in a crossmatch with one donor unit. An antibody to a high-frequency antigen can react with most routine panel cells.

Clinical significance varies with specificity and context. The laboratory should use current guidance rather than infer risk solely from the system name. A weak or unusual pattern may require reference investigation, particularly when other clinically significant antibodies have not been excluded.

Suppressed expression through regulatory mechanisms can complicate phenotype interpretation. A serological result showing weak Lutheran expression is not automatically a simple structural null allele. Molecular and family investigations may be needed in selected cases, but they should be driven by the clinical compatibility question.

14.2 Diego, Colton and membrane transport proteins

Diego antigens are associated with the anion exchanger band 3, encoded by SLC4A1. Colton antigens are associated with aquaporin-1, encoded by AQP1. These examples connect blood-group antigens with important membrane transport functions. A blood-group antibody can therefore recognise a protein that also has a physiological role beyond transfusion compatibility.

Antibodies to selected antigens in these systems can cause haemolytic transfusion reactions or HDFN. Their frequency in routine practice depends partly on the donor and patient population. A low-frequency antigen in one population may be more relevant in another, so reagent selection and donor-search planning should not rely on a single universal frequency table.

A negative routine screen cannot exclude an antibody to an antigen absent from the screening cells. When one crossmatch is incompatible despite a negative screen, donor-specific low-frequency antigens are among the possibilities. Technical error, donor-cell coating and other explanations must also be considered.

14.3 Dombrock and difficult serological patterns

Dombrock antigens are carried on a glycosylphosphatidylinositol-linked protein. Antibodies can be weak, variable and difficult to identify, sometimes occurring with other specificities. They can be clinically significant despite a less dramatic in-vitro pattern.

Molecular typing can be particularly useful where reliable serological reagents are limited. However, the prediction must match the tested variants and be interpreted by an appropriate laboratory. The absence of an easy routine reagent does not justify assuming that a relevant antigen is absent.

Historical records are important because difficult antibodies can become undetectable or be described incompletely. A reference report should preserve the evidence, specificity and recommended component strategy in a form accessible during future transfusions.

14.4 High-frequency and low-frequency antigens

An antibody to a high-frequency antigen often reacts with most routine panel cells. The autocontrol may be negative if the patient lacks the target, but this pattern is not unique to that explanation. Multiple alloantibodies, autoantibodies, drug effects and technical interference can produce broad reactivity. The investigator should work through the differential rather than name a rare specificity from panreactivity alone.

An antibody to a low-frequency antigen may produce a negative screen and an incompatible crossmatch with a particular donor. Additional donor typing and selected rare reagent cells can help. The rarity of the target does not necessarily mean that the antibody is clinically insignificant.

Rare-donor searches should be coordinated. Repeatedly testing random stock without a defined antigen requirement can waste time and material. The laboratory should provide the reference service with the patient's history, phenotype or genotype, raw reactions, methods and clinical urgency.

14.5 Nomenclature is part of safety

Similar names, superscripts and historical abbreviations can be confused. The report should use standard antigen and antibody notation consistently, with plain-language clarification where needed. An information system must preserve the distinction between, for example, anti-K and anti-k or anti-Jka and anti-Jk3. A typographical difference can represent a very different component requirement.

The current ISBT database is the authority for evolving system and allele nomenclature. A dated print textbook should teach how to use that authority rather than pretend that its table will remain complete indefinitely. The scientific principles endure; the catalogue continues to develop.

High-frequency does not mean universal

An antigen described as high-frequency occurs in a large proportion of a defined population, but rare negative phenotypes exist. An antibody against that antigen can react with nearly every routine panel cell. The broad pattern may resemble an autoantibody, yet the mechanism is alloimmunity against a target absent from the patient's own cells.

The autocontrol, DAT, phenotype, genotype, reaction phase and response to selected treatments can help distinguish possibilities, but none is universally decisive in isolation. Recent transfusion and mixed cell populations can complicate the patient's apparent phenotype. Reference cells and specialised methods may be necessary. [FB02, FB03]

A rare-donor search should begin with a sufficiently secure requirement. An unconfirmed broad antibody label can trigger an unnecessary and difficult search, while an underestimated clinically significant specificity can expose the patient to harm. The reference investigation and clinical urgency should therefore proceed in coordinated communication rather than in separate queues.




Figure FB14. A broad reaction pattern can reflect autoantibody, high-frequency-antigen alloantibody, treatment interference or mixtures. The autocontrol, DAT, history and selected methods help separate them. Original CDIL educational schematic; not patient data.

Worked cases 40–42

Case 40 — Negative screen, one incompatible donor

The antibody screen is negative, but one donor unit is incompatible and several others are compatible. The learner concludes that the crossmatch must be wrong.

Reasoned answer. An antibody to a low-frequency antigen carried by that donor but absent from the screening cells is one possibility. Technical and donor-related causes also require review. The crossmatch provides information not necessarily represented by the screening panel. The investigation should examine the specific donor and reaction pattern rather than discard the result.

Case 41 — Panreactivity is not a specificity

All routine panel cells react, and the autocontrol is negative. A trainee reports anti-k without testing rare cells or establishing the patient's phenotype.

Reasoned answer. The pattern supports consideration of an antibody to a high-frequency antigen, but it does not identify which one. Multiple antibodies and other causes remain possible. Extended phenotype or genotype, selected cells and reference investigation are needed. A rare specificity must be demonstrated, not guessed from a broad pattern.

Case 42 — A capital letter changes the requirement

A historical report says anti-k, but a new request is entered as anti-K. The laboratory searches routine K-negative stock.

Reasoned answer. Anti-k and anti-K target different antigens with very different donor availability. The transcription error changes the compatibility requirement. The original report must be reconciled, and the correct specificity retained in the information system. Standard notation and verification of imported history are direct patient-safety measures.

15 | Antigen Frequency, Dosage and the Mathematics of Finding Units

Antigen-frequency calculations help estimate the scale of a donor search. They do not replace actual unit testing or reliable donor records. A useful calculation states the population, the antigen-negative fraction, the number of required units and the assumptions about independence. Without those conditions, a precise-looking answer can be misleading. [FB02, FB03]

15.1 Expected yield from a single requirement

If the fraction of donors lacking antigen X is p, the expected number of X-negative units among n independently selected units is n multiplied by p. For a fictional p of 0.25, screening 20 units gives an expected yield of five. The actual yield can be smaller or larger because of sampling variation.

The reciprocal calculation, required units divided by the negative fraction, gives a rough planning estimate. To obtain four units when p is 0.25, the simple estimate is 16 screened units. This is an expectation, not a confidence guarantee. A laboratory planning a time-critical procedure may need a more conservative search strategy and early supplier involvement.

The probability of finding no suitable unit in n independent selections is (1-p) raised to n. With p equal to 0.25 and n equal to 10, that probability is approximately 5.6%. This calculation helps explain why a small search can fail even when the phenotype is not exceptionally rare.

15.2 Multiple antigen requirements

If two antigen-negative characteristics are independent, their joint probability is the product of the separate probabilities. For fictional negative fractions of 0.30 and 0.40, the joint fraction would be 0.12. Ten required double-negative units would then suggest an expectation of about 83.3 units screened, rounded upward for a practical whole-unit estimate.

Independence is often a strong assumption. Antigens within the same system or linked loci may be inherited together, and population structure can create additional associations. Multiplying unrelated published percentages from different populations can produce an unreliable estimate. Local donor data or a supplier's characterised inventory are preferable where available.

A molecularly typed donor registry changes the problem. Rather than screening random units, the service may search existing records for the required phenotype. The estimate then concerns inventory availability, donation timing, component suitability and transport, not only biological frequency.

15.3 Dosage and the information content of a panel

Dosage affects antibody exclusion, not merely reaction strength. A nonreactive cell is informative only if it expresses the antigen adequately for the antibody and method being considered. A panel containing many cells can still provide weak exclusion evidence if the relevant antigen appears only in heterozygous expression or in technically compromised tests.

The number of independent informative cells matters more than the total number of tubes. Repeating the same donor cell several times improves confidence in reproducibility but does not create several genetically independent antigen profiles. The investigator should distinguish analytical repeats from independent biological evidence.

A commonly taught "rule of three" uses reactive antigen-positive and nonreactive antigen-negative cells to support a specificity under selected assumptions. It is not a universal statistical certificate, and it does not replace exclusion of additional antibodies, attention to

dosage or the validated laboratory policy. The pattern must make biological sense and fit the patient's antigen status.

15.4 Probability of a pattern is not clinical significance

A statistically suggestive association between reactivity and an antigen supports identification, but it does not by itself establish the antibody's clinical effect. Specificity, class, thermal behaviour, history and the clinical setting remain relevant. Conversely, a clinically important historical antibody does not become irrelevant because a current small panel lacks a statistically elegant pattern.

The laboratory should avoid presenting a probability calculated from a simplified teaching panel as a precise probability that the patient's antibody has a particular name. Real investigations can involve correlated antigens, mixed antibodies and imperfect tests. The calculation is one part of the evidence, not the entire interpretation.

15.5 Planning under urgency

A component-search plan should include the required phenotype, number of units, acceptable alternatives under authorisation, expected availability and escalation time. If rare units may be needed, contacting the supplier early is more useful than completing a large random search before communicating the problem.

The clinical team needs an honest estimate, not a guarantee. "The estimated yield is low; reference and rare-donor support have been requested" provides actionable information. The laboratory should update the estimate as actual inventory evidence replaces population assumptions.

Expected yield and probability of success are not the same

If 20% of available donors are suitable, screening ten randomly selected independent donors gives an expected yield of two. It does not guarantee two suitable units. The probability of no suitable donor in that model is 0.8 raised to the tenth power, approximately 10.7%. The probability of at least one is therefore about 89.3%. These calculations answer a planning question, not an individual compatibility decision.

The independence assumption can fail. Blood-group traits may be genetically linked, and the available donor population may not resemble the population from which a published frequency was estimated. Multiplying marginal negative frequencies can therefore give a misleading estimate for a multi-antigen requirement. [FB03, FB04]

Inventory planning should combine appropriate population data with actual typed stock, supplier capability, transport time and the patient's urgency. A statistical estimate helps explain why a search may be difficult; it does not authorise release of an untested unit or replace confirmation of the required antigen status.




Figure FB15. Synthetic independent-selection model with suitability probability 0.20. The chance of finding at least one suitable donor is 1 − 0.8^n. Real donor traits may be linked and population frequencies may differ. Original CDIL educational schematic; not patient data.

Worked cases 43–45

Case 43 — Expected four does not mean guaranteed four

A fictional antigen-negative frequency is 25%, and four units are needed. The learner promises that screening exactly 16 units will provide all four.

Reasoned answer. Sixteen gives an expected yield of four, not a guarantee. Sampling variation can produce fewer suitable units. Planning should account for urgency, available characterised inventory and supplier support. The estimate is useful only when its probabilistic nature is communicated.

Case 44 — Multiplying linked frequencies

Two antigen-negative frequencies from the same blood-group system are multiplied as if they were independent. The resulting estimate conflicts with the donor registry.

Reasoned answer. Linked inheritance can invalidate the independence assumption. The joint phenotype frequency or actual registry data should be used where available. Multiplication is not wrong as arithmetic; it is wrong when the biological assumptions are unsupported. The calculation must follow the genetics, not the other way around.

Case 45 — Three repeats of one cell

A single antigen-positive cell is tested three times and reacts consistently. A trainee counts this as three independent antigen-positive cells for identification support.

Reasoned answer. The repeats demonstrate reproducibility with one cell source. They do not provide three independent antigen profiles or exclude correlated antigens. Appropriate additional cells and the complete identification process are needed. Analytical replication and independent biological evidence answer different questions.

16 | Reagents, Controls and the Meaning of a Valid Reaction

A reagent is part of the measurement system, not merely a bottle that happens to be available. Its identity, specificity, potency, storage, expiry and validated use determine what a reaction can mean. Reagent cells also carry biological information: their antigen profile, preservation and condition affect antibody detection. A correct interpretation requires both the patient result and evidence that the system was capable of producing a reliable result. [FB02, FB05, FB15]

16.1 Antisera and reagent-cell identity

An antigen-typing reagent must be used for its intended target and method. Monoclonal reagents can differ in the epitopes they recognise, which is particularly relevant in variant expression. A reaction with one reagent may not resolve every qualitative antigen difference. The laboratory should know the reagent's claimed use and limitations rather than treating all bottles with the same antigen name as interchangeable.

Screening and identification cells have defined antigen profiles. The profile sheet belongs to the specific lot, not to the product name in general. Using an old lot's antigen map with new cells can produce a convincing but false antibody identification. Lot identity must remain linked to the raw reaction record and interpretation.

Reagent cells are also specimens that deteriorate. Haemolysis, contamination, inappropriate storage or age-related changes can affect performance. Visual inspection and the manufacturer's acceptance requirements complement routine quality control. A passed control does not authorise use of visibly compromised material outside the validated conditions.

16.2 Positive and negative controls answer different questions

A positive control demonstrates that the system can detect the intended reaction under the selected conditions. A negative control helps identify nonspecific reactivity or contamination. The controls should challenge the relevant part of the method. An extremely strong positive may remain reactive even when sensitivity has deteriorated enough to miss weak patient antibodies.

Antigen-typing controls should be selected according to the reagent and procedure. When weak expression is clinically important, the quality system should consider whether the control material adequately tests that requirement. Control design is a scientific decision linked to the method's intended use, not a ritual in which any known positive is sufficient.

A failed control invalidates the affected testing until the problem is resolved. The laboratory should determine the scope: one specimen, one reagent, one run or a broader period since the last acceptable check. Results already issued may require review if the failure could have affected them. The response should be proportionate to evidence, documented and communicated through the quality system.

16.3 Lot changes and comparability

A new reagent lot can differ in cell antigen expression, reagent potency or other properties. Lot acceptance should establish that performance remains suitable for the intended use. Comparing only obvious strong positives and negatives may miss a clinically important shift near the detection boundary.

A fictional lot comparison illustrates the point. Ten strong positive specimens and ten negatives agree between lots, but two weak clinically relevant specimens become nonreactive with the new lot. Overall agreement may still look high, yet the discordance occurs exactly where sensitivity matters. The laboratory should investigate those specimens rather than accept the lot based only on the percentage agreement.

The comparison record should identify specimens, methods, expected outcomes, acceptance criteria and discrepancies. Criteria should be defined before the results are examined. Retrospectively changing the rule to make a problematic lot pass undermines the purpose of validation.

16.4 Equipment and environmental control

Centrifugation, incubation temperature, timing and dispensing can influence reactions. Equipment settings should be verified for the actual method and device. A time or speed copied from another centrifuge may not produce the same physical conditions. Maintenance and calibration records support reliability but do not replace observation of unusual performance during a run.

Temperature excursions require an assessment of duration, magnitude, affected material and manufacturer guidance. Simply returning a reagent to the refrigerator does not prove that performance has been restored. The laboratory should quarantine or evaluate affected material under its procedure and document the decision.

Automation adds traceable dispensing and image capture but also creates software, barcode and interface risks. A reagent loaded under the wrong identity can cause systematic error across many specimens. Positive identification and controlled configuration are therefore part of analytical quality.

16.5 Document the invalid result, not just the successful repeat

When an investigation reveals an omitted reagent or failed control, the original invalid result should remain traceable. The final accepted result should be linked to the corrective action. Deleting the failure from the record prevents learning and can conceal the scope of affected testing.

A reliable quality culture distinguishes human error from blame while preserving accountability. Staff should be able to report a near miss promptly. The laboratory then examines contributing conditions such as workload, look-alike labels, interruptions and unclear procedures.

The goal is to make the next correct action easier and the next error more detectable.

A control is informative only for the failure it can detect

A reagent control may identify nonspecific agglutination, a positive control may demonstrate reagent activity, and a negative control may reveal unwanted background. These controls answer different questions. A single control labelled "pass" does not establish that every stage of the method worked or that the specimen belongs to the correct patient.

Control material should be suitable for the method and sufficiently challenging for the intended purpose. Strongly reactive cells may remain positive despite reduced sensitivity that would affect a weak antibody. Conversely, an unstable weak control can generate false alarms if its expected behaviour has not been established. [FB02, FB05, FB15]

When a control fails, the associated patient results should be handled according to the validated procedure. Selectively accepting reassuring-looking patient results while rejecting only difficult ones creates bias. The investigation should determine which runs, reagents and specimens may be affected and document the basis for repeating or releasing results.




Figure FB16. Positive, negative, reagent and process controls answer different questions. A pass in one category cannot establish the identity or validity of every patient result. Original CDIL educational schematic; not patient data.

Worked cases 46–48

Case 46 — The wrong antigen map

New panel cells are tested, but the worksheet contains the previous lot's antigen profile. The reactions appear to identify anti-E.

Reasoned answer. The interpretation is invalid because the biological identities assigned to the cells are wrong. The correct lot profile must be obtained, and the investigation reassessed from the raw results. Agreement with a familiar pattern does not rescue a mismatched reagent map. Any issued result based on the wrong map requires controlled review.

Case 47 — A strong control hides reduced sensitivity

A deteriorating method still detects a 4+ control but misses a weak antibody specimen used in lot comparison. The learner accepts the method because the routine control passed.

Reasoned answer. The strong control may not challenge the clinically important detection boundary. The weak-specimen failure

requires investigation against predefined acceptance criteria. Quality control should be appropriate to the intended sensitivity, not merely capable of showing that some reaction is possible.

Case 48 — Reagent returned after a temperature excursion

A reagent is found outside its validated storage range and is put back into the refrigerator. Testing resumes without assessment.

Reasoned answer. Restoring storage temperature does not demonstrate preserved performance. The excursion's duration and magnitude, manufacturer guidance and laboratory procedure must be reviewed. Affected testing may need to be held or evaluated. The disposition should be documented rather than assumed from the reagent's current temperature.

17 | DAT, IAT and Elution: Three Related but Different Questions

The direct antiglobulin test, indirect antiglobulin test and eluate investigation are often discussed together, but they examine different locations of antibody activity. The DAT examines coating on the patient's cells. The IAT examines sensitisation produced when plasma or serum is incubated with selected cells. Elution investigates antibody recovered from coated cells. Their combined pattern can be more informative than any one result. [FB02, FB05]

17.1 What a DAT establishes

A positive DAT indicates that the method detected immunoglobulin, complement or another target specified by the reagent on the tested red cells. A polyspecific result may be followed by monospecific testing to characterise the coating. The result should identify the reagents and reaction pattern rather than simply say "immune positive."

The DAT is not a direct measurement of red-cell survival. Some patients with a positive result have no clinically important haemolysis, while selected immune haemolytic processes can produce a negative routine DAT. The clinical interpretation considers haemoglobin trend, reticulocytes, bilirubin, lactate dehydrogenase, haptoglobin and other relevant findings, with attention to their own limitations.

Recent transfusion can create a mixed population in which only donor cells are sensitised. The DAT may therefore be weak or mixed-field even when a clinically significant alloantibody is involved. The proportion of affected cells and the method's sensitivity influence detection. A weak DAT should not automatically be dismissed as unimportant.

17.2 Plasma and cell-bound antibody can differ

An antibody can be concentrated on circulating cells and be weak or undetectable in plasma. Conversely, plasma can contain an antibody that is not currently coating the patient's cells because the patient lacks the target antigen. The relationship between DAT and IAT is therefore mechanistic, not a requirement that both must always be positive together.

An alloantibody in a patient who has recently received antigen-positive donor cells can appear in plasma and in an eluate from the mixed red-cell population. A warm autoantibody can produce broad plasma and eluate reactivity, but the pattern must be interpreted with controls and history. Drug-associated or passive-antibody effects can produce other combinations.

The autocontrol compares the patient's plasma with the patient's cells under the selected in-vitro conditions. It is not identical to the DAT. A positive autocontrol can arise for several reasons, including autoantibody and recent transfusion with sensitised or antigen-positive donor cells. The investigator should not use it as a one-step definition of autoimmunity.

17.3 Elution and its controls

Elution removes antibody from cells through a defined chemical or physical method. The eluate is then tested against appropriate reagent cells. The method can damage cells and alter antibody recovery, so its suitability depends on the question and laboratory validation.

Washing before elution is important because residual plasma antibody can contaminate the recovered material. Testing a final wash or another appropriate control helps determine whether the eluate's reactivity can be attributed to cell-bound antibody rather than carried-over plasma. A reactive wash control can make the eluate interpretation unreliable.

A negative eluate does not prove that the DAT was false. The coating may involve complement without recoverable IgG, the antibody may not be recovered efficiently by the method, or the target may not be

represented on the test cells. The result should be interpreted within the method's scope.

17.4 A pattern matrix

DAT	Plasma IAT	Eluate	Main question raised
Positive	Broadly reactive	Broadly reactive	Autoantibody or another broad-reactivity mechanism; exclude underlying alloantibodies
Positive after transfusion	Specific reactivity	Matching specificity	Possible sensitisation of transfused antigen-positive cells; investigate haemolysis and history
Positive	Nonreactive	Nonreactive	Coating type, drug/passive effects, recovery limits and clinical context
Negative	Specific reactivity	Not indicated solely by this pattern	Alloantibody in plasma may be present without coating the patient's own antigen-negative cells

This matrix is an original teaching aid, not a diagnostic algorithm. Each row contains several possible explanations. The actual investigation requires the patient's history, specimen quality, reagent details and clinical evidence. The purpose is to prevent the learner from treating any single combination as a unique diagnosis.

17.5 Reporting and escalation

A useful report states the DAT specificity, plasma findings, eluate findings and limitations separately before integrating them. If a transfusion reaction is suspected, the laboratory follows the urgent reaction-investigation pathway and communicates relevant findings promptly. A complete antibody name should not be awaited before reporting a valid result that may affect immediate care.

The laboratory should also preserve the pretransfusion specimen and unit information where available. Comparing pre- and post-transfusion results can help distinguish a pre-existing finding from a new event. The conclusion should remain open to nonimmune causes of haemolysis and to multiple simultaneous mechanisms.

The three compartments of antiglobulin evidence

The DAT examines material already attached to the patient's red cells. The IAT examines what the patient's plasma can attach to reagent or donor cells under laboratory conditions. An eluate examines antibody recovered from sensitised cells by a specified elution method. The three tests sample different compartments of the case.

A DAT-positive, plasma-screen-negative pattern is therefore possible. Antibody may be predominantly cell-bound, the plasma concentration may be below detection, or the bound material may have a different specificity or mechanism. Conversely, a plasma alloantibody can be present while the DAT is negative if the patient's circulating cells do not carry the relevant target. [FB02, FB16]

An eluate's interpretation depends on controls, the elution method and the available antigen-bearing test cells. A panreactive eluate can support a warm autoantibody pattern in the right context, while a specific eluate after transfusion can contribute to an alloimmune investigation. Neither result independently proves the severity or cause of haemolysis.




Figure FB17. The DAT examines coating already on patient cells; the IAT tests plasma reactivity in vitro; an eluate examines antibody recovered from coated cells. A positive DAT alone does not prove haemolysis. Original CDIL educational schematic; not patient data.

Worked cases 49–51

Case 49 — Positive DAT, negative plasma screen

A patient has a positive DAT but a nonreactive plasma antibody screen. The trainee says the DAT must be wrong because no antibody is free in plasma.

Reasoned answer. Cell-bound and circulating antibody are different compartments. Antibody may be concentrated on cells, complement may be the detected coating, or another mechanism may be present. The DAT reagent pattern, clinical context and appropriate further investigation are needed. The two results are not inherently contradictory.

Case 50 — A reactive final wash

An eluate reacts with panel cells, but the final wash control is also reactive. The investigator reports a definitive cell-bound specificity.

Reasoned answer. Residual plasma antibody may have contaminated the eluate. The control undermines the claim that the recovered reactivity came specifically from the cells. The investigation must be repeated or reported with the appropriate limitation under the validated method. A positive eluate is not interpretable independently of its preparation controls.

Case 51 — Weak DAT after transfusion

A recently transfused patient has a weak DAT and a new specific alloantibody. Only a minority of circulating cells are expected to be donor-derived.

Reasoned answer. A small sensitised donor-cell population can produce a weak overall DAT. The result may still be clinically important and should be integrated with haemolysis markers, unit antigen status and the pretransfusion record. Reaction strength does not directly measure the severity or total clinical significance of the event.

18 | From Antibody Screening to Identification

An antibody screen is designed to detect clinically relevant red-cell antibodies using a small set of characterised reagent cells. An identification panel provides a larger and more informative set of antigen combinations. The transition from screen to identification is not merely "more of the same test." It is a structured process of generating, testing and excluding specificity hypotheses. [FB01, FB02]

18.1 What the screening cells represent

Screening cells are selected to express important antigens, often with homozygous expression where dosage matters. Their coverage is broad but not unlimited. Antibodies to low-frequency antigens absent from the cells can be missed, and weak antibodies may fall below detection. The current lot's profile should be available to the investigator.

A reactive screen can arise from an alloantibody, autoantibody, therapeutic antibody, passive antibody or technical interference. The reaction phase and pattern across cells provide clues. Haemolysis and atypical appearances should be recorded when relevant. The screen does not name the antibody by itself.

A nonreactive screen is interpreted with the patient's history and the method's limitations. It does not remove a previous clinically significant antibody from the record. It also does not eliminate the possibility of a donor-specific incompatibility to an antigen not represented on the screening cells.

18.2 Organise the investigation before adding tests

Review identity, collection timing, transfusion and pregnancy history, medication, previous antibodies and current urgency. Then examine the raw reactions, controls and reagent lot. This order prevents an elaborate panel investigation from being built on a specimen or reagent error.

The investigator should identify the main pattern: selected cells reactive, all cells reactive, mixed strengths, phase-dependent reactivity or an inconsistent pattern. Each suggests a different starting set of hypotheses. The next test should distinguish between those hypotheses rather than simply increase the number of results.

Patient antigen typing can support an alloantibody hypothesis because a person usually forms an alloantibody to an antigen they lack. Recent transfusion, DAT positivity and variant expression can make serological phenotyping difficult. Genotyping or reference methods may be needed. A positive patient antigen result should not be ignored merely because the panel seems to fit a familiar antibody.

18.3 Exclusion and confirmation are complementary

Nonreactive cells help exclude antibodies to antigens they express adequately under the method. Reactive cells help establish an association with a candidate antigen. Both types of evidence are required. A pattern that fits anti-E may also fit another antigen carried on the same cells, so selected cells are needed to separate correlated possibilities.

Dosage must be considered in exclusion. A heterozygous cell may be insufficiently sensitive for a weak antibody to selected antithetical systems. The laboratory's validated rule determines how many and which cells are required. Textbook examples simplify the antigen map to teach logic; a real identification must cover the full relevant antigen set.

Confirmation also includes compatibility with the patient's phenotype or genotype and relevant treatment effects. If the patient appears to express the antigen, consider recent transfusion, variant expression, autoantibody or an incorrect specificity assignment. The investigator

should resolve the conflict rather than selecting only the evidence that supports the initial guess.

18.4 A small teaching pattern

Cell	E	K	Jka	Fya	IAT reaction
A	+	-	+	-	2+
B	-	+	+	+	0
C	+	+	-	+	2+
D	-	-	-	-	0
E	+	-	-	+	2+
F	-	+	+	-	0

Within this deliberately limited model, reactivity follows E, not K, Jka or Fya. That makes anti-E the leading hypothesis for the displayed antigens. The model does not show every blood-group antigen or the full dosage information, so it is not a complete clinical identification. The next steps include appropriate confirmation, patient antigen assessment and exclusion of additional antibodies using the complete validated panel.

The value of the table is the comparison. Cell B is K-positive but nonreactive, weakening a K-only explanation in the model. Cell E is E-positive but Jka-negative and reactive, weakening a Jka-only explanation. The investigator should explain these contrasts rather than simply circle the E column.

18.5 The final result is an integrated conclusion

A completed investigation records the specificity established, additional antibodies adequately excluded, unresolved reactivity, patient antigen information and component requirement. If the evidence remains incomplete, the report should say so and identify the next step or reference referral. A precise unresolved statement is safer than an unsupported complete identification.

A screening set is a sample of antigen expression

Screening cells are selected to present clinically important antigens, but the set is finite. Antigen combinations, dosage and rare targets may not be represented equally. A negative screen means that the method did not detect relevant reactivity against those cells under the test conditions; it is not a census of every possible antibody.

Identification panels expand the available antigen contrasts. The key is not simply a larger number of cells, but informative differences between cells. A cell positive for both E and Jka cannot by itself distinguish anti-E from anti-Jka. Cells that separate those targets can provide much stronger evidence. [FB01, FB02]

A panel worksheet should preserve reaction phase and grade because these may reveal more than one antibody population. However, grade differences alone do not establish multiple specificities: antigen density, affinity, concentration and technical variation can also change intensity. The interpretation must connect the pattern with controlled comparisons.

Selected cells can isolate an anti-E hypothesis

Cell	E	Jka	K	IAT
1	+	+	−	2+
2	−	+	+	0
3	+	−	+	2+
4	−	−	−	0

Invented reaction data • limited teaching panel, not a clinical identification

Figure FB18. Synthetic limited teaching panel. E-positive cells react and selected E-negative cells do not. A clinical identification still requires adequate exclusion, confirmation and patient-specific evidence. Original CDIL educational schematic; not patient data.

Worked cases 52–54

Case 52 — A screen name used as a diagnosis

One screening cell reacts, and the learner reports anti-D because the cell is D-positive.

Reasoned answer. The cell carries many antigens, and its D positivity does not uniquely explain the reaction. A panel and selected cells are needed to distinguish candidate specificities, with history and patient typing. A screening reaction is the beginning of an investigation, not a one-cell antibody identification.

Case 53 — Correlated antigens

Every E-positive cell in a small panel is also K-positive, and every reactive cell has both antigens. The learner chooses anti-E without additional cells.

Reasoned answer. The displayed data cannot separate E from K as the explanation. Selected cells with E-positive/K-negative and

E-negative/K-positive profiles are needed, together with the complete investigation. Correlation in a small panel is not proof of specificity. The next experiment should break the correlation.

Case 54 — Patient antigen result conflicts with the hypothesis

A panel suggests anti-Fya, but the patient's current red cells type Fya-positive. The patient was recently transfused.

Reasoned answer. Donor cells may influence the current phenotype, but other explanations also require consideration. Historical typing, transfusion timing and appropriate genotyping or reference work can help establish the patient's underlying profile. The apparent conflict should be resolved explicitly rather than ignored or used to reject the hypothesis prematurely.

19 | Panel Interpretation: Evidence, Dosage and Exclusion

A panel worksheet is a map of controlled comparisons. Each reagent cell has a known antigen profile, and each reaction records what the patient's specimen did under defined conditions. The scientist's task is to identify a pattern that explains the reactions while testing alternatives. The process is closer to experimental reasoning than to solving a word-search puzzle. [FB02, FB05]

19.1 Read the whole pattern first

Before crossing out antigen columns, examine reaction strength, phase, haemolysis, autocontrol and control validity. A mixture of strong and weak reactions can reflect dosage, multiple antibodies or method effects. Uniform broad reactivity suggests a different investigation from three selected positive cells. The pattern should guide the strategy.

An inconsistent result should be checked for technical causes such as cell identity, dispensing, contamination or recording errors. Biological explanations remain possible, but they should not be used to excuse a failed control. The raw data must be reliable before detailed interpretation has meaning.

Temperature and method can separate components of a mixture. A cold-reactive antibody may dominate one phase, while an IgG alloantibody becomes evident at the antiglobulin phase. Modified methods can help, but they must preserve the ability to detect clinically significant antibodies relevant to the patient.

19.2 Use nonreactive cells carefully

A nonreactive cell can exclude an antibody only if the relevant antigen is present in an informative form and the test is sensitive enough. For selected systems, homozygous expression is required by the laboratory's exclusion policy. The investigator should mark which cells provide valid exclusion evidence rather than counting every plus sign equally.

The table below is a closed teaching model for Kidd dosage. Other antigen differences are intentionally omitted, so the model cannot serve as a complete patient investigation.

Cell	Jka	Jkb	Expression relevant to Jka	IAT reaction
1	+	-	Homozygous-pattern expression	2+
2	+	+	Heterozygous-pattern expression	0
3	-	+	Jka absent	0
4	+	-	Homozygous-pattern expression	2+
5	+	+	Heterozygous-pattern expression	Weak
6	-	+	Jka absent	0

The pattern is compatible with a weak anti-Jka showing dosage. Cell 2 must not be used as decisive evidence against anti-Jka simply because it is Jka-positive. Cells 1 and 4 are more informative for that question. The complete clinical investigation would still require appropriate confirmation and exclusion of other antibodies.

19.3 Separate a hypothesis from a confirmed specificity

A leading hypothesis should explain both positive and negative cells. If an antigen-positive cell is unexpectedly negative, ask whether dosage, antigen strength, method sensitivity or another factor explains it. If an antigen-negative cell is positive, ask whether a second antibody, technical problem or incorrect antigen profile is present. Do not delete the inconvenient cell from the worksheet without a documented reason.

Selected cells are powerful because they are chosen to distinguish competing explanations. If anti-E and anti-Jka are both possible, an E-positive/Jka-negative cell and an E-negative/Jka-positive cell provide more information than another cell positive for both. Experimental value depends on the contrast, not merely on increasing the panel size.

A patient phenotype or genotype consistent with lacking the candidate antigen supports an alloantibody interpretation. It does not prove the specificity alone. Many absent antigens are possible targets, and the antibody evidence must still identify which one is involved.

19.4 The limits of simplified statistical rules

A pattern supported by several antigen-positive reactive and antigen-negative nonreactive cells is more persuasive than a one-cell association. However, the cells may carry correlated antigens, and the results may not be independent in the statistical sense assumed by a classroom calculation. Multiple antibodies can also distort the association.

The laboratory's validated identification criteria should therefore govern the conclusion. A "rule of three" is a useful educational shorthand in some settings, not a universal substitute for expert interpretation, dosage assessment and exclusion of additional clinically significant antibodies. The report should not claim a precise probability of correctness from a simplified panel unless the statistical assumptions and method truly support it.

19.5 Record why alternatives were excluded

An exclusion worksheet is most useful when another qualified scientist can follow the logic. It should show the cells used, antigen expression, relevant phase and limitations. A column crossed out without an informative cell is not evidence. Review should identify unsupported exclusions before a component is selected.

If the investigation remains incomplete, the laboratory should communicate the uncertainty and obtain reference support where needed. The goal is not to produce a named antibody on every worksheet; it is to support the safest valid compatibility decision.

Exclusion is conditional on the test opportunity

To exclude an antibody using a nonreactive cell, the relevant antigen must be present in an expression pattern and test phase capable of revealing that antibody. A nonreactive antigen-negative cell provides no exclusion evidence for that specificity. A heterozygous cell may provide weaker exclusion evidence for a dosage-sensitive antibody than an appropriately selected homozygous cell.

The phrase "ruled out" should therefore be supported by the worksheet, not used as a ritual. The laboratory's validated criteria specify the required observations and any exceptions. Additional cells may be necessary when a panel lacks adequate expression or when mixtures obscure interpretation. [FB02]

Statistical association can support an identification, but it is not a substitute for biological plausibility and adequate exclusion of additional antibodies. Patient phenotype or genotype, verified history and confirmatory testing help complete the argument. A beautiful pattern can still be misleading if the specimen, treatment history or reagent conditions were misunderstood.

Dosage can alter the opportunity for detection

Cell	Jka	Jkb	IAT
1	+	−	2+
2	+	+	weak
3	−	+	0
4	+	−	2+

Invented reaction data • limited teaching panel, not a clinical identification

Figure FB19. Synthetic Kidd example. Stronger reactions on Jk(a+b−) cells support a dosage effect; a nonreactive heterozygous cell does not provide the same exclusion opportunity. Original CDIL educational schematic; not patient data.

Worked cases 55–57

Case 55 — An inconvenient negative cell

A panel mostly fits anti-Jka, but one Jk(a+b+) cell is negative. The learner discards the cell as a laboratory error without checking dosage or quality.

Reasoned answer. Dosage can explain weaker reactivity with heterozygous cells. Technical error is possible but must be demonstrated, not assumed because the result is inconvenient. The investigator should use suitable homozygous cells, review controls and preserve the original observation. A good hypothesis explains exceptions or identifies the additional evidence needed.

Case 56 — The most informative next cell

The remaining hypotheses are anti-E alone or anti-E plus anti-Jka. An E-positive/Jka-positive cell is proposed as the next test.

Reasoned answer. That cell is likely to react under both hypotheses and therefore provides limited discrimination. An

E-negative/Jka-positive cell, with appropriate dosage and other antigen information, is more useful for detecting a separate Kidd component. The next test should be selected for its ability to distinguish explanations.

Case 57 — A crossed-out column without evidence

A review finds that anti-S was excluded even though no suitable nonreactive S-positive cell was tested.

Reasoned answer. The exclusion is unsupported. Appropriate cells and the validated method are needed, or the unresolved possibility must remain documented. An incomplete worksheet should not be made to look complete by a crossed-out antigen name. Component selection depends on the actual evidence, not the visual appearance of a finished form.

20 | Multiple Alloantibodies: Separating Overlapping Patterns

Multiple antibodies can produce a pattern that no single antigen explains. Some cells react because of one antibody, others because of another, and cells carrying both targets may show stronger or otherwise altered reactions. The investigator must separate the components without assuming that reaction strengths add in a simple arithmetic way. [FB02]

20.1 Recognise the possibility of a mixture

A single-specificity hypothesis may explain most but not all reactions. Antigen-negative reactive cells are especially important clues. Before proposing a mixture, verify cell identity, controls and technical consistency. Once the data are reliable, selected cells can test whether a second specificity accounts for the residual pattern.

The autocontrol and DAT contribute context but do not automatically divide the problem into "allo" or "auto." A recently transfused patient can have complex cell populations, and autoantibodies can coexist with alloantibodies. The investigation should remain open to more than one mechanism.

Patient phenotype or genotype helps constrain plausible alloantibodies. Recent transfusion can make serological typing unreliable, and IgG coating can interfere with some typing methods. Molecular or reference support may be needed before using the patient's antigen profile as decisive evidence.

20.2 A two-antibody teaching panel

The following original synthetic panel illustrates anti-E plus anti-Jka within a deliberately restricted antigen set. Jka-positive cells are assumed to have informative expression for this model unless otherwise stated. The grades are chosen for teaching and do not imply that two antibodies always produce the sum of their separate strengths.

Cell	E	Jka	K	Fya	S	IAT
1	+	-	-	+	-	2+
2	-	+	-	-	+	1+
3	+	+	+	-	-	3+
4	-	-	+	+	+	0
5	+	-	-	-	+	2+
6	-	+	+	+	-	1+
7	-	-	-	-	-	0
8	+	+	-	+	+	3+

Cells 1 and 5 demonstrate reactivity when E is present and Jka is absent. Cells 2 and 6 demonstrate a separate reaction when Jka is present and E is absent. Cells 4 and 7 lack both and are nonreactive. This pattern supports a two-component explanation within the displayed model. K, Fya and S do not independently explain the pattern because suitable positive cells for those antigens are nonreactive or because reactive cells lack them.

The table is not a complete clinical identification. It omits many antigens, detailed dosage information and the full confirmation set. A real investigation must use the laboratory's criteria to confirm both specificities and exclude additional clinically significant antibodies.

20.3 Choose cells that isolate each component

To confirm anti-E independently, use E-positive cells lacking Jka and other unresolved target antigens. To confirm anti-Jka, use E-negative cells with appropriate Jka expression. The negative comparison cells should lack the candidate antigen while retaining informative expression of alternatives where possible.

This process can become difficult when several antigens are correlated in available panel cells. Reference panels, selected donors or molecularly characterised cells may be needed. The investigator should not force a conclusion merely because the routine panel has been exhausted.

Enzyme treatment can help distinguish components when their antigen sensitivities differ, but it can also enhance both or remove one entirely. Adsorption may separate antibodies under selected conditions. Each modified method must be chosen for a specific purpose and interpreted with its limitations.

20.4 Component selection for a mixture

If anti-E and anti-Jka are confirmed and clinically significant, selected red cells should lack both corresponding antigens and meet the complete compatibility requirements. Finding a unit negative for only one target does not resolve the other. The laboratory should also retain the patient's historical antibodies, even if they are not visible in the current mixture.

The donor search may be more difficult than a simple multiplication suggests because antigen frequencies can be associated. Characterised inventory and supplier support are often more efficient than random screening. The clinical team should receive an early estimate of availability and any delay.

A serologically compatible unit should still be verified against the required antigen profile where policy requires. Compatibility alone may fail to protect against a weak or evanescent historical antibody. The plan must integrate both observed and historical risks.

20.5 Communicate the resolved and unresolved components

The final report should identify each established specificity and any remaining unexplained reactivity. It should not use a vague phrase such as "multiple antibodies" when the individual requirements are known. Conversely, it should not list a speculative specificity as confirmed merely to make the report appear complete.

A second qualified review can be valuable in complex cases. The reviewer should examine the raw pattern and exclusion evidence, not only the final antibody names. The most dangerous errors are often plausible-looking conclusions that no one has tested against the original data.

Mixtures are solved by finding separating evidence

When anti-E and anti-Jka coexist, cells carrying both targets may react strongly, cells carrying one may react less strongly, and cells carrying neither may be negative. This pattern is suggestive, but the strength ordering is not guaranteed. Concentration, dosage and method can change it. The decisive evidence comes from cells that isolate one target while removing the other.

Selected-cell testing is therefore an experiment. The proposed antibody predicts a result in a deliberately chosen antigen context. Agreement strengthens the hypothesis; disagreement requires reconsideration. Repeating uninformative cells merely reproduces the ambiguity. [FB02]

Chemical treatment and adsorption can create additional contrasts, but they also change the system. Enzymes can remove some targets and enhance others; adsorption can remove antibodies against antigens present on the adsorbing cells. The learner should always ask which information the manipulation reveals and which information it destroys.

Mixtures require cells that separate targets

Cell	E	Jka	IAT
1	+	−	2+
2	−	+	1+
3	+	+	3+
4	−	−	0

Invented reaction data • limited teaching panel, not a clinical identification

Figure FB20. Synthetic anti-E plus anti-Jka model. Cells expressing one target at a time are more informative than cells carrying both. Reaction strength is illustrative, not a quantitative concentration scale. Original CDIL educational schematic; not patient data.

Worked cases 58–60

Case 58 — One antibody cannot explain every positive cell

Anti-E explains several reactions, but an E-negative, Jka-positive cell is also reactive. Controls are acceptable.

Reasoned answer. A second antibody is one important possibility. The investigator should select additional E-negative cells with informative Jka expression and appropriate comparison cells, while considering other antigens and mechanisms. The extra positive cell should not be ignored or assigned to anti-E despite lacking the target.

Case 59 — A unit negative for only one target

A patient has confirmed anti-E and anti-Jka. An E-negative unit is selected without checking Jka status because its routine crossmatch is weakly nonreactive.

Reasoned answer. The component plan must address both clinically significant specificities. A weak or variable antibody can escape

detection in a particular crossmatch. Reliable antigen-negative selection and the appropriate compatibility method are required under policy. One satisfied requirement does not cancel the other.

Case 60 — Stronger reaction does not prove two antibodies

A cell carrying E and Jka reacts 3+, while a cell carrying only E reacts 2+. The learner declares two antibodies solely from the difference in strength.

Reasoned answer. Reaction strength can vary with antigen density, dosage and method conditions. The difference is compatible with a mixture but does not prove it. Independent reactivity with E-negative/Jka-positive cells and the complete confirmation process are needed. The causal contrast, not the numerical grade alone, establishes the second component.

21 | Enzyme Methods and Chemical Treatment of Red Cells

Treating red cells can reveal a useful pattern by changing the membrane structures available to antibodies. The same treatment can remove evidence needed to exclude another specificity. Advanced serology therefore treats modification as an experiment with a defined question, appropriate controls and explicit blind spots. A treated panel is not a more accurate version of every untreated panel; it is a different analytical system. [FB02, FB05]

21.1 Proteolytic enzymes alter the surface

Common enzyme methods use proteases that modify selected membrane proteins and influence the physical environment of agglutination. In many routine applications, Rh and Kidd reactions are enhanced, while Duffy and M/N antigens are destroyed or substantially weakened. Effects on other antigens vary with the enzyme and conditions. The laboratory must use the documented properties of its actual validated treatment rather than a universal mnemonic.

Enhancement can make a weak antibody easier to detect, but it can also amplify clinically insignificant cold reactivity or create nonspecific patterns. A stronger reaction after treatment does not identify the antibody. The result must still correlate with antigen expression and fit the rest of the investigation.

Loss of reactivity can be equally informative. If an untreated pattern disappears after an enzyme that destroys the candidate antigen, the change supports that hypothesis. However, several antigens may be destroyed by the same treatment. The experiment narrows possibilities; it does not uniquely name the antibody without additional evidence.

21.2 One-stage and two-stage concepts

In a two-stage approach, cells are treated and prepared before exposure to the patient's antibody. In a one-stage approach, treatment and antibody reaction occur within a combined process. These formats can produce different sensitivities and interferences. The operational details belong to the manufacturer and validated procedure; a textbook should not imply that the methods are interchangeable because they use the same enzyme name.

Treatment must be adequately controlled. Over-treatment, under-treatment, cell damage and incomplete removal of reagents can affect the result. A suitable control demonstrates the intended change and, where relevant, preservation of an antigen that should remain detectable. The laboratory should not infer successful treatment solely because the patient specimen became easier to interpret.

The antigen profile of treated cells should be understood. An untreated lot sheet does not fully describe the modified surface. Records should identify the original cells, treatment method, date, controls and resulting limitations.

21.3 Reducing agents and disulfide-dependent structures

Dithiothreitol disrupts disulfide bonds and can alter antigens including those in the Kell system. It is widely used in selected investigations of anti-CD38 therapeutic interference, but its effect is not restricted to CD38. Other susceptible antigens must be considered under the laboratory's validated strategy. [FB11]

A negative DTT-treated screen does not establish that every clinically significant alloantibody has been excluded. The laboratory may need pretreatment phenotype or genotype information and an appropriate component-selection plan to address targets destroyed by treatment. This is a central example of gaining one kind of information while losing another.

Other chemical methods can remove bound immunoglobulin or alter selected antigens. Their use requires method-specific validation and

knowledge of the affected structures. A reagent that helps resolve a DAT-positive phenotype may also change the antigen being typed. The investigator must know which conclusions remain valid after treatment.

21.4 A treatment-effect worksheet

Observation	Supported inference	What is not established
Reactivity increases after enzyme treatment	A treatment-enhanced specificity or other enhanced interaction is possible	The antibody's name or clinical severity
Reactivity disappears after treatment	A target may have been removed or the reaction environment altered	A unique specificity or absence of all antibodies
DTT-treated cells become nonreactive during anti-CD38 therapy	The interference may have been reduced	Exclusion of antibodies to DTT-sensitive antigens
Control cells do not show the expected treatment effect	The modified method may be invalid	A reliable patient interpretation from that treatment

The worksheet is deliberately mechanistic. It prevents the laboratory from turning a useful treatment response into a broader conclusion than the experiment supports.

21.5 Preserve the untreated evidence

The original untreated pattern should remain available for comparison. It may contain the only evidence for an antibody to an antigen destroyed by treatment. A final report should identify which results came from modified cells and how the blind spots were addressed.

When several treatments are used, the investigation can become difficult to follow. A concise table of specimen, cell preparation, method, control and result helps another scientist reconstruct the logic. The aim is not to accumulate methods but to answer the

compatibility question with the smallest reliable set of informative experiments.

Treatment changes the analytical target, not just the background

Proteolytic enzymes alter exposed red-cell membrane structures. Depending on the enzyme and conditions, some antigens are weakened or destroyed while reactions involving other systems become more readily detected. Reduced surface charge and altered accessibility can contribute to enhanced agglutination. The treated cell is therefore a different analytical reagent from the untreated cell.

Dithiothreitol is a reducing agent rather than a proteolytic enzyme. Its effects depend on disulphide-sensitive structures, including clinically important Kell antigens under commonly used red-cell treatment procedures. A negative DTT-treated screen cannot exclude an antibody whose target has been destroyed. [FB02, FB11]

The interpretation should explicitly connect the manipulation with the target. "The reaction disappeared after treatment" means that the interaction no longer produced the same signal in the altered system. It does not prove that the original antibody was clinically insignificant, nor does it uniquely name the specificity. Untreated-cell findings, selected cells and appropriate controls remain part of the investigation.




Figure FB21. Enzymes and reducing agents are not interchangeable. The altered antigen landscape creates both useful contrasts and blind spots. Original CDIL educational schematic; not patient data.

Worked cases 61–63

Case 61 — Enzyme enhancement mistaken for anti-Rh proof

All reactions become stronger after enzyme treatment. The investigator reports an Rh antibody without antigen correlation.

Reasoned answer. Several specificities and nonspecific interactions can be enhanced. The treatment response is a clue, not an identification. The laboratory must examine the antigen pattern, patient profile and additional tests. A method effect cannot replace specificity evidence.

Case 62 — A destroyed antigen disappears from the investigation

An untreated specimen suggests anti-Fya. After enzyme treatment, the panel is negative, and the investigator deletes the original finding.

Reasoned answer. Destruction of Duffy antigens can explain the loss of reactivity. The untreated result remains important and should

be investigated with suitable cells. The negative treated panel does not contradict the original hypothesis in the way the learner assumes; it may support the mechanism while creating an exclusion blind spot.

Case 63 — Treatment control fails

A DTT-treated preparation does not show the expected control change. The patient result is nevertheless easier to read.

Reasoned answer. Ease of interpretation is not proof of valid treatment. The failed control requires investigation and prevents acceptance of conclusions that depend on the intended modification. The method should be repeated or replaced under the validated procedure, with the original data preserved.

22 | Adsorption and Elution: Separating Antibody Populations

Adsorption removes selected antibodies from plasma by exposing it to cells carrying the corresponding targets. Elution recovers antibody from sensitised cells. Used carefully, these methods can separate components of a complex mixture and reveal clinically significant alloantibodies hidden by broad reactivity. Used without attention to cell selection and history, they can also remove the very antibody the laboratory needs to detect. [FB02, FB05]

22.1 The logic of adsorption

When plasma is incubated with an appropriate red-cell preparation, antibodies can bind to antigens on those cells. The remaining plasma may then show less of the adsorbed reactivity. The experiment depends on antigen expression, antibody concentration, cell quantity, method conditions and completeness of adsorption.

A decrease in broad reactivity does not prove that every interfering antibody has been removed. Repeated adsorption may be required under the validated procedure, and controls or post-adsorption checks help assess the result. The process also dilutes or otherwise changes the specimen, which can reduce the detectability of weak antibodies.

The choice of cells determines what is removed. If adsorbing cells carry an antigen corresponding to an underlying alloantibody, that antibody may be adsorbed as well. A negative adsorbed plasma result can therefore be falsely reassuring unless the cell-selection strategy preserves the information needed for exclusion.

22.2 Autoadsorption and recent transfusion

Autoadsorption uses the patient's own cells to remove an autoantibody, with preparation appropriate to the method. It can be useful because the patient's cells ordinarily lack the antigens against which the patient has alloantibodies. However, recent transfusion introduces donor cells that may carry those antigens, creating a risk of removing an underlying alloantibody.

The patient's red cells may also be heavily coated or insufficient in quantity, requiring specialised preparation or an alternative approach. The decision to use autoadsorption depends on transfusion timing, cell availability and the validated procedure. It should not be chosen automatically whenever the autocontrol is positive.

A molecularly predicted phenotype can help plan the investigation but does not physically remove donor cells from a mixed specimen. The analytical strategy must still address the actual cells present in the tube.

22.3 Alloadsorption and differential cell selection

Alloadsorption uses selected donor cells with known antigen profiles. Different adsorbing cells can be chosen to preserve or remove particular antibody components, allowing comparisons among the remaining plasma fractions. The method is especially useful when autoadsorption is unsuitable.

The cell profiles must be chosen deliberately. If every adsorbing cell carries Jka, an anti-Jka may be removed from every fraction and become invisible. A differential strategy uses complementary profiles and interprets the resulting pattern. The laboratory should document which antibodies each adsorbing cell could remove.

Alloadsorption can also remove antibodies to high-frequency antigens, making their exclusion difficult. The method's limitations should remain explicit in the report and component plan. Reference-laboratory expertise is valuable when multiple antibodies, rare phenotypes or urgent clinical needs complicate the investigation.

22.4 Elution as a targeted question

An eluate can help characterise antibody bound to cells, including donor cells after transfusion or cells affected by an autoimmune process. The result depends on the elution method and the antibody's properties. A negative result does not prove absence of all cell-associated immune activity.

Preparation controls are essential. Residual plasma can contaminate the eluate, and inappropriate washing can make a cell-bound interpretation unreliable. The final wash or other method-specific control should be evaluated before the eluate is used to assign specificity.

The plasma, adsorbed plasma and eluate should be labelled distinctly. Confusing these materials can create a false sequence of results. Each represents a different experimental fraction with different information content.

22.5 Interpret the experiment as a whole

Suppose broad plasma reactivity is removed by a validated adsorption, revealing a pattern consistent with anti-E. The result suggests that an underlying alloantibody was obscured by the original broad component. The laboratory must still confirm anti-E, exclude other antibodies within the method's limits and select components accordingly.

If no specific reactivity remains, the conclusion should state what the adsorption strategy could reasonably exclude. It should not claim that every possible alloantibody is absent. A carefully designed negative investigation is useful, but its limits must be understood by the scientist and the clinical team.

Adsorption follows the antigens on the adsorbing cells

During adsorption, antibodies in plasma can bind to the targets expressed by the adsorbing red cells. The remaining plasma is then tested to determine which reactivities persist. This can separate overlapping populations, but it also creates a predictable blind spot: an antibody against an antigen present on all adsorbing cells may be removed together with the unwanted reactivity.

Autoadsorption uses the patient's own cells and can be valuable in selected autoantibody investigations. Recent transfusion complicates the method because the circulating sample may contain donor cells carrying antigens absent from the patient. Those donor cells could adsorb an alloantibody that the investigation is intended to uncover. [FB02, FB16]

Alloadsorption uses selected donor cells with known antigen profiles. Comparing separately adsorbed aliquots can reveal which specificities remain, provided the design includes informative antigen contrasts. Adequate adsorption may require repeated steps under validated conditions. The final interpretation should record the cells used, their relevant antigen status, the adsorption conditions and the limitations of the resulting plasma.




Figure FB22. A plasma aliquot is exposed to cells with a known antigen profile. Antibody against those targets can be removed; the remaining plasma is tested. The design determines which antibodies may be hidden. Original CDIL educational schematic; not patient data.

Worked cases 64–66

Case 64 — Autoadsorption after recent transfusion

A patient was transfused recently, and the current cells are a mixture of recipient and donor populations. The investigator chooses autoadsorption without considering donor antigens.

Reasoned answer. Donor cells in the preparation can adsorb clinically significant alloantibodies, potentially hiding them. The laboratory should use the appropriate alternative or reference strategy based on history and validation. The term "patient cells" does not guarantee that every cell in the tube is genetically the patient's own.

Case 65 — Every adsorbing cell carries the same target

All three selected adsorption cells are Jka-positive. After treatment, the plasma is nonreactive. The investigator reports that anti-Jka is excluded.

Reasoned answer. Anti-Jka could have been removed by all three adsorptions. The negative fractions do not provide the claimed exclusion. Cell selection must be designed to preserve informative contrasts, and the report must acknowledge the blind spot. A negative result after selective removal is not equivalent to a negative untreated specimen.

Case 66 — A hidden anti-E emerges

Broad reactivity decreases after a valid adsorption, and the remaining plasma reacts with E-positive but not appropriate E-negative cells.

Reasoned answer. The findings support investigation of an underlying anti-E that was previously obscured. Confirmation, patient antigen assessment and exclusion of additional antibodies remain necessary. The component plan should account for the established specificity and the limitations of the adsorption method, not merely the reduced overall reaction strength.

23 | Warm Autoantibodies and Autoimmune Haemolytic Anaemia

Warm autoantibodies can produce broad reactivity in pretransfusion testing and may be associated with haemolysis. The laboratory must solve two related questions: whether immune red-cell destruction is occurring and whether clinically significant alloantibodies are hidden by the autoantibody. The presence of an autoantibody does not remove the need for transfusion support when clinically necessary. [FB02, FB16]

23.1 A serological pattern is not the whole syndrome

A warm-reactive autoantibody often produces an IgG-positive DAT and broad IAT reactivity, with or without complement. An eluate may be broadly reactive. These patterns are useful but not universal. The diagnosis of autoimmune haemolytic anaemia requires evidence of haemolysis and clinical assessment, not only a positive DAT.

Haemoglobin decline can have many causes, including bleeding, reduced production and dilution. Reticulocyte response may be altered by marrow disease, treatment or severe illness. Bilirubin, lactate dehydrogenase and haptoglobin are helpful in context but are not perfectly specific. The laboratory should support an integrated assessment rather than assign causation from one abnormal marker.

Some patients have positive DAT findings without clinically important red-cell destruction. Others may have immune haemolysis with a routine DAT that is negative or weak because of the coating's density, class or method sensitivity. Specialist investigation may be required when the clinical and routine laboratory findings conflict.

23.2 Broad reactivity can hide alloantibodies

A warm autoantibody may react with most routine reagent cells, obscuring differences that would otherwise reveal an alloantibody. The patient may also have been transfused previously and have historical specificities. The investigation should therefore include reliable history and an appropriate strategy to detect underlying alloantibodies.

Adsorption, selected methods and phenotype or genotype information can help. Recent transfusion and IgG coating can complicate serological phenotyping and autoadsorption. Reference-laboratory support may be needed, especially when time is limited or multiple antibodies are suspected.

A negative adsorbed-plasma investigation should be interpreted within the method's coverage. The laboratory should state which significant antibodies were adequately addressed and any residual uncertainty. The goal is a defensible component plan, not an unsupported declaration that all antibodies have been removed.

23.3 The problem with "least incompatible"

When an autoantibody reacts broadly, many donor units may show similar serological incompatibility. Ranking them by a small difference in reaction strength does not necessarily identify a safer unit. The phrase "least incompatible" can imply a biological ranking that the test has not established.

A more informative approach describes the patient's autoantibody, the work performed to exclude or address alloantibodies, the antigen-matching strategy and the clinical authorisation for transfusion. The treating team needs to understand the residual risk and the risk of not transfusing. A laboratory should not delay a necessary transfusion indefinitely merely because the autoantibody prevents a completely negative crossmatch.

This does not mean that compatibility testing is abandoned. It means that the interpretation distinguishes expected autoantibody reactivity from avoidable alloantigen incompatibility. The authorised transfusion-medicine team balances the evidence and urgency.

23.4 Matching and historical information

Extended phenotype or genotype can support selection of appropriately matched units, particularly in patients who require repeated transfusion. The exact matching strategy depends on the patient's profile, antibody history, clinical condition and available inventory. It should be documented and reviewed rather than improvised for each unit.

A historical alloantibody remains relevant even if the current broad pattern prevents its independent demonstration. The laboratory should not remove the restriction because it cannot be seen through the autoantibody. Reliable records can provide information that the current specimen cannot.

23.5 Communication during an urgent case

The report should separate the serological finding from the clinical diagnosis and component decision. For example, it can state that broad IgG reactivity is consistent with a warm autoantibody, describe the underlying alloantibody investigation and identify the selected antigen requirements. The clinical team should receive an estimate of the investigation time and any unresolved limitations.

If the patient is unstable, escalation should occur while testing continues. The laboratory should not wait until every advanced method is complete before discussing the available options. Safety depends on coordinated decisions, not on the absence of uncertainty.

Haemolysis requires evidence beyond a positive DAT

A DAT demonstrates immunoglobulin or complement on red cells under the method's detection conditions. It does not directly measure the rate of red-cell destruction. Some patients have a positive DAT without clinically important haemolysis, while selected cases of immune haemolysis can be DAT-negative by a routine method. The clinical investigation should therefore examine haemoglobin trends, reticulocytes, bilirubin, lactate dehydrogenase, haptoglobin and other relevant findings in context.

In warm autoimmune haemolytic anaemia, IgG-coated cells can be removed by macrophages, particularly through Fc-mediated recognition. Partial membrane removal can contribute to spherocyte formation. Complement involvement varies and may add another pathway of clearance. These mechanisms help explain why the DAT pattern and the severity of anaemia need not have a simple one-to-one relationship. [FB16]

Transfusion testing must also search for underlying alloantibodies. Panreactivity attributed to an autoantibody can obscure a clinically significant specificity. The aim is to select appropriate blood through a complete investigation and an urgency-based clinical plan, not to rank units by an unvalidated "least incompatible" reaction score.




Figure FB23. The clinical diagnosis combines cell coating with independent evidence of red-cell destruction and the patient context. A single positive DAT is insufficient. Original CDIL educational schematic; not patient data.

Worked cases 67–69

Case 67 — A positive DAT treated as proof of haemolysis

A patient has a strong IgG DAT but stable haemoglobin and no current evidence of increased red-cell destruction. The report draft diagnoses active autoimmune haemolytic anaemia.

Reasoned answer. The DAT establishes coating detectable by the method. The clinical syndrome requires evidence of haemolysis and assessment of alternatives. The report should describe the serology and support further interpretation without overstating what it proves. Strong coating is not a direct quantitative measure of destruction.

Case 68 — Choosing the weakest crossmatch

Ten units are all reactive because of a broad autoantibody. One reacts slightly less strongly, and the learner calls it biologically safest without addressing alloantibodies.

Reasoned answer. Small grade differences do not reliably rank in-vivo safety in this setting. The priority is identifying or addressing underlying alloantibodies, using appropriate antigen matching and obtaining the authorised clinical decision. The report should explain that work rather than rely on the vague label "least incompatible."

Case 69 — A necessary transfusion delayed indefinitely

A severely anaemic, unstable patient has a warm autoantibody. The laboratory refuses to discuss release until a completely negative crossmatch is obtained.

Reasoned answer. A negative crossmatch may not be achievable because of the autoantibody. The laboratory must urgently involve the transfusion-medicine and treating teams to balance the risks of transfusion and delay, while completing the most informative testing possible. The presence of serological incompatibility does not automatically make withholding necessary treatment safer.

24 | Cold Antibodies, Complement and Biphasic Haemolysis

Cold-reactive antibodies are common laboratory findings, but their clinical importance varies widely. The relevant questions are the antibody's thermal range, specificity, complement behaviour and relationship to the patient's symptoms and haemolysis. A high titre at a very low temperature is not a universal severity score. [FB02, FB16]

24.1 Thermal amplitude and the circulating environment

An antibody that reacts only at markedly low laboratory temperatures may have limited relevance under ordinary physiological conditions. An antibody whose activity extends toward temperatures encountered in the peripheral circulation can have greater potential for clinical effects. Thermal amplitude therefore provides information distinct from titre.

The measured range depends on the method, incubation and endpoint. It should be reported with the conditions rather than as an unexplained label. A textbook diagram showing a sharp temperature boundary is a simplification; real reactivity can change gradually and be influenced by concentration and complement.

Clinical history is essential. Cold-associated symptoms, haemolysis, infection, lymphoproliferative disease and other factors may guide the investigation. The laboratory should not diagnose a cold-antibody disease solely because routine testing detects an incidental cold agglutinin.

24.2 Complement coating and the DAT

Cold antibodies can bind to red cells and activate complement. The antibody may dissociate as conditions change while complement fragments remain on the cells. This helps explain a DAT that is positive for complement with little or no IgG detected. The pattern is informative but not unique to one diagnosis.

Complement activation can contribute to red-cell clearance or intravascular injury depending on the mechanism and regulation. The clinical investigation should assess haemolysis and competing causes. A complement-positive DAT does not itself prove that the current haemoglobin fall is due to the cold antibody.

Specimen handling can influence findings. Collection and transport conditions for specialised cold-antibody investigations should be agreed with the testing laboratory. Improvised warming or cooling after a specimen has been mishandled may not restore the original information.

24.3 Prewarm methods and their limits

Prewarm techniques can reduce selected cold-reactive interference during testing. They require a validated procedure that controls the relevant materials and conditions. The purpose is to improve detection of clinically relevant antibodies, not simply to eliminate all visible reactivity.

Some methods can reduce sensitivity for weak clinically significant antibodies. The laboratory must understand and document that limitation. A negative result after prewarming should be interpreted with the history and the complete investigation, not as a universal exclusion of alloantibodies.

Alternative platforms, adsorption and reference methods may be needed when interference remains complex. The choice depends on the clinical question and the properties of the antibody, not on a preference for whichever method gives the cleanest-looking result.

24.4 Paroxysmal cold haemoglobinuria

A biphasic haemolysin can bind under cold conditions and cause complement-mediated haemolysis after warming. The classical association is an anti-P specificity investigated through a Donath–Landsteiner test. The method requires careful specimen handling and controls, including consideration of complement availability. It should be performed by a laboratory with the appropriate expertise.

A negative specialised test may be limited by specimen timing, antibody concentration, handling or method sensitivity. The result must be integrated with the clinical presentation. The laboratory should not treat the name of the test as a guarantee that every biological possibility has been excluded.

24.5 Component support and patient management

The transfusion service should communicate the clinically relevant findings and provide components through the authorised plan. Warming devices and other management measures, when indicated, require approved equipment and clinical protocols. A textbook should not suggest improvised heating of blood components or assume that warming eliminates every immune risk.

The laboratory also needs to distinguish antibody-related analytical interference from true patient abnormalities. Cold agglutination can affect some automated blood-count measurements. Appropriate laboratory correction and review may be required before interpreting indices or haemoglobin relationships. The transfusion and haematology laboratories should communicate when the same specimen problem affects both investigations.

Temperature, complement and specimen handling interact

A cold-reactive antibody can bind red cells in cooler parts of the circulation and activate complement. On warming, the antibody may dissociate while complement fragments remain on the cells. A DAT pattern dominated by complement can therefore persist even when the original immunoglobulin is not easily demonstrated on the warmed cells.

Biphasic haemolysins illustrate a different temperature-dependent mechanism: binding and complement fixation occur under one temperature condition, while haemolysis becomes evident after warming. The specialised investigation must reproduce the relevant sequence with appropriate controls. A routine cold agglutinin result is not interchangeable with a Donath–Landsteiner test. [FB16]

Specimen handling can influence both the measured antibody and the red-cell count. Cold agglutination may cause analyser artefacts, including an apparent reduction in red-cell count and changes in calculated indices. Warming under the laboratory's validated procedure can help investigate the artefact, but it does not by itself diagnose the patient's clinical syndrome or eliminate the need for haemolysis assessment.




Figure FB24. A simplified cold-antibody sequence shows why complement may remain detectable after antibody dissociation. This does not substitute for specialised testing of a biphasic haemolysin. Original CDIL educational schematic; not patient data.

Worked cases 70–72

Case 70 — Titre and thermal amplitude disagree

A specimen has a high titre at 4°C but little demonstrated reactivity at warmer conditions. Another has a lower cold titre but broader thermal activity. The learner ranks risk using titre alone.

Reasoned answer. The ranking ignores the temperature range in which the antibody can act. Clinical significance requires thermal behaviour, complement activity, specificity and patient evidence. Neither titre alone supplies a universal risk score. The two measurements answer different questions.

Case 71 — Complement-positive DAT after antibody dissociation

The DAT is C3-positive, while little IgG is detected. A student says this proves that no antibody could have initiated the coating.

Reasoned answer. An antibody can bind under one condition, activate complement and later dissociate while complement

fragments remain. The pattern is compatible with several mechanisms and requires clinical interpretation. Absence of detectable IgG at the time of testing does not establish that antibody played no role.

Case 72 — Improvised warming

A staff member proposes warming a blood component with an unapproved device to solve a cold-antibody problem quickly.

Reasoned answer. Component warming must use approved equipment and the authorised clinical protocol. Improvised heating can damage the product and does not resolve all compatibility issues. The laboratory should communicate the antibody findings and support the appropriate transfusion plan rather than substitute an uncontrolled physical intervention.

25 | Drugs, Therapeutic Antibodies and Serological Interference

Medication can influence immunohaematology through several mechanisms. A drug may contribute to immune haemolysis, alter antigen or antibody expression, introduce passive antibodies or interfere directly with the analytical system. These mechanisms should be distinguished because they require different investigations and have different clinical implications. [FB02, FB11, FB17]

25.1 Drug-associated immune haemolysis

Selected drugs can be associated with antibodies that react through drug-dependent or other mechanisms. The clinical investigation requires a careful medication timeline, haemolysis evidence and specialised laboratory testing where appropriate. A positive DAT during treatment does not automatically establish that the drug caused haemolysis.

The timing of exposure and specimen collection is important. A sample collected before the drug was given cannot show a biological effect caused by that later dose. A result released after treatment began may still represent a pretreatment specimen. Chronology must use collection time, not only report time.

Drug-dependent antibody investigations are specialised. The required drug preparation, metabolites, controls and analytical conditions may differ. A negative routine panel cannot exclude every drug-related mechanism. Reference-laboratory consultation can help select an appropriate investigation without exposing staff to unvalidated procedures.

25.2 Anti-CD38 treatment and broad IAT reactivity

Daratumumab and other anti-CD38 therapies can bind CD38 on reagent red cells and produce broad reactivity in indirect antiglobulin testing. This can obscure alloantibodies and delay component provision. The interference may persist after treatment, so the medication history should remain visible beyond the day of administration. [FB11]

Before treatment, an appropriate baseline can include ABO/RhD grouping, antibody screening and extended phenotype or genotype according to the programme. Once therapy has begun, validated interference-resolution methods are used. The laboratory should not interpret every broadly reactive panel in this setting as a new warm autoantibody without considering the drug.

ABO and RhD grouping are generally not affected in the same way as IAT antibody investigations, but the actual method and any anomalous results must still be assessed. The presence of a known drug interference does not authorise ignoring unrelated grouping discrepancies.

25.3 DTT and the hidden antigen problem

DTT-treated cells are an established strategy for selected anti-CD38 interference. The treatment reduces CD38-related reactivity but also destroys or alters other antigens, notably Kell. The laboratory must account for the resulting inability to exclude antibodies to affected targets. A negative treated screen is not a complete all-antigen clearance. [FB11]

Reliable pretreatment phenotype or genotype information helps guide selection. Where Kell status is not established, the authorised strategy commonly includes K-negative red cells for patients who are not known to be K-positive, with attention to the full local policy and other antibody requirements. This is a method-aware safety response, not a universal statement that DTT affects only K.

Other methods may use neutralisation, alternative reagents or specialised cells. Their suitability depends on the therapeutic

antibody and validation. A method developed for one drug should not automatically be applied to every monoclonal therapy.

25.4 Anti-CD47 and other emerging interferences

Therapies directed at other red-cell-associated targets can produce different patterns, including effects on grouping or broad serological reactivity. The laboratory should obtain the exact drug name and consult current product and reference guidance. The category "immunotherapy" is too broad to determine the analytical strategy.

New treatments and assay designs continue to develop. A publication should therefore teach the mechanism and the process for checking current guidance, rather than freeze an incomplete list of drug names as exhaustive. The key questions are what the drug binds, whether reagent or patient cells express that target and which validated method can preserve detection of clinically important antibodies.

25.5 Reporting without concealing uncertainty

The final report should state the interference suspected or demonstrated, the method used to address it, relevant blind spots and the component plan. The treatment history should be retained in the transfusion record. A future admission may occur at a different hospital, so patient-held information and reliable interinstitutional communication can reduce delay.

If urgent transfusion is needed before complete resolution, the transfusion-medicine team should balance the available evidence and clinical risk through the emergency pathway. The laboratory should not allow a known analytical interference to become an unexplained barrier to necessary care.

Therapeutic interference and drug-dependent haemolysis are different mechanisms

Daratumumab can bind CD38 expressed on reagent red cells and produce panreactivity in indirect antiglobulin testing. This is an analytical interference caused by a therapeutic antibody interacting with the test system. It does not mean that every such patient has a newly formed red-cell alloantibody or clinically significant immune haemolysis.

Drug-dependent immune haemolysis is a different problem. Antibody reactivity may depend on the presence of a drug or a drug-associated structure under specialised testing conditions. A temporal association between drug administration and anaemia is not enough to establish this mechanism; the investigation requires clinical review and appropriate reference methods. [FB11, FB17]

Both situations demonstrate the importance of a complete medication history. The laboratory needs the agent, timing and relevant baseline results. Treating all medication-related interference as one phenomenon can lead to an unsuitable test strategy. A method that removes anti-CD38 interference does not automatically investigate every form of drug-associated haemolysis.




Figure FB25. DTT treatment can remove anti-CD38 interference while altering Kell and other sensitive antigens. A negative treated-cell screen must be interpreted within the validated component-selection strategy. Original CDIL educational schematic; not patient data.

Worked cases 73–75

Case 73 — The missing drug name

A request says only "on cancer treatment." The panel is broadly reactive, and the laboratory begins a prolonged autoantibody investigation before learning that the patient receives anti-CD38 therapy.

Reasoned answer. The exact medication history could have directed an appropriate interference strategy earlier. Broad treatment categories are insufficient when drugs have distinct analytical effects. The laboratory should obtain and retain the specific product, timing and baseline information. The drug does not explain every possible abnormality, but it is a major hypothesis that should be evaluated promptly.

Case 74 — A negative DTT screen called complete clearance

After DTT treatment, all screening cells are nonreactive. The report states that every clinically significant red-cell antibody is excluded.

Reasoned answer. DTT-sensitive antigens may no longer be available for testing. The conclusion must be limited to the validated method and supplemented by history, phenotype or genotype and the authorised matching plan. The treatment resolves a particular interference while creating known blind spots; it does not produce an unlimited negative result.

Case 75 — Report time creates false causation

A DAT result is released after a new drug starts, but the sample was collected beforehand. The learner attributes the DAT to the new treatment.

Reasoned answer. The chronology does not support that causal explanation. The specimen represents the pretreatment state at collection. The laboratory should correct the timeline and investigate other explanations. Accurate timestamps are part of mechanism-based reasoning, not merely administrative metadata.

26 | Serological and Electronic Crossmatching

Crossmatching is the final compatibility assessment linking a selected donor red-cell component to an identified recipient under a defined pathway. It can involve a physical serological test or a validated electronic process. The two approaches have different eligibility conditions, but both depend on reliable patient identity, current valid testing, historical information and correct component selection. [FB01, FB02]

26.1 What a serological crossmatch tests

A serological crossmatch exposes donor red cells to the recipient's plasma or serum using the required method. The test can reveal incompatibility not represented by the screening cells, including an antibody to a low-frequency antigen carried by that donor. It also provides a final check within the compatibility system, although it cannot compensate for incorrect patient identity or every error after issue.

The method and phase are selected according to the patient's findings and applicable policy. A patient with a clinically significant antibody history generally requires a strategy that addresses that antibody, including antigen-negative units and appropriate antiglobulin compatibility testing. A current negative screen does not automatically make a simplified crossmatch pathway appropriate.

A positive crossmatch requires investigation of the reaction, donor unit, patient history and controls. Possible explanations include an alloantibody, autoantibody, donor-cell coating, drug interference or a technical problem. The laboratory should not assume that every incompatibility is caused by the antibody already identified in the patient.

26.2 Electronic crossmatch is a validated decision system

An electronic crossmatch does not physically mix donor cells and patient plasma. A validated information system uses reliable grouping, antibody and component data to determine eligibility and compatibility. This requires strict control of the inputs, software logic, interfaces, user permissions and audit trail.

Eligibility commonly requires a current negative antibody screen and no history of a clinically significant antibody, together with verified ABO information and other applicable requirements. The exact criteria are defined by the relevant standards and local validation. The Canadian clinical guide explicitly distinguishes this eligible population from patients with significant antibody histories. [FB01]

The absence of a tube does not make the process less scientific. Its safety depends on validated rules and reliable independent data. Conversely, a computer-generated label does not guarantee correctness if the underlying patient record is wrong or a historical antibody warning has been lost during data migration.

26.3 Independent ABO confirmation

Many systems require an independent confirmation of ABO before routine electronic issue or group-specific selection. The purpose is to reduce the risk that a single wrong-blood-in-tube event controls the decision. The exact acceptable sources and exceptions belong to local policy.

Two aliquots from one collection do not provide the same independence as two separately identified collection events. Repeating the same tube on another analyser can detect an analytical discrepancy but cannot establish that the original tube came from the intended patient. The safety control must match the type of error it is intended to detect.

A historical result is useful only if it is reliably linked to the patient and meets the policy's requirements. Merged records, temporary identifiers and imported results require careful reconciliation. The

information system should make uncertainty visible rather than silently converting it into a confirmed group.

26.4 Unit identification and segment linkage

The donor-cell specimen used for crossmatching must be reliably associated with the selected component. Unit identifiers, segment identity and records should remain linked throughout testing and issue. A compatible reaction with cells from the wrong unit is not evidence about the unit that reaches the patient.

The component must also meet nonserological requirements such as the intended product type, modifications, expiry and special patient needs. Crossmatch compatibility does not prove that irradiation, antigen matching, cytomegalovirus-related selection or other requirements have been satisfied. The final issue process combines these independent checks.

26.5 When the pathway changes

A new antibody, a changed clinical history, an expired specimen or an unresolved grouping discrepancy can make a previously eligible electronic pathway inappropriate. The system should prevent unauthorised override and require a documented alternative process. The scientist should understand why the rule exists so that an alert is not treated as a technical obstacle to bypass.

Emergency release has a separate authorisation and documentation pathway. It is not an electronic crossmatch performed with missing data. The report and issue record should clearly distinguish completed compatibility testing from components released before completion because of clinical urgency.

The crossmatch connects a patient result to a particular unit

A serological crossmatch tests the patient's plasma against red cells from a specific donor unit under a defined method. It can reveal incompatibility not apparent from a broad group label. Its sensitivity and scope depend on the procedure, the patient's current antibodies and the antigen expression on the donor cells.

Electronic issue replaces selected serological steps only within a validated system and for eligible patients. The system must have reliable ABO data, appropriate current screening results, relevant historical information and functioning decision rules. It is not simply the absence of a manual test. [FB01, FB02]

A crossmatch also cannot protect against an identity error that occurs after testing. The compatible unit must reach the correct patient and be checked at administration. The laboratory and bedside processes therefore form a continuous chain: the final identity check is not redundant merely because compatibility testing was accurate.




Figure FB26. A validated electronic process depends on reliable group data, an acceptable current screen and history, and functioning rules. Missing information is not a negative result. Original CDIL educational schematic; not patient data.

Worked cases 76–78

Case 76 — A historical antibody lost during migration

The current screen is negative, and the new computer system offers electronic issue. An archived report documents anti-Fya that was not migrated into the structured antibody field.

Reasoned answer. The historical clinically significant antibody remains relevant and makes the displayed eligibility incomplete. The

record must be corrected, and component selection should follow the appropriate antigen-negative and serological pathway. Data migration is a clinical safety process, not merely a software transfer.

Case 77 — Two tests from one wrong tube

A specimen is tested twice on different instruments and gives the same ABO group. The laboratory counts this as independent confirmation of the patient's identity.

Reasoned answer. The tests provide analytical agreement but share the same collection event. If the tube contains another person's blood, both can agree perfectly. Independent confirmation requirements must address the preanalytical identity risk through the authorised process. The safeguard cannot be replaced by repeated measurement of the same unidentified material.

Case 78 — Compatible cells from the wrong segment

A serological crossmatch is negative, but the segment used belongs to a different donor unit from the one prepared for issue.

Reasoned answer. The result applies to the tested donor cells, not the selected component. The unit linkage is broken, and the compatibility assessment must be corrected under the laboratory procedure. A valid reaction cannot be transferred to another unit merely because both share an ABO label.

27 | Selecting Red Cells, Plasma and Platelets

Component selection combines immunohaematology with the patient's clinical needs and the characteristics of the product. The laboratory must distinguish ABO compatibility, antigen matching, antibody history and special component requirements. A product that satisfies one requirement may still fail another. [FB01, FB18]

27.1 Red-cell compatibility direction

For red cells, the principal ABO question is whether donor A or B antigens will encounter the recipient's antibodies. Group O red cells lack A and B and can be used in selected circumstances across ABO groups, but they still carry many non-ABO antigens. Antibody history, RhD considerations and other requirements remain relevant.

ABO-identical components are often preferred where appropriate and available, but alternatives may be used under policy. The laboratory should distinguish identical from compatible and explain any substitution in the record. The availability of a compatible alternative does not authorise ignoring a known clinically significant alloantibody.

RhD selection depends on the recipient, component and clinical situation. Avoiding D exposure is particularly important in selected patients, including those with future pregnancy potential. Emergency policies may allocate limited D-negative stock differently according to risk and supply. These decisions should follow the authorised programme rather than a universal textbook slogan.

27.2 Plasma compatibility reverses the antibody direction

Plasma contains donor antibodies that may react with the recipient's red-cell antigens. The compatibility logic therefore differs from red-cell transfusion. AB plasma lacks the usual anti-A and anti-B, while group O plasma can contain both. A red-cell compatibility table cannot be read unchanged as a plasma table.

Low-titre plasma-containing products and emergency plasma policies require specific definitions and controls. Titre results are method-dependent, and there is no single universal number that makes every product safe for every recipient. The product label, supplier specification and local protocol determine use.

The volume of incompatible plasma and the recipient's size can influence risk. This is particularly relevant in small children and when repeated components are given. The laboratory should consider the complete product exposure, not only the number of bags.

27.3 Platelets involve cells and plasma

Platelet products carry plasma and may express ABO antigens to varying degrees. ABO-identical platelets are often desirable, but supply and clinical urgency can require alternatives under policy. Both the recipient's response to donor platelet antigens and donor plasma antibodies may matter.

RhD is a red-cell antigen, but residual red cells in platelet components can create sensitisation considerations for selected D-negative recipients. The product type, residual red-cell content and current prophylaxis policy influence management. It is incorrect to say that platelets themselves are simply "RhD-positive cells" in the same sense as red cells.

Platelet refractoriness can involve nonimmune causes, HLA antibodies or platelet-specific antibodies. A poor increment should not immediately be attributed to ABO or HLA incompatibility without evaluating timing, dose and the clinical setting. Specialised selection may be required after an appropriate investigation.

27.4 Special component requirements are independent checks

Irradiation addresses the risk of transfusion-associated graft-versus-host disease in specified settings; it does not make a component ABO-compatible or remove every pathogen. Leucocyte reduction reduces white-cell content but does not replace irradiation when irradiation is indicated. Washed components reduce selected plasma constituents but have their own preparation, expiry and clinical-use considerations.

Cytomegalovirus-related component strategies depend on the patient group and national policy. The laboratory should use the current programme rather than equate every leucocyte-reduced or seronegative product with an identical risk category. A request must specify the relevant requirement clearly.

The final issue check should therefore verify product type, patient identity, compatibility, antigen requirements, modifications, expiry and authorisation. A negative crossmatch is one part of this checklist, not evidence that all other conditions have been met.

27.5 Explain substitutions and limitations

When an ideal product is unavailable, the transfusion-medicine and treating teams may agree on an alternative based on urgency and risk. The laboratory should document the reason, the requirement not fully met and the authorisation. It should not silently substitute a product and leave the bedside team to infer the difference.

A controlled plan is especially important for patients with multiple antibodies, rare phenotypes or repeated transfusions. Advance communication before surgery or delivery can prevent avoidable emergency decisions. The safest component is not always the first available unit; it is the product selected through an informed, timely and traceable process.

Plasma and red cells reverse the principal ABO direction

For red-cell transfusion, the major concern is recipient plasma antibody reacting with donor red-cell antigens. For plasma transfusion, donor plasma antibodies can react with the recipient's red cells. This reversal explains why a compatibility mnemonic for red cells cannot be reused unchanged for plasma.

Platelets introduce additional considerations because they carry variable ABO expression and are suspended in plasma. ABO-identical products are often preferred when feasible, but selection depends on clinical urgency, inventory and the service's controls for incompatible plasma and component preparation. Platelets do not express RhD as a red-cell antigen; RhD exposure concerns residual red cells in the product. [FB18, FB23]

Component selection also includes requirements unrelated to ABO, such as irradiation in defined situations or antigen-negative red cells for a known antibody. Each requirement should have a clinical or laboratory basis. An unexplained accumulation of special labels can make supply unnecessarily difficult, while omission of a genuine requirement can create preventable harm.




Figure FB27. Red-cell selection considers recipient antibodies against donor cells. Plasma selection considers donor antibodies against recipient cells. This simplified diagram is not a full component-selection chart. Original CDIL educational schematic; not patient data.

Worked cases 79–81

Case 79 — Irradiation mistaken for compatibility

A unit is irradiated for a high-risk patient but is not compatible with the patient's ABO requirements. A learner assumes that irradiation has made it safe.

Reasoned answer. Irradiation addresses a different biological risk and does not remove A or B antigens. ABO compatibility and all other requirements remain necessary. Component modifications should be understood by purpose rather than treated as a general "extra-safe" label.

Case 80 — Platelet RhD terminology

A trainee says that D-negative recipients can never receive a platelet product labelled D-positive because the platelets express D exactly like red cells.

Reasoned answer. RhD concerns red-cell antigen expression; residual red cells in platelet products create the relevant sensitisation issue. Product characteristics, patient risk and current prophylaxis policy determine management. The correct mechanism supports a more accurate decision than a misleading statement about platelet antigen expression.

Case 81 — A silent substitution

An antigen-matched unit is unavailable, and a different product is issued without recording the unmet requirement or contacting the authorised clinician.

Reasoned answer. The substitution changes the risk assessment and requires a controlled decision. The laboratory should communicate availability, alternatives and urgency, obtain the required authorisation and document the plan. Supply pressure does not justify hiding a clinically relevant difference.

28 | Pregnancy, Maternal Antibodies and HDFN

Haemolytic disease of the fetus and newborn occurs when maternal antibodies cross the placenta and affect fetal or neonatal red cells or erythroid production. The risk depends on antibody specificity, class, fetal antigen expression, previous history and the current pregnancy. Laboratory testing supports prevention, recognition and monitoring, but it does not replace specialist fetal assessment. [FB10, FB19]

28.1 Maternal IgG and the fetal target

IgG can cross the placenta through receptor-mediated transport. If the fetus carries a relevant antigen that the mother lacks, maternal IgG alloantibody may bind fetal cells. The biological consequences vary by specificity and include haemolysis and, with some antibodies such as anti-K, suppression of erythropoiesis.

An antibody found in maternal plasma does not prove that the fetus carries the target. Paternal and fetal antigen investigations may clarify risk within the authorised clinical pathway. Noninvasive fetal genotyping is available for selected antigens in some systems, but availability, validation and interpretation vary. A textbook should not promise that every antigen can be established noninvasively in every jurisdiction.

Previous severe HDFN is an important part of risk assessment. A current low titre may not provide reassurance equivalent to that in a first uncomplicated pregnancy. The laboratory report should preserve the history and communicate the specificity accurately.

28.2 Screening and follow-up are programme-specific

Antenatal grouping and antibody-screening schedules are established by national or institutional guidance. The 2025 British Society for Haematology guideline describes testing at booking and at 28 weeks to identify ABO/D status and clinically significant antibodies. This is a labelled UK framework, not a universal schedule imposed on all countries. [FB10]

When an antibody is detected, identification is essential because different specificities have different fetal and transfusion implications. Some antibodies are unlikely to affect the fetus but can delay provision of blood for the mother. The laboratory should therefore communicate both obstetric risk and component-supply considerations.

Monitoring can involve quantification or titration according to the antibody and local programme. The methods are not interchangeable. Serial results should use a consistent validated approach, and a change should be interpreted with the method's variability and the patient's history.

28.3 Anti-D prevention and interpretation

Rh immune globulin reduces the risk of alloimmunisation in eligible D-negative patients under current programmes. Eligibility, timing and dose depend on the product, gestational context, sensitising event and assessment of fetomaternal haemorrhage where indicated. This book does not substitute a single international dosing schedule for those local requirements.

Passive anti-D after prophylaxis can be detectable. The laboratory should use administration history, previous results and the clinical context to distinguish likely passive antibody from an immune response, recognising that routine serology may not provide a definitive distinction from one specimen. The uncertainty should be discussed with the obstetric team.

An established immune anti-D response is not removed by prophylactic immunoglobulin. Conversely, an uncertain or casually

assigned immune label should not cause appropriate prophylaxis to be withheld without the authorised assessment.

28.4 Fetal and neonatal investigations

Specialist fetal monitoring may include Doppler assessment and other clinical measures according to current guidance. A laboratory titre is not a direct measurement of fetal haemoglobin. The learner should understand that the blood-bank result identifies and follows a risk factor, while fetal assessment evaluates its consequences.

After birth, the neonatal investigation can include blood group, DAT, haemoglobin and bilirubin, with additional tests as indicated. The DAT's strength does not directly predict the severity of disease. Some antibody-mediated processes can affect erythroid production, and the timing of anaemia or bilirubin rise requires clinical monitoring.

ABO-associated HDFN differs in several respects from many non-ABO antibody problems. It should not be assumed to require the same antenatal titre approach or to have an identical severity pattern. The clinical and laboratory pathway must match the mechanism being investigated.

28.5 Plan transfusion support before an emergency

The mother and infant may need different component-selection considerations, but maternal antibody information is central to neonatal compatibility. Antigen-negative requirements, crossmatching approach and special component modifications should be planned with the transfusion service.

Rare antibodies or multiple specificities can make compatible blood difficult to obtain. Early referral and supplier communication are important before delivery or a planned procedure. A complete antenatal record is therefore both a diagnostic resource and a supply-planning tool.

Placental transfer and fetal antigen expression create the risk

Maternal IgG can cross the placenta through receptor-mediated transport. If it recognises an antigen expressed on fetal red cells or erythroid precursors, it can contribute to fetal anaemia. Maternal IgM generally does not cross the placenta in the same way, so antibody class and biological behaviour matter alongside specificity.

The fetus's antigen status determines whether the target is present. Paternal testing, fetal genotyping and other investigations may help assess that status within specialist pathways. The laboratory should not assume that every pregnancy in an antibody-positive mother has an antigen-positive fetus, nor that a reassuring previous pregnancy guarantees the same outcome in the next one. [FB10]

Maternal titres or quantitative antibody measurements can support surveillance for selected specificities, but method consistency and specificity-specific guidance are important. A titre measured by one method is not automatically interchangeable with another laboratory's result. Fetal assessment integrates these laboratory findings with obstetric evidence rather than treating a single number as a complete measure of risk.




Figure FB28. Original placental-transfer schematic. Fetal antigen status and maternal antibody characteristics determine the relevant risk; titres alone do not provide a complete fetal assessment. Original CDIL educational schematic; not patient data.

Worked cases 82–84

Case 82 — Maternal antibody does not prove fetal antigen

Anti-c is identified in maternal plasma. A learner states that the fetus must be c-positive because the antibody is present.

Reasoned answer. Maternal sensitisation history does not establish the antigen status of the current fetus. Appropriate paternal or fetal investigation may clarify risk within the clinical pathway. The laboratory should identify the antibody and support specialist assessment without inventing fetal genotype from the maternal result.

Case 83 — A titre treated as fetal haemoglobin

A rising maternal titre is reported, and the trainee converts it directly into a predicted fetal haemoglobin concentration.

Reasoned answer. A titre is a method-dependent antibody endpoint, not a direct fetal haemoglobin measurement. It can inform risk and monitoring, but fetal assessment uses the authorised specialist

framework. The proposed numerical conversion has no validated basis.

Case 84 — Delivery planned without a rare-antibody supply discussion

A pregnant patient has an antibody to a high-frequency antigen, but the transfusion service is first contacted when urgent blood is required during delivery.

Reasoned answer. Earlier communication could have supported reference investigation and rare-unit planning. The immediate situation still requires urgent coordinated care, but the case identifies a preventable system gap. Antenatal antibody findings should inform both fetal monitoring and maternal/neonatal component availability.

29 | Neonatal and Paediatric Compatibility

Infants are not small adults in immunohaematology. Their antibody production, maternal antibody exposure, blood volume and transfusion indications create different testing and component requirements. A valid neonatal pathway recognises these differences while maintaining the same core principles of identity, traceability and controlled selection. [FB19]

29.1 Maternal antibodies shape the early investigation

Maternal IgG can be present in the infant's circulation and can react with transfused red cells. The neonatal antibody investigation may therefore use maternal or infant material according to the programme. The laboratory should know whose specimen was tested and how it relates to the infant's compatibility plan.

Reverse ABO grouping is not interpreted as in an immunologically mature adult. Expected antibodies may be absent, and detected antibodies can be maternal. The age-specific procedure determines which tests are required and how the group is assigned. Applying an adult discrepancy rule without considering development can produce unnecessary or incorrect conclusions.

A maternal antibody history remains relevant even if a current infant specimen is weakly reactive or nonreactive. The selected red cells must account for clinically significant maternal antibodies under the authorised neonatal pathway.

29.2 Small volumes amplify some risks

A small component volume can represent a substantial proportion of an infant's blood volume. Plasma antibodies, additive solutions, potassium accumulation and other product characteristics may therefore have different implications than in a large adult. The relevant requirements depend on the transfusion type, infant's condition and local neonatal policy.

Component aliquots can reduce donor exposure when prepared and stored under validated conditions. The identity of the parent unit, aliquot, preparation time and expiry must remain traceable. An aliquot is not an unlabelled portion that can be handled independently of the original component record.

Dose calculations require weight, prescribed volume and product information. The laboratory should verify units and communicate discrepancies, but it should not independently replace the clinician's prescription with a textbook rule. All numerical examples here are teaching calculations, not patient orders.

29.3 Intrauterine and exchange transfusion

Intrauterine and exchange transfusions have specialised component requirements. Antigen compatibility with maternal antibodies, irradiation, preparation, freshness and other characteristics are governed by current programmes and supplier specifications. These products should be planned with the transfusion-medicine service rather than assembled through a generic neonatal checklist.

The distinction between a simple top-up transfusion and an exchange procedure is important. The volumes, exposure and physiological goals differ. A product suitable for one indication may not meet the requirements of another. The request must identify the intended procedure clearly.

After intrauterine transfusion, the infant's circulating red cells can be largely donor-derived. Serological grouping and phenotype interpretation must account for that history. The apparent result does not simply reveal the infant's inherited antigen profile.

29.4 DAT and bilirubin in context

A positive neonatal DAT can support the presence of antibody coating, but it does not by itself quantify haemolysis or predict the entire clinical course. Bilirubin and haemoglobin monitoring follow the neonatal clinical pathway, with attention to age in hours and other risk factors. A laboratory should not apply an adult reference framework to neonatal bilirubin interpretation.

A negative DAT does not exclude every cause of neonatal anaemia or jaundice. Nonimmune causes, low-level coating and erythroid effects may be relevant. The investigation should remain clinically directed and avoid using one test as a universal explanation or exclusion.

29.5 Transition to later childhood

As maternal antibodies decline and the child's immune system develops, testing requirements change. The laboratory should follow the age thresholds and conditions defined by its current policy rather than extending a neonatal shortcut indefinitely. Repeated transfusions and chronic disease can introduce alloimmunisation and matching issues that require a more individualised plan.

Paediatric identity controls remain essential. Similar names, multiple births, temporary identifiers and weight changes can create specific risks. The record should preserve a unique identity and current weight where dosing depends on it, with careful reconciliation when temporary identifiers are replaced.

Neonatal serology reflects maternal as well as infant biology

An infant's plasma can contain maternally derived IgG, and the infant may not yet have the expected pattern of naturally occurring ABO antibodies used in adult reverse grouping. The laboratory must therefore use an age-appropriate pretransfusion procedure. The Canadian guidance cited here omits routine reverse grouping in infants younger than four months; this is a labelled programme rule, not a universal age definition for every jurisdiction. [FB01, FB19]

A positive neonatal DAT may reflect antibody coating without establishing the severity of haemolysis. The clinical team evaluates bilirubin, haemoglobin, feeding, gestational age and other relevant factors. A weak DAT cannot be used alone to dismiss a clinically concerning infant, and a positive DAT does not automatically dictate one treatment.

Small component volumes create additional technical and traceability demands. Aliquots must remain linked to the parent unit, and the selected product must meet the infant's specific requirements. Dose calculations should carry units explicitly and be independently checked under the clinical procedure. The numerical examples in this book teach dimensional reasoning, not prescribing authority.




Figure FB29. Paediatric aliquots retain parent-unit traceability and applicable special requirements. The drawing does not specify a clinical dose or storage interval. Original CDIL educational schematic; not patient data.

Worked cases 85–87

Case 85 — Maternal anti-K omitted from the infant plan

The infant's current screen is weakly nonreactive, and the laboratory prepares K-positive red cells despite documented maternal anti-K.

Reasoned answer. Maternal antibody history remains relevant to neonatal compatibility. The authorised pathway should account for the clinically significant specificity and appropriate antigen-negative selection. A weak current result does not erase the exposure or justify ignoring the maternal record.

Case 86 — A dosing unit error

A fictional 3.2-kg infant has an authorised order for 10 mL/kg. A learner calculates 320 mL.

Reasoned answer. The arithmetic is 3.2 multiplied by 10, giving 32 mL, not 320 mL. The tenfold error could be serious in a small patient. The example illustrates dimensional checking and independent verification; it is not a recommendation that every infant should receive that dose.

Case 87 — Donor cells after intrauterine transfusion

An infant's red-cell phenotype differs from the predicted inherited profile after several intrauterine transfusions. A student declares the genetic result incorrect without reviewing the treatment history.

Reasoned answer. Donor-derived cells can dominate the circulating population. Serology and genotype may therefore be describing different biological sources. The laboratory should integrate the intrauterine-transfusion history and use the authorised neonatal testing strategy. The apparent discrepancy is not resolved by rejecting one method automatically.

30 | Suspected Transfusion Reactions and the Laboratory Investigation

A suspected transfusion reaction requires prompt clinical assessment and a coordinated laboratory response. The laboratory does not begin by deciding that the event must be immune haemolysis. Fever, respiratory symptoms, hypotension, pain and other findings can arise through several mechanisms, and more than one process may be present. The investigation should protect the patient, preserve evidence and establish the most defensible explanation. [FB18, FB20]

30.1 Immediate communication and identity checks

The bedside team follows its reaction protocol, including stopping the transfusion when indicated, assessing the patient and notifying the appropriate clinicians and transfusion service. The laboratory supports this response with urgent identity and component checks and the required testing. This textbook does not replace the institution's emergency clinical protocol.

The first laboratory question includes whether the correct component reached the correct patient. Patient identifiers, unit number, compatibility label, issue record and bedside documentation must be reconciled. A clerical discrepancy can be more immediately important than an advanced antibody panel. The remaining component and relevant specimens should be handled according to the reaction-investigation procedure.

A new specimen must be collected with rigorous identification. The pretransfusion specimen, post-transfusion specimen and donor segment should remain distinct. Mixing their labels can destroy the chronology needed to interpret the event.

30.2 Investigating haemolysis

Visual plasma haemolysis, haemoglobin change, bilirubin, lactate dehydrogenase, haptoglobin and urine findings can contribute to the assessment, but each has limitations. Collection-related haemolysis can mimic an in-vivo finding. Bleeding, dilution, liver disease and other conditions can affect laboratory markers. The interpretation should consider the complete clinical course.

Repeat ABO/RhD testing, antibody screening, DAT and crossmatch investigations may be indicated under the protocol. Comparing pre- and post-transfusion results helps determine whether a finding is new. An eluate or additional antibody identification may be useful when sensitised donor cells are suspected.

A negative DAT does not exclude every haemolytic reaction. Extensive destruction of incompatible cells, low-level coating or nonimmune mechanisms can affect the result. Conversely, a positive DAT without haemolysis does not prove that the transfusion caused the symptoms. The laboratory should report the evidence and its limits.

30.3 Acute and delayed patterns

Acute immune haemolysis can occur when pre-existing antibodies react with transfused cells, including severe ABO incompatibility. Delayed haemolysis can follow an anamnestic response to an antigen encountered in the transfusion. The timing of symptoms, haemoglobin changes and new antibody findings helps organise the investigation but does not uniquely determine the cause.

A delayed serological reaction can involve a newly detected antibody without clear evidence of haemolysis. It should be distinguished from a delayed haemolytic reaction because the clinical consequence differs. Both findings may affect future component selection and should be recorded accurately.

Hyperhaemolysis and complex post-transfusion haemolytic syndromes require specialist assessment, particularly in patients with haemoglobinopathies. The laboratory should communicate

promptly and avoid recommending further transfusion solely from a low haemoglobin value without the relevant clinical review.

30.4 Nonimmune and nonhaemolytic possibilities

Bacterial contamination, mechanical or thermal damage, incompatible solutions and other nonimmune processes can cause or mimic haemolysis. Fever can reflect febrile nonhaemolytic reactions, infection or the underlying illness. Allergic reactions, circulatory overload and acute lung injury require different clinical assessments.

TACO and TRALI are not diagnosed by an antibody screen. Their definitions and investigations involve respiratory findings, timing, fluid status and other clinical criteria, with donor investigations in selected circumstances. The transfusion laboratory should support the current haemovigilance framework without forcing every respiratory event into one category from a single result.

If contamination is suspected, appropriate patient and component cultures and supplier notification may be required under the protocol. Related components may need to be traced or quarantined. The laboratory's role extends beyond the single specimen to protecting other recipients when a product-related risk is plausible.

30.5 Close the investigation and preserve learning

The final conclusion should distinguish the reaction category, severity, imputability and evidence according to the applicable haemovigilance system. Uncertainty should be recorded explicitly. A provisional suspicion may change as additional results arrive, and corrected conclusions must reach the treating team and relevant reporting systems.

The patient's record should retain newly identified antibodies and future component requirements. The quality review should examine contributing process failures without assuming that every reaction was preventable or that every error was caused by one person's carelessness. The purpose is both immediate patient care and prevention of recurrence.

A reaction investigation tests competing mechanisms

Fever, hypotension, dyspnoea or haemoglobinuria during transfusion can arise through different mechanisms. Immune haemolysis, bacterial contamination, allergic reactions, circulatory overload and other causes require different evidence. The first response follows the emergency reaction procedure; the subsequent investigation should avoid assigning a final category from one symptom alone.

A clerical check can reveal an identity or unit mismatch that immediately changes the risk assessment. Comparison of pre- and post-transfusion specimens can identify new haemolysis or serological changes. Microbiology testing, respiratory assessment and other investigations are selected according to the clinical presentation and current protocol. [FB20]

The report should distinguish a newly detected abnormality from proof of causation. A positive DAT found after transfusion may have been present before it. Haemolysis in a poorly collected sample may be in vitro rather than intravascular. Preserved pretransfusion material, accurate timing and clinical correlation help resolve these possibilities.




Figure FB30. A reaction investigation compares pretransfusion evidence, administration timing, symptoms and post-event specimens. The timeline helps distinguish association from established causation. Original CDIL educational schematic; not patient data.

Worked cases 88–90

Case 88 — A new antibody without demonstrated haemolysis

An antibody becomes detectable after transfusion, but the patient has no established haemoglobin fall or other evidence of increased red-cell destruction. The learner labels the event a proven delayed haemolytic reaction.

Reasoned answer. The serological finding is important, but haemolysis has not been established. A delayed serological reaction may be the more appropriate description pending the complete assessment. The antibody should still be retained in the history and considered for future selection. Accurate classification prevents both underreporting and overstatement.

Case 89 — Haemolysed post-transfusion specimen from a difficult collection

A post-transfusion tube is visibly haemolysed after a difficult draw. The pretransfusion sample is clear, but clinical evidence is incomplete.

Reasoned answer. In-vivo haemolysis is possible, but collection-related damage must be considered. The laboratory should follow the reaction protocol, obtain appropriate additional evidence and avoid assigning causation from appearance alone. A correctly collected repeat specimen and the broader clinical markers may help resolve the discrepancy.

Case 90 — Respiratory distress called an antibody reaction from a negative screen

A patient develops respiratory distress during transfusion. The antibody screen is negative, and a trainee concludes that no transfusion reaction is possible.

Reasoned answer. Many transfusion reactions are not excluded by a red-cell antibody screen. TACO, TRALI, allergy, contamination and other causes require clinical assessment and the relevant investigation. The screen answers a specific immunohaematological question, not whether every transfusion-related complication is absent.

31 | Repeated Transfusion, Haemoglobinopathies and Alloimmunisation

Patients who receive repeated red-cell transfusions face cumulative exposure to donor antigens. The compatibility problem is therefore longitudinal: today's selection should account for past antibodies and future transfusion needs. In haemoglobinopathies, particularly sickle cell disease, alloimmunisation and complex haemolytic reactions can make transfusion support especially demanding. A planned matching strategy is safer than rebuilding the patient's history during each emergency. [FB21]

31.1 Establish the baseline before exposure where possible

An extended antigen profile obtained before transfusion can provide a valuable reference. Serology and genotyping offer complementary information, and molecular methods can help identify variants not fully resolved by common reagents. The appropriate profile and matching strategy follow current specialist guidance and local resources.

After transfusion, donor cells can complicate serological phenotyping. The current circulating phenotype may not represent the patient's inherited red-cell profile. Reliable baseline records and genotyping can reduce this uncertainty, although molecular interpretation must account for method coverage and any history of haematopoietic transplantation.

The record should be accessible across institutions where the patient receives care. A patient-held antibody card can help but does not replace verified laboratory records. Imported information must be linked to the correct person, with the original specificity and supporting evidence preserved.

31.2 Matching reduces selected risks but is not a guarantee

Prophylactic matching for selected antigens can reduce alloimmunisation in defined patient groups. The exact extent of matching depends on the condition, antibody history, genotype, current guideline and donor availability. A textbook should not prescribe one universal panel for every repeatedly transfused patient.

Rh variants can complicate apparently matched transfusions. A patient may express common Rh antigens serologically but lack particular epitopes, allowing alloimmunisation despite routine matching. Molecular characterisation and specialist interpretation can help refine the plan. The problem is not solved by assuming that every patient and donor with the same five common Rh antigen results is identical at all relevant epitopes.

Matching also has supply consequences. Very extensive requirements can limit available units and delay treatment. The transfusion-medicine team balances preventive benefit, known antibodies, clinical urgency and inventory. These decisions should be planned and documented, not improvised by an individual operator under pressure.

31.3 Evanescent antibodies and fragmented records

A clinically significant antibody can become undetectable over time. If the patient attends a new institution with no access to the earlier record, a negative current screen may lead to antigen re-exposure. This is a system vulnerability rather than proof that the antibody never existed.

Permanent retention of verified antibody history is therefore important. The information system should distinguish confirmed historical specificities from unverified notes while ensuring that important restrictions remain visible. A record that says only "crossmatch difficult" does not provide the antigen requirements needed for safe selection.

Communication should include unresolved or variant findings where they affect care. A reference laboratory's detailed report may contain the reason that ordinary serological matching is insufficient. Reducing that report to a broad positive/negative flag can lose essential information.

31.4 Delayed haemolysis and hyperhaemolysis

A delayed haemolytic transfusion reaction can involve destruction of transfused cells after an immune response becomes evident. Hyperhaemolysis is a complex clinical syndrome in which haemoglobin may fall below the pretransfusion level and destruction can involve more than the transfused population. Specialist assessment is essential, and the laboratory should not assume that a negative antibody screen excludes the syndrome.

The investigation considers timing, haemoglobin fractions where relevant, reticulocyte response, haemolysis markers, DAT, antibody findings and the transfusion record. These measurements require clinical integration. A low haemoglobin result alone does not determine whether further transfusion is the safest immediate treatment.

Urgent communication is necessary when such a reaction is suspected. The laboratory should preserve specimens and unit information and involve the transfusion-medicine team. The final diagnosis and management require the appropriate clinical expertise and current guidance.

31.5 A durable support plan

A long-term plan should state the verified antigen profile, historical antibodies, current matching requirements, special component needs, reference contacts and emergency alternatives. It should be reviewed when new antibodies, treatment or transplantation changes the situation.

The plan should also distinguish routine availability from emergency contingencies. A patient who needs rare units may benefit from advance scheduling and supplier coordination. The goal is to reduce

both alloimmunisation risk and avoidable delay, recognising that no matching strategy eliminates every possible complication.

Matching policy is supported by both evidence and biology

ASH guidance for sickle cell disease recommends prophylactic matching for Rh C/E or C/c/E/e and K rather than ABO/RhD alone. It also supports early extended antigen profiling, preferably before the first transfusion, and recognises that broader matching can provide additional protection in selected circumstances. The strength of evidence differs between recommendations and should not be flattened into one universal rule. [FB21]

The biological rationale is reduction of antigen exposure to targets that commonly stimulate clinically significant alloantibodies. However, variant Rh expression and antibodies to other systems can still cause problems. Matching reduces selected risks; it does not eliminate every possible immune response.

A durable plan combines the verified profile, antibody history, patient condition and donor availability. When a new antibody develops despite matching, investigate the mechanism rather than assuming that the concept of matching has failed. The case may reveal a variant, an unrecognised exposure or an additional antigen requirement.




Figure FB31. The clinically significant antibody history remains relevant even when a current screen is negative. Matching and specialist plans should follow the verified record. Original CDIL educational schematic; not patient data.

Worked cases 91–93

Case 91 — A matched label conceals a Rh variant

A patient with sickle cell disease develops an Rh antibody despite units matched for the common C, c, E and e profile. The learner assumes that matching must have been performed incorrectly.

Reasoned answer. A technical error should be considered, but qualitative Rh variants can create epitope differences not captured by common serological matching. Molecular and reference investigation may clarify the mechanism. The event does not automatically invalidate every previous test; it identifies the need for a more detailed compatibility assessment.

Case 92 — The current negative screen erases history

A patient's anti-Jkb is not detectable at the new hospital, and the old antigen restriction is removed.

Reasoned answer. Evanescence does not erase immunological memory or historical significance. The verified antibody should

remain in the record and component plan. The new service should obtain the original report and reconcile it accurately. A current assay result and a historical biological risk are different forms of evidence.

Case 93 — More blood ordered without reaction review

After transfusion, a patient's haemoglobin falls below the pretransfusion value and a complex haemolytic syndrome is suspected. A trainee recommends immediate additional units solely from the low number.

Reasoned answer. The situation requires urgent specialist clinical assessment because additional transfusion may have particular risks in a hyperhaemolytic or delayed-reaction setting. The laboratory should communicate the trend and relevant findings promptly and support the authorised plan. A numerical trigger cannot replace evaluation of the mechanism causing the fall.

32 | Genotyping, Mixed Populations and Haematopoietic Transplantation

Molecular testing can predict selected blood-group antigens and clarify complex serology. Its value is greatest when the laboratory understands what biological material was tested and which variants the method detects. After transfusion or haematopoietic transplantation, red cells, nucleated cells and plasma antibodies may originate from different sources or reflect different time points. [FB02, FB03, FB22]

32.1 A molecular prediction has a defined scope

Targeted assays detect selected variants associated with antigen expression. Broader sequencing can identify additional changes, but interpretation still depends on evidence connecting sequence to phenotype. A novel variant may not have a fully established serological effect. The report should distinguish detected sequence information from predicted antigen expression.

Assay coverage matters. Structural variants, hybrids, copy-number changes and regulatory variants may not be captured by every platform. A negative result for a common allele is not proof that no other mechanism can affect the antigen. Serological discordance should prompt review rather than automatic dismissal of one method.

Phase can also be important: determining which variants occur together on the same inherited allele may affect interpretation. A list of detected changes without the relevant phase information can be insufficient for a complete prediction in complex systems.

32.2 Recent red-cell transfusion

Mature donor red cells can alter the serological phenotype of the circulating specimen but do not normally provide the nucleated-cell DNA used for routine patient genotyping. This makes molecular testing useful in many recently transfused patients. However, the laboratory should consider residual donor leucocytes, unusual clinical circumstances and the method's validated specimen requirements rather than state that transfusion can never affect any molecular investigation.

The result should be linked to the patient's clinical history. If the current red-cell phenotype and genotype differ, donor-cell mixture may explain the discrepancy. The report should state which result is being used for underlying antigen prediction and which describes the current circulating population.

32.3 Haematopoietic transplantation changes the source problem

After haematopoietic stem-cell transplantation, nucleated blood cells can become donor-derived. A blood DNA specimen may therefore reflect the donor haematopoietic genotype rather than the recipient's original genotype. Red-cell and plasma patterns can change at different rates during engraftment and immune reconstitution.

ABO-incompatible transplantation can create major, minor or bidirectional incompatibility patterns. Major incompatibility concerns recipient antibodies against donor red-cell antigens; minor incompatibility concerns donor-derived antibodies against recipient red cells. Bidirectional incompatibility includes both directions. The support plan must follow the transplant programme's phase-specific requirements.

A single current ABO result should not replace the documented donor–recipient plan during transition. Component selection may need to protect against antibodies and antigens from both sources. The laboratory should know the transplant date, donor group, recipient group, engraftment status and current antibodies.

32.4 Chimerism and mixed-field interpretation

Mixed-field serology can reflect two cell populations, while molecular chimerism assays examine the contribution of different genetic sources. These measurements are related but not interchangeable. A small donor-derived nucleated-cell population and the proportion of donor red cells need not be identical at the same time point.

The method's detection limit and target cells affect interpretation. A result described as complete donor chimerism under one assay does not necessarily mean that every cell in every tissue is donor-derived. Reports should retain the specimen type, cell population and analytical sensitivity.

The laboratory should avoid using blood-group changes to infer transplant success or failure without the appropriate haematology and molecular evidence. Immunohaematology contributes to the support plan, but it is not a standalone transplant-outcome assessment.

32.5 Reconcile records without deleting history

The patient's original blood group and antibody history remain important even when the current haematopoietic phenotype changes. The information system should represent the transition clearly rather than overwrite the old record as if it had been wrong. Donor and recipient identities must remain distinct and linked through the transplant record.

A controlled change plan should specify when component requirements can change and who authorises that change. The decision should be based on the programme's criteria, not on the first convenient-looking current result. Clear documentation prevents different shifts or institutions from applying incompatible assumptions.

Genotype depends on which cells supplied the DNA

Most mature red cells lack nuclei, so routine patient genotyping commonly uses DNA from nucleated cells. After ordinary red-cell transfusion, molecular testing can therefore help predict the patient's underlying antigen profile when serological phenotyping is obscured by donor red cells. The laboratory still considers specimen quality, residual donor leucocytes and method-specific limitations.

After haematopoietic transplantation, circulating nucleated cells may become donor-derived. Blood DNA can then describe the donor haematopoietic genotype rather than the recipient's original genotype. A nonhaematopoietic specimen may be needed for a different biological question, with collection and interpretation directed by the specialist laboratory. [FB02, FB22]

The report should state the source and intended inference. "Predicted red-cell antigen expression from this genotype" is not the same statement as "the current circulating red cells all have this phenotype." Mixed populations and transition phases require both molecular and serological evidence.




Figure FB32. After haematopoietic transplantation, blood DNA, circulating red cells and plasma antibodies may reflect different sources and time points. Use the phase-specific donor–recipient plan. Original CDIL educational schematic; not patient data.

Worked cases 94–96

Case 94 — Blood DNA after transplantation

A recipient's blood genotyping result after haematopoietic transplantation matches the donor rather than the recipient's historical profile. A learner calls the result a specimen error without reviewing chimerism.

Reasoned answer. Donor-derived nucleated blood cells can determine the DNA result after transplantation. Identity still requires verification, but the biological source of the tested cells is central. The laboratory should interpret the result within the transplant history and use the appropriate specimen or historical data for the intended question.

Case 95 — One current ABO result replaces the transplant plan

During an ABO-incompatible transplant transition, the current forward group resembles the donor. A scientist immediately changes every component requirement without authorisation.

Reasoned answer. Antigens, antibodies and cell populations can change at different rates. The phase-specific transplant-support plan should govern the transition, using the required evidence and authorised decision. One current forward group does not establish that all incompatibility risks have disappeared.

Case 96 — Historical antibodies deleted after engraftment

The information system removes the recipient's previous alloantibodies when the donor group becomes established.

Reasoned answer. The history should remain traceable and interpreted within the transplant plan rather than erased. Its relevance can change, but deletion prevents informed review and can create future confusion. Controlled records should distinguish original recipient information, donor information and current support requirements.

33 | Antibodies to High-Frequency Antigens and Rare-Donor Support

An antibody to a high-frequency antigen can react with nearly every routine reagent or donor cell available locally. The problem is difficult because ordinary panels provide little antigen-negative comparison evidence and compatible units may be scarce. The response requires precise investigation, early communication and access to characterised rare cells and donors. [FB02, FB03]

33.1 Panreactivity begins a differential

Broad reactivity with a negative autocontrol can suggest an alloantibody to a high-frequency antigen, but it is not unique to that explanation. Multiple alloantibodies, drug effects, technical interference and selected autoantibody patterns can produce similar results. The laboratory should first confirm that the pattern is real and review the patient's transfusion and treatment history.

Patient phenotype or genotype can identify absent high-frequency targets and guide selected testing. A rare antigen-negative cell can be highly informative when it breaks the otherwise uniform pattern. The interpretation should also consider whether the patient has additional antibodies that react with the selected rare cell.

A rare phenotype should not be assigned from a single negative antigen-typing reaction without adequate controls. Weak expression, reagent limitations and cell coating may complicate the result. Reference confirmation is often essential because the component consequences are substantial.

33.2 High-titre, low-avidity patterns

Some antibodies historically grouped as high-titre, low-avidity produce weak, variable or delicate reactions with many cells. The category describes a serological pattern rather than a single antigen system or uniform clinical significance. Examples include selected Chido/Rodgers and Knops-related specificities, but the actual antibody should be characterised where necessary. [FB02]

Neutralisation or inhibition can help investigate selected specificities, with appropriate dilution controls. The procedure may reveal an underlying clinically significant antibody previously obscured by the broad pattern. A successful inhibition step does not remove the need for a complete remaining-plasma assessment.

The laboratory should avoid labelling every weak panreactive specimen HTLA and stopping. Such a shortcut can conceal clinically important antibodies or technical problems. The conclusion must be supported by the specific pattern and validated investigation.

33.3 Rare-donor search and frozen inventory

Rare-donor programmes maintain information about donors with uncommon antigen profiles and may provide frozen components. Availability depends on confirmed phenotype, donation timing, component preparation, transport and regulatory requirements. A database match is not the same as a unit physically available for immediate transfusion.

The requesting laboratory should communicate the exact antigen requirements, antibody history, number of units, clinical urgency and planned date. Overly broad or ambiguous requests can delay the search. The reference laboratory and supplier can help determine whether every requested restriction is necessary and how to prioritise limited inventory.

Family testing may be useful in selected rare phenotypes, but it requires consent, appropriate donor qualification and careful interpretation. A relative is not automatically a suitable or safe donor, and related donations can introduce additional component requirements under policy.

33.4 Clinical urgency and unavoidable uncertainty

When compatible units are unavailable and the patient's need is urgent, the transfusion-medicine and treating teams must balance the risks of delay against the available alternatives. The laboratory provides the best established serological information and the likely significance of the unresolved incompatibility. It should not make an independent clinical decision to withhold all support indefinitely.

The record should state what was known, which units were selected, the unmet requirement if any and the authorisation. Follow-up monitoring and continued investigation may be needed. An emergency decision is not made safer by describing it afterward as if full compatibility had been established.

33.5 Preserve the solution for the next admission

Once a rare specificity or phenotype is established, the result should be recorded in a durable, accessible form. The patient may need a clear antibody card and a documented reference contact. Future planned procedures should trigger early supplier communication.

The record should include the method and confidence of the identification. An uncertain historical rare-antibody label can impose substantial restrictions, while a missing confirmed label can expose the patient to risk. Accurate classification and traceable evidence protect both the patient and the limited donor resource.

Rare support requires a precise target

An antibody to a high-frequency antigen can make routine panel cells and donor units broadly reactive. The reference laboratory may use rare cells, molecular information, adsorption, inhibition or other specialised techniques to define the specificity. A rare phenotype should be confirmed by methods appropriate to the suspected system.

The search for suitable units then depends on the actual requirement, the patient's urgency and the clinical significance of the antibody. Frozen inventories and international donor networks can be valuable, but transport, preparation and regulatory requirements

affect timing. A rare-donor database entry is not equivalent to an immediately available, verified component. [FB02, FB15]

A patient-specific record should preserve the confirmed phenotype or genotype, antibody specificity, compatible-unit history and reference contact. This turns a difficult first investigation into a usable future plan. The information should remain accessible across care settings, particularly when the patient is likely to require repeated transfusion.




Figure FB33. A confirmed target, suitable donor search, component preparation and transport all affect the support plan. A database match is not an immediately available unit. Original CDIL educational schematic; not patient data.

Worked cases 97–99

Case 97 — One rare cell breaks the pattern

Routine cells are uniformly reactive, but a well-characterised cell lacking a candidate high-frequency antigen is nonreactive. The patient also appears to lack that antigen.

Reasoned answer. The contrast strongly supports the candidate specificity, but confirmation and exclusion of additional antibodies remain necessary. The rare cell's full antigen profile and control validity must be considered. The result is more informative than

another routine positive cell because it tests the proposed target directly.

Case 98 — A registry match mistaken for immediate stock

A donor registry identifies a suitable phenotype, and the learner promises the clinical team that units will arrive within an hour without contacting the supplier.

Reasoned answer. A donor record does not establish current component availability, preparation or transport time. The supplier must confirm inventory and logistics. The laboratory should communicate an evidence-based estimate and update it as arrangements are made, rather than convert a database match into a delivery guarantee.

Case 99 — A vague rare-antibody label

An old record says "rare antibody" but contains no specificity or reference report. The patient now needs surgery.

Reasoned answer. The laboratory should retrieve the original evidence and begin appropriate current investigation early. The vague label is clinically relevant but insufficient to define exact antigen requirements. It should not be ignored, nor should an arbitrary rare phenotype be assumed. Accurate historical reconstruction can prevent both unsafe exposure and unnecessary restriction.

34 | Platelet Antibodies, HLA, HPA and Refractoriness

A poor platelet increment after transfusion can arise through immune or nonimmune mechanisms. Infection, fever, bleeding, consumption, splenic sequestration and other clinical factors are common contributors. HLA or platelet-specific antibodies may also be important. The laboratory investigation should therefore begin with a reproducible clinical pattern and correctly timed measurements rather than a reflex assumption that every low count is antibody-mediated. [FB23]

34.1 Define the response being measured

A post-transfusion platelet count depends on the baseline count, timing, dose and the patient's distribution and consumption of platelets. A corrected count increment adjusts the observed increment for body surface area and platelet dose under a specified formula. It is useful only when the inputs are reliable and the timing matches the clinical framework.

A count drawn too late or after intervening bleeding and treatment may answer a different question from an early post-transfusion count. The laboratory should preserve the collection times and component details. A calculation cannot repair missing or inappropriate source data.

Thresholds and the required number of poor responses vary by guideline and programme. This book explains the calculation but does not impose one universal definition of refractoriness. The clinical team should use the current local or national framework.

34.2 A worked corrected count increment

For an illustrative formula using platelet increment in platelets per microlitre, body surface area in square metres and dose in units of 10^11 platelets, CCI equals increment multiplied by body surface area divided by dose. A fictional increment of 20,000/µL, body surface area 1.8 m² and dose 3.0 × 10^11 gives 12,000 under that convention.

If the platelet count is expressed in 10^9/L, the numerical increment is 20 rather than 20,000. The formula and reporting convention must account for that unit change. A thousandfold error can arise when the units are mixed. The laboratory should state the convention used and verify the dimensions.

The calculated value is not a diagnosis by itself. Timing, repeated responses and clinical causes of consumption remain necessary for interpretation. A normal early increment followed by a poor later count may suggest a different mechanism from a consistently poor early response.

34.3 HLA and platelet-specific antibodies

Platelets express HLA class I, and antibodies to relevant HLA antigens can contribute to immune refractoriness. HPA antibodies recognise platelet-specific polymorphic targets and can be involved in selected transfusion and pregnancy-related conditions. HLA and HPA are different systems and require different investigations.

Antibody detection should be interpreted with the donor antigen and clinical pattern. A positive HLA antibody screen does not establish that every available platelet unit will be ineffective. The specificity, strength under the assay, donor compatibility and programme's selection method matter.

Platelet crossmatching, HLA-selected components or other strategies can be used under specialist guidance. The best approach depends on antibody profile, available inventory and urgency. The laboratory should not promise a guaranteed increment from a matched label because nonimmune consumption can persist.

34.4 Fetal and neonatal alloimmune thrombocytopenia

Maternal antibodies to fetal platelet antigens can cause fetal or neonatal thrombocytopenia in an alloimmune setting. This is different from red-cell HDFN. The relevant antigen systems, laboratory methods and management pathways differ, even though maternal IgG transfer is a shared principle.

The investigation requires specialist platelet-immunology support and clinical assessment. Maternal and paternal or fetal antigen information may be relevant, with appropriate consent and current guidance. A routine red-cell antibody screen does not exclude platelet alloantibodies.

34.5 Coordinate laboratory and clinical evidence

A useful report states the antibody findings, method, relevant antigen interpretation and selection implications. It should also acknowledge that a poor increment can have nonimmune causes. The transfusion service, haematology team and supplier should agree on how response will be measured after selected components are given.

Repeated counts without a timing plan can create data without resolving the mechanism. The investigation is strongest when the next transfusion is treated as a controlled clinical observation with appropriate baseline and follow-up measurements, while the patient's urgent needs remain the priority.

Correcting the increment separates dose from response

The platelet increment is the post-transfusion count minus the pretransfusion count. The corrected count increment adjusts that change for body surface area and platelet dose. When the increment is expressed per microlitre and the dose is expressed in units of 10^11 platelets, CCI equals increment multiplied by body surface area and divided by the dose number. The unit convention must be stated because alternative reporting systems use different numerical scales.

For an increment of 20,000/µL, body surface area 1.8 m² and dose 3 × 10^11, the calculation is 20,000 × 1.8 / 3 = 12,000. Using the number 20 from a count expressed in 10^9/L without converting the convention would produce a value on a different scale. [FB23]

Timing and repetition matter. A poor early response can suggest immune destruction, but fever, infection, bleeding, consumption, splenomegaly and product factors can also affect recovery. Refractoriness is not synonymous with HLA alloimmunisation. The clinical and laboratory investigation should distinguish immune from nonimmune explanations before selecting specialised support.




Figure FB34. Synthetic example: increment 20,000/µL × body surface area 1.8 m² ÷ dose 3 (in 10^11 platelets) = 12,000. Timing and nonimmune causes remain part of interpretation. Original CDIL educational schematic; not patient data.

Worked cases 100–102

Case 100 — A thousandfold CCI error

A platelet increment is 20 × 10^9/L. The learner inserts 20 into a formula requiring platelets per microlitre and reports a value a thousand times too small.

Reasoned answer. Twenty × 10^9/L equals 20,000/µL. The formula's units must match the inputs. The calculation should be

corrected and interpreted only within the programme's timing and threshold framework. Dimensional analysis prevents an apparently severe poor-response label created solely by unit mismatch.

Case 101 — HLA antibody as the only explanation

A patient has a poor platelet increment, active bleeding and fever. HLA antibodies are detected, and the learner attributes the entire response to immunity.

Reasoned answer. Immune and nonimmune mechanisms can coexist. The antibody finding is relevant but does not eliminate bleeding, consumption or other causes. Correctly timed increments and the clinical context are needed to guide selection and expectations. Matched components may not fully correct a nonimmune problem.

Case 102 — Red-cell screen used to exclude platelet disease

A neonate has severe thrombocytopenia, but the maternal red-cell antibody screen is negative. The learner says alloimmune thrombocytopenia is excluded.

Reasoned answer. Red-cell screening does not test the platelet-specific antigen systems involved in that condition. Specialist platelet-antibody and antigen investigations may be required. Similar maternal–fetal mechanisms do not make the laboratory assays interchangeable.

35 | The Reference-Laboratory Consultation

A reference laboratory adds specialised reagents, methods and expertise when routine testing cannot resolve a clinically important problem. Referral is not a failure of the local scientist. It is an appropriate extension of the diagnostic system, provided the referral includes reliable material, clear questions and enough context to guide the work. [FB02, FB15]

35.1 Refer a question, not just a tube

A useful referral states the clinical urgency, transfusion or pregnancy context, raw reaction pattern, methods used, controls, previous antibodies and relevant treatment. The reference scientist needs to know what remains unresolved and which decisions depend on the answer. A label saying "positive screen" may be insufficient.

Specimen requirements should be agreed before dispatch. Volume, anticoagulant, red-cell availability, transport temperature and timing can affect the methods available. Sending an unsuitable or exhausted specimen can delay the investigation more than an early telephone consultation would have.

The local laboratory should retain appropriate material and records. A reference investigation may require comparison with earlier samples or donor segments. The chain of identity and collection chronology must remain intact across institutions.

35.2 Avoid destroying evidence before referral

Repeated adsorption, enzyme treatment or other modifications can consume specimen and alter the available information. The local laboratory should consider the likely reference needs before using all material. Modified fractions should be labelled clearly and sent only with full method details when requested.

The original raw observations are valuable even when the local interpretation is uncertain. A complete worksheet, reagent lot profile

and images can help the reference laboratory understand a pattern that may change with time or specimen condition. The referral should not include only the final suspected antibody name.

A technically invalid local result should be identified as such. Concealing a failed control or specimen problem can lead the reference scientist down an inappropriate path. Accurate limitations improve the consultation.

35.3 Communicate interim findings

Complex investigations can take time. The reference laboratory may provide interim information that supports a component plan before every specificity is fully characterised. The local and clinical teams should understand which conclusions are established and which remain provisional.

An interim report should not be copied into the permanent record as a final confirmed specificity without the later reconciliation. Conversely, clinically important interim warnings should not be lost because they were communicated by telephone. The record should capture the date, recipient and content of critical communication.

The laboratory should agree on who is responsible for updating the clinical team and supplier. Ambiguous responsibility can leave everyone assuming that someone else has communicated a change.

35.4 Standards and method authority

Reference laboratories operate under applicable accreditation and standards frameworks. AABB's 14th edition of Standards for Immunohematology Reference Laboratories became effective in April 2026. This edition is a current standards reference, not a claim that CDIL or a reader's laboratory is accredited to it. The proprietary standards must be obtained and implemented through the appropriate organisation. [FB15]

A textbook can explain the reasoning behind quality requirements but should not reproduce a licensed standard as if it were an authorised local procedure. Laboratories must verify the current edition, national requirements and their scope of accreditation.

35.5 Close the loop

When the final report arrives, reconcile it with the local record, component restrictions and patient-held information. If the final interpretation differs from the preliminary one, the change should be communicated and documented. The report should remain accessible for future admissions.

The local laboratory can also learn from the investigation. A review of the decisive method, missed clue or specimen requirement can improve future practice. The purpose is not to memorise one rare answer but to understand why the reference strategy worked and when a similar referral would be appropriate.

Referral quality determines how much the specialist can infer

A reference laboratory receives a selected view of the case. Missing transfusion dates, treatment names, reaction phases or historical antibodies can change the interpretation of the same specimen. The referral should therefore state the clinical question, urgency, tests already performed, controls, specimen timing and the specific unresolved issue.

Sending only the final local interpretation can conceal useful discordance. Original reaction grids, instrument images and relevant raw observations allow the reference team to evaluate the reasoning. Conversely, sending every unrelated record without identifying the question can obscure the essential information. A concise structured summary with supporting data is more useful than either extreme. [FB02, FB15]

The final reference report should be incorporated into a patient support plan. An intricate antibody name without its practical component requirements is not enough for the next emergency. The local and reference services should agree on what is confirmed, what remains uncertain and which future findings require renewed investigation.




Figure FB35. A useful referral connects the clinical question with original observations and relevant history. The final report should become a practical patient-support plan. Original CDIL educational schematic; not patient data.

Worked cases 103–105

Case 103 — All material consumed before referral

A local laboratory performs repeated modified tests until no untreated plasma remains. The reference service then requests original material to investigate an unresolved mixture.

Reasoned answer. Early consultation could have preserved the necessary evidence and avoided recollection or delay. Specimen use should be planned around the likely investigation. The referral should clearly identify which fractions remain and what treatments were applied, rather than presenting modified material as untreated plasma.

Case 104 — A preliminary specificity becomes permanent

An interim report says "anti-U suspected; confirmation pending." The local system records confirmed anti-U and never reconciles the final report, which identifies a different specificity.

Reasoned answer. The provisional status was lost. The record must distinguish suspected from confirmed findings and include a process for reviewing final reports. Incorrect permanent restrictions can delay future transfusion, while missing the correct specificity can create risk. Closing the loop is part of the investigation.

Case 105 — Accreditation claimed from reading a standard

A laboratory obtains the current AABB reference-laboratory standard and tells patients it is now AABB-accredited.

Reasoned answer. Accessing or studying a standard does not confer accreditation. Accreditation requires the organisation's applicable process and documented approval. The laboratory should describe its actual status accurately and use the standard to guide implementation without inventing a credential.

36 | Automation, Information Systems and Controlled Downtime

Automation changes the distribution of work in a transfusion laboratory, but it does not remove responsibility for the result. Instruments identify specimens, dispense reagents, incubate reactions, acquire images and apply interpretation rules. Information systems connect those results to historical antibodies, component records and release decisions. A failure at any connection can make a technically correct reaction unsafe for the wrong patient. [FB01, FB02, FB15]

36.1 Follow the complete information path

A specimen barcode identifies a record; it does not independently prove that the blood came from the person named on the label. Positive patient identification and correct collection remain upstream requirements. When a laboratory accession number is generated, the relationship between that number, the patient identifier and the physical tube must remain traceable through aliquots and instrument racks.

An instrument result may move through middleware before reaching the laboratory information system. Middleware can translate reaction grades, apply rules and flag exceptions. Each translation should preserve the meaning of the original result. A weak or mixed-field reaction must not become an uncomplicated negative merely because the receiving system lacks a corresponding field.

The release process adds another layer. A result can be analytically complete but not yet authorised, or authorised for reporting without satisfying electronic issue requirements. The system should distinguish these states explicitly. A green instrument status is not a universal permission to transfuse.

36.2 Validate rules, not only interfaces

Interface testing should examine the actual clinical decision rules. Test cases include a patient with no previous record, a conflicting historical ABO group, an expired specimen, a historical clinically significant antibody, a newly reactive screen, a component with the wrong antigen status and a manually amended result. The expected behaviour should be defined before testing.

A successful transmission of one routine ABO result is insufficient validation. The system must handle exceptional and contradictory data safely. It should also preserve audit trails: who changed a result, when it changed, the previous value and the reason for amendment. Silent overwriting makes later investigation difficult.

Access permissions should match roles. The ability to enter a result need not include authority to override a compatibility restriction. Shared accounts obscure accountability and should not be used as a convenience substitute for appropriate access management. A temporary emergency workflow should still identify the responsible operator and authorising clinician.

36.3 Automated reaction images require interpretation

Column agglutination and solid-phase systems produce method-specific patterns. Image-analysis algorithms classify those patterns under validated conditions. Air bubbles, fibrin, haemolysis, abnormal cell settling, mixed populations and dispensing problems can create images that require human review. The operator should know the system's flags and its limitations rather than treating every unusual image as a software defect.

Review should connect the image with the reagent, specimen and control data. A reaction that appears weak can be clinically important, whereas a visually striking artefact may not represent antibody binding. The response is structured investigation, not an arbitrary rule that automation always wins or manual reading always wins.

The original image and interpretation should be retained according to the laboratory's record policy. Repeating the test without preserving the discrepant result can erase useful evidence. Where an amended result affects an issued component, the communication and clinical consequences must be addressed promptly.

36.4 Downtime is a different controlled process

A planned downtime procedure identifies the minimum records needed to continue safely: patient identity, verified historical groups and antibodies, current specimen validity, component identity and status, compatibility results, special requirements and issue traceability. The procedure should state which functions must stop if the required information cannot be obtained.

Paper or local backup records should not be assumed complete simply because they are available. Their last update time and scope matter. A backup taken before a newly identified anti-K was entered may omit a critical restriction. Staff must understand how to obtain recent changes and how to escalate uncertainty.

When normal service returns, reconciliation is essential. Components issued during downtime, results generated manually, emergency releases and amendments must be entered without creating duplicate or contradictory records. A second check should confirm that the permanent record represents what actually happened. Recovery is not complete when the server restarts; it is complete when the clinical and inventory histories have been reconciled.

Validation must challenge the unsafe path

A software rule is meaningful because of the states it permits and blocks. To test an electronic issue process, the laboratory should deliberately present cases that must not pass: conflicting ABO records, historical significant antibodies, expired samples, invalid controls, unresolved manual edits and inappropriate component attributes. A rule that works only on routine eligible patients has not demonstrated safe exception handling.

The test should follow the complete path from specimen accession through instrument, middleware, laboratory system and issue

interface. A correct rule in one application can be defeated by a translation or timing problem elsewhere. For example, a result amended after a unit was allocated may not automatically revoke the allocation unless that behaviour has been designed and verified. [FB01, FB02, FB15]

Audit trails and recovery procedures are part of the same safety argument. The system should preserve the sequence of changes and support reconciliation after interruption. A technically restored database is not clinically restored until the patient, result and inventory histories agree.




Figure FB36. A safe interface preserves mixed-field and weak reactions, amendments and historical restrictions. Testing only a routine positive/negative transfer is insufficient. Original CDIL educational schematic; not patient data.

Worked cases 106–108

Case 106 — A missing reaction category

An instrument transmits mixed-field ABO reactions as a blank field because the interface mapping contains only positive and negative options. The receiving system treats the blank as negative.

Reasoned answer. This is an unsafe translation, not an acceptable simplification. The result should trigger an exception and remain

unavailable for automatic release until resolved. Interface validation must include all clinically meaningful reaction categories and the handling of missing data. Previous affected records require a risk-based review because the same mapping error may have altered earlier decisions.

Case 107 — Historical antibodies disappear during downtime

A backup list contains the patient's ABO group but no antibody history. Staff assume that the absence of an entry means no previous antibodies.

Reasoned answer. Absence from an incomplete backup is not a verified negative history. The laboratory should follow its downtime procedure, seek the required records and escalate any urgent release decision. A backup's content and update time define what it can support. It cannot safely be treated as a complete clinical history without evidence.

Case 108 — Recovery creates two units with one identity

During manual issue, a unit number is transcribed incorrectly. After system recovery, the inventory shows one unit still available even though it was transfused.

Reasoned answer. Reconciliation should compare the physical inventory, manual issue record and patient transfusion documentation. Correct the record through an auditable process, investigate any possible duplicate allocation and assess patient consequences. Restarting the information system did not resolve the traceability failure.

37 | Validation, Quality Control and Measurement Reasoning

A transfusion test should perform adequately for its intended use in the laboratory that operates it. Validation or verification examines that performance before routine implementation and after significant changes. Quality control then monitors whether the established process continues to behave as expected. Neither activity is equivalent to checking that an instrument powers on. [FB02, FB15, FB24]

37.1 Start with the intended claim

The study design follows the claim. Verification of an established ABO method, evaluation of a new antibody screen and validation of an electronic issue rule ask different questions. The protocol should define specimen types, patient populations, reaction categories, clinically significant challenges, acceptance criteria and the handling of disagreement.

A panel containing only strong positives and clear negatives may miss weaknesses near the decision boundary. Appropriate challenge material can include weak reactions, mixed-field specimens, dosage-sensitive antibodies, relevant interfering conditions and historical cases. The study should reflect the risks of intended use without treating a small convenience set as a universal performance estimate.

Acceptance criteria should be written before results are known. Changing the criterion after observing an inconvenient failure turns the study into a justification exercise. An unexpected discrepancy may reveal a limitation that requires additional investigation, restricted use or rejection of the method.

37.2 Agreement is not automatically accuracy

Two methods can agree and both be wrong. When a comparator is not an independent reference standard, the resulting measures are appropriately described as agreement measures. Positive percentage agreement and negative percentage agreement should not automatically be renamed sensitivity and specificity. The distinction matters because the truth of the clinical condition has not necessarily been established. [FB24]

Discrepancies require an investigation plan. Repeating only the discordant samples with a favoured method can introduce bias. A useful review examines the original results, specimen history, reagent characteristics, reaction phase, method limitations and any independent evidence. The final report should preserve unresolved findings rather than delete them to improve the apparent percentage.

Sample size affects uncertainty. Observing no failures in a small study does not prove that the true failure rate is zero. The number and diversity of challenges should be interpreted alongside confidence intervals and the consequences of missed detection.

37.3 Precision, bias and categorical performance

For a quantitative measurement, precision describes the spread of repeated results and bias describes a systematic difference from an appropriate reference. A method can be precise but biased, or relatively unbiased on average but too imprecise for the intended decision. These concepts remain distinct even when both contribute to total uncertainty.

Many immunohaematology results are categorical or semiquantitative. Agglutination grades are ordered categories, not an interval scale with guaranteed equal spacing. A change from 1+ to 2+ should not be treated as a measured doubling of antibody concentration. Reproducibility can be assessed through repeated classification under defined conditions, while clinically important category changes deserve specific review.

A control's expected result should match the question being monitored. A strong positive control may detect gross reagent failure

but may not reveal reduced sensitivity for weak antibodies. The control strategy should therefore consider both process stability and the ability to detect failures that matter clinically.

37.4 Lot changes and method changes

A reagent-lot comparison asks whether the new material performs acceptably against the established requirements. It should not rely solely on manufacturer labelling or one routine specimen. The relevant antigen expression, antibody reactivity, control behaviour and known difficult specimens may all matter, depending on the reagent.

Changing an incubator, centrifugation programme, diluent, reagent volume, reading algorithm or specimen type can change performance. A laboratory should assess the significance of each change rather than assume that an unchanged test name means an unchanged method. The manufacturer's instructions and the laboratory's validated procedure define the operating conditions.

Documentation should connect the change, study results, decision, authorisation and implementation date. Staff training and revised instructions should be complete before routine use. A validated method can still fail if the implemented workflow differs from the one evaluated.

37.5 External assessment and learning from failure

External quality assessment provides an independent challenge, but a successful return does not prove that every daily process is safe. The samples may not test patient identification, urgent communication, information interfaces or component issue. Internal quality monitoring and incident learning remain necessary.

When a challenge is failed, the investigation should identify the mechanism. Possibilities include transcription, interpretation, reagent problems, incorrect procedure, sample deterioration or an unsuitable assumption about the specimen. Corrective action should address the cause and include evidence that the change works. Retraining alone is not a complete response when the underlying system makes the same error likely.

Zero observed failures still leaves uncertainty

Suppose a method passes 30 independent challenges and fails none. The observed failure proportion is zero, but the true underlying failure probability is not proven to be zero. Under a simple binomial model, an approximate upper 95% bound is often estimated by 3/n when no events are observed; here it is about 10%. This is a teaching approximation, not a replacement for an appropriate exact interval or a risk-based validation design.

The example explains why a small perfect series cannot establish exceptional reliability. More samples narrow statistical uncertainty, while more diverse challenges test different failure mechanisms. Neither a large set of nearly identical easy specimens nor a tiny set of difficult specimens alone answers every intended-use question. [FB24]

A validation conclusion should describe what was actually tested and the uncertainty that remains. It should not transform an observed agreement percentage into a universal claim about clinical sensitivity. This disciplined language makes the report more useful to the laboratory that must decide whether the evidence is sufficient for implementation.




Figure FB37. Synthetic target plots. Tight clustering can still be biased; a broad spread can average near the target. Neither pattern alone establishes fitness for clinical use. Original CDIL educational schematic; not patient data.

Worked cases 109–111

Case 109 — Perfect agreement in twenty samples

A new screen agrees with the current method in twenty selected routine specimens. The report claims 100% clinical sensitivity for all alloantibodies.

Reasoned answer. The study establishes only the observed agreement in those specimens. It does not provide a sufficiently broad reference-standard study of all relevant antibodies or populations. The report should describe the comparator, sample selection and uncertainty accurately, and the laboratory should complete the intended-use validation with appropriate challenges.

Case 110 — Reaction grades become concentrations

A report states that a 4+ reaction contains twice as much antibody as a 2+ reaction.

Reasoned answer. Agglutination grades are semiquantitative ordered observations and do not establish that numerical

relationship. Antibody concentration, affinity, antigen density, method and reaction conditions all influence the result. A quantitative claim requires an appropriate calibrated method rather than arithmetic performed on grade labels.

Case 111 — A control passes after a procedural change

The laboratory shortens incubation and obtains the expected result with a strong positive control. It concludes that weak-antibody sensitivity is unchanged.

Reasoned answer. A strong control may remain reactive despite a clinically important loss of sensitivity. The procedural change requires a suitable performance assessment, including relevant weak challenges, before implementation. Passing one control does not validate a different method.

38 | Haemovigilance, Incidents and Effective Corrective Action

Haemovigilance follows adverse events and errors across the transfusion chain so that future harm can be prevented. The chain includes donor collection, component preparation, testing, storage, prescribing, identification, administration and follow-up. A laboratory incident may have consequences outside the laboratory, and an apparently bedside event may reveal an upstream information failure. [FB20, FB25]

38.1 Separate event description from causation

An event report should first describe what happened, using times, observations, identifiers and available records. Causation is then assessed from evidence. Writing that a reaction was caused by a component before the investigation is complete can narrow the inquiry prematurely; writing that no relationship exists without reviewing the evidence can be equally misleading.

Severity, imputability and preventability are related but different judgements. Severity concerns the impact on the patient. Imputability concerns the strength of the relationship to transfusion. Preventability concerns whether a different process could reasonably have avoided the event. A severe event is not automatically definitely attributable to transfusion, and a near miss can reveal a highly preventable hazard even without patient harm.

Definitions vary across surveillance systems. A service should use the current definitions required for its reporting programme and retain the underlying clinical observations. This allows later reassessment if classification changes. The textbook's conceptual categories do not replace a national haemovigilance case definition.

38.2 Preserve evidence promptly

The investigation may require pre- and post-transfusion specimens, the component container and tubing, laboratory results, issue records, patient observations and microbiology samples where indicated. The clinical team and laboratory should follow the current reaction procedure, including urgent treatment and communication responsibilities.

Evidence preservation must not delay necessary care. The laboratory's role is to coordinate timely testing and traceability while the clinical team manages the patient. A retrospective search becomes harder when the component has been discarded or specimens are not linked to the relevant time point.

A timeline helps distinguish sequence from assumption. Record when symptoms began, when the transfusion stopped, when samples were collected and when results were communicated. Differences between collection time and reporting time can be important. A result obtained hours later may not represent the patient's condition at the start of the event.

38.3 Near misses identify weak barriers

A wrong-patient specimen detected before issue is not a successful collection process. It is a failure intercepted by a later barrier. The investigation should identify why the specimen was collected or labelled incorrectly and why the intercepting control worked. Removing that control because no harm occurred would reverse the learning.

Rates need denominators. Ten incidents among ten thousand collections and ten incidents among one hundred thousand collections are not the same frequency. Reporting intensity also matters: a rise in reports can reflect better reporting rather than a true increase in hazardous practice. The service should examine both counts and process information.

Categories should be sufficiently precise to support action. A label such as "human error" says little about why the event occurred. Interruptions, look-alike identifiers, poorly designed screens,

inaccessible historical records and unclear responsibility may all contribute. The investigation should test these possibilities rather than assume that staff inattention is the only mechanism.

38.4 Corrective action needs a measurable effect

An action plan should identify the cause it addresses, the responsible person, the implementation date and the evidence used to judge effectiveness. A revised label layout may reduce ambiguity; a mandatory identity check may intercept a mismatch; an interface rule may block an unsafe issue. Each change should be evaluated in the workflow where it is expected to work.

Education can be appropriate, but attendance at a training session is not proof that the hazard has been controlled. Observe the relevant behaviour or measure the process outcome. A good measure might be compliance with two-identifier collection checks, the rate of unresolved duplicate records or the frequency of unauthorised overrides, depending on the incident.

Unintended consequences should also be monitored. A safety rule that causes excessive false blocks may encourage workarounds. The solution is not to abandon the rule automatically, but to refine it so that it protects against the intended hazard while remaining usable.

Rates, severity and reporting intensity must be interpreted together

An incident rate divides a defined event count by an appropriate opportunity count. The denominator might be collections, issued components or transfusion episodes, depending on the question. Changing the denominator changes the meaning. A service should not compare rates from different definitions as if they were the same measure.

Severity provides another dimension. A lower overall incident rate can coexist with a serious event requiring urgent investigation. Reporting intensity also affects observed counts: a safer reporting culture may initially increase reports by making previously hidden near misses visible. [FB20, FB25]

A useful dashboard therefore combines rates with case review, process measures and reporting context. The purpose is to identify and control mechanisms of harm, not to produce the smallest possible number. Suppressing reports improves the appearance of the dashboard while making the system less able to learn.




Figure FB38. Synthetic audit: 12/6,000 = 2 per 1,000; 9/3,000 = 3 per 1,000. The count falls while the observed rate rises. Reporting practice and uncertainty also matter. Original CDIL educational schematic; not patient data.

Worked cases 112–114

Case 112 — A near miss is dismissed

A second-group check detects a wrong-patient sample before any component is issued. The event is closed because no transfusion occurred.

Reasoned answer. The patient was protected by a downstream barrier, but the collection failure remains important. The service should investigate its cause, preserve the successful barrier and implement an appropriate corrective action. A near miss can expose the same pathway that would produce serious harm if the next barrier failed.

Case 113 — Counts fall while the rate rises

Reported identification incidents fall from 12 in 6,000 collections to 9 in 3,000 collections.

Reasoned answer. The rates are 2 per 1,000 and 3 per 1,000, respectively. The count fell, but the observed rate increased by 50%. Interpretation should also consider reporting practice and statistical uncertainty. The arithmetic prevents a misleading claim of improvement based only on the smaller count.

Case 114 — Training is the only evidence

After a release error, all staff attend a lecture. The corrective action is marked effective without testing the changed process.

Reasoned answer. Attendance establishes participation, not effectiveness. The laboratory should assess whether the specific failure mechanism has been controlled, using observation, challenge cases or appropriate process measures. A change in knowledge is useful only if the unsafe pathway is actually reduced.

39 | Emergency Contingencies, Scarcity and Accountable Allocation

Emergency transfusion decisions balance the harm of delay against the risks of incomplete compatibility information. The laboratory should support a prepared, authorised process rather than leave a single operator to improvise. Scarcity adds another challenge: a component may be suitable in principle but not available in the required time. [FB01, FB02, FB18, FB25]

39.1 Define urgency with the clinical team

The clinical team should communicate the patient's condition, the time available and the anticipated component requirement. "Urgent" without a time frame is difficult to operationalise. The laboratory should communicate what is known, which tests remain incomplete and the expected availability of alternatives.

A pretransfusion specimen should be collected before transfusion when feasible without delaying life-saving care. Once donor cells are circulating, some investigations become more difficult. However, inability to obtain a specimen immediately does not by itself justify withholding an authorised emergency release when the clinical risk of delay is unacceptable.

Emergency components follow the service's established policy. The use of group O red cells, selection of RhD-positive or RhD-negative units, and transition to group-specific support depend on patient characteristics, stock and verified testing. These choices should not be reduced to an unqualified universal-donor slogan.

39.2 Continue the investigation after issue

Emergency release is not the end of compatibility work. The laboratory should complete the required testing, review historical records and notify the clinical team promptly of any finding that changes risk. A newly detected clinically significant antibody may require a revised component plan and additional patient assessment.

The record should state what was incomplete at the time of issue and who authorised the release. It should not be retrospectively rewritten as fully compatible because later results were reassuring. Accurate documentation preserves the decision context and supports learning.

The transition to routine selection should be controlled. A preliminary group result, an unresolved discrepancy or an unverified outside record should not be treated as equivalent to completed testing. The service's procedure should define the evidence required before changing component selection.

39.3 Scarcity is a clinical and organisational problem

Rare antigen-negative units, extensively matched components and some specially prepared products can take time to obtain. The laboratory should contact the supplier and reference service early, verify the actual requirement and identify alternatives. An unnecessarily broad restriction can consume scarce stock without benefit; an inadequately investigated restriction can expose the patient to harm.

Allocation decisions should follow transparent clinical criteria and authorised policy. Ability to pay, social influence or staff preference should not substitute for clinical priority. Where demand exceeds supply, the responsible clinical and organisational leaders should document the rationale and review the decision as circumstances change.

Inventory counts require context. A unit can be physically present but unavailable because it is reserved, unsuitable for the patient, outside temperature limits or awaiting resolution of a quality concern. A realistic availability estimate includes testing, transport and preparation time, not merely the number on the shelf.

39.4 Transport and contingency communication

Transport arrangements should protect component integrity and traceability. The validated packaging, temperature requirements, documentation and handover responsibilities depend on the component and route. A courier's departure time alone does not establish that the product will remain suitable throughout the journey.

Communication should be closed-loop. The receiving team should confirm the patient's identity, component requirement, special restrictions and arrival plan. If the clinical situation changes, the laboratory and supplier need an update so that scarce resources are not directed by an obsolete request.

After the emergency, review whether the plan worked. Delayed transport, unclear authorisation, inaccessible records and conflicting component requests can be corrected before the next event. Preparedness is demonstrated by a functioning process, not by the existence of an unread policy document.

Emergency release is a decision under constrained information

The laboratory may know the patient's group but not have completed the antibody investigation, or it may have no reliable group at all. These are different information states and should lead to different authorised pathways. The clinical risk of delay determines how much uncertainty can be tolerated while further testing continues.

The decision record should preserve the state of knowledge at release. Later results can confirm or revise the interpretation but cannot retroactively make unavailable information available. This is why emergency-release documentation should not be overwritten as routine compatibility documentation after a reassuring result. [FB01, FB02]

Scarcity creates a second constraint. The best theoretical component may not arrive in time, while an available alternative has a different risk profile. The transfusion-medicine clinician and treating team should make the benefit–risk decision using the laboratory's most

accurate description of options, limitations and expected delays. Silence about uncertainty is not safer than clear, accountable communication.




Figure FB39. The record should preserve what was incomplete at release and add later findings without rewriting the original decision. Clinical urgency determines the authorised pathway. Original CDIL educational schematic; not patient data.

Worked cases 115–117

Case 115 — A later negative screen rewrites the event

Uncrossmatched emergency red cells are issued under authorisation. Testing later finds no antibody, and the issue record is changed to "fully crossmatched at release".

Reasoned answer. The record must preserve the actual status at release. Later reassuring results can be added, but they do not change what information was available during the emergency decision. Accurate chronology is essential for accountability and future review.

Case 116 — Three units on the shelf

The inventory lists three rare units. One is reserved for another critical patient, one has an unresolved temperature excursion and one requires transport from a distant centre.

Reasoned answer. The physical count is not the immediately available suitable inventory. The service should verify each unit's status and communicate a realistic plan, involving the responsible clinical and supplier teams. The temperature-affected unit cannot be assumed usable without the required assessment.

Case 117 — A patient deteriorates while a perfect match is sought

A patient with complex antibodies develops life-threatening bleeding. Staff continue searching for an ideal component without updating the transfusion-medicine clinician.

Reasoned answer. Clinical urgency changes the risk balance and requires immediate specialist communication. The laboratory should present the known antibody findings, available alternatives and expected delays so an authorised decision can be made. A technically ideal search cannot be allowed to proceed in isolation from the patient's deteriorating condition.

40 | Integrated Immunohaematology Case Conference

Complex cases are solved by organising evidence, not by choosing the most familiar antibody name. A disciplined conference separates verified observations, proposed mechanisms, unresolved questions and decisions. It should produce a defensible component plan and a clear record of what would change that plan. [FB01, FB02, FB15]

40.1 Reconstruct the case before interpreting the panel

Begin with the patient, not the reaction grid. Confirm identity, transfusion and pregnancy history, previous antibodies, treatment, transplantation and the timing of the current specimen. Then identify the clinical question: routine preoperative preparation, unexplained haemolysis, urgent bleeding, pregnancy surveillance or another defined problem.

Review the quality of the evidence. Were specimens collected at relevant times? Are historical reports verified? Did controls meet requirements? Were tests performed before or after transfusion or treatment? A technically detailed panel cannot repair a specimen attributed to the wrong patient.

A timeline should connect biological events and laboratory observations. A newly positive DAT after transfusion, an antibody detected after a period of evanescence, or panreactivity after anti-CD38 treatment becomes more interpretable when the sequence is visible. Timing supports a hypothesis but does not prove it alone.

40.2 Distinguish a pattern from a completed identification

A pattern can suggest one or more specificities. Identification requires adequate support, consideration of additional clinically significant antibodies and appropriate confirmation. Dosage, antigen expression, method sensitivity and treatment effects all affect the strength of the evidence.

When the pattern is incomplete, state what information is missing. Selected cells may separate overlapping antibodies; a phenotype or genotype may test biological plausibility; an adsorption can reveal a hidden specificity; a reference method may resolve a high-frequency antigen problem. Each additional test should answer a defined question rather than simply enlarge the result sheet.

Negative evidence should be interpreted with equal care. A nonreactive cell that expresses an antigen weakly or heterozygously may not exclude a dosage-sensitive antibody. A negative post-treatment reaction may reflect destruction of the target antigen. A negative current screen does not erase a verified historical antibody.

40.3 Translate the investigation into a component plan

The report should connect the findings to the patient's requirements. State verified antibodies, antigen restrictions, compatibility method, special component needs, unresolved limitations and the urgency plan. Avoid vague phrases that force the next team to reconstruct the investigation from scratch.

The plan should also state what is not implied. An antigen-negative selection for one antibody does not guarantee freedom from all alloimmunisation risk. A compatible crossmatch does not exclude every nonimmune transfusion reaction. A genotype prediction does not resolve every variant outside the assay's coverage.

Communication should be proportionate to risk. A finding that changes an imminent transfusion requires direct, documented communication, not only a report placed in an electronic queue. The

receiving clinician should understand the practical consequence and the expected availability of components.

40.4 Teach uncertainty without normalising indecision

Uncertainty is not a reason to stop thinking. It should be made specific and linked to an action. The laboratory may be uncertain about an antibody specificity but certain that routine electronic issue is inappropriate. It may be uncertain whether a DAT explains haemolysis but certain that urgent clinical evaluation is necessary.

A defensible decision records the available evidence, the alternatives considered, the time constraints and the responsible authorisation. Later evidence may change the interpretation. Updating the conclusion is appropriate; pretending that the earlier uncertainty never existed is not.

The final educational question is whether the learner can transfer the reasoning to a different patient. Memorising that one example contained anti-E is insufficient. The learner should explain how positive and negative cells supported the hypothesis, which alternatives remained, what confirmation was needed and how the clinical context changed the plan.

A complete conclusion has four parts

A useful final case conclusion identifies the observations, the interpretation, the practical consequence and the remaining limitation. For example: a defined reaction pattern and confirmed antigen-negative patient profile support a particular alloantibody; future red-cell selection should meet the corresponding antigen requirement and compatibility procedure; additional specified uncertainties remain under investigation.

The four parts prevent two common failures. A list of observations without interpretation leaves the clinical team to infer the meaning. A confident interpretation without its supporting observations makes the conclusion difficult to audit or update. A component instruction without a limitation can imply more protection than the evidence establishes. [FB01, FB02]

The learner's goal is therefore not simply to name an antibody. It is to build an argument that another qualified professional can understand, check and use. That argument remains open to revision when new evidence appears, while preserving the patient-safety actions justified by what is already known.




Figure FB40. The four parts make the conclusion traceable and useful. New evidence can revise the interpretation without erasing the original observations. Original CDIL educational schematic; not patient data.

Worked cases 118–120

Case 118 — Panreactivity after treatment

A patient receiving daratumumab has a new panreactive IAT. Baseline records show no previous clinically significant antibody. DTT-treated screening cells are nonreactive, and the patient's Kell status is not reliably documented.

Reasoned answer. Anti-CD38 interference is a plausible explanation, supported by the treatment history and the effect of DTT, but the treated-cell method has antigen blind spots. The component plan should follow the validated anti-CD38 procedure, including appropriate Kell protection unless a reliable result supports a different selection. The report should preserve the interference and

method limitations rather than state that all antibodies have been excluded.

Case 119 — Delayed haemolysis with a disappearing antibody

A previously transfused patient has falling haemoglobin and biochemical evidence of haemolysis after a recent transfusion. The current plasma shows weak anti-Jka, and an outside record documents anti-Jka several years earlier. The pretransfusion screen at the new hospital was negative.

Reasoned answer. The history supports an evanescent antibody with possible anamnestic reappearance and a delayed haemolytic reaction, but the diagnosis requires the full clinical and laboratory investigation. The verified anti-Jka history should be retained permanently and incorporated into future selection. The negative pretransfusion screen did not establish absence of immunological memory. The event also identifies a record-transfer vulnerability.

Case 120 — One specimen, three biological sources

A patient has undergone an ABO-incompatible haematopoietic transplant and has also received red-cell transfusions. Current forward grouping is mixed-field, reverse grouping is weak, and blood DNA testing reflects the donor haematopoietic genotype.

Reasoned answer. The specimen contains information from different biological sources and time points. Donor-derived nucleated cells, transfused red cells, emerging graft-derived red cells and residual plasma antibodies need not produce one simple inherited pattern. The laboratory should apply the documented transplant-phase support plan, reconcile donor and recipient records and involve the transplant/reference team. Neither one current serological result nor the blood genotype alone should overwrite the complete history.

Applied laboratory workshops | From reaction to accountable decision

The following workshops use invented patients, units, reaction grades and inventory data. They teach interpretation, not a manufacturer's operating procedure. No small panel here is a sufficient substitute for a validated identification panel, a complete antigen profile or a reference-laboratory investigation. Each problem separates the observations, the permitted inference and the action that remains conditional. The model answers are part of the textbook: attempt the interpretation before reading them. [FB01, FB02, FB05]

Workshop 1 — An ABO discrepancy is a disagreement to explain

The observations

A fictional adult's correctly labelled specimen produces the following results in a validated routine method. The forward tests examine the patient's red cells with grouping reagents; the reverse tests examine the patient's plasma with known reagent cells. Treat the grades as observations, not as a completed blood-group assignment.

Test	Observation	What the test directly examines
Anti-A with patient cells	4+	Detectable A-related reactivity on the cells
Anti-B with patient cells	0	No B-related reaction in this method
Anti-D with patient cells	3+	Detectable D reactivity under the method
Required control	0	No control reaction detected

Test	Observation	What the test directly examines
Patient plasma with A1 cells	1+ at room temperature	Unexpected reverse-group reactivity
Patient plasma with B cells	4+	Expected anti-B-like reverse reactivity

The forward pattern resembles group A, but the reverse A1 reaction prevents an unqualified concordant assignment. Repeating the same method reproduces the pattern. The record contains no verified previous group. The patient is clinically stable; no urgent component release is requested.

Reasoning from a pattern rather than naming a group

One hypothesis is an A subgroup with anti-A1. Another is a cold-reactive antibody acting against an antigen on the A1 reagent cells. Reagent-specific or specimen-related effects remain possible. A1 cells are not antigenically blank except for A1: they carry many other red-cell antigens. A positive A1 tube therefore cannot by itself identify anti-A1. Nor does strong forward anti-A reactivity prove a specific A subgroup. The investigation should obtain relevant history, verify technique and controls, and use selected cells and appropriate subgroup investigations through the laboratory's validated pathway. [FB02, FB05]

Suppose the extended teaching investigation finds that the plasma reacts with two A1 cell samples but not with appropriately selected A2 or O cells at the tested phase. An approved A1 lectin investigation is nonreactive with the patient's cells, with acceptable controls. These observations support the proposed A2/anti-A1 explanation in this bounded exercise. They do not demonstrate that every A2 person has anti-A1, that every anti-A1 is clinically significant, or that no other antibody could coexist. Thermal behaviour, methods, antibody history and the actual clinical purpose remain relevant.

The laboratory should not force a disputed result into the information system merely because one explanation is attractive. It should document the observations and resolution criteria, retain the record

of the discrepancy, and apply its approved component-selection policy. If an urgent need arises before resolution, emergency component support is a clinical-laboratory decision under the emergency-release pathway, not permission to guess the patient's group.

Mastery task and worked answer

Task. A learner proposes, “The group is definitely A2 because the reverse A1 tube is positive.” Identify the missing evidence and explain why testing an O cell can help but cannot settle every possibility.

Worked answer. The reverse reaction identifies reactivity with that reagent cell, not necessarily anti-A1. The learner needs a controlled investigation that separates A1-related reactivity from other antigen targets and considers the patient's phenotype and history. O cells remove A and B expression from the comparison, but they retain many non-ABO antigens and usually express H strongly. A result with one O cell can therefore be informative without excluding every cold antibody or rare phenotype. The correct conclusion is a supported, documented resolution within the method's limitations, not an inference from one positive tube.

Transfer question. Would a previous verified group A result justify ignoring today's new reverse discrepancy? **Answer.** No. History is valuable evidence, but changed antibodies, recent transfusion, transplantation, treatment, specimen error or analytical effects can alter today's pattern. Concordance should be investigated rather than presumed from history alone.

Workshop 2 — Mixed-field reactions and the identity of the cell population

Reading two populations

A mixed-field reaction contains visibly reactive and nonreactive red-cell populations within one test. It is not simply another name for a weak uniform positive. A weak reaction describes limited aggregate strength; mixed field describes heterogeneity. The distinction matters because a recent transfusion or a transplant can introduce or generate cells with different antigen expression. Some subgroup phenomena and technical conditions can also create mixed-field appearances. A photograph or reaction grade must be interpreted with the method and history. [FB01, FB02, FB22]

In this fictional case, a patient previously documented as group A received emergency group O red cells. Two days later, forward anti-A testing shows mixed field. Reverse testing remains compatible with the patient's previously established plasma pattern. The student is asked to explain how apparently conflicting forward results can arise without a spontaneous change in the patient's inherited ABO genes.

The transfused O cells lack A and B antigens. The patient's circulating A cells retain A expression. Anti-A can therefore agglutinate one population while leaving another nonreactive. The test is sampling a mixed circulating population, not a purified representation of the patient's original cells. A strong enough transfused population can complicate phenotyping of other antigens as well. Historical typing, transfusion dates, component groups, current testing and, where appropriate, molecular evidence must be reconciled.

A counting exercise with a strict boundary

An image-analysis teaching model counts 600 events classified as population X and 400 as population Y. The fraction assigned to X is 600/1,000 = 60%. This is a percentage of the model's counted events. It is not automatically the percentage of the patient's total red-cell mass, the donor-cell survival fraction, or the volume of donor blood remaining. Classification error, sampling, cell recovery, event selection and the measurement technology can all alter the relation between a displayed population and an in-vivo quantity.

Now suppose 100 events are excluded because their classification is uncertain. Reporting 600/900 = 66.7% without explaining the exclusion would change the denominator and make the apparent proportion rise even though the original X count is unchanged. The report must state whether percentages refer to all acquired events, accepted events or another defined population. This denominator discipline is equally important in flow cytometry and laboratory quality dashboards.

Worked interpretation

A defensible report would describe the mixed-field observation and its likely relation to the documented recent transfusion, while maintaining the laboratory's requirements for final group interpretation and component selection. It would not erase the discrepancy from the audit trail or use a recent transfusion sample as unquestioned evidence of the patient's pretransfusion phenotype.

Task. A technologist says, “The negative cells prove the patient has lost the A gene.” **Answer.** The test measures antigen expression on the sampled circulating cells. It does not establish the patient's germline genotype. A mixed population after transfusion offers a direct alternative explanation. Genetic conclusions require an appropriate molecular investigation, including attention to specimen source in transplant recipients.

Task. Can genotype solve every mixed-field question immediately? **Answer.** No. Molecular testing predicts antigen expression from the alleles and regions examined. Rare variants, assay coverage, transplant chimerism and the source of nucleated cells can

complicate interpretation. The genotype must be integrated with serology and the patient's treatment history rather than treated as an infallible override.

Workshop 3 — Separating two antibodies with informative cells

Constructing the question

An identification panel should be read as a set of comparisons. A cell that is positive for both candidate antigens does not distinguish their contributions. A cell lacking both may demonstrate background behaviour, but it cannot show which of the two targets accounts for a positive reaction. Informative selected cells deliberately separate competing hypotheses. [FB02, FB05]

The following invented eight-cell panel contains only the antigen columns required for the exercise. It is deliberately incomplete and cannot support exclusion of unlisted antibodies. All reactions were obtained in the same approved antiglobulin-phase method with acceptable controls.

Cell	E	K	Jk(a)	Reaction
1	+	−	−	2+
2	−	+	−	2+
3	+	+	−	3+
4	−	−	+	0
5	+	−	+	2+
6	−	+	+	2+
7	−	−	−	0
8	+	+	+	3+

The pattern is compatible with anti-E plus anti-K in this simplified matrix: E-only and K-only cells react, cells lacking both do not, and

double-positive cells also react. A single anti-Jk(a) does not explain cells 1 and 2 or the nonreactive Jk(a)-positive cell 4. The grades on double-positive cells should not be treated as an arithmetic sum of two antibodies. Reaction strength depends on antigen density, antibody properties, method and interactions, not a rule that 2+ plus 2+ equals 4+.

What remains before an identification is accepted

The investigator must confirm that the observations are reproducible and appropriately controlled, assess the patient's antigen status where reliable, review previous antibodies and recent transfusion, and consider clinically significant specificities not represented by the abbreviated table. Selected-cell evidence must meet the laboratory's validated identification and exclusion criteria. A historical anti-Jk(a), for example, remains relevant even if this limited current panel does not demonstrate it. A negative reaction cannot erase an established clinically significant antibody history. [FB01, FB02]

In a recently transfused patient, apparent E or K positivity on serologic typing may reflect donor cells rather than the patient's native phenotype. Molecular testing or an appropriate pretransfusion specimen may be needed. The aim is to establish a coherent explanation with known limitations, not to make each item fit a preferred answer by discarding inconvenient data.

Worked release reasoning

Once anti-E and anti-K are confirmed under the actual procedure, candidate red-cell units should satisfy the relevant antigen-negative selection and compatibility requirements. The abbreviated panel does not determine every possible Rh matching issue, all historical antibodies, or the urgency of release. The report should state the identified specificities, the basis for component selection, any additional unresolved reactivity and the agreed clinical plan.

Task. Choose the two most informative cells for showing that both E- and K-related reactivity contribute. **Answer.** Cells 1 and 2 separate the targets: cell 1 has E without K, and cell 2 has K without E. Their reactions are more discriminating than a double-positive cell alone. Their unlisted antigen profiles still matter in a real investigation.

Task. Why is cell 7 useful? **Answer.** It lacks both proposed targets and is nonreactive, supporting the coherence of the model. One double-negative cell is not a universal negative control for every possible antibody, because unlisted antigens and method-specific effects remain possible.

Workshop 4 — Dosage and the danger of a convenient negative cell

The model

Some antibodies react more strongly with cells expressing an antigen from two relevant alleles than with heterozygous expression. This dosage effect is important when selecting cells to investigate or exclude antibodies in systems such as Kidd, Duffy and MNS. It is not a promise that every antibody in those systems will show an identical pattern. Reagent-cell profiles and the validated exclusion procedure govern the actual investigation. [FB02, FB12, FB13]

Reagent cell	Jk(a)	Jk(b)	Untreated antiglobulin reaction
A	+	−	2+
B	+	+	0
C	−	+	0
D	+	−	2+
E	+	+	Weak positive
F	−	+	0

The pattern supports a Jk(a)-related hypothesis in this limited model. The nonreactive heterozygous cell B does not safely exclude anti-Jk(a). Cells A and D supply a stronger comparison for an antibody that reacts with apparent double-dose expression. However, the word “homozygous” in a reagent profile should be interpreted according to the system and information supplied; routine serologic

antigen combinations are not an unrestricted molecular genotype certificate.

History changes the question

Suppose the patient has a verified anti-Jk(a) recorded two years earlier, but today's screening cells are nonreactive. The question is not, “Can we prove that the old result has vanished from biological relevance?” Antibody concentration can decline below the method's detection threshold while immunologic memory remains. Exposure to antigen-positive cells may then stimulate a response associated with a delayed haemolytic reaction. Historical clinically significant antibodies should therefore inform selection even when the current screen is negative. [FB01, FB12]

This does not mean every falling antibody concentration predicts a reaction in every exposure. It means that a negative current assay is narrower evidence than “the patient has no relevant immune history.” Laboratory records preserve information that may not be recoverable from a single present-day specimen.

Applying the principle to a release decision

A request for electronically issued red cells arrives with a negative current screen. The system has a historical anti-Jk(a) flag. Silencing that flag because the screen is negative would convert a detection limit into an unsupported safety conclusion. Electronic issue is conditional on the service's validated eligibility rules, including antibody history. The history must be evaluated, appropriate antigen-negative units selected and the required compatibility procedure applied.

Task. Does stronger enzyme-phase reactivity prove anti-Jk(a)? **Answer.** No. Enzyme treatment can enhance some reactions and alter or destroy other antigens, changing the information available. The result supports a method-dependent hypothesis but must be reconciled with untreated-cell results, antigen profiles and other possible antibodies. A treatment effect is not a unique molecular fingerprint.

Task. Why should the report preserve both the current negative screen and the historical antibody? **Answer.** They answer different

questions. The screen describes detectable reactivity under today's conditions; the historical record describes a previously demonstrated clinically significant specificity. Keeping both supports a transparent, clinically useful selection decision.

Workshop 5 — A treatment removes interference and creates a blind spot

The clinical-laboratory setting

A fictional patient receiving an anti-CD38 therapeutic antibody has broad reactivity in an indirect antiglobulin test. A baseline record was obtained before treatment. The laboratory uses a validated DTT-based investigation through an authorised pathway. DTT-treated reagent cells remove the broad interference in this exercise, but DTT also changes antigen expression, including destruction of Kell-system reactivity under commonly used conditions. The treated-cell result must therefore be interpreted as a different measurement, not as an unchanged panel that has simply become cleaner. [FB02, FB11, FB17]

Observation	Untreated cells	DTT-treated cells
Broad indirect antiglobulin reactivity	Present	Not detected
Kell antigen information	Available as expressed on untreated cells	Not reliably preserved by this treatment
Ability to exclude every clinically significant antibody	No	No
Need for history and a validated selection policy	Yes	Yes

The disappearance of panreactivity supports the expected interference explanation in context. It does not prove that the patient lacks every alloantibody. An antibody against an antigen damaged by treatment may become invisible. The correct component-selection policy therefore accounts for the treatment's blind spots and the

patient's reliable antigen information. The specific requirements depend on the validated procedure and local authority; this textbook does not replace that procedure with a universal bedside rule.

A reasoning error to avoid

A learner writes, “DTT gives a negative screen, therefore unrestricted electronically issued blood is safe.” The first clause is an analytical observation. The second is a release decision that requires additional conditions. It ignores the patient's antibody history, treatment-related antigen losses, system eligibility rules and any separate unresolved discrepancy. A result can be technically valid while an inference drawn from it is unsafe.

The laboratory should communicate with the clinical team and, where applicable, the reference service before treatment or early in the treatment course. Baseline phenotype or genotype information, a durable treatment alert and a plan for urgent support can prevent delays. The therapeutic antibody can also affect other laboratory methods, including some serum-protein investigations, so a cross-disciplinary alert may be useful. The persistence of interference varies with the treatment and patient; use the current product and specialist guidance rather than assuming a fixed clearance date for every person. [FB17]

Worked documentation

An appropriate educational report might state that treatment-related interference was investigated using the named validated approach, that no additional reactivity was demonstrated within that approach's detection and antigen limitations, and that component selection followed the applicable history and antigen requirements. It should not say “all antibodies excluded” unless the claim is genuinely supported, which this bounded example is not.

Task. Why is a pre-treatment sample valuable even if molecular typing is planned? **Answer.** It provides a serologic baseline before interference and may establish an antibody history or phenotype that becomes difficult to obtain later. Molecular testing adds important information but has its own allele coverage and interpretation limits; it does not make every baseline observation redundant.

Task. What should accompany a treated-cell negative result?
Answer. The method, relevant limitations, historical findings, applicable selection requirements and any unresolved concern. A naked “negative” conceals the change in what the assay was capable of detecting.

Workshop 6 — Inventory probability without promises

Expected availability is not guaranteed availability

An inventory calculation helps plan a search but cannot authorise a component. A unit must still be correctly identified, satisfy all selection requirements and pass the required compatibility pathway. Population antigen frequencies are estimates that depend on the donor population, typing method and sampling. Correlated antigens cannot always be multiplied as though they were independent. [FB02, FB03, FB14]

In a simplified teaching inventory, the probability that a randomly selected unit lacks antigen X is 0.30, and the probability that it lacks antigen Y is 0.40. **Only for this exercise**, assume independence. The probability of a unit lacking both is 0.30 × 0.40 = 0.12, or 12%. Screening 100 units would yield an expected count of 12 eligible units. “Expected” is a long-run average, not a promise that every batch of 100 contains exactly 12.

To obtain an expected ten units, divide the desired count by the eligibility probability: 10/0.12 = 83.33, so 84 is the next whole-number planning estimate. This is not a 100% success threshold. It also excludes other constraints such as ABO group, storage status, irradiation requirements, inventory reservation and transport time. Each additional requirement can reduce practical availability.

Probability of finding none

If each unit independently has a 0.20 probability of meeting a specified requirement, the probability that all ten screened units fail is (1 − 0.20)^10 = 0.8^10 ≈ 0.1074, or 10.74%. The probability of at least one success is therefore about 89.26%. A student who reports “ten units gives a 200% chance because 10 × 20% = 200%” has confused expected counts with probability. The expected number of successes is two; the probability of at least one must remain between zero and one.

For a 95% chance of at least one success under the same assumptions, solve 1 − 0.8^n ≥ 0.95. This gives n ≥ log(0.05)/log(0.8) ≈ 13.43, so 14 independent units meet the model's threshold. That calculation still does not guarantee a unit in the real inventory. It is a planning model with explicit assumptions.

Translating mathematics into service action

When a patient's requirements make routine inventory unlikely to suffice, early reference-service and rare-donor coordination is more useful than repeatedly screening a small local shelf without a plan. Reliable historical typing and genotyping can narrow the search, while clinical discussion clarifies urgency and alternatives. A probability estimate should be communicated with its assumptions and expected time implications, not offered as a substitute for confirmed availability.

Task. The actual donor population has correlated X and Y expression. What happens to the 12% estimate? **Answer.** It may be wrong because the independence assumption fails. Use an appropriate joint frequency or actual typed-inventory data. Multiplying two marginal percentages does not recover the joint probability when the traits are associated.

Task. A search identifies a phenotypically suitable unit. Is it released immediately? **Answer.** No. Suitability is one part of the release chain. Identity, component requirements, condition, history, compatibility testing and authorised release must still be satisfied.

Workshop 7 — Corrected count increment and platelet refractoriness

Why a raw increment is incomplete

A platelet count increment compares the post-transfusion and pretransfusion counts. It is affected by the transfused dose, recipient size, timing and many clinical conditions. A corrected count increment, or CCI, adjusts the observed increment for body-surface area and the platelet dose using a specified unit convention. It supports investigation but does not independently diagnose HLA-mediated refractoriness. Repeated properly timed observations and assessment of immune and nonimmune causes remain necessary. [FB23]

For this workshop, use the convention:

CCI = platelet increment per microlitre × body-surface area in square metres ÷ platelet dose expressed in 10^11 platelets.

A fictional adult has a pretransfusion count of 8 × 10^9/L and a count of 28 × 10^9/L at an appropriately documented early post-transfusion time. The increment is 20 × 10^9/L. Because 1 × 10^9/L equals 1,000/µL, the increment is 20,000/µL. Body-surface area is 1.8 m² and the documented dose is 3.0 × 10^11 platelets. CCI = 20,000 × 1.8/3.0 = **12,000** in this convention.

Comparing two episodes

Episode	Increment, ×10^9/L	BSA, m²	Dose, ×10^11	CCI using /µL convention
A	20	1.8	3.0	12,000
B	5	1.8	3.0	3,000
C	10	1.5	2.5	6,000

The values demonstrate why dose and recipient size must remain attached to the calculation. They are not universal treatment thresholds. The service should use its current clinical guideline, timing requirements and repeated-measurement definition when

investigating refractoriness. Mixing a count expressed in ×10^9/L with a formula expecting /µL creates a factor-of-1,000 error. A result of “12” may reflect a different explicit convention, but it must not be compared directly with a threshold written for “12,000.”

Interpreting a low result

A low early increment can occur with immune destruction, but clinical consumption, infection, bleeding, splenic sequestration, component factors and other conditions can contribute. HLA or HPA antibody testing is targeted to the appropriate clinical pattern and pathway. Detection of an antibody is not sufficient by itself to prove that it caused every poor increment. The clinical team and transfusion service should integrate the count trajectory, timing, dose, clinical state and antibody findings when selecting support.

HLA-selected or otherwise matched platelets require an organised service process. Matching does not eliminate all nonimmune consumption, so a patient may still have a disappointing increment. Continued monitoring tests whether the selected strategy is achieving the intended clinical and laboratory effect rather than assuming that the product label guarantees success.

Task. Why should an unexpectedly low result be checked against the sample time and component record? **Answer.** A mistimed count or incorrect dose changes the meaning of the calculation. Without accurate timing and dose, the laboratory may attribute a poor response to immune destruction when the measurement itself is not comparable.

Task. Does a satisfactory early CCI prove that the patient has no bleeding risk? **Answer.** No. CCI measures a count response within a defined interval. Bleeding risk and clinical haemostasis depend on additional patient and treatment factors. The numerical response supports, but does not replace, clinical assessment.

Workshop 8 — Validation data, agreement and uncertainty

What a comparison study can establish

A new method is compared with an existing laboratory method on 100 deliberately selected teaching specimens. The comparison is not against a perfect biological truth. Therefore the first measures are agreement and discordance, not automatically diagnostic sensitivity and specificity. Sample selection also matters: a study containing few weak or difficult reactions may overstate how well the method performs in the very situations that create risk. [FB24]

Comparison	Existing method positive	Existing method negative
New method positive	28	4
New method negative	3	65

Overall agreement is (28 + 65)/100 = 93%. Positive percent agreement, using the existing method's positive results as the denominator, is 28/(28 + 3) = 90.3%. Negative percent agreement is 65/(65 + 4) = 94.2%. These denominators answer different questions. Reporting only 93% hides the seven discrepant specimens and the asymmetry between positive and negative comparisons.

Investigating the discrepancies

The four new-positive/old-negative specimens may represent increased detection, nonspecific reactivity, a method-related effect or another explanation. The three new-negative/old-positive specimens may represent missed weak antibodies, differences in antigen expression, analytical variation or an error in either method. A discrepant result should be investigated through a planned reference approach rather than assigned to whichever method the laboratory prefers.

Suppose all seven discrepancies involve weak reactions near the decision boundary. This would support additional studies around that boundary, but it would not excuse the discrepancies as unimportant.

A weak clinically significant antibody can matter. The validation should connect analytical performance to intended use, including the effect on investigation, release and patient safety.

Zero failures do not prove zero risk

An additional challenge set of 30 specimens produces no observed failures. Under a simple independent-binomial approximation, the “rule of three” gives an approximate upper 95% bound of 3/30 = 10% for an unobserved failure probability. This is a teaching approximation, not a universal laboratory acceptance rule. Its purpose is to show why zero observed events in a small sample does not establish perfect performance. More appropriate exact intervals, study designs and acceptance criteria may be needed for actual validation.

The laboratory should define acceptance criteria before examining results, include relevant difficult specimens, document deviations, and establish ongoing monitoring. A method that passes initial validation can still fail through a later reagent change, software update, operator error or unrecognised limitation. Validation is an evidence-based decision about intended use, not a permanent exemption from quality control.

Task. May 90.3% positive agreement be called sensitivity? **Answer.** Not without a suitable reference standard and study design supporting that interpretation. The existing method is a comparator, not automatically the truth. Use the correct agreement terminology and explain the discrepancy-resolution process.

Task. Why should the study retain every discordant specimen rather than exclude “awkward” cases? **Answer.** Selective exclusion biases the performance estimate and removes information about the conditions most likely to challenge the method. Exclusions require justified, pre-specified or transparently documented reasons, not convenience.

Workshop 9 — A transfusion reaction timeline and a closed communication loop

The fictional incident

At 10:00 a red-cell unit is started under an authorised clinical process. At 10:12 the patient develops new symptoms. The bedside team stops the transfusion, assesses and supports the patient, and activates the local reaction pathway. At 10:18 the transfusion laboratory receives a call. The first report says only, “The patient reacted to blood.” That message identifies a concern but is too incomplete to guide a focused investigation.

A useful structured communication includes verified patient identity, component identity, start and stop times, symptoms and observations, volume administered if reliably known, relevant treatment and transfusion history, and what action has already been taken. The receiving person should repeat critical identifiers and clarify the immediate clinical question. Urgent care proceeds according to the clinical protocol while laboratory investigation addresses identity, incompatibility, haemolysis, contamination and other possibilities as appropriate. [FB18, FB20, FB25]

Distinguishing classifications

A reaction occurring during transfusion is temporally associated with transfusion. That timing does not establish its mechanism or prove imputability. Acute haemolysis, febrile reactions, allergy, bacterial contamination, circulatory overload, lung injury and unrelated clinical deterioration can overlap in presentation. Definitions used for surveillance have specific criteria and time windows; they should not be substituted for bedside clinical judgement or copied without checking the current reporting system.

The laboratory's initial investigation must not focus so narrowly on one attractive mechanism that it misses an identity problem. A correctly performed test on the wrong specimen does not validate the patient-component match. Clerical reconciliation, pre- and post-transfusion specimen assessment, relevant serology and further testing are selected through the actual pathway. The report should

distinguish observations from provisional interpretation and from the final classified event.

Closing the loop

A laboratory calls a critical result at 11:05. The recipient's name and read-back are documented. At 11:20 an amended result clarifies that an earlier observation was affected by specimen quality. The amendment must reach the responsible clinical team; entering it silently into the information system is not equivalent to communication. The record should preserve the original result, correction, reason, time and recipient rather than overwrite the event as though it never occurred.

Follow-up also includes the patient's future transfusion record. A newly identified clinically significant antibody should be retained in a durable, retrievable form. An incident investigation may identify changes needed in identification, storage, sampling, transport or communication. The objective is to reduce recurrence without replacing a systems analysis with a search for one person to blame.

Task. Is a positive post-transfusion DAT proof that the transfused unit caused the symptoms? **Answer.** No. It indicates detectable coating of red cells under the test conditions. Pretransfusion findings, evidence of haemolysis, specificity, timing and alternative explanations are needed to establish the mechanism and relationship to the event.

Task. Why is a negative DAT not a universal exclusion of haemolysis? **Answer.** The test has method and biological limitations, and haemolysis can have nonimmune causes. Rapid clearance or low levels of detectable coating can complicate interpretation. The investigation should address the whole clinical-laboratory pattern.

Workshop 10 — Measuring improvement without hiding exposure

Counts and rates

A laboratory reports 12 identification near misses among 6,000 specimens in one period and nine among 3,000 in a later period. The raw count fell from 12 to nine, a reduction of 25%. The rate, however, rose from 12/6,000 × 1,000 = 2 per 1,000 specimens to 9/3,000 × 1,000 = 3 per 1,000. The relative rate increase is (3 − 2)/2 × 100 = 50%. Both numerical statements can be true because they use different denominators. [FB24, FB25]

A report that declares improvement from the falling count alone would be misleading. The laboratory should show the numerator, denominator, event definition and observation period. Changes in reporting culture, case mix, sampling and detection can also affect observed rates. More reported near misses may reflect worse performance, better detection, or both. The data require interpretation rather than a favourable headline.

The intervention

The service introduces bedside label printing and a structured identification check. A subsequent period contains four near misses among 4,000 specimens: 1 per 1,000. This is encouraging but does not by itself prove that the intervention caused the reduction. The comparison may be affected by staffing, workload, reporting, patient population or random variation. A credible improvement report describes these limitations, follows the outcome over time and checks whether the intervention created new problems.

For example, label-printing availability may improve one step while downtime causes workarounds. A balancing measure could track delays, relabelling attempts or episodes in which staff bypass the intended workflow. The intervention should be evaluated as part of a functioning system, not merely as an equipment purchase.

From corrective action to sustained control

A corrective action record should identify the observed problem, contributing conditions, agreed change, owner, implementation date, evidence of implementation and a measure of effectiveness. Training attendance is evidence that staff attended training; it is not automatically evidence that the risky behaviour changed. A post-training competency observation or audit may provide more direct evidence of the intended outcome.

The investigation should preserve patient safety and confidentiality. Examples used for teaching or quality meetings should minimise unnecessary identifying details. The aim is to learn from a real event without allowing a wider audience to access information irrelevant to the improvement question.

Task. A manager proposes a target of zero reported near misses and rewards departments with no reports. What is the risk? **Answer.** The incentive may suppress reporting rather than eliminate hazards. A low reported count can coexist with poor detection or fear of blame. The service should value transparent reporting, timely response and demonstrable reduction in risk, not silence alone.

Task. What would make a claim of sustained improvement stronger? **Answer.** Consistent definitions, adequate exposure data, repeated observations, attention to case mix and reporting, evidence that the intended process changed, and monitoring for unintended consequences. The conclusion should match the strength of the evidence rather than exceed it.

Cumulative mastery assessment | 120 questions with reasoned answers

These questions test mechanism, interpretation and accountable action. They are not an external certification examination. Each group refers to the corresponding chapter and its cited evidence. Write an answer before reading the explanation, and identify the observation that would change your conclusion. The cases are fictional; actual decisions require the authorised clinical and laboratory pathway.

Chapter 1 — The transfusion decision chain

1. Why is a compatible crossmatch not a complete transfusion authorisation?

Answer. It addresses compatibility under a defined test or validated process. It does not establish that the component belongs to the intended patient, that the indication is appropriate, or that all product and bedside requirements are satisfied. Safe transfusion requires a connected chain from request and identity through selection, release, administration and reassessment.

2. What is lost when a laboratory reports only “blood ready”?

Answer. The message can conceal which units are ready, for whom, under what conditions, and whether unresolved findings remain. A useful communication identifies the patient and components, the status of testing, any restrictions and the person responsible for the next action. Availability and authorisation should not be confused.

3. Why can a near miss be educational even when no patient receives the wrong component?

Answer. It reveals a failure pathway that happened to be intercepted. The interception may depend on one person's attention rather than a reliable system. Investigating the conditions, barriers and recovery allows the service to strengthen protection before a

similar sequence reaches a patient. Absence of harm does not mean absence of risk.

Chapter 2 — Red-cell antigens

4. How can an antigen be present in a membrane without being a membrane protein itself?

Answer. Some blood-group determinants are carbohydrate structures carried on membrane glycoproteins or glycolipids. The recognised epitope is not always the protein backbone. This distinction explains why glycosyltransferase activity and precursor structures can determine expression, while other systems depend more directly on a specific membrane protein sequence.

5. Why does a negative serologic phenotype not always prove gene deletion?

Answer. Expression can be reduced or altered by variants, regulation, disease, treatment or the sampled cell population. The reagent and method also have detection limits. Serology describes detectable antigen expression under those conditions; a conclusion about the underlying gene requires suitable molecular evidence and interpretation.

6. What is the practical value of knowing a blood-group protein's physiological role?

Answer. It connects nomenclature with biology and helps explain unusual phenotypes. Transporters, adhesion molecules and membrane-complex components may have functions beyond serving as antibody targets. The clinical significance of an antibody still requires evidence about its behaviour; a protein's physiological importance does not alone predict transfusion risk.

Chapter 3 — Antibody significance

7. Does an antibody that reacts strongly at room temperature necessarily cause the greatest transfusion risk?

Answer. No. Reaction strength at one temperature is not a universal measure of clinical significance. Specificity, thermal range,

immunoglobulin class, complement involvement, method and patient context matter. A weaker reaction in a clinically relevant phase may be more important than a striking cold reaction. Investigation should explain the pattern rather than rank risk by grade alone.

8. Why is an alloantibody different from an autoantibody?

Answer. An alloantibody recognises an antigen that differs among members of the same species and is absent from the individual's relevant native antigen profile. An autoantibody reacts with the individual's own antigens. In recently transfused or transplanted patients, defining the relevant cell population can be difficult, so history and reliable typing are essential.

9. Can an antibody be clinically significant even when it is not detectable today?

Answer. Yes. A previously demonstrated clinically significant antibody may decline below current detection while immune memory persists. The historical finding remains relevant to future antigen exposure and component selection. Today's negative screen is evidence about present detectability, not proof that the patient's immunologic history has been erased.

Chapter 4 — Agglutination and antiglobulin testing

10. Why can IgG-coated red cells fail to visibly agglutinate without antiglobulin reagent?

Answer. Antibody binding and visible bridging are different events. IgG may sensitise cells without producing a macroscopic lattice under the test conditions. Antiglobulin reagent can reveal appropriate cell-bound immunoglobulin or complement-related targets. The result depends on washing, reagent specificity, cell condition and other controlled method steps.

11. What can residual unbound immunoglobulin do in an antiglobulin procedure?

Answer. It can interfere with the intended detection system, including neutralising antiglobulin activity in relevant methods. This is why washing and procedural controls are not optional decorative

steps. A negative result without valid controls may be uninterpretable rather than evidence that sensitisation is absent. Follow the validated method and manufacturer instructions.

12. Why should a reaction grade not be translated directly into antibody concentration?

Answer. The grade reflects the visible result of a particular antigen-antibody system under specified conditions. Antigen density, affinity, class, medium, incubation, centrifugation and reading all contribute. A 3+ reaction is not a universal concentration unit, and grades from different methods cannot automatically be compared as quantitative measurements.

Chapter 5 — Specimen identity and validity

13. Why is recollection preferable to correcting an uncertain patient label from memory?

Answer. Memory does not restore a trustworthy link between patient and specimen. Relabelling can conceal uncertainty and allow technically correct testing to be assigned to the wrong person. The service should follow its rejection, recollection and urgent-exception policies, preserving the discrepancy rather than manufacturing confidence in an uncertain identity.

14. Why do recent pregnancy and transfusion affect specimen-validity rules?

Answer. They can expose the patient to foreign red-cell antigens and alter the antibody picture over time. A previously valid sample may no longer represent the current risk context. The precise validity interval is jurisdiction- and policy-dependent; this book labels the Canadian 96-hour example rather than presenting it as a universal international rule.

15. Can a long-standing hospital number replace checking the patient's current identifiers?

Answer. No. The number is useful only when it is correctly linked to the person at the current encounter. Misregistration, duplicate records or selection of another chart can still occur. Identification

requires the approved active process, appropriate identifiers and reconciliation of discrepancies at the point where the specimen is obtained.

Chapter 6 — ABO and H

16. Why are ordinary group O red cells not suitable for every rare ABO-related phenotype?

Answer. Ordinary O cells lack A and B but generally retain H. A person with a clinically relevant antibody against H, as in an appropriate H-deficient phenotype, may react with those cells. “Universal donor” is an oversimplification that ignores rare antigens, other antibodies and component-specific compatibility requirements.

17. Why are red-cell and plasma ABO compatibility directions different?

Answer. Red-cell selection considers antigens on the donor cells exposed to recipient antibodies. Plasma selection considers donor antibodies that may encounter recipient red-cell antigens. The direction of the relevant antigen-antibody exposure changes with the component. A red-cell compatibility table should not be copied unchanged into a plasma rule.

18. What does a forward ABO test measure that a reverse test does not?

Answer. Forward testing examines antigen-related reactivity on the patient's red cells with known reagents. Reverse testing examines the patient's plasma against known reagent red cells. Their agreement supports interpretation, but age, immunologic state, transfusion and other factors can alter expected findings. They are complementary observations rather than duplicate tests.

Chapter 7 — ABO discrepancies

19. Why is weak reverse grouping in a young infant interpreted differently from an unexpected adult discrepancy?

Answer. The expected antibody pattern develops with age, and maternal antibodies and neonatal physiology affect interpretation.

Adult expectations cannot simply be imposed on an infant. The laboratory should apply its age-specific validated procedure; the Canadian guidance discussed in this book does not require routine reverse grouping for infants under four months.

20. What is the first danger of forcing an unresolved ABO result into a single computer field?

Answer. It can make uncertainty invisible to later staff and allow selection rules to operate on a falsely definitive group. The investigation and any temporary component strategy should be documented explicitly. A software requirement for a value does not create biological evidence and should be addressed through an authorised exception pathway.

21. Does a cold-reactive antibody explain every unexpected reverse-group reaction?

Answer. No. It is one hypothesis among several, including subgroup-related findings, specimen or reagent problems, altered antibody production and mixed populations. Selected cells, controls, temperature behaviour and clinical history help distinguish explanations. A familiar cause should not become a shortcut that prevents investigation of a different problem.

Chapter 8 — Rh variants

22. Why should donor and recipient D interpretation not be assumed identical?

Answer. Their risk questions differ. Donor testing aims to prevent D-bearing cells from being labelled in a way that exposes a susceptible recipient. Recipient interpretation considers the person's variant and risk of anti-D formation. Validated policies therefore may handle weak or variant reactions differently according to the role and molecular result.

23. What is the limitation of the statement “all weak D patients can be treated as D positive”?

Answer. Weak serologic expression encompasses different molecular situations. The joint statement discussed in this book supports

specified management for defined weak D types 1, 2 and 3, not every variant. Other variants may require different handling. Molecular identification and applicable clinical guidance are needed before extending that conclusion.

24. How can partial D differ from merely reduced antigen density?

Answer. A partial D protein may lack or alter epitopes recognised by some anti-D antibodies, whereas reduced expression concerns the amount of detectable antigen. The categories are biologically and serologically complex and can overlap in testing. A reaction grade alone does not define the molecular variant or its clinical management.

Chapter 9 — Kell

25. Why can anti-K cause fetal anaemia through more than destruction of mature red cells?

Answer. Kell-related targets are expressed during erythroid development, so anti-K can affect erythroid precursors as well as mature cells. This helps explain why fetal risk cannot be inferred solely from a simple model of peripheral haemolysis or from titre alone. Specialist pregnancy assessment follows the relevant guideline and clinical findings.

26. What is the consequence of treating cells with a reagent that destroys Kell reactivity?

Answer. A negative treated-cell result cannot exclude antibodies whose targets are no longer adequately expressed. The method has gained or changed one form of analytical discrimination while losing another. History, reliable antigen information and the validated component-selection strategy must account for that blind spot.

27. Why should K and k not be described as positive and negative versions of the same result?

Answer. They name distinct antigens within the Kell system. A person lacking K commonly expresses k, but rare phenotypes and variants exist. The notation identifies antigen specificity, not a

general quality grade. Accurate system terminology is important when interpreting antibodies and searching for suitable donor units.

Chapter 10 — Kidd

28. What connects Kidd biology with a membrane transport function?

Answer. Kidd antigens are associated with a red-cell urea transporter. This gives the system a physiological identity beyond its serologic name. Clinical interpretation still focuses on the antibody, antigen expression, history and test conditions; the transport function alone does not determine whether an individual reaction is clinically significant.

29. Why are Kidd antibodies important in delayed transfusion-reaction reasoning?

Answer. They may become difficult to detect over time and later reappear after antigen exposure. Historical records can therefore protect a patient when the current screen is nonreactive. A delayed haemolytic pattern requires a complete investigation, but an evanescent clinically significant antibody is a key mechanism to consider.

30. Is a nonreactive Jk(a+b+) cell always sufficient to exclude anti-Jk(a)?

Answer. No. Dosage can make a heterozygous cell less informative for exclusion than an appropriately selected cell with stronger relevant expression. The laboratory must use its validated exclusion criteria and adequate antigen profiles. One convenient negative reaction should not override a coherent antibody hypothesis or a verified historical finding.

Chapter 11 — Duffy

31. Why can a regulatory variant affect Duffy expression differently in different tissues?

Answer. Gene regulation can be tissue-specific. An erythroid-associated promoter variant may alter red-cell expression

without eliminating expression everywhere in the body. This distinction is important for interpreting genotype and antibody risk. It prevents the incorrect assumption that every red-cell-negative phenotype represents complete absence of the protein from all tissues.

32. What is the practical limitation of an enzyme-treated panel for Duffy investigation?

Answer. Common enzyme treatments can alter or destroy relevant Duffy antigen reactivity. A negative enzyme-phase result therefore may reflect loss of the target rather than absence of antibody. Untreated-cell evidence and the validated investigation remain essential. Treatment effects should be used as discriminating information, not as universal rule-out evidence.

33. Why should ancestry not replace an actual antigen or genotype result?

Answer. Population frequencies describe groups, not a particular patient's phenotype. Individual variation and mixed ancestry make inference unreliable for component selection. Population knowledge can help plan a donor search, but the required patient and unit information must be established through appropriate records and testing rather than appearance or assumed background.

Chapter 12 — MNS

34. Why are M, N, S and s not interchangeable labels?

Answer. They represent different determinants associated with glycophorin biology. Antibodies against them can differ in typical reactivity and clinical significance. The system includes complex variants, so a simple four-antigen summary is only an introduction. Interpretation requires specificity, phase, history and the relevant molecular or serologic context.

35. Can all anti-M be dismissed as harmless cold reactivity?

Answer. No. Many examples have limited clinical significance under particular conditions, but clinically relevant behaviour can occur. The reaction phase, thermal characteristics, immunoglobulin contribution

and clinical setting matter. A categorical dismissal ignores exceptions and can be particularly problematic in pregnancy or when reactivity persists in a clinically relevant method.

36. What does an unusual glycophorin variant teach about a negative screening panel?

Answer. Screening cells cannot represent every rare antigenic structure. An antibody may be missed if the relevant target is absent from the cells used. A negative screen is bounded by antigen coverage and method sensitivity. Incompatible crossmatches or a suggestive history can justify further investigation despite a nonreactive routine screen.

Chapter 13 — Lewis, P1PK and I

37. How does adsorption from plasma make Lewis expression unusual?

Answer. Lewis antigens on red cells are acquired from circulating substances rather than being expressed solely through the same intrinsic membrane-synthesis model used for many other systems. Physiological changes can therefore alter the apparent red-cell phenotype. The result should be interpreted with context rather than assumed to reflect a permanent change in inherited genes.

38. Why is thermal amplitude relevant to a cold-reactive antibody?

Answer. It describes the temperature range over which the antibody reacts, which can be more clinically informative than a striking titre at a low temperature alone. Method and patient context remain important. A high cold titre does not automatically predict activity at clinically relevant temperatures or establish the cause of haemolysis.

39. What changes in I-related expression occur during normal early development?

Answer. The relative expression of i and I structures changes as red cells mature after birth. This developmental biology helps explain age-related serologic patterns. It does not justify assigning a clinical

antibody solely from the patient's age; appropriate reagent cells, methods and clinical evidence are still required.

Chapter 14 — Rare and high-frequency antigens

40. Why can an antibody to a high-frequency antigen produce broad panel reactivity?

Answer. Most routine reagent cells may carry the target, so many or all cells react. That appearance can resemble other causes of panreactivity. Autocontrol, patient antigen information, selected rare cells, treatment studies and specialist investigation help distinguish the possibilities. Broad reactivity is a starting pattern, not an antibody identification.

41. Why does a negative autocontrol not exclude every complex antibody problem?

Answer. It only describes reactivity with the tested autologous cell preparation under those conditions. Recent transfusion, cell availability, method limitations and mixed antibodies can complicate interpretation. A negative result may support an alloimmune hypothesis, but it does not identify the target or rule out every clinically important alternative.

42. What should be communicated before a rare-donor search begins?

Answer. The service needs verified patient identity, required specificity and evidence, urgency, component number and characteristics, history, available specimens and contact details for decisions. A request without a clear clinical timeframe or reliable antigen requirement wastes scarce resources and can delay support. The plan should be updated as the investigation evolves.

Chapter 15 — Probability and donor selection

43. What does an expected yield of five suitable units from twenty screened mean?

Answer. Under the model's probability, repeated comparable searches would average five suitable units. A particular search may

yield fewer or more. Expected count is not a guarantee and does not replace actual unit typing or compatibility requirements. The estimate should retain its population and independence assumptions.

44. When is multiplying two antigen-negative frequencies inappropriate?

Answer. It is inappropriate when the relevant traits are not independent or the frequencies come from unsuitable populations. Linked or correlated expression can make the joint probability different from the product of marginal frequencies. Use joint data or actual inventory records when available, and state assumptions when using a simplified teaching estimate.

45. Why can an inventory that contains a suitable phenotype still fail to meet the clinical need?

Answer. Other requirements may remain: ABO suitability, product condition, expiry, irradiation or other modifications, reservation, transport and required compatibility testing. Availability is a multidimensional service question. The phenotype is necessary information in many cases, but it is not the entire release specification.

Chapter 16 — Reagents and controls

46. Why must reagent lot changes be assessed rather than treated as identical replacements?

Answer. Lots can differ in characteristics that affect performance near important detection limits or with particular specimens. Verification establishes suitability in the laboratory's intended use. Acceptable routine controls are important but may not reveal every clinically relevant difference, so the change assessment should match the reagent and method risk.

47. What is the difference between a control failure and a patient-positive result?

Answer. A control failure raises doubt about whether the test system behaved as required. It may invalidate interpretation of patient results in the affected run. A patient-positive result is meaningful

only within a valid system and appropriate specimen context. The two should not be combined into a diagnosis before the method problem is resolved.

48. Can repeating a test until a preferred answer appears be quality control?

Answer. No. Unplanned repetition can select a convenient result and hide variation or error. Repeats should follow defined criteria, preserve all observations and investigate discordance. A valid resolution explains why results differed and why the final interpretation is supported, rather than discarding every result that conflicts with expectations.

Chapter 17 — DAT, IAT and elution

49. What distinguishes the direct from the indirect antiglobulin test?

Answer. The DAT examines coating of the sampled red cells that occurred in vivo or before the test preparation. The IAT examines sensitisation produced when plasma or serum is incubated with test cells under laboratory conditions. They answer related but different questions and neither alone provides a complete diagnosis of immune haemolysis.

50. What does an eluate investigation add?

Answer. It examines material removed from sensitised red cells, helping investigate the specificity associated with cell-bound antibody in an appropriate context. The method has recovery and specificity limitations. A positive eluate should be interpreted with the DAT, plasma findings, transfusion history and evidence of haemolysis, not as an isolated diagnosis.

51. Why can a DAT be positive without clinically important haemolysis?

Answer. Detectable coating does not necessarily produce sufficient destruction to cause a haemolytic syndrome. The amount and type of coating, complement activity, cell clearance and patient context matter. Clinical findings and laboratory evidence of haemolysis

establish whether the serologic observation is associated with a clinically significant process.

Chapter 18 — Screening

52. Why is an antibody screen not a miniature guarantee against all incompatibility?

Answer. It depends on the antigens present on screening cells and the method's detection characteristics. Rare targets, weak antibodies, changing concentrations or technical limitations can escape detection. History and crossmatch findings may reveal additional concerns. A negative screen should be stated within its scope rather than translated into absence of every antibody.

53. What does reactivity with only one screening cell suggest?

Answer. It suggests a target or effect associated with that cell under the tested conditions, but it does not identify the specificity. The cell's antigen profile, controls, repeatability and a broader investigation are needed. Multiple candidate antigens can coexist on the same cell, so one positive result cannot uniquely assign the cause.

54. Why should a previously positive screen not be silently deleted after a negative repeat?

Answer. The discordance may reveal weak reactivity, specimen or reagent effects, method variation or an error requiring explanation. Deleting the first result removes information and can falsely imply an uncomplicated negative history. Retain both observations and document the investigation and basis for the final interpretation.

Chapter 19 — Panel interpretation

55. What makes a selected cell informative for distinguishing two candidate antibodies?

Answer. It expresses one proposed target without the other, while its broader profile and expression strength are suitable for the question. Such a cell separates hypotheses more effectively than a cell positive for both targets. Even an informative cell does not replace the full validated identification and exclusion requirements.

56. Why is crossing out every antigen found on a nonreactive cell unsafe?

Answer. Antibody detection may depend on dosage, phase, treatment, expression strength and method sensitivity. A nonreactive cell is only valid exclusion evidence under the appropriate conditions. Uncritical rule-out ignores these limitations and can eliminate a clinically significant specificity that a more suitable cell would demonstrate.

57. How should an unexplained reaction be handled after a likely antibody is found?

Answer. It remains a finding to explain. The identified antibody may coexist with another specificity, an autoantibody, interference or a technical problem. A satisfactory interpretation accounts for the meaningful observations rather than stopping at the first plausible label. Unresolved reactivity should be communicated and managed through the appropriate specialist pathway.

Chapter 20 — Multiple antibodies

58. Why might removing one antibody reveal another?

Answer. A dominant pattern can mask a weaker or more restricted specificity. An appropriate adsorption or selected-cell strategy may separate their contributions. The separation method can also lose relevant antibodies or alter targets, so its limitations must be understood. A cleaner pattern is useful only when the changed detection scope is documented.

59. Does a stronger reaction on a double-positive cell quantify the relative concentrations of two antibodies?

Answer. No. Reaction grade is influenced by many non-additive factors. A double-positive cell may support a mixture hypothesis, but its grade is not a concentration equation. Distinguishing the antibodies requires informative selected cells, appropriate methods, history and sufficient evidence under the validated investigation.

60. Why must historical antibodies remain in a multiple-antibody selection plan?

Answer. One or more may be below current detection while still biologically relevant. Selecting units only for the currently dominant specificity can expose the patient to a previously implicated antigen. A complete plan reconciles current findings with verified history and documents how all relevant requirements are satisfied.

Chapter 21 — Enzymes and DTT

61. Why is a treated-cell panel a different analytical system from the untreated panel?

Answer. Treatment changes antigen accessibility or integrity and may alter nonspecific effects. It can enhance some reactions while weakening or eliminating others. The treated result therefore has a different information content. Interpretation requires knowing what was preserved, changed and lost, rather than regarding treatment as a universal improvement in sensitivity.

62. Can disappearance of reactivity after DTT establish that no alloantibody is present?

Answer. No. DTT can remove an interference while also destroying relevant antigen targets. Antibodies against those targets may no longer be detectable in the treated system. Historical findings, reliable phenotype or genotype and the validated selection policy must account for the blind spots before component release is considered.

63. Why must treatment controls be appropriate to the intended question?

Answer. The laboratory needs evidence that the treatment achieved the expected effect without invalidating the required detection. A generic positive control may not demonstrate the specific antigen changes or losses relevant to interpretation. Controls should support the validated method and its claimed purpose, including known limitations.

Chapter 22 — Adsorption and elution

64. What is the essential distinction between adsorption and elution?

Answer. Adsorption removes selected antibody reactivity from a fluid phase using suitable material, while elution removes bound material from sensitised cells for investigation. They address different parts of the antigen-antibody interaction. Their results depend on the cells, conditions and recovery, so neither can be interpreted without the method's selection and loss characteristics.

65. Why is recent transfusion important before autoadsorption?

Answer. The patient's circulating red cells may include donor cells carrying antigens absent from the patient's native cells. Using that mixed population can remove clinically significant alloantibodies and obscure the investigation. The laboratory must assess transfusion history and select an appropriate validated strategy, often with specialist support.

66. Can a negative adsorbed plasma result prove that the original broad reactivity was harmless?

Answer. No. It describes what remains detectable after a procedure that deliberately removes reactivity and may have additional losses. The clinical meaning of the original antibody and any masked alloantibody requires the full investigation. Method-induced disappearance should not be equated with absence of patient risk.

Chapter 23 — Warm autoantibodies

67. Why is the phrase “least incompatible” a poor basis for ranking donor units?

Answer. Comparing reaction grades caused by a broadly reactive autoantibody does not establish which unit is clinically safest. The important work is to assess alloantibodies, reliable antigen requirements, urgency and the overall clinical plan. Unit selection should be based on defensible criteria rather than a misleading competition among incompatible reaction strengths.

68. Does panreactivity remove the need to investigate alloantibodies?

Answer. No. Autoantibodies can coexist with clinically significant alloantibodies and make them harder to detect. History, phenotype or genotype and appropriate adsorption or reference techniques may be required. The clinical urgency and laboratory limitations should be discussed openly so that investigation supports rather than silently delays necessary care.

69. Why can a strongly positive DAT coexist with a less dramatic clinical course?

Answer. Serologic intensity and clinical haemolysis are related imperfectly. Coating type, cell clearance, marrow response, treatment and other factors influence the clinical picture. The DAT is one observation in a broader assessment, not a numerical severity score that can replace haemoglobin trends and other clinical-laboratory evidence.

Chapter 24 — Cold and biphasic antibodies

70. How can complement contribute to haemolysis after an antibody binds at a cooler temperature?

Answer. Antibody binding can initiate complement, and complement-related effects may persist as cells return to warmer conditions. The precise mechanism depends on the antibody and disease context. This explains why temperature-dependent binding and subsequent injury cannot be reduced to a single room-temperature reaction grade.

71. Why should a cold-agglutination specimen be handled according to a defined pathway?

Answer. Temperature changes can alter cell aggregation and the distribution of antibody between plasma and cells, affecting results. The collection, transport and preparation requirements should be coordinated with the laboratory. Improvised warming or cooling can change the evidence and create misleading comparisons between specimens.

72. What makes a biphasic haemolysin concept different from ordinary agglutination?

Answer. The mechanism involves binding and complement-related injury across different temperature phases rather than visible cell clumping alone. A specialised investigation requires appropriate controls and clinical context. A photograph of aggregates cannot diagnose that mechanism, and a routine cold-reactive pattern should not be assigned a specialised label without evidence.

Chapter 25 — Drugs and therapeutic antibodies

73. Why is the medication history part of a serologic investigation rather than an administrative extra?

Answer. Drugs and therapeutic antibodies can alter immune mechanisms or interfere directly with testing. Knowing the agent and timing can explain broad reactivity, guide method selection and identify limitations. Without that history, staff may misclassify interference as a new alloantibody or fail to plan safe component support.

74. What distinguishes an analytical interference from proof of drug-induced haemolysis?

Answer. Interference changes the test result without necessarily causing the patient's red cells to be destroyed. Drug-induced haemolysis requires a compatible clinical-laboratory mechanism and investigation. The two can produce overlapping serologic observations, so the report must not convert a known assay effect into a clinical diagnosis automatically.

75. Why should an anti-CD38 alert be durable across care settings?

Answer. Interference may persist beyond a single treatment visit and can delay testing elsewhere. A reliable record allows the receiving service to anticipate the problem, retrieve baseline information and use its validated approach. The alert should identify the therapy and relevant dates without claiming a universal fixed date when interference must end.

Chapter 26 — Crossmatch and electronic issue

76. What does electronic issue require beyond functioning software?

Answer. It requires a validated system, reliable patient and component data, defined eligibility, appropriate testing and history, safeguards, trained staff and a controlled exception process. Automation executes rules; it does not make incorrect inputs true. Software availability alone is not evidence that a patient qualifies for electronic issue.

77. Why is a manual override clinically consequential?

Answer. It can bypass a barrier designed to prevent an unsafe selection or release. Overrides require authority, a documented reason, review of the underlying condition and an audit trail. Repeated overrides may indicate a system problem. A convenient workaround should not become an undocumented alternative to the validated process.

78. Can a compatible unit resolve an unexplained patient ABO discrepancy?

Answer. No. The crossmatch and the discrepancy answer different questions. A unit may be suitable under a temporary authorised strategy while the patient's group remains unresolved. The laboratory must preserve and investigate the discrepancy, document the component rationale and avoid using one compatible result as proof of a final blood group.

Chapter 27 — Component-specific compatibility

79. Why are platelets not simply small red-cell units for compatibility purposes?

Answer. Their antigen expression, plasma content and clinical use differ. ABO considerations, HLA or HPA issues and residual red-cell exposure can all matter in appropriate settings. A red-cell compatibility rule cannot be copied mechanically to platelets. Selection should follow the current component-specific clinical and laboratory policy.

80. Why can RhD considerations arise with platelet transfusion when platelets do not express D as red cells do?

Answer. Residual red cells in a platelet component can expose the recipient to D antigen. The significance depends on component preparation, recipient context and the applicable prevention policy. The mechanism should be explained accurately rather than stating that the platelet itself carries the same D antigen expression as a red cell.

81. Why is a component's label necessary but not sufficient at administration?

Answer. The label must be correctly matched to the intended patient and request, and the component's condition, timing and special requirements must be assessed. A correctly labelled unit can still be administered to the wrong person if the bedside process fails. Identity verification links the laboratory product to the clinical recipient.

Chapter 28 — Pregnancy and HDFN

82. Why does a maternal antibody titre not independently determine fetal severity?

Answer. Antibody specificity, previous pregnancy history, fetal antigen status and specialist monitoring all contribute. Some mechanisms, including anti-K effects on erythropoiesis, make simple titre-based assumptions particularly unreliable. Titration is a method-dependent observation within a clinical pathway, not a universal standalone measure of fetal anaemia.

83. What information does fetal antigen assessment add?

Answer. It helps determine whether the fetus expresses the target relevant to a maternal antibody. If the target is absent under a reliable assessment, the specific antibody-related risk differs from that of an antigen-positive fetus. The test's scope, timing and limitations must be respected, and specialist guidance governs management.

84. Why must passive and immune anti-D be interpreted cautiously?

Answer. Prophylactic anti-D can produce detectable reactivity, while immune anti-D has different implications. Timing, documented administration, prior results and the serologic pattern inform interpretation, but one routine result may not distinguish them conclusively. The laboratory should communicate uncertainty and use the applicable pregnancy pathway rather than assume either explanation.

Chapter 29 — Neonatal testing

85. Why can an infant's current plasma antibody pattern reflect maternal immunity?

Answer. Maternal IgG can cross the placenta and remain in the infant for a period after birth. The infant's findings therefore cannot be interpreted using only an adult model of independently produced antibodies. Maternal history and testing, infant identity and the clinical condition are essential to appropriate investigation and component selection.

86. What is the main safety lesson in a neonatal aliquot calculation?

Answer. Units, prescribed volume, patient weight and the actual component must remain linked. A correct arithmetic product does not establish a clinically appropriate dose. The prescription, preparation, labelling, identity and administration checks still apply. Small-volume care can magnify the consequences of unit or decimal errors.

87. Does a positive neonatal DAT establish the need for a particular treatment?

Answer. No. It supports an assessment of red-cell coating but does not by itself quantify haemolysis or determine management. The infant's clinical state, bilirubin and haemoglobin course, antibody context and specialist pathway guide care. Laboratory evidence should inform, not impersonate, the authorised clinical decision.

Chapter 30 — Reaction investigation

88. Why should the unit and specimen identity be rechecked even when an immune mechanism seems obvious?

Answer. A clerical or identification error can create or accompany incompatibility and may be missed if staff focus only on antibody specificity. Identity reconciliation is a foundational part of the investigation. An elegant serologic explanation does not repair a wrong-patient sample or a misassigned component.

89. What is the difference between temporal association and imputability?

Answer. Temporal association means the event occurred in relation to the transfusion timeline. Imputability assesses how likely transfusion was to have caused it, using the evidence and defined framework. Timing alone is not causation, and surveillance classification should not be confused with the full clinical diagnostic process.

90. Why should a corrected critical result be actively communicated?

Answer. The clinical team may already be acting on the earlier information. A silent electronic amendment may not reach the responsible person promptly. The correction needs a documented communication loop that identifies the change, reason, time and recipient while preserving the original record and audit trail.

Chapter 31 — Sickle-cell disease and chronic support

91. Why is an extended antigen profile ideally established before extensive transfusion?

Answer. Subsequent circulating donor cells can complicate serologic phenotyping, and early information supports matching and investigation. Genotyping can provide valuable additional detail, particularly for variants, but also has method limitations. The profile should be reliable, accessible and interpreted within the current disease-specific transfusion guidance.

92. Why can Rh alloimmunisation occur despite apparently matched routine Rh phenotypes?

Answer. Variant RH alleles can alter epitopes in ways not fully captured by routine antigen labels. Two people with similar serologic results may not be molecularly identical for clinically relevant expression. Genotype-informed investigation and specialist matching can therefore be important, especially in chronically transfused populations.

93. What makes hyperhaemolysis reasoning more complex than destruction of donor cells alone?

Answer. The clinical pattern can involve loss of both transfused and the patient's own red cells, with haemoglobin falling below the pretransfusion level. Management is specialist and urgency-dependent. The laboratory should recognise and communicate the concerning pattern without replacing the clinical pathway with a simplistic instruction either always to transfuse or never to transfuse.

Chapter 32 — Genotyping and transplantation

94. Why does a molecular assay not necessarily predict every antigen expressed on a cell?

Answer. It examines specified regions and variants, and expression can be affected by additional genetic or regulatory factors. Rare alleles or complex rearrangements may fall outside coverage. Molecular results are powerful evidence but require interpretation with the assay's scope, serology, history and the clinical question.

95. How can a stem-cell transplant complicate the meaning of a blood-derived DNA sample?

Answer. Nucleated blood cells may reflect donor-derived haematopoiesis rather than the recipient's original genotype. Chimerism and timing can further complicate interpretation. The laboratory must know the transplant history and specimen source before assigning a molecular result to the intended biological identity.

96. Why should an ABO transition after transplantation be managed as a process?

Answer. Red cells, plasma antibodies and engraftment do not necessarily change synchronously. Component requirements can differ across phases, and mixed populations may persist. A coordinated transplant-transfusion policy integrates the donor and recipient groups, current findings and clinical phase rather than changing one computer field and assuming the transition is complete.

Chapter 33 — Rare-donor services

97. Why is early referral preferable to exhausting local inventory first?

Answer. Rare-unit identification, confirmation, transport and preparation may take time. Early communication allows parallel planning and clarifies whether the clinical need can wait. Waiting until routine stock is exhausted can convert a manageable problem into an emergency without improving the evidence for selection.

98. What distinguishes a predicted rare phenotype from a confirmed available unit?

Answer. Prediction concerns antigen information; availability also requires an actual suitable component with verified identity, condition, location and release status. A donor database entry is not the same as a unit ready for use. The service must confirm all operational and compatibility requirements before promising support.

99. Why should rare-donor information be protected?

Answer. It can include identifiable health and genetic information. Access should be limited to authorised purposes, with appropriate consent, governance and secure communication. The clinical value of a rare phenotype does not remove the donor's privacy interests or permit unrestricted sharing of their record.

Chapter 34 — Platelet refractoriness

100. Why is a single low post-transfusion platelet count insufficient to diagnose immune refractoriness?

Answer. Timing, dose, baseline count, bleeding, infection, consumption, sequestration and other factors can affect the response. Repeated appropriately timed measurements and a structured investigation are needed. Antibody testing and selected products are useful within that pathway, not as automatic consequences of one disappointing count.

101. Which unit error changes a CCI calculation by a factor of 1,000?

Answer. Using an increment expressed in ×10^9/L in a formula expecting platelets per microlitre without converting it. One ×10^9/L equals 1,000/µL. The formula and comparison threshold must use the same convention; a bare number without units can be dangerously misleading.

102. Why may HLA-selected platelets still produce a poor increment?

Answer. Matching addresses a relevant immune mechanism, but nonimmune consumption and other clinical factors may continue. The selected strategy also has practical and biological limitations. Follow-up counts and clinical assessment are needed to evaluate the response rather than treating the product's selection label as a guarantee of success.

Chapter 35 — Reference consultation

103. What makes a referral specimen useful beyond sufficient volume?

Answer. Reliable identity, appropriate collection and handling, relevant history, previous results, current therapies, the clinical question and urgency are essential. A well-preserved tube without context may be impossible to interpret efficiently. The referring and receiving services should agree on requirements and maintain communication as the investigation develops.

104. Why should unresolved findings be described instead of hidden in the referral?

Answer. They guide method choice and prevent the receiving service from repeating an incomplete assumption. Describing the pattern, controls and previous attempts helps distinguish a true complex antibody from a technical or specimen issue. Referral is a transfer of evidence and responsibility, not merely shipment of a sample.

105. Does a reference-laboratory report remove the local service's release responsibility?

Answer. No. The local service must integrate the report with current patient identity, component requirements, clinical urgency and its authorised procedures. Specialist interpretation informs selection, but the final local actions still require accountable verification and communication. Responsibilities should be explicit rather than assumed to have disappeared with referral.

Chapter 36 — Automation and downtime

106. Why must an interface map preserve both result value and meaning?

Answer. A code can be transferred correctly as text while being interpreted incorrectly by the receiving system. Units, flags, historical status, reaction grades and amended results require semantic validation. Interface testing should follow the clinical decision pathway, not merely confirm that a message reached the next computer.

107. What is the danger of using a screenshot as the only downtime record?

Answer. It may omit provenance, timing, amendments, full identifiers or the actions taken. It also creates privacy and version-control risks. A controlled downtime process should specify authoritative records, verification, communication and reconciliation after recovery rather than rely on informal images of an interrupted workflow.

108. Why is post-downtime reconciliation a safety step?

Answer. Manual issues, results, reservations and amendments must be incorporated accurately into the restored system without duplication or loss. Otherwise later decisions may rely on incomplete history or incorrect inventory. Recovery is not complete merely because the computers restart; the clinical and audit records must also be reconciled.

Chapter 37 — Validation and quality control

109. What does overall agreement conceal in a method-comparison study?

Answer. It can hide the distribution and clinical importance of discordant positive and negative results, especially when negatives dominate the sample. Positive and negative agreement, difficult specimens and discrepancy investigations provide additional information. A high overall percentage should not replace an analysis of the cases where the methods disagree.

110. Why are acceptance criteria best defined before seeing the validation results?

Answer. Predefined criteria reduce the temptation to alter the standard until the observed data pass. They connect the study to intended use and clinical risk. Deviations or revised criteria may sometimes be justified, but they must be transparent and supported rather than silently chosen to produce a favourable conclusion.

111. Does zero observed failure in thirty specimens establish perfect performance?

Answer. No. A small sample can miss uncommon failures. The simple rule-of-three approximation gives an upper 95% bound near 10% when no failures occur in thirty independent observations. Actual validation may require different statistics and designs, but the central lesson is that absence of observed failure is not proof of zero risk.

Chapter 38 — Haemovigilance

112. Why should event definitions remain stable when comparing periods?

Answer. A change in what counts as an event can alter the numerator without any real change in safety. Comparisons require consistent definitions or a transparent adjustment for changes. Reporting intensity, exposure and case mix also matter. An attractive trend can be misleading when the underlying measurement has changed.

113. How can a falling event count coexist with a rising event rate?

Answer. Exposure may fall faster than the count. Twelve events in 6,000 specimens equal two per 1,000, while nine in 3,000 equal three per 1,000. The count decreases but the rate increases. Both numerator and denominator should be reported so that service decisions are not based on a misleading headline.

114. Why is training attendance not sufficient evidence that a corrective action worked?

Answer. Attendance shows participation, not necessarily changed practice or reduced risk. Effectiveness should be assessed through measures linked to the problem, such as observed competency, process adherence or event rates with appropriate context. The evaluation should also check whether the change created new delays or workarounds.

Chapter 39 — Emergency allocation

115. Why does urgency change the balance of a decision without eliminating accountability?

Answer. Delay can itself cause harm, so the clinical and laboratory teams may need an authorised emergency strategy before all routine testing is complete. The decision must still identify what is known, what remains uncertain, who authorised release and how follow-up testing and communication will occur. Emergency does not mean undocumented.

116. What should happen when a later result changes the suitability of an emergency-issued unit?

Answer. The laboratory should promptly communicate with the responsible clinical team, assess whether the unit has been administered and follow the relevant investigation and replacement pathway. The original emergency decision and the new evidence should remain in the record. Silent retrospective editing cannot manage a current patient risk.

117. Why is a universal emergency stock rule insufficient for every patient?

Answer. Rare phenotypes, known antibodies, pregnancy-related considerations, prior reactions and special component requirements can change the risk. The service needs an approved policy with escalation routes for exceptions. Standard emergency stock improves readiness, but it does not abolish the need to recognise patients whose requirements fall outside the default.

Chapter 40 — Integrated conference

118. What should a final case presentation distinguish explicitly?

Answer. It should separate verified observations, inferred mechanisms, unresolved alternatives and the authorised action plan. This prevents a plausible explanation from being mistaken for a proven fact. The presentation should also identify the evidence that would change the conclusion and the person responsible for follow-up.

119. Why is an internally consistent story not enough to validate an investigation?

Answer. A story can be coherent while built on a wrong specimen, incomplete antigen coverage or a biased interpretation. Each important inference must remain linked to reliable observations and appropriate methods. Contradictory data should be investigated rather than removed to preserve the narrative. Scientific reasoning tests the story against evidence.

120. What is the final educational goal of blood-bank serology?

Answer. It is to convert reliable laboratory evidence into safe, traceable support for the patient, while recognising uncertainty and scope. Naming an antibody is important, but competent practice also requires understanding mechanism, selecting appropriate components, communicating limitations, documenting decisions and learning from outcomes. Accuracy and accountability belong to the same professional task.

Applied glossary | Meaning, use and limits

These definitions support retrieval and interpretation. Each entry includes a source anchor, and the subject index points to teaching locations in this PDF. A concise definition does not replace the full mechanism and case discussion in the relevant chapter.

ABH precursor

A carbohydrate structure involved in expression of ABO-related determinants. H provides a substrate for relevant A or B transferase activity. Ordinary group O cells generally retain H, which explains why they are not suitable for every rare H-deficient patient with clinically relevant anti-H. [FB06]

ABO discrepancy

Disagreement within the expected ABO testing pattern or between current and reliable historical information. It is a problem to investigate, not a blood group to guess. Forward and reverse results, controls, patient age, transfusion, transplantation and other context determine the resolution pathway. [FB02]

Adsorption

Removal of selected antibody reactivity from a fluid phase using appropriate cells or other material. The procedure can help separate complex mixtures but may also remove clinically relevant antibodies. Cell choice, recent transfusion and method limitations must remain part of the interpretation. [FB02]

Agglutination grade

A method-defined description of visible red-cell aggregation. It is not a universal antibody concentration or clinical-severity scale. Grades depend on reagent cells, antibody properties and test conditions, so comparisons across methods or phases require appropriate caution. [FB05]

AHG

Antihuman globulin reagent used to detect relevant immunoglobulin or complement-related coating of red cells in an appropriate method. Its specificity and procedural requirements matter. A negative result is interpretable only when specimen preparation, controls and reagent performance satisfy the validated procedure. [FB05]

Alloadsorption

Adsorption using selected non-autologous red cells to investigate antibody mixtures. Their antigen profiles determine which antibodies may be removed or retained. The method is particularly useful in appropriate complex cases, but it requires careful design and does not automatically preserve every clinically significant alloantibody. [FB02]

Alloantibody

Antibody against an antigen differing among people and absent from the individual's relevant native antigen profile. Exposure can occur through transfusion or pregnancy. Clinical significance depends on specificity and behaviour, and verified historical findings may remain relevant when the current assay is nonreactive. [FB01]

Alloimmunisation

Development of an immune response to foreign antigens from another person. In transfusion practice it can complicate later component selection and contribute to reactions. Prevention and matching strategies depend on patient group, exposure, antigen information and current clinical guidance. [FB21]

Anamnestic response

A renewed immune response after re-exposure to a previously encountered antigen. It helps explain why a historical antibody can become clinically relevant despite low current detectability. A negative present-day screen does not establish that the corresponding immune memory is absent. [FB12]

Antibody exclusion

A justified conclusion that a specified antibody has not been demonstrated within the capabilities of an appropriate investigation. It requires suitable antigen expression and method conditions. One negative cell is not universally sufficient, especially when dosage, treatment or weak reactivity limits detection. [FB02]

Antibody identification

A structured interpretation linking a reaction pattern to a supported specificity or mixture. It integrates panels, selected cells, controls, phenotype or genotype, history and method limitations. A plausible label is not complete until important contradictory or unexplained reactions are addressed. [FB02]

Antibody screen

Testing with selected reagent cells to detect unexpected red-cell antibody reactivity under specified conditions. It does not represent every rare antigen or detect every weak antibody. Historical information and incompatible crossmatches can reveal concerns outside the routine screen's coverage. [FB01]

Antigen frequency

Proportion of a defined population expressing an antigen under the relevant classification. It supports inventory planning but does not identify an individual patient's or unit's phenotype. Frequencies from different populations or correlated antigens should not be combined without justified assumptions. [FB03]

Antigen profile

A set of established antigen findings for a patient or donor. Its reliability depends on method, timing, recent transfusion and variants. An extended profile supports matching and investigation, but it should be interpreted with its scope rather than treated as coverage of every blood-group antigen. [FB21]

Antigen-negative unit

A component whose relevant red cells lack a specified antigen according to reliable information. It must also satisfy the other applicable selection and release requirements. A single antigen-negative label is not a complete compatibility certificate for every antibody or clinical circumstance. [FB01]

Autoadsorption

Adsorption using the patient's own red cells in a suitable investigation. Recent transfusion can introduce donor cells and make the procedure remove alloantibodies unintentionally. Eligibility and method selection therefore depend on history and the validated specialist pathway, not merely availability of a patient sample. [FB16]

Autoantibody

Antibody reacting with a self-associated red-cell target in the relevant context. It may coexist with alloantibodies and does not always cause haemolysis. Broad reactivity requires investigation of clinical significance and masked specificities rather than immediate assignment of every reaction to an innocuous autoantibody. [FB16]

Autocontrol

Reaction of the patient's plasma or serum with an appropriate preparation of the patient's red cells. It helps frame an investigation but has limitations, particularly after transfusion or with mixed populations. A positive or negative result is not by itself a complete distinction between all auto- and alloimmune processes. [FB02]

Biphasic haemolysin

An antibody-associated mechanism in which binding and haemolysis-related events occur across different temperature phases. It requires a specialised investigation with controls. Routine cold agglutination or a positive DAT alone cannot establish this mechanism or substitute for the appropriate clinical-laboratory assessment. [FB16]

Blood group system

An organised classification of related red-cell antigens defined through genetic and molecular relationships by the relevant international authority. System counts and terminology evolve. This edition identifies the dated ISBT release rather than presenting historical counts as permanent facts. [FB03]

Bombay phenotype

A rare H-deficient phenotype with important ABO-related compatibility implications. Ordinary group O cells can be incompatible because they retain H. Identification and support require appropriate specialist investigation and rare-component planning rather than the oversimplified universal-donor rule. [FB06]

CCI

Corrected count increment, a platelet-response calculation adjusted for body-surface area and transfused platelet dose under a stated unit convention. Timing and units are essential. It supports refractoriness investigation but does not independently establish an immune cause or replace clinical assessment. [FB23]

Cell suspension

A preparation of red cells at a defined concentration and in an appropriate medium for testing. Concentration, washing and handling affect reactions. An unstandardised suspension can change the antigen-antibody conditions and make apparently comparable tests analytically different. [FB05]

Chimerism

Presence of genetically distinct cell populations within one individual in a relevant context, including transplantation. It can complicate serologic and molecular interpretation. The specimen's cell source and transplant history must be known before a result is assigned to the recipient's original genotype. [FB22]

Clinically significant antibody

An antibody with evidence of potential clinical consequences in the relevant setting, such as transfusion or pregnancy. Significance is not determined solely by reaction grade. Specificity, phase, history, method and clinical context guide investigation and component selection. [FB14]

Cold agglutinin

An antibody producing red-cell aggregation under cooler test conditions. Clinical significance depends on thermal range and other properties, not merely a high low-temperature titre. Specimen handling and appropriate investigations help distinguish analytical effects from a clinically important haemolytic process. [FB16]

Compatibility

Suitability of a donor component for a recipient within a specified immunologic and clinical context. It is component-specific and broader than one laboratory reaction. Identity, history, antigen requirements, product characteristics and authorised testing or issue rules must remain connected. [FB01]

Complement-mediated haemolysis

Red-cell injury involving complement activation in an appropriate immune mechanism. Detectable complement coating and clinical haemolysis are not identical observations. The investigation integrates serology, timing, clinical findings and alternative causes rather than inferring the entire mechanism from one positive test. [FB16]

Component selection

Choosing a blood component that satisfies the patient's relevant requirements and the service's authorised policy. ABO, antibodies, modifications, condition, availability and urgency can all matter. Selection is an accountable decision process, not simply choosing the unit with the weakest reaction. [FB18]

Concordance

Agreement among relevant observations, such as forward and reverse grouping or current and historical results. It supports interpretation but is not self-validating when all data share an error. Discrepancies require explanation, while apparent agreement still depends on reliable identity and valid methods. [FB01]

Crossmatch

A compatibility assessment between recipient information or plasma and a proposed donor unit through an authorised serologic or electronic process. Its scope must be stated. A compatible result does not independently establish the clinical indication, bedside identity or every special component requirement. [FB01]

Cryopreserved rare unit

A rare red-cell component preserved through an authorised freezing programme for future support. Actual use requires availability, preparation and release processes, not merely a database entry. This book does not substitute generic storage times or thawing instructions for the service's validated procedure. [FB14]

D antigen

A Rh-system antigen whose expression can vary with molecular variants. Routine positive or negative labels do not capture every epitope difference. Donor, recipient and pregnancy interpretation may differ, and defined weak D genotypes should not be generalised to every serologically weak reaction. [FB07]

Daratumumab interference

Anti-CD38-related interference in relevant laboratory assays, including indirect antiglobulin testing. Validated mitigation can change the available antigen information, particularly with DTT. Baseline testing, treatment history and durable communication help prevent avoidable delays and unsupported conclusions about antibody absence. [FB11]

DAT

Direct antiglobulin test examining detectable coating of sampled red cells by relevant immunoglobulin or complement-related material. It is distinct from the IAT. A positive DAT may occur without significant haemolysis, and a negative result does not exclude every immune or nonimmune haemolytic process. [FB16]

Delayed haemolytic reaction

A haemolytic event arising after transfusion within the relevant clinical and reporting framework, often involving an immune response to an antigen exposure. Timing definitions are system-specific. Historical antibodies and post-transfusion findings are important, but the diagnosis requires the complete clinical-laboratory pattern. [FB20]

Discordance

A meaningful disagreement between results, methods or history. It is evidence to investigate rather than an inconvenient value to delete. The cause may be biological, analytical, specimen-related or clerical, and the resolution should preserve the original observations and the basis for the final interpretation. [FB24]

Donor typing

Establishment of antigen information for donor cells through an authorised method. Its purpose and labelling rules can differ from recipient management, particularly for D variants. A donor result must be linked to the actual component and reliable identification before it supports selection. [FB03]

Dosage

A pattern in which antibody reactivity differs with the relevant antigen expression associated with one versus two allelic contributions. It affects selected-cell interpretation in several systems. The effect is not universal, and reagent profiles and validated exclusion criteria remain essential. [FB02]

DTT

Dithiothreitol, a reducing agent used in selected validated serologic investigations. It can remove certain interferences while altering or destroying antigen targets, including Kell-related reactivity under common conditions. A negative treated-cell test therefore has different limitations from an untreated test. [FB11]

Duffy system

A blood-group system associated with ACKR1 biology and clinically relevant antigen and regulatory variation. Red-cell expression can differ from tissue expression in specific genotypes. Population frequency cannot replace individual testing, and method treatment can affect the information available for antibody exclusion. [FB13]

Electronic issue

Release through a validated computer-supported compatibility process for eligible patients and components. It requires reliable data, testing, history, safeguards and authorised rules. It is not simply a faster form of printing a label, and a software override does not create eligibility. [FB01]

Eluate

Material recovered from sensitised red cells through an elution procedure for further investigation. Its findings depend on method recovery and limitations. The result should be interpreted with DAT, plasma testing, history and haemolysis evidence rather than assigned a diagnosis in isolation. [FB16]

Elution

Removal of bound material from red cells for investigation. It differs from adsorption, which removes selected reactivity from a fluid phase. The method can help characterise coating but does not guarantee complete recovery or exclude every clinically relevant antibody when the eluate is nonreactive. [FB16]

Emergency release

Authorised component issue when clinical urgency requires a strategy before routine testing is fully complete. The decision must state what is known, what remains uncertain, who authorised it and how follow-up occurs. Emergency status changes the risk balance without eliminating documentation or accountability. [FB01]

Enzyme treatment

Modification of reagent or patient cells using a defined enzyme method to alter antigen accessibility and reactions. It can enhance some findings and weaken or destroy others. The treated panel is a different analytical system, not a universally more sensitive version of the untreated panel. [FB02]

Epitope

A molecular feature recognised by an antibody. Antigen labels can conceal epitope variation, particularly in complex systems such as Rh. A serologically similar phenotype does not guarantee identical epitope expression, which helps explain selected alloimmunisation despite apparently matched routine typing. [FB07]

Erythroid precursor

A developing cell in the red-cell lineage. Immune effects on precursors can reduce red-cell production as well as cause destruction of mature cells. Anti-K-related fetal anaemia illustrates why a simple peripheral-haemolysis model does not explain every mechanism of HDFN. [FB10]

Extended matching

Selection considering additional antigens beyond a basic compatibility strategy. Its scope depends on the patient group and current guidance. It can reduce selected alloimmunisation risks but cannot eliminate every variant, antibody or nonimmune transfusion complication. [FB21]

False negative

A negative result when the specified target or condition is present according to an appropriate reference. The term requires a defined truth standard. In method comparisons without such a standard, negative discordance should not automatically be labelled a false negative of the new method. [FB24]

False positive

A positive result when the specified target or condition is absent according to an appropriate reference. It is different from an unexplained positive comparison result. Determining the cause requires suitable investigation rather than assuming that whichever method is newer or preferred must be correct. [FB24]

Fetal antigen status

Evidence about whether the fetus expresses the antigen relevant to a maternal antibody. The result can refine risk assessment but depends on method, timing and scope. It should be integrated into the specialist pregnancy pathway rather than interpreted as a complete assessment of fetal health. [FB10]

Forward grouping

Testing the patient's red cells with known ABO reagents to examine antigen-related reactivity. It complements reverse grouping of plasma against known cells. Age, transfusion, transplantation, variants and technical effects can complicate expected patterns, requiring controlled interpretation. [FB01]

Genotype

The genetic findings established by an appropriate assay at specified loci or regions. It can predict antigen expression but has coverage and interpretation limits. Recent stem-cell transplantation and specimen source can change which biological population a blood-derived result represents. [FB22]

Haemolysis

Destruction of red cells through immune, mechanical, infectious or other mechanisms, or as a specimen artefact. Serologic findings help selected investigations but do not establish all causes. Clinical context and appropriate laboratory evidence distinguish in-vivo disease from collection-related sample damage. [FB20]

Haemovigilance

Organised surveillance and learning across the transfusion chain to identify, analyse and reduce adverse events and risks. It includes more than counting reactions. Definitions, denominators, reporting culture, corrective action and effectiveness assessment are essential to interpreting trends and improving safety. [FB25]

HDFN

Haemolytic disease of the fetus and newborn associated with maternal antibodies against relevant fetal or neonatal red-cell antigens. Mechanisms can include impaired erythropoiesis as well as haemolysis. Antibody specificity, fetal status, history and specialist monitoring guide assessment and management. [FB10]

High-frequency antigen

An antigen present on red cells of most people in the relevant population. An antibody against it can react with most routine panel cells and complicate unit selection. Broad reactivity requires specialist differentiation from autoantibodies, interference and other causes. [FB03]

Historical antibody

A previously verified antibody finding retained in the patient's record. A clinically significant history can remain relevant after current reactivity falls below detection. Records should preserve both the old finding and today's result rather than treating a negative screen as permission to delete the history. [FB01]

HLA-selected platelets

Platelets selected through an authorised strategy addressing relevant HLA compatibility or antibody concerns. They may improve support in an appropriate immune-refractoriness context but do not overcome every nonimmune cause of poor increments. Response monitoring remains necessary. [FB23]

HPA

Human platelet antigen terminology used for platelet-specific antigen systems. HPA-related antibodies have distinct roles from HLA antibodies and red-cell antibodies. Investigation and component selection depend on the clinical setting and specialist service, not on a general red-cell compatibility table. [FB23]

Hyperhaemolysis

A concerning post-transfusion pattern in which haemoglobin can fall below the pretransfusion level, with destruction involving more than donor cells alone. It requires specialist clinical assessment. Laboratory recognition and communication are crucial, but treatment is not reduced to an unconditional always-transfuse or never-transfuse rule. [FB21]

IAT

Indirect antiglobulin test examining sensitisation produced by incubating plasma or serum with test cells in the laboratory. It differs from the DAT's examination of sampled cell coating. Detection depends on antigen coverage, reagent specificity, method conditions and valid controls. [FB05]

Imputability

Assessment of the likelihood that transfusion caused an observed event under the relevant framework. It differs from temporal association. A symptom during transfusion requires prompt care and investigation, but timing alone does not prove the mechanism or final surveillance classification. [FB20]

Incompatibility

A finding or relationship indicating that the proposed component does not satisfy the relevant compatibility assessment. Its mechanism and clinical significance require interpretation. Reaction-grade ranking should not replace investigation of alloantibodies, antigen requirements, identity and the authorised clinical plan. [FB16]

Informed release decision

An authorised decision that explicitly integrates evidence, urgency, limitations and responsibilities. It is particularly important when testing is incomplete or complex. Documentation should identify the patient, components, unresolved issues, decision-maker and follow-up rather than imply certainty that the evidence does not provide. [FB01]

Inventory probability

A planning estimate of the chance or expected yield of suitable units under stated population and independence assumptions. It is not a guarantee of available compatible components. Actual typing, other product requirements, transport and release procedures remain necessary. [FB14]

Irradiation requirement

A component modification requirement determined by the relevant clinical indication and current policy. It is separate from ABO or antibody compatibility. A serologically compatible unit can still fail a patient's special requirements, so the full specification must remain attached to the request and release process. [FB18]

K antigen

A Kell-system determinant with important transfusion and pregnancy implications. It is not a synonym for all Kell expression, and k is a distinct antigen rather than a negative grade. Reliable typing and current clinical guidance inform selection and HDFN assessment. [FB09]

Kell system

A blood-group system with membrane-complex biology and clinically significant antibodies. Effects on erythroid precursors contribute to important pregnancy mechanisms. DTT-related loss of reactivity creates a method limitation, so treated-cell negatives require an appropriate selection strategy. [FB09]

Kidd system

A blood-group system associated with a urea transporter and antibodies that can show dosage and declining detectability. Historical findings are particularly important in delayed-reaction reasoning. A currently negative screen does not exclude the significance of a previously established Kidd antibody. [FB12]

Least incompatible

A phrase that can misleadingly imply that weaker autoantibody-related crossmatch reactions identify a safer unit. The important work is to investigate alloantibodies and select components through reliable antigen information, urgency and the authorised clinical strategy, not rank units by a misleading reaction contest. [FB16]

Lewis system

A blood-group system whose red-cell antigens are acquired through adsorption from circulating substances. Expression can change with physiological context. The apparent phenotype should not automatically be interpreted as a permanent change in germline genes or used without considering the antibody's actual behaviour. [FB14]

Low-frequency antigen

An antigen uncommon in the relevant population and potentially absent from routine screening cells. An antibody against it may be encountered through an incompatible donor crossmatch despite a negative screen. The screen's antigen coverage is a defined limitation, not proof that every possible donor will be compatible. [FB03]

Mixed-field reaction

A reaction showing visibly reactive and nonreactive cell populations rather than a uniformly weak result. Recent transfusion, transplantation, selected subgroup phenomena and other conditions can contribute. History and method are needed to explain the population mixture before assigning a final phenotype. [FB02]

MNS system

A complex blood-group system associated with glycophorin structures and variants. Antibodies differ in behaviour and clinical significance. A simple M, N, S and s table is a foundation, not complete coverage of every rare determinant or method-dependent reaction. [FB04]

Molecular prediction

Inference about antigen expression based on tested genetic variants. It can resolve important serologic questions but depends on assay coverage, allele interpretation and specimen source. It should be reconciled with clinical history and serology rather than treated as an unrestricted guarantee of every expressed epitope. [FB22]

Near miss

An error or hazardous sequence intercepted before the intended adverse outcome occurs. It reveals weaknesses and successful barriers in the process. Investigation should address contributing conditions and recurrence risk rather than dismiss the event because no component reached the wrong patient. [FB25]

Negative percent agreement

Proportion of comparator-negative results also negative by the new method in a method-comparison study. It is not automatically clinical specificity when the comparator is not a truth standard. The denominator and study population must be stated, and discrepant cases require investigation. [FB24]

Nonimmune refractoriness

Poor platelet response associated with factors other than the targeted alloimmune mechanism, such as consumption or sequestration in an appropriate clinical context. It can coexist with antibodies. Selected platelets do not guarantee a satisfactory increment when other causes remain active. [FB23]

Panreactivity

Reactivity with most or all cells in the tested set. Possible explanations include autoantibodies, antibodies to high-frequency antigens, therapeutic interference and technical effects. The pattern is not a diagnosis; controls, history, selected methods and specialist investigation distinguish its causes. [FB02]

Partial D

A molecular or antigenic situation in which some D epitopes are altered or absent. It is not defined by a single reaction grade and should not be confused with every reduced-expression result. Genotype and applicable guidance inform donor, recipient and pregnancy handling. [FB07]

Passive antibody

Antibody acquired through transfer rather than produced by the recipient's own response. Prophylaxis, therapeutic products and maternal transfer provide examples. A detectable result may therefore have a different meaning from active immunisation, and timing and records are essential to interpretation. [FB10]

Patient phenotype

The antigen expression established for the patient's relevant native red cells under an appropriate method. Recent donor-cell circulation can complicate serologic interpretation. A current sample should not be assumed to represent the pretransfusion phenotype without history and suitable evidence. [FB21]

Platelet increment

Difference between post-transfusion and pretransfusion platelet counts at defined times. It is a response measure, not a complete assessment of haemostasis. Dose, recipient size, timing, clinical consumption and other factors influence interpretation; CCI adds a specified adjustment rather than a diagnosis. [FB23]

Platelet refractoriness

An inadequate platelet response established through the relevant repeated-measurement clinical framework. It can involve immune or nonimmune mechanisms. A single low count or a detected antibody alone is insufficient; timing, dose, clinical state and appropriate investigations must be integrated. [FB23]

Positive percent agreement

Proportion of comparator-positive specimens also positive by the new method in a comparison study. It should not automatically be called sensitivity without an appropriate truth standard and design. The clinically important discordant cases must remain visible rather than hidden within overall agreement. [FB24]

Pretransfusion specimen

A specimen collected for compatibility-related testing before the relevant transfusion event. Its identity, timing and validity are essential. A pretransfusion label does not itself guarantee suitability when recent exposure, storage or identification requirements have not been met. [FB01]

Prophylactic anti-D

Administered anti-D used within an authorised prevention pathway. It can produce detectable serologic reactivity, complicating distinction from immune anti-D. Administration records, timing, previous findings and clinical guidance inform interpretation; a single routine result may not resolve the distinction conclusively. [FB10]

Quality control

Activities monitoring whether an analytical system performs as required during use. It is distinct from initial validation and does not replace specimen identity or clinical interpretation. Control failures require investigation and assessment of affected results rather than repeated testing until an acceptable value appears. [FB05]

Rare donor

A donor with an uncommon antigen profile useful for selected patients. A rare-donor record must be linked to verified typing, appropriate governance and actual component availability. Privacy and consent remain important; clinical usefulness does not justify unrestricted disclosure of genetic or health information. [FB14]

Reaction investigation

A coordinated clinical-laboratory assessment of an adverse event temporally associated with transfusion. Immediate care and identity checks accompany appropriate testing. The process distinguishes observations, mechanisms, alternative causes and surveillance classification, preserving communication and follow-up responsibilities. [FB20]

Reagent cell

A characterised red-cell preparation used for grouping, screening, identification or controls. Its antigen profile, expression, condition and method compatibility determine what it can show. A cell positive for a target is not necessarily adequate exclusion evidence under every dosage or treatment condition. [FB05]

Reference laboratory

A specialist service supporting complex investigations, selected testing and expert interpretation. Referral requires reliable specimens, history and a clear question. Its report informs local decisions but does not remove the referring service's responsibility for patient identity, component release and clinical communication. [FB15]

Reverse grouping

Testing the patient's plasma with known ABO reagent cells to examine expected antibody-related reactivity. It complements forward grouping. Developmental age, immune state and other conditions affect expected results, so adult patterns cannot be imposed uncritically on infants or altered clinical contexts. [FB01]

Rh system

A complex blood-group system involving D and other important antigens, with substantial molecular variation. Routine serologic labels do not capture every epitope difference. Current nomenclature, genotype and patient-specific evidence are needed for selected variant and alloimmunisation investigations. [FB07]

Rule of three

An approximate upper 95% bound of three divided by the sample size when no events are observed in a simple independent-binomial setting. It illustrates that zero observed failures do not prove zero risk. It is not a universal validation sample-size rule or acceptance standard. [FB24]

Selected cell

A reagent or donor cell chosen because its antigen profile and expression help answer a specific hypothesis. It can separate competing antibodies more effectively than a double-positive cell. Selection must also account for unlisted targets, dosage and the validated investigation requirements. [FB02]

Serologic weak D

A reduced or method-dependent D reaction pattern requiring interpretation in its donor, recipient or pregnancy context. It encompasses different molecular situations. The management of defined weak D types 1, 2 and 3 must not be generalised to every serologically weak or variant result. [FB08]

Specificity

The antigen target attributed to an antibody through sufficient evidence. In clinical-test statistics the same word has a different meaning. A panel's pattern supports specificity only within antigen coverage, method conditions and the complete investigation; one positive cell does not uniquely identify the target. [FB02]

Specimen validity

The period and conditions under which a specimen is acceptable for a defined testing and clinical purpose. Exposure history and local rules matter. The Canadian 96-hour example in this book is jurisdiction-labelled and should not be silently substituted for another service's approved interval. [FB01]

Thermal amplitude

Temperature range over which an antibody reacts under defined test conditions. It can be more informative about clinical behaviour than a high low-temperature titre alone. The result remains method-dependent and must be interpreted with clinical findings and other serologic evidence. [FB16]

Titre

A method-defined dilution endpoint. It is not an absolute antibody concentration, and results depend on cells, method, phase and reading criteria. Pregnancy interpretation requires specificity, history and specialist guidance rather than treating one titre as a universal measure of fetal severity. [FB10]

Traceability

Ability to reconstruct the links among donor, component, testing, patient, release, administration and outcome through reliable records. It requires more than a label or barcode. Amendments and emergencies must remain auditable so that later investigation can identify what actually occurred. [FB25]

Transfusion history

Verified information about previous component exposure, antibodies, reactions and related clinical events. It can change current interpretation even when today's screen is negative. Reliable access and durable records prevent the loss of clinically significant information when a patient moves between services. [FB01]

Unit identity

The unique, reliable association between a component and its records throughout preparation, testing, release and administration. Correct testing cannot compensate for a misidentified unit. The identity must be checked at each relevant transition rather than assumed from an earlier stage. [FB18]

Validation

Evidence-based confirmation that a method or process is suitable for its intended use. It includes relevant performance, limitations and acceptance criteria. It is not a permanent guarantee, and later changes in software, reagents or workflow require controlled assessment and monitoring. [FB24]

Warm autoantibody

An autoantibody with relevant reactivity under warmer testing conditions, often complicating compatibility investigations. It can coexist with alloantibodies and may or may not cause haemolysis. Selection should address the complete evidence and urgency rather than rely on the phrase least incompatible. [FB16]

Wrong blood in tube

A specimen-identity failure in which the blood in a labelled tube is not from the intended patient. Laboratory results may be technically correct yet assigned to the wrong person. Prevention relies on a reliable collection-identification process; later relabelling from memory cannot restore certainty. [FB01]

References and evidence notes

[FB01] Canadian Blood Services. Pre-transfusion testing. Clinical Guide to Transfusion. 2020.

https://professionaleducation.blood.ca/en/transfusion/clinical-guide/pre-transfusion-testing

Canadian specimen validity, infant testing, compatibility and emergency-release framework; jurisdiction labelled.

[FB02] UK Joint Professional Advisory Committee. Guidelines for the Blood Transfusion Services: 13.3 Pre-transfusion testing.

https://www.jpac.org.uk/guidelines/red-book/chapters/13/13-3/

ABO discrepancies, antibody investigation, complex mixtures, autoantibodies and therapeutic interference.

[FB03] International Society of Blood Transfusion. Blood Group Database: release v19, September 2026.

https://blooddatabase.isbtweb.org/release

Current classification and nomenclature; database records may change after this edition.

[FB04] Dean L. Blood Groups and Red Cell Antigens. NCBI Bookshelf; 2005.

https://www.ncbi.nlm.nih.gov/books/NBK2261/

Foundational molecular biology only. Historical system counts and broad clinical shortcuts are not adopted.

[FB05] UK Joint Professional Advisory Committee. Red cell immunohaematology: Chapter 13.

https://www.jpac.org.uk/guidelines/red-book/chapters/13/

Method controls and reagent/interpretive requirements; local validated procedures govern operation.

[FB06] Dean L. The Hh blood group. Blood Groups and Red Cell Antigens.

https://www.ncbi.nlm.nih.gov/books/NBK2268/

ABH precursor biology and H-deficient phenotypes.

[FB07] ISBT; Dean L. Rh-system nomenclature and molecular background.

https://blooddatabase.isbtweb.org/database

Current ISBT definitions; foundational background in FB04.

[FB08] AABB, CAP and partner organisations. Joint Statement on Phasing-In RHD Genotyping for Pregnant Women and Other Females of Childbearing Potential with a Serologic Weak D Phenotype. 2015.

https://www.aabb.org/docs/default-source/default-document-library/positions/statement150722.pdf

Defined weak D types 1, 2 and 3; not a blanket rule for every variant.

[FB09] Dean L. Blood Groups and Red Cell Antigens: Kell system.

https://www.ncbi.nlm.nih.gov/books/NBK2261/

Kell/Kx biology; current pregnancy guidance in FB10.

[FB10] British Society for Haematology. Guideline for the investigation and management of red cell antibodies in pregnancy. 2025.

https://cms.b-s-h.org.uk/guidelines/guidelines/guideline-for-the-investigation-and-management-of-red-cell-antibodies-in-pregnancy

Maternal antibody assessment and HDFN risk; specialist protocols govern management.

[FB11] Chapuy CI and colleagues. Resolving daratumumab interference. Transfusion. 2015. doi:10.1111/trf.13069; international validation study, 2016. doi:10.1111/trf.13789.

https://pubmed.ncbi.nlm.nih.gov/25764134/

DTT removes anti-CD38 interference while creating antigen blind spots; see also FB02.

[FB12] Dean L. The Kidd blood group. Blood Groups and Red Cell Antigens.

https://www.ncbi.nlm.nih.gov/books/NBK2272/

Urea transporter, dosage and delayed-reaction mechanisms.

[FB13] Dean L; ISBT. Duffy/ACKR1 biology and current nomenclature.

https://blooddatabase.isbtweb.org/database

Foundational molecular background in FB04; clinical genotype matching in FB21.

[FB14] Canadian Blood Services. Serological best practices.

https://professionaleducation.blood.ca/en/transfusion/best-practices/serological-best-practices

Specificity-dependent interpretation, including anti-M and Lewis. Third-party illustrations not reproduced.

[FB15] AABB. Standards for Immunohematology Reference Laboratories, 14th edition: release announcement. 23 February 2026; effective 1 April 2026.

https://www.aabb.org/news-resources/news/article/2026/02/23/aabb-releases-14th-edition-of-irl-standards

Edition and effective-date verification only. No licensed standard clauses reproduced or certification asserted.

[FB16] Johnson ST, Puca KE. Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory. Hematology ASH Educ Program. 2022:96–104. doi:10.1182/hematology.2022000406.

https://pubmed.ncbi.nlm.nih.gov/36485094/

Specialist clinical-laboratory reasoning, adsorption, DAT and transfusion support.

[FB17] Australian Commission on Safety and Quality in Health Care. Darzalex concentrate for infusion: medicine information.

https://www.safetyandquality.gov.au/medicine-finder/darzalex-concentrate-for-infusion

Therapeutic anti-CD38 interference; drug-dependent immune haemolysis requires separate specialist investigation.

[FB18] Canadian Blood Services. Blood administration. Clinical Guide to Transfusion.

https://professionaleducation.blood.ca/en/transfusion/clinical-guide/blood-administration

Component identity, administration and patient-specific requirements.

[FB19] Canadian Blood Services. Clinical Guide to Transfusion.

https://professionaleducation.blood.ca/en/transfusion/clinical-guide-transfusion

Neonatal, obstetric and special-population framework; specimen testing details in FB01.

[FB20] Centers for Disease Control and Prevention. NHSN Biovigilance Component and 2026 Hemovigilance Module resources.

https://www.cdc.gov/nhsn/biovigilance/index.html

Current surveillance definitions and reporting framework; national definitions are jurisdiction-specific.

[FB21] Chou ST and colleagues; American Society of Hematology. ASH 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4:327–355.

https://ashpublications.org/bloodadvances/article/4/2/327/440607

Antigen profiling, matching, delayed haemolysis and hyperhaemolysis; recommendation certainty varies.

[FB22] UK Joint Professional Advisory Committee. Molecular typing and complex pre-transfusion investigations.

https://www.jpac.org.uk/guidelines/red-book/chapters/13/

Source-aware genotype/phenotype interpretation; transplant programme requirements remain specific.

[FB23] Canadian Blood Services. Platelet transfusion, alloimmunization and management of platelet refractoriness.

https://professionaleducation.blood.ca/en/transfusion/clinical-guide/platelet-transfusion-alloimmunization-and-management-platelet

CCI, timing, HLA/HPA and immune versus nonimmune refractoriness. Unit conventions stated in teaching.

[FB24] U.S. Food and Drug Administration; WHO, CDC and CLSI. Diagnostic-test statistical reporting guidance; Laboratory Quality Management System Handbook.

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-guidance-reporting-results-studies-evaluating-diagnostic-tests-guidance-industry-and-fda

Agreement versus accuracy and validation uncertainty. Companion: https://www.who.int/publications/i/item/9789241548274 .

[FB25] World Health Organization. A guide to establishing a national haemovigilance system. 2016.

https://www.who.int/publications/i/item/9789241549844

Incident learning, traceability, corrective action and haemovigilance systems.

B1 | ABO discrepancy: two questions, not a majority vote

An adult is referred before an elective procedure. The independently verified identifier agrees with the request, and there is no immediate requirement for transfusion. Forward grouping gives strong anti-A reactivity and no anti-B reactivity, but the reverse group contains a weak unexpected reaction with A1 reagent cells. The laboratory worker proposes calling the group A because two of the three observations point that way. This is the first reasoning error: forward and reverse grouping investigate different biological material, not interchangeable votes in an election. [FB01, FB02]

The fictional observations below assume that the routine reagent controls and specimen acceptance checks passed. They are an abbreviated teaching set, not a complete antibody panel or a patient-specific blood-selection protocol. A reaction graded 1+ describes an observation in the stated method; it is not a concentration and does not, by itself, establish clinical significance.

Observation	Result	Question answered
Patient cells + anti-A	4+	Is A antigen detected?
Patient cells + anti-B	0	Is B antigen detected?
Patient plasma + A1 cells	1+	Unexpected plasma reactivity?
Patient plasma + B cells	4+	Expected anti-B present?
Patient plasma + O cells	0	Broad cold reactivity in this set?

Explain the discrepancy before naming its cause

The forward pattern is compatible with A expression, whereas the extra A1-cell reaction needs an explanation. An A subgroup with anti-A1 is one possibility; a cold-reactive antibody or another reagent-related issue is also possible. The nonreactive O-cell observation narrows the illustrative pattern, but does not exclude every non-ABO antibody. The next investigation should separate hypotheses, not simply repeat the same three reactions until a favoured answer appears. Rechecking history, method, specimen and controls prevents an attractive biological explanation from hiding an identification or technical problem.

Choose an informative comparison

A comparison of appropriately selected A1 and A2 reagent cells may help test an anti-A1 hypothesis under validated conditions. Patient-cell subgroup investigation and the temperature range of plasma reactivity answer additional questions. If the extra reaction disappears at clinically relevant conditions, that finding must still be interpreted with the complete investigation. The laboratory should not convert a room-temperature reaction into a universal rule about transfusion risk, or infer a definitive subgroup from one reagent result.

Resolve the action separately

An elective setting allows investigation before a definitive group-dependent issue decision. An urgent setting requires communication with the authorised transfusion decision-maker and the locally validated unresolved-group pathway. Calling a group merely to unblock a computer field is not a scientific resolution. The report should state what is established, what remains unresolved and what testing or referral is underway. The eventual record must preserve the discrepancy and its explanation so that a future worker does not rediscover it from scratch.

Counterfactual: a positive O-cell result

Suppose the O cells also reacted. A simple anti-A1 explanation would no longer account for the whole pattern. The worker would consider additional reactivity, including cold-reactive antibodies, while reviewing test conditions and the autocontrol as appropriate. This counterfactual shows why the O-cell comparison is useful: it tests a competing explanation. It is not a substitute for a full screen or a reason to ignore dosage, antigen expression or specimen history.

Mastery questions and reasoned answers

1. Why is “two tests agree” not sufficient?

Forward grouping examines antigens on patient cells; reverse grouping examines antibodies in patient plasma. An unexplained contradiction between these measurements requires investigation, not voting.

2. What does this case actually establish?

It establishes a discrepancy that can be investigated. The small model set does not establish a final subgroup, antibody specificity, clinical significance or a transfusion prescription.

3. Write an appropriate interim message.

“Forward A-pattern result with unresolved additional reverse-group reactivity. Confirmation is in progress; use the authorised unresolved-group pathway if urgent components are needed.” The clinical urgency and responsible recipient should be documented.

Evidence and limits: FB01, FB02; Chapters 6–7. Data and analysis are original fictional teaching material.

B2 | Panel interpretation: separate two overlapping targets

A reactive screen is followed by a short selected-cell investigation. The patient has a documented transfusion history. In the fictional table, K and E are the two candidate antigens, but only these candidate columns are shown. All other clinically relevant antigens and the laboratory controls still need to be assessed in the actual full panel. A learner circles every reactive cell and concludes that the strongest reaction must identify the only antibody. The conclusion fails because reaction strength is affected by several variables and mixtures can produce overlapping patterns. [FB02, FB04]

The point of selected cells is to create a contrast. Cells expressing both candidate antigens are poor discriminators between those candidates: either antibody, or both, could contribute to the result. Cells carrying one candidate but not the other provide more informative evidence.

Selected cell	E	K	IAT
A	+	0	2+
B	0	+	2+
C	+	+	3+
D	0	0	0
E	+	0	2+
F	0	+	1+

What pattern supports a mixture?

Reactivity with the E-positive/K-negative cells supports an E-associated component, while reactivity with the E-negative/K-positive cells supports a K-associated component. The double-negative cell does not react in this example. Together, these observations are more consistent with two candidate specificities than with the claim that only the strongest cell identifies one antibody. Nevertheless, the table remains an incomplete model: another unshown antigen could correlate with either selected group.

Why the double-positive cell does not finish the case

The 3+ result with cell C is not the sum of two measured antibody concentrations. Agglutination grading is ordinal, and the relationship between antibody amount and observed grade is not linear. Antigen density, affinity, method and incubation conditions can affect strength. A 3+ reaction therefore cannot be divided into a 2+ anti-E and a 1+ anti-K contribution. The useful role of cell C is consistency with the hypothesis, not quantitative separation.

Use patient information without overclaiming

A reliable pre-transfusion phenotype or appropriately interpreted genotype can support whether the patient lacks the candidate antigens. Recent transfusion can make a current serological phenotype misleading because donor and patient cells may coexist. A positive DAT can also complicate some antigen typing. The investigator must state the source and limitations of the patient antigen information rather than treating a printed phenotype as context-free truth.

Move from identification to component requirements

A supported mixture is only one part of the issue decision. The laboratory still excludes additional clinically significant antibodies within the method’s capabilities, honours relevant historical antibodies and selects components through the approved compatibility process. A negative reaction against a single double-negative panel cell does not prove that any unit lacking E and K is suitable for this patient. Unit identity, appropriate antigen information and the required crossmatch remain separate requirements.

Design the next discriminating cells

The best additional cells are independent examples that separate E from K and cover the remaining relevant candidate antigens with suitable expression. Merely adding more double-positive cells increases the number of observations without resolving the central ambiguity. A useful investigation plan names which interpretation each selected cell could support or weaken before testing it. This makes the panel a planned experiment rather than a search for a visually satisfying pattern.

Mastery questions and reasoned answers

1. Which observations are most discriminating?

A and E separate E from K; B and F separate K from E. Cell D provides a double-negative comparison. Cell C alone cannot separate the candidates.

2. Can 3+ be treated as 2+ plus 1+?

No. Reaction grades are ordinal method observations, not additive concentration measurements.

3. What is an appropriate provisional conclusion?

“Selected-cell findings support E- and K-associated reactivity; complete identification, additional exclusion and patient-antigen correlation are required.” The wording should not claim that an abbreviated teaching panel authorises issue.

Evidence and limits: FB02, FB04, FB05; Chapters 18–20. Antigen columns are deliberately incomplete.

B3 | Historical anti-Jka: a negative screen does not erase a risk

A hospital information system receives an outside record documenting anti-Jka identified several years earlier. The current antibody screen is nonreactive. A newly appointed worker suggests deleting the old alert because a current result should take precedence over an old one. The proposal confuses a measurement below present detection with evidence that an immune history never occurred. Historical information can change the compatibility pathway even when today’s assay is negative. [FB01, FB12]

In this fictional case, the external report is not accepted solely because a name appears similar. Staff verify identifiers, the issuing laboratory, the report date and whether the specificity was actually established. Once verified, that history becomes part of the patient’s enduring transfusion record. The question is how to honour reliable history without treating unverified imported text as fact.

Time point	Documented observation	Interpretive limit
Earlier episode	Anti-Jka identified	Verify record belongs to this patient
Current visit	Screen nonreactive	Below detection is not no memory
Component selection	Antigen requirement retained	Apply current compatibility procedure
Future handover	History remains visible	Do not silently retire the alert

Explain the biology without predicting certainty

An antibody may weaken over time while immune memory remains. Re-exposure to the corresponding antigen can stimulate a renewed response. Kidd antibodies are particularly important in teaching about delayed haemolytic reactions, but the history does not mean that every re-exposure inevitably causes an identical reaction. The laboratory uses history to reduce avoidable risk rather than claiming to predict a particular patient’s exact immune response.

Separate the test from the eligibility rule

A negative current screen answers a present analytical question under the assay conditions. Electronic crossmatch eligibility answers a broader policy question incorporating history and validated system requirements. Under the Canadian framework cited in this book, a history of a clinically significant antibody excludes the simple negative-screen electronic-crossmatch pathway. Other adopted standards must be checked directly; the safe principle is not to remove a relevant history simply to make a patient eligible for automation.

Resolve conflicting identity data

Suppose the imported report contains a different date of birth. The laboratory must investigate the mismatch rather than either discarding the antibody or merging records immediately. Temporary handling should preserve the uncertainty and use the approved escalation route. The eventual resolution must record why the report was linked or not linked. A permanent antibody flag assigned to the wrong person can also cause harm through unnecessary delays and inappropriate assumptions.

Communicate urgency and uncertainty together

If components become urgently necessary while the historical identity is being clarified, the transfusion service and clinical team need a shared account of the remaining risk. The message should distinguish “history verified” from “history reported but not verified,” and identify what can be provided under the emergency procedure. Neither a computer warning nor an unresolved record should silently replace a documented, authorised clinical risk decision.

Evaluate the information-system control

A useful system preserves the original antibody finding, its provenance and any subsequent clarification. It should make relevant history visible during selection and issue, not only in a scanned document several screens away. Testing the control requires a realistic scenario: can the worker find the history when the current screen is negative, and does the system prevent an inappropriate routine issue route? Counting the presence of an alert is less informative than observing whether it changes the workflow correctly.

Mastery questions and reasoned answers

1. What does the current negative screen establish?

No relevant reactivity was detected by the current test under its conditions. It does not establish absence of a verified historical antibody or immune memory.

2. Should an uncertain outside report be copied as a confirmed antibody?

No. Verify identity and provenance. Preserve the reported concern and manage urgency through the approved pathway while confirmation is pending.

3. What would demonstrate effective corrective action after a missed alert?

A realistic retest of the revised workflow, including a negative current screen with a verified historical antibody, demonstrates more than a memo stating that staff were informed.

Evidence and limits: FB01, FB12, FB25; Chapters 5, 10, 26 and 36. No actual patient or incident is described.

B4 | Daratumumab and DTT: removing interference creates a blind spot

A patient receiving an anti-CD38 therapeutic antibody has broadly reactive indirect antiglobulin testing. The laboratory has an appropriate pretreatment history but cannot locate a documented K phenotype. A validated DTT-treated-cell investigation removes the broad reactivity. The proposed final report says, “All antibodies excluded.” That conclusion is too strong. An intervention that removes unwanted reactivity can also alter the antigens needed to reveal another antibody. [FB02, FB11]

This exercise considers interpretation only. It is not a recipe for preparing DTT or treating cells. Reagent concentration, preparation, controls, timing, acceptable performance and safety belong to a validated procedure. Treating cells without those controls would introduce a new uncertain experiment rather than resolve the original one.

Investigation	Observation	What remains unresolved
Untreated reagent cells	Broad IAT reactivity	Drug effect versus other causes
Validated DTT-treated cells	Nonreactive	DTT-sensitive antigen targets
Pretreatment K result	Unavailable	Patient K status not established
Current clinical need	Not immediately life-threatening	Time to complete approved plan

Interpret the change in relation to the method

Loss of broad reactivity after the validated treatment supports an interference-sensitive explanation in the appropriate medication context. It is not a universal proof that the therapeutic drug was the only possible cause. Controls must show that the treated cells and detection system can still demonstrate the responses they are expected to detect. A negative result in a disabled detection system is not reassuring.

Name the antigen limitation

DTT treatment affects Kell antigens and other susceptible targets. Consequently, nonreactivity with treated cells cannot be used to exclude an antibody to an antigen that treatment has destroyed. This is a general experimental principle: a negative observation is informative only when the target and detection pathway remain capable of producing a positive observation. The source references describe strategies to mitigate the compatibility consequences; local procedures define the adopted pathway.

Make the component decision through the authorised method

The laboratory considers pretreatment typing, reliable genotype information, antibody history and appropriately selected components. A K-negative requirement is commonly part of a strategy when the patient’s K-positive status is not established, but this does not mean that every DTT-sensitive antigen issue has been solved. A specialist consultation may be necessary when history or a rare phenotype changes the ordinary assumptions. Do not treat the letter K as a substitute for the entire compatibility investigation.

Explain the result to the clinical team

A useful message says that the medication can interfere with testing, which method was used to investigate, which limitations remain and the expected time to suitable components. It does not describe the patient as “incompatible with all blood” merely because the untreated panel is broadly reactive. Conversely, it does not promise absence of all antibodies after the interference has been reduced.

Use pretreatment planning as a safety intervention

Before a therapy likely to affect serology, baseline grouping, antibody investigation and appropriate antigen profiling can preserve information that becomes difficult to obtain later. The exact profile and tests depend on the adopted guidance and patient circumstances. The educational lesson is the value of acquiring a reliable baseline before an intervention changes the measurement, not the automatic ordering of a fixed list for every patient.

Mastery questions and reasoned answers

1. Why is “all antibodies excluded” incorrect?

The treated cells cannot demonstrate antibodies to targets removed by treatment. The negative result has a method-specific scope.

2. Which missing record matters in this case?

Reliable pretreatment antigen information, including K status, can inform the compatibility plan. Its absence must be acknowledged, not reconstructed from an unvalidated current test.

3. What makes the treatment investigation interpretable?

Validated treatment, appropriate controls, medication/history correlation, and explicit recognition of the antigen blind spots. Reagent treatment alone is not a result.

Evidence and limits: FB02, FB11, FB17; Chapters 21 and 25. Primary studies: doi:10.1111/trf.13069 and doi:10.1111/trf.13789.

B5 | A positive DAT: distinguish coating, destruction and causation

An inpatient has an IgG-positive direct antiglobulin test. The haemoglobin is lower than on admission, and a colleague immediately records “autoimmune haemolytic anaemia.” The DAT provides evidence of material attached to red cells under the test conditions. It does not, alone, measure the rate of red-cell destruction or establish why the attachment occurred. The lower haemoglobin adds information, but bleeding, dilution and other causes remain possible. [FB16]

The fictional sequence below deliberately includes several observations that can move independently. Students should explain what each measurement contributes rather than combining them into one undifferentiated “positive haemolysis test.” The clinical team determines the diagnosis from the full patient assessment; the laboratory contributes valid measurements and bounded interpretations.

Finding	Observation	Do not infer automatically
DAT anti-IgG	Reactive	Autoimmune cause established
DAT anti-C3d	Nonreactive	All complement involvement excluded
Haemoglobin trend	Falling	Haemolysis is the only cause
Recent transfusion	Documented	All circulating cells are patient cells
Eluate	Investigation pending	Its specificity is already known

Begin with the analytical question

A monospecific DAT result helps characterise detectable red-cell coating. Reagent specificity and method sensitivity matter. The result should be interpreted with controls and the laboratory’s definition of positivity. A negative complement component does not make every possible immune mechanism impossible, and a strong IgG reaction is not a numerical measure of haemolysis severity.

Build independent evidence of haemolysis

The clinical and laboratory evaluation considers the haemoglobin trajectory, reticulocyte response, bilirubin, lactate dehydrogenase, haptoglobin and other findings in context. None is perfectly specific in every patient. For example, a biochemical marker may be affected by liver disease, inflammation or specimen quality. The aim is converging evidence, not a requirement that every marker must change in a stereotyped direction before clinical action is considered.

Ask which cells are coated

After recent transfusion, donor and recipient red cells may coexist. An alloantibody can bind transfused cells, so a positive DAT in that context is not automatically an autoantibody. Historical antibodies, pre-transfusion findings, a repeat specimen and specialist testing may distinguish possibilities. A current phenotype derived from the mixed population must also be interpreted cautiously.

Keep eluate interpretation bounded

An eluate can help investigate antibody recovered from red cells, but the method, controls and target-cell panel determine what a reactive pattern means. A nonreactive eluate is not a universal exclusion of immune destruction. A reactive eluate matching an antigen on a transfused population can add evidence to a suspected delayed reaction, but the clinical chronology and other findings remain essential.

Write a report that helps rather than anchors

A useful laboratory comment may describe IgG coating detected and recommend correlation with transfusion/medication history and evidence of haemolysis. It should not assign an autoimmune diagnosis unsupported by the work performed. Premature labels can anchor subsequent clinicians, suppress further investigation and make a later correction difficult. Clearly distinguishing observation from interpretation preserves the ability to learn from the next result.

Mastery questions and reasoned answers

1. Does a positive DAT prove haemolysis?

No. It detects red-cell coating under the method conditions. Evidence of destruction and its cause must be established separately.

2. Why does recent transfusion change interpretation?

The sample may contain donor cells, and alloantibody binding to those cells can produce a positive DAT. It also complicates current serological phenotyping.

3. What is the main reporting error?

Transforming one analytical finding into a complete causal diagnosis. The report should state the finding, method limits and necessary clinical correlation.

Evidence and limits: FB16, FB20; Chapters 17, 23 and 30. Specialist framework: doi:10.1182/hematology.2022000406.

B6 | Adsorption: the cells used determine what can disappear

A broadly reactive plasma sample requires investigation for masked alloantibodies. A learner suggests using the patient's current cells for autoadsorption because that would seem to remove only self-reactivity. The patient, however, was recently transfused. Current circulating cells may include donor cells carrying antigens that the patient lacks. Using those cells could remove an alloantibody as well as the intended autoantibody. [FB02, FB16]

The fictional model uses only one candidate antigen, E, to make the logic visible. In practice, multiple antigens and several method effects must be considered. Adsorption is a specialist laboratory procedure requiring validation and appropriate material; the case does not specify operating temperatures, incubation times or treatment recipes.

Material used for adsorption	Relevant feature	Interpretive consequence
Untreated plasma	Broad reactivity	Underlying specificity may be masked
Current "patient" cells	May include E-positive donor cells	Anti-E might also be removed
Selected donor cells	Known antigen profile	What remains depends on profile
Post-adsorption plasma	More selective pattern	Reassess limitations before exclusion

Describe adsorption as a selective removal experiment

Antibody binds to targets present on the adsorbing cells. The remaining plasma therefore reflects both the starting antibody population and the antigen content and capacity of the material used. "Reactivity disappeared" cannot be interpreted without asking what was capable of being removed. The experiment changes the sample; it does not simply make an invisible antibody visible without consequence.

Why recent transfusion matters to autoadsorption

The label on the tube identifies whose circulation was sampled, not the origin of every red cell in that circulation. Transfused cells can carry nonself antigens and adsorb a corresponding alloantibody. Treating the mixture as a pure patient-cell population creates an exclusion blind spot. A reliable transfusion history is therefore part of the scientific method, not merely administrative background.

Use selected cells to separate possibilities

Alloadsorption uses selected donor cells with known profiles to investigate patterns. Comparing what remains after different adsorptions can help distinguish antibodies, but each selected cell population can remove antibodies to its own antigens. An antibody to a high-frequency antigen may be removed by all available ordinary donor-cell populations. The investigation plan must name these limitations and identify when rare cells, genotype information or reference-laboratory support are required.

Check for incomplete removal and loss of signal

Persistence of broad reactivity may reflect insufficient adsorption or another reactive component. Complete disappearance does not prove that every clinically significant specificity was excluded. Dilution and treatment can also change sensitivity. Appropriate controls and a validated endpoint are necessary to interpret the post-adsorption sample. A procedural checkbox saying “adsorption performed” is not a description of what the experiment demonstrated.

Translate uncertainty into a usable handover

The reference-laboratory request should include specimen identity, transfusion and pregnancy history, medications, prior antibodies, methods used, reaction patterns and clinical urgency. The receiving specialist should be able to see which cell populations were used and what conclusions remain provisional. Repeating an undocumented experiment wastes scarce specimen and time; clear records allow the next investigation to build on the evidence already obtained.

Mastery questions and reasoned answers

1. What false assumption threatens this autoadsorption plan?

That every red cell in the current specimen is the patient’s own cell. Recent transfusion can introduce cells carrying targets for an alloantibody.

2. Why are selected donor-cell profiles essential?

They determine which antibodies can be removed and which post-adsorption findings are informative. A removed target cannot be excluded from the residual plasma alone.

3. What would make the referral more useful?

A reaction-level account of the adsorption design and controls, relevant history, remaining question and clinical urgency, rather than only the label “panagglutinin.”

Evidence and limits: FB02, FB16; Chapters 22–23 and 35. The table is a conceptual experiment, not a validated method.

B7 | Platelet increments: preserve the denominator and the timing

A fictional patient has a platelet count of 8 × 10^9/L before transfusion and 20 × 10^9/L at the specified early post-transfusion measurement. Body surface area is 1.8 m^2 and the product contains 3.0 × 10^{11} platelets. A student reports a corrected count increment of 7,200; another reports 7.2. Both may be expressing the same calculation with different count units. The apparent disagreement cannot be resolved by choosing the larger number. The units must be written explicitly. [FB23]

These values are invented to teach the calculation. They do not define an adequate increment for every patient, product or sampling interval. Interpretation of refractoriness requires a properly timed series, clinical assessment and the adopted service definition, not one isolated numerical threshold.

Quantity	Given value	Working form
Pre-transfusion count	8 × 10^9/L	8,000/μL
Post-transfusion count	20 × 10^9/L	20,000/μL
Increment	12 × 10^9/L	12,000/μL
Body surface area	1.8 m^2	Multiplier
Platelet dose	3.0 × 10^{11}	3.0 in 10^{11} units

Carry out the calculation transparently

Using counts per microlitre, the increment is 20,000 − 8,000 = 12,000/μL. Multiplying by 1.8 m^2 gives 21,600, and dividing by a dose of 3.0 in units of 10^{11} platelets gives a CCI of 7,200 in that convention. Starting with the increment as 12 × 10^9/L yields the corresponding displayed number 7.2. The difference is a factor of 1,000 in the count unit, not a biological difference in response.

Ask whether the inputs belong together

The pre- and post-counts must refer to the intended transfusion episode, and the platelet dose must describe the actual product administered. A count drawn after another intervention, an assumed dose substituted for a recorded dose, or a wrong-patient result undermines the calculation even when the arithmetic is perfect. Timing also matters because an early increment and later survival answer related but different questions.

Do not diagnose immune refractoriness from one low value

Infection, fever, consumption, bleeding, splenic sequestration and other nonimmune factors can reduce response. Immune causes require appropriate investigation, including relevant antibody testing when indicated. Repeated poor responses under suitable measurement conditions are more informative than a single unstandardised post-count. HLA or platelet-specific antibody findings also require interpretation with the clinical and transfusion pattern.

Use a comparison that tests the proposed mechanism

If an immune cause is suspected and appropriately selected components are tried, the response should be measured in a comparable way. Changing both the product strategy and the timing of the post-count makes the effect harder to interpret. A useful record preserves product characteristics, dose, collection times and important clinical events so that the clinical team can compare like with like.

Transfer the lesson to other calculations

Many clinical formulas hide a unit convention. A number without its denominator, unit scale and time point is an incomplete result. Before memorising a threshold, reproduce a worked calculation and identify the units used by the reference and local report. A safe calculator or spreadsheet should label inputs and reject implausible unit combinations rather than returning a plausible-looking number for every entry.

Mastery questions and reasoned answers

1. Which answer is arithmetically correct: 7.2 or 7,200?

Both can represent this example if the count-unit conventions are stated consistently. An unlabeled number is not a complete CCI report.

2. Would a low CCI establish anti-HLA-mediated refractoriness?

No. The measurement must be valid and interpreted over an appropriate clinical/transfusion series, with immune and nonimmune causes assessed.

3. What should a calculation check validate besides subtraction?

Patient/episode identity, specimen times, actual administered dose, body surface area, unit convention and whether intervening events make the comparison invalid.

Evidence and limits: FB23; Chapter 34. Arithmetic independently reproducible from the invented inputs above.

B8 | Finding antigen-negative units: an expectation is not a guarantee

A fictional inventory has an estimated antigen-negative fraction of 0.20 for target X and 0.10 for target Y. A student multiplies the fractions and predicts that 2% of units will lack both antigens. The calculation is mathematically correct only under an independence assumption that may not hold for real blood-group antigens or a selected donor inventory. Another student says that screening 50 units will therefore guarantee one suitable unit. That second claim is incorrect even within the simplified independent model.

The model is useful because it separates three ideas: the fraction expected to satisfy a condition, the average number of successes in a sample, and the probability of obtaining at least one success. Actual inventory planning uses reliable local antigen-frequency data, linked inheritance where relevant, donor selection effects and confirmed typing. [FB04, FB05]

Calculation	Result	Meaning
0.20×0.10	0.02	Assumed double-negative fraction
50×0.02	1	Expected number in 50 units
$(1 - 0.02)^{50}$	≈ 0.364	Probability of no success
$1 - (1 - 0.02)^{50}$	≈ 0.636	Probability of at least one

Explain why the expected value is not a promise

In repeated samples of 50 units from this imagined independent population, the average number of double-negative units would approach one. Any single batch could contain none, one or several. The probability of zero successes is the product of 50 failure probabilities, 0.98^{50}, approximately 0.364. Thus a batch with no suitable unit is not evidence of a laboratory mistake merely because the expected count was one.

Calculate a planning quantity with its assumptions visible

For at least a 95% chance of finding one success in the model, solve $1 - 0.98^n \geq 0.95$. Taking logarithms gives $n \geq \log(0.05)/\log(0.98)$, approximately 148.3, so the smallest whole number is 149. This is not a clinical instruction to test 149 donor units. It is a demonstration of how much larger a high-probability requirement can be than a simple expected-value estimate.

Identify why the real problem is harder

Antigens may be associated through linkage or population structure, and the local donor inventory may differ from the population used to estimate frequencies. Repeated units from the same donor are not independent new draws. The available units may also have other required attributes: ABO/Rh compatibility, age, processing, irradiation or other patient-specific requirements. Multiplying marginal fractions without checking these dependencies can substantially misrepresent availability.

Turn the calculation into communication, not false precision

A laboratory can use a clearly labelled estimate to discuss likely difficulty and whether early reference-service or rare-donor support is appropriate. The message should not promise an exact turnaround time from a probability alone. Confirmed antigen-negative units still need the relevant compatibility and issue checks. An inventory estimate concerns availability; it does not authorise a particular component for a patient.

Test the sensitivity of the estimate

If the true double-negative fraction were 0.01 instead of 0.02, the probability of finding at least one in 50 would fall to about 0.395. This shows why modest errors in a rare-event fraction can matter operationally. Reporting a range and the assumptions may be more honest than presenting a single percentage with several decimal places. The appropriate level of precision is determined by evidence, not by the number of digits a calculator can display.

Mastery questions and reasoned answers

1. Why does 50 × 0.02 = 1 not guarantee a unit?

It is an expected count over repeated samples. Individual samples vary; in this model, about 36.4% of samples of 50 have no success.

2. What assumption allows 0.20 × 0.10?

Independence of the two antigen-negative conditions in the sampled population. Real antigen associations and inventory selection may violate it.

3. What remains after a suitable phenotype is found?

Confirm identity, typing validity, all other component requirements and the required compatibility/issue process. The frequency calculation does not replace those checks.

Evidence and limits: FB04, FB05; Chapter 15. Probability calculations are original, bounded mathematical models.

B9 | Delayed haemolysis: reconstruct the sequence before assigning a label

A fictional patient’s haemoglobin rises after transfusion and falls again several days later. The patient has a new reactive antibody investigation and laboratory findings concerning for haemolysis. The team suspects a delayed haemolytic transfusion reaction. A student asks whether the new antibody result is enough to close the investigation. It is not: chronology, alternative explanations, component identity and evidence of haemolysis must be considered together. [FB20, FB21]

The table gives relative times rather than prescribing a surveillance definition. National haemovigilance systems have specific reporting criteria, and a patient can require urgent clinical management before every surveillance field is resolved. Clinical treatment, laboratory investigation and formal event classification are connected activities, but they are not the same activity.

Relative time	Fictional observation	Investigation question
Before transfusion	Baseline sample available	What was detected then?
After transfusion	Expected initial rise	Which components were given?
Several days later	Haemoglobin falls	Bleeding, dilution or destruction?
Current investigation	New antibody reactivity	Specificity and implicated antigen?
Follow-up	Further results pending	Who owns the next action?

Reconstruct an auditable timeline

The investigation links the patient, pre-transfusion specimen, component identifiers, issue and administration times, symptoms and subsequent samples. A later sample alone cannot reconstruct all earlier events. Comparing pre- and post-transfusion findings may clarify whether an antibody was previously undetectable, whether the current DAT changed and whether implicated donor cells carry the relevant antigen. The strength of the conclusion depends on the quality and completeness of those links.

Evaluate competing explanations

A falling haemoglobin may reflect bleeding, haemodilution, reduced production, haemolysis or combinations. Clinical context and appropriate biochemical findings help assess the mechanism. The presence of an antibody does not prove that every fall in haemoglobin is immune destruction. Conversely, a weak or negative routine test does not automatically exclude a serious clinical complication. The laboratory should communicate concerning findings promptly rather than wait for a perfectly tidy mechanism.

Recognise the special problem of hyperhaemolysis

In selected patients, particularly within haemoglobinopathy care, haemolysis can involve transfused cells and the patient’s own cells, and the haemoglobin can fall below the pre-transfusion level. This requires specialist assessment. It must not be reduced to an automatic instruction to give more red cells whenever the haemoglobin falls. The source guidance discusses the difficult balance between further transfusion and the risk of worsening haemolysis; individual management is outside the scope of this exercise.

Separate reporting certainty from clinical urgency

A surveillance label may remain provisional while urgent patient care proceeds. The communication should identify observed findings, the suspected relationship to transfusion, tests pending and the responsible clinical/laboratory team. A categorical label without its evidence can mislead future care, but excessive reluctance to communicate a serious suspicion can also delay action.

Make the learning durable

After the acute episode, confirmed clinically significant antibody information must remain accessible. The final investigation should reconcile provisional and definitive interpretations, identify preventable process failures if any, and document patient-specific future support requirements. Not every adverse event reflects a preventable error. Haemovigilance is strongest when it distinguishes unavoidable biological risk from correctable system failures without erasing either.

Mastery questions and reasoned answers

1. What is missing from “new antibody, therefore delayed reaction”?

A linked clinical and laboratory timeline, evidence of haemolysis, component/antigen correlation where available and assessment of alternative explanations.

2. Why distinguish clinical treatment from surveillance classification?

The patient may need urgent specialist management while formal classification remains provisional. A surveillance definition does not replace bedside judgement.

3. What is the lasting information-system requirement?

Preserve verified antibody and reaction history, relevant component requirements and the final interpretation with provenance so that future care benefits from the investigation.

Evidence and limits: FB20, FB21, FB25; Chapters 30–31 and 38. No management regimen or transfusion threshold is prescribed.

B10 | Emergency release: uncertainty must travel with the component

A fictional patient with life-threatening bleeding arrives under a temporary identifier. The laboratory has not completed compatibility testing. The clinical team requests immediate components through the emergency-release process. One worker interprets “emergency” as permission to bypass identity documentation; another refuses to release anything until a complete antibody investigation is finished. Both responses overlook the purpose of an authorised contingency pathway: timely treatment with explicit, controlled uncertainty. [FB01, FB18]

The details of emergency component selection depend on the patient, inventory, clinical service and applicable standards. This exercise does not prescribe an ABO/Rh selection for every emergency. It examines the information and accountability needed when the usual sequence cannot be completed before treatment.

Required distinction	Example message	Why it matters
Identity	Temporary identifier verified	Preserves later reconciliation
Testing status	ABO established; screen pending	Does not imply full compatibility
Authorisation	Named emergency-release decision	Makes the exception accountable
Component trail	Unique unit and issue time	Links later investigation
Follow-up	Testing and reconciliation assigned	Prevents unfinished work disappearing

Do not confuse incomplete testing with absent controls

Emergency release may occur before testing is complete, but patient/component identification, traceability and the documented authorised decision remain essential. The record must show what was known at the time, not be rewritten later to suggest that all results preceded issue. Retrospective testing can improve subsequent decisions and identify risk; it cannot change the chronological facts of the first decision.

Create a safe transition to the next phase

When additional results become available, the laboratory and clinical team reassess the component strategy under the adopted protocol. Switching from emergency components to another selection requires a controlled decision, not an automatic assumption based on one newly populated field. The history of components already transfused can also affect interpretation of subsequent specimens.

Reconcile identifiers without losing events

A temporary identifier may later be linked to a confirmed identity. The merge must preserve specimens, results, component issue, administration and adverse-event information. If records split across identities, an antibody history or emergency transfusion may become invisible. Reconciliation is therefore a clinical safety task. A software merge is not complete until the relevant linked information is accessible and the audit trail is intact.

Use specific status language

“Uncrossmatched” and “incompatible” are not synonyms. A component released before crossmatching has an incomplete testing status; demonstrated incompatibility is a different finding. Likewise, “ABO group known” does not mean that all non-ABO antibody concerns are resolved. A concise, accurate status statement helps the clinical team understand the actual uncertainty without exaggerating or minimising it.

Close the loop after the crisis

The emergency process should identify who completes outstanding testing, communicates significant findings, confirms the final component trail and reviews deviations. A patient leaving the resuscitation area does not eliminate those obligations. A useful review examines both speed and control: whether treatment was delayed unnecessarily, whether identity and authorisation were preserved, and whether unresolved risks reached the responsible team in time.

Mastery questions and reasoned answers

1. Which controls remain important during emergency release?

Identity, component traceability, authorised decision-making, accurate testing-status communication and assigned follow-up remain important even when full testing cannot precede issue.

2. Can retrospective results be dated as if available before issue?

No. The record must preserve actual chronology. Later results inform later decisions and the investigation of the earlier event.

3. Why is a temporary-identifier merge a safety task?

It determines whether antibody history, samples and component events remain linked to the correct person after the emergency.

Evidence and limits: FB01, FB18, FB25; Chapters 5, 26–27, 36 and 39. Apply the adopted emergency-release protocol.

B11 | Verification study: agreement is not the same as truth

A fictional laboratory compares a new screening platform with its current method using 200 specimens. The methods agree on 190 and disagree on 10. A report states that the new assay is “95% accurate.” The arithmetic 190/200 = 95% is correct, but the label is not justified unless the comparison design establishes a suitable reference standard and the relevant accuracy measures. Two methods may agree and both be wrong, or disagree because one detects an effect the other does not. [FB24]

The table below treats the existing method as a comparator, not as unquestionable truth. The specimens were selected for this exercise; their mixture is not a prevalence estimate for the laboratory’s future patient population. Positive and negative agreement should not be silently renamed sensitivity and specificity.

New platform	Comparator reactive	Comparator nonreactive	Total
Reactive	36	6	42
Nonreactive	4	154	158
Total	40	160	200

Name the quantities correctly

Overall agreement is (36 + 154)/200 = 95%. Positive percent agreement relative to the comparator is 36/40 = 90%. Negative percent agreement is 154/160 = 96.25%. These measurements describe the relationship between the methods in this dataset. They do not automatically establish clinical sensitivity, clinical specificity or the probability that a future reactive result represents a clinically significant antibody.

Investigate the discordant specimens

The ten disagreements deserve structured investigation: specimen quality, medication interference, antigen expression, method sensitivity, controls, handling and the actual antibody findings may all matter. Resolving a disagreement should not consist of automatically declaring the existing method correct. An independent, appropriately designed adjudication process can add information, but its criteria must be explicit and avoid bias in favour of either platform.

Consider the specimen spectrum

A study consisting mainly of clear negatives and strong positives may show excellent agreement while missing weak clinically important antibodies, mixed reactions or interference-prone specimens. Verification should reflect the intended use and relevant challenge conditions. The question is not simply whether a large number of specimens was tested, but whether the selected material tests the important failure modes and whether uncertainty is adequately characterised.

Do not hide uncertainty behind percentages

A 90% positive agreement estimate based on 40 comparator-reactive specimens is less precise than the same percentage from thousands of appropriate specimens. Confidence intervals and the study design help communicate that uncertainty. Reporting 90.000% would add digits without adding evidence. The decision to implement must consider the nature of disagreements and clinical consequences, not only whether an overall percentage exceeds an arbitrary target.

Link verification to ongoing quality

A successful initial study does not establish that every later reagent lot, software update or operator workflow performs identically. Change control, appropriate quality control, proficiency evaluation and incident learning remain necessary. The verification report should define the validated use, exclusions and required follow-up so that later users know what was actually demonstrated rather than remembering only the headline “95%.”

Mastery questions and reasoned answers

1. Why is 95% “accuracy” an unsupported label here?

The study establishes agreement with a comparator. Without an adequate reference standard and design, agreement cannot simply be called diagnostic accuracy.

2. Calculate positive and negative agreement.

Positive: 36/40 = 90%. Negative: 154/160 = 96.25%. The comparator and denominator must be named.

3. What could a high overall agreement conceal?

Poor performance in rare but clinically important subgroups or weak/interference-prone specimens, especially when clear negatives dominate the dataset.

Evidence and limits: FB24; Chapter 37. Original invented dataset; FDA diagnostic-test statistical-reporting guidance supports the measurement distinctions.

B12 | Transfusion handover: resolve a discrepancy without destroying evidence

A fictional laboratory discovers that a component label and a computer issue record disagree on one identifier. The component has not left the controlled laboratory area. A supervisor proposes printing a new label and deleting the first issue record so that the final paperwork will look correct. This would remove the visible discrepancy without establishing how it arose. The safer immediate response is to prevent unintended issue, preserve the evidence and use the authorised reconciliation process. [FB18, FB25]

The example is deliberately a near miss rather than a completed transfusion. An absence of patient harm does not make the event unimportant. It provides an opportunity to study a control failure before the same combination of conditions reaches a patient.

Stage	Appropriate evidence	Unsafe shortcut
Contain	Component secured; status clear	Leave it beside ready-to-issue units
Reconstruct	Original labels, audit trail, times	Delete contradictory records
Resolve	Authorised identity/record reconciliation	Relabel from memory
Resume	Independent check of corrected state	Assume printing equals verification
Learn	Test effectiveness of corrective action	Count attendance at a briefing only

Contain the risk before explaining it

The first objective is to prevent an uncertain component from being selected or issued. The status should be visible to everyone who might handle it. Containment is not the same as deciding that the component is unusable; it creates time and control for a justified resolution. The laboratory should avoid destroying potentially informative labels or records in the rush to restore a tidy work area.

Reconstruct the event from independent sources

The investigation compares the specimen record, component identifier, request, issue transaction, label-generation history and operator actions. Sources may disagree, and their timestamps may reflect different events. A print time is not necessarily a verification time; a scanned code is not necessarily evidence that the correct item was in front of the operator. The analysis should establish what each record actually represents before choosing which one to trust.

Distinguish a corrected record from a concealed event

An authorised correction preserves the original information, the reason for change, the responsible person and the actual correction time. It makes the current state usable without pretending that no discrepancy occurred. Deleting or overwriting the first record can impair later investigation and remove the evidence needed to determine whether another specimen or component was also affected.

Design corrective action around the failure mechanism

If the problem arose from two open patient records and a label printed from the wrong window, a general reminder to “be careful” does not directly test or remove the hazard. A more informative response examines the workflow, interface, identity checks and independent verification. The best change depends on the investigated cause; a forcing function that creates a different unsafe workaround is not automatically an improvement.

Measure effectiveness with a realistic challenge

After the change, a simulated attempt to reproduce the confusing sequence can test whether the revised system prevents or detects it. The test should include ordinary workload and foreseeable exceptions without exposing patients to risk. Document the outcome, residual limitations and review date. Counting staff who attended training measures implementation, not whether the control works during the task.

Close the communication loop

The final event record should distinguish containment, factual findings, authorised correction, effect on other records, corrective action and effectiveness evidence. Information relevant to future patient care must reach the appropriate clinical or transfusion record. A completed investigation folder is not useful if the verified history remains inaccessible to the next person making an issue decision.

Mastery questions and reasoned answers

1. Why is reprinting a label not enough?

It changes the appearance of the record without establishing component identity or the cause and extent of the discrepancy. The corrected state requires authorised reconciliation and verification.

2. Is an event without patient harm irrelevant to haemovigilance?

No. A near miss can reveal a failure mode and support prevention. It should be analysed proportionately under the adopted reporting system.

3. What distinguishes implementation from effectiveness?

Implementation shows that a change or training occurred. Effectiveness shows, through a suitable test or outcome evidence, that the targeted failure is prevented or detected as intended.

Evidence and limits: FB18, FB25; Chapters 36–38. Original fictional systems investigation; no actual institution or staff member is described.

What an antiglobulin result actually observes

Original contrast • Read with Chapters 4 and 17

DIRECT ANTIGLOBULIN TEST

Patient red cells → detect coating already present on those cells

Different questions—not sequential steps

INDIRECT ANTIGLOBULIN TEST

Patient plasma + selected cells under test conditions → investigate binding in vitro

The patient’s cells and the patient’s plasma are not interchangeable starting materials. A DAT finding does not itself establish haemolysis, and an IAT finding does not identify an antibody specificity without further investigation. Reagent specificity, controls and method limitations define the conclusion. [FB05, FB16]


Explain it: Why is “positive Coombs test” an incomplete handover?

Reasoned answer: It does not identify whether DAT or IAT was performed, the specimen/cells tested, reagent specificity, method or clinical question. Those distinctions are essential to interpretation.

Original conceptual comparison, not an assay instruction sheet. Sources: FB05 and FB16. Case B5 on page 326 extends this distinction to a recent-transfusion scenario.

Reaction strength is not a concentration

Original synthetic tube appearances • Not patient images or a manufacturer grading chart



Dispersed cells **Small clusters** **Large clusters**

These schematic appearances illustrate dispersed cells and aggregation. They are not a reference for assigning tube or gel grades. Method-specific grading requires the validated procedure, proper resuspension or reading conditions, controls and supervised comparison with genuine examples. A stronger visual reaction does not imply a proportionately greater antibody concentration. [FB04, FB05]

Explain it: Can two 1+ reactions be added to equal a 2+ reaction?

Reasoned answer: No. Reaction grades are ordinal observations in a particular method. They are not additive concentration units, and appearances from different platforms cannot be treated as the same scale without validation.

Original vector model with deliberately synthetic geometry. No patient specimen, microscopy image or proprietary grading chart is reproduced. Read Case B2, page 317, for a worked panel interpretation.

Evidence and navigation for the advanced cases

Original fictional laboratories • Source identifiers resolve to pages 310–313

Cases B1–B4: discrepancy, mixtures and interference

Pages 314–325 investigate ABO discordance, discriminating panel cells, historical antibody information and a treatment-related antigen blind spot. The data are intentionally bounded, and incomplete antigen columns are labelled. They cannot authorise a transfusion.

Cases B5–B8: mechanisms and denominators

Pages 326–337 distinguish DAT positivity from haemolysis, adsorption from definitive exclusion, count increments from unit conventions, and an expected inventory count from a guarantee. The numerical examples are original and independently reproducible.

Cases B9–B12: investigation and system reliability

Pages 338–349 connect clinical chronology, emergency-release information, method comparison and near-miss investigation. They separate observations, interpretations and authorised decisions. None describes an actual patient or institution.

Current nomenclature and evidence

The ISBT database release identified in this edition is September 2026, v19 (49 systems and 400 antigens). This dated observation is not a permanent biological limit. Official source: https://blooddatabase.isbtweb.org/release . The chapter references distinguish current guidance from older foundational biology.

How to test your understanding

Answer each case question before reading its reasoning. Identify the unsafe assumption, the next informative observation and the limits of the final report. The following subject index links selected teaching locations throughout the core chapters, workshops, glossary and these advanced case laboratories.

Subject index

Selected teaching, applied cases and glossary locations • PDF cover = page 1

Numbers link to the relevant teaching. A glossary location gives a concise definition; use the chapter and worked cases for the complete explanation.

A

ABH precursor
287

ABO discrepancy
45, 235, 275, 287, 314

Adsorption
18, 41, 79, 287, 329, 330

Agglutination grade
288

AHG
288

Alloadsorption
133, 135, 288, 330

Alloantibody
21, 23, 34, 288, 327, 328

Alloimmunisation
54, 55, 167, 288

Anamnestic response
14, 22, 24, 289

Anti-D
49, 51, 53

Anti-E
10, 52, 53, 318, 329

Anti-Jka
13, 20, 64, 320

Anti-K
12, 25, 43, 318

Anti-M
75, 76, 77

Antibody exclusion
91, 289

Antibody identification
58, 96, 112, 289

Antibody screen
10, 13, 29, 289, 320

Antigen frequency
58, 90, 289

Antigen profile
17, 38, 52, 290, 329

Antigen-negative unit
12, 290

Antigen-negative units
12, 20, 23, 335, 336

Autoadsorption
133, 135, 136, 290, 329, 330

Autoantibody
21, 80, 87, 290, 327, 329

Autocontrol
21, 86, 87, 290, 315

B

Biphasic haemolysin
80, 83, 145, 291

Blood group system
291

Bombay phenotype
41, 291

Subject index

Selected teaching, applied cases and glossary locations • PDF cover = page 1

Numbers link to the relevant teaching. A glossary location gives a concise definition; use the chapter and worked cases for the complete explanation.

C

CCI
200, 201, 202, 291, 332, 333

Cell suspension
45, 291

Chimerism
54, 191, 192, 292

Clinically significant antibody
39, 78, 108, 292, 321, 339

Cold agglutinin
143, 146, 292

Compatibility
8, 9, 10, 292, 318, 320

Complement-mediated haemolysis
145, 292

Component selection
14, 21, 25, 293, 320, 341

Concordance
237, 293

Corrected count increment
199, 200, 201, 332

Crossmatch
8, 14, 84, 293, 318, 321

Cryopreserved rare unit
293

D

D antigen
276, 293

Daratumumab
150, 152, 233, 323

Daratumumab interference
294

DAT
23, 25, 26, 294, 318, 326

Delayed haemolysis
178, 185, 234, 338

Delayed haemolytic reaction
66, 178, 181, 294

Discordance
97, 189, 206, 294, 352

Donor typing
86, 294

Dosage
16, 17, 20, 295, 315

DTT
59, 60, 62, 295, 323, 324

Duffy
16, 69, 70

Duffy system
69, 295

E

Electronic crossmatch
156, 157, 321

Electronic issue
13, 156, 158, 295

Eluate
28, 29, 102, 295, 326, 327

Elution
102, 103, 105, 296

Subject index

Selected teaching, applied cases and glossary locations • PDF cover = page 1

Numbers link to the relevant teaching. A glossary location gives a concise definition; use the chapter and worked cases for the complete explanation.

Emergency release
10, 14, 157, 296, 341, 342

Enzyme treatment
53, 64, 70, 296

Epitope
16, 18, 19, 296

Erythroid precursor
296

Extended matching
56, 297

F

False negative
297

False positive
297

Fetal antigen status
61, 170, 276, 297

Forward grouping
40, 48, 234, 297, 314, 316

G

Genotype
10, 15, 16, 298, 318, 324

H

Haemolysis
21, 23, 25, 298, 326, 327

Haemovigilance
179, 220, 283, 298, 338, 339

HDFN
51, 75, 79, 298

High-frequency antigen
74, 84, 86, 298, 330

Historical antibodies
10, 11, 14, 318, 324

Historical antibody
70, 92, 122, 299, 322, 352

HLA
8, 161, 199, 333, 334

HLA-selected platelets
281, 299

HPA
199, 200, 249, 299

Hyperhaemolysis
178, 185, 279, 299, 339

I

IAT
28, 31, 34, 299, 317, 323

Imputability
179, 220, 252, 300

Incompatibility
8, 108, 139, 300, 342

Informed release decision
300

Inventory probability
20, 90, 91, 300, 335, 336

Irradiation requirement
300

ISBT
79, 82, 86, 352

Subject index

Selected teaching, applied cases and glossary locations • PDF cover = page 1

Numbers link to the relevant teaching. A glossary location gives a concise definition; use the chapter and worked cases for the complete explanation.

K

K antigen
58, 301

Kell
43, 57, 58, 324

Kell system
57, 127, 262, 301

Kidd
16, 17, 63, 321

Kidd system
63, 301

L

Least incompatible
139, 141, 142, 301

Lewis
39, 79, 81

Lewis system
301

Low-frequency antigen
84, 85, 86, 302

M

Mixed-field reaction
29, 45, 47, 302

MNS
74, 75, 76

MNS system
74, 302

Molecular prediction
54, 189, 302

N

Near miss
98, 220, 223, 302, 347, 349

Negative percent agreement
250, 303, 344

Nonimmune refractoriness
303

P

Panel interpretation
114, 269, 317, 351

Panreactivity
47, 86, 88, 303

Partial D
52, 55, 262, 303

Passive antibody
28, 108, 167, 303

Patient phenotype
67, 71, 116, 304

Platelet increment
199, 200, 201, 304

Platelet refractoriness
161, 199, 200, 304, 332, 333

Positive agreement
251, 345

Positive percent agreement
250, 304, 344

Pretransfusion specimen
22, 36, 105, 304

Subject index

Selected teaching, applied cases and glossary locations • PDF cover = page 1

Numbers link to the relevant teaching. A glossary location gives a concise definition; use the chapter and worked cases for the complete explanation.

Prophylactic anti-D
277, 305

Q

Quality control
45, 96, 101, 305, 345

R

Rare donor
305

Reaction investigation
68, 180, 181, 305

Reagent cell
47, 114, 237, 305

Red-cell genotyping
15, 17, 19

Reference laboratory
41, 185, 195, 306

Reverse grouping
40, 46, 48, 306, 314, 316

Rh system
51, 306

RhD
8, 49, 51

Rule of three
91, 116, 251, 306

S

Sample validity
33, 34, 37

Selected cell
263, 269, 306, 317, 319

Serologic weak D
307

Sickle cell disease
71, 76, 183

Specificity
10, 13, 16, 307, 316, 320

Specimen validity
211, 307

T

Thermal amplitude
23, 24, 26, 307

Titre
23, 26, 42, 307

Traceability
10, 29, 35, 308, 342, 343

Transfusion history
10, 50, 176, 308, 317, 330

Transfusion reaction
64, 105, 177, 338

U

Unit identity
308, 318

V

Validation
28, 98, 103, 308, 329, 351

W

Warm autoantibody
103, 105, 139, 308

Subject index

Selected teaching, applied cases and glossary locations • PDF cover = page 1

Numbers link to the relevant teaching. A glossary location gives a concise definition; use the chapter and worked cases for the complete explanation.

Weak D
52, 54, 55

Wrong blood in tube
9, 156, 309